Mathematical modelling of mammalian mitochondrial metabolism by Ghaisas, A
 
WWW.BROOKES.AC.UK/GO/RADAR 
RADAR 
Research Archive and Digital Asset Repository 
 
 
Mathematical modelling of mammalian mitochondrial metabolism 
Amar S Ghaisas (2015)  
 
https://radar.brookes.ac.uk/radar/items/9bf901fa-a34e-4cbf-8b5c-a4d2d25fa482/1/ 
 
Note if anything has been removed from thesis:   
 
Copyright © and Moral Rights for this thesis are retained by the author and/or other copyright owners. A copy 
can be downloaded for personal non-commercial research or study, without prior permission or charge. This 
thesis cannot be reproduced or quoted extensively from without first obtaining permission in writing from the 
copyright holder(s). The content must not be changed in any way or sold commercially in any format or medium 
without the formal permission of the copyright holders. 
 
 
 
When referring to this work, the full bibliographic details must be given as follows: 
Ghaisas, A S, (2015), Mathematical modelling of mammalian mitochondrial metabolism, PhD, Oxford Brookes 
University 
 
 
 
 
Powered by LATEX
Mathematical modelling of mammalian
mitochondrial metabolism
Amar Suresh Ghaisas
A thesis submitted in partial fulfilment of the requirements of
Oxford Brookes University
for the award of the degree Doctor of Philosophy
Cell Systems Modelling Group
School of Life Sciences
December 2015

Contents
List of Figures 9
List of Tables 18
Acronyms A
Abstract
1 Introduction 1
1.1 Metabolism . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1
1.1.1 Heart mitochondrial metabolism . . . . . . . . . . . . . . . . 3
1.2 Control of TCA cycle . . . . . . . . . . . . . . . . . . . . . . . . 3
1.2.1 Anaplerotic reactions . . . . . . . . . . . . . . . . . . . . . . 4
1.2.2 TCA cycle unspanning . . . . . . . . . . . . . . . . . . . . . 5
1.2.3 Metabolic homeostasis & TCA cycle . . . . . . . . . . . . . . 6
1.3 Mathematical modelling . . . . . . . . . . . . . . . . . . . . . . 7
1.3.1 Need for mathematical models . . . . . . . . . . . . . . . . . 7
1.3.2 Model definition and formulation . . . . . . . . . . . . . . . . 8
1.3.2.1 Stoichiometry . . . . . . . . . . . . . . . . . . . . . . . . 8
1.3.2.2 Classification of metabolites . . . . . . . . . . . . . . . . 8
1.3.2.3 Rate equations . . . . . . . . . . . . . . . . . . . . . . . 9
1.3.3 Models of TCA cycle . . . . . . . . . . . . . . . . . . . . . . 10
1.3.4 Different types of model analyses . . . . . . . . . . . . . . . . 10
1.3.4.1 Elementary modes identicalness . . . . . . . . . . . . . . 11
1.3.4.2 Elementary modes & physiology . . . . . . . . . . . . . 13
1.4 Metabolic regulation . . . . . . . . . . . . . . . . . . . . . . . . 14
1.4.1 Metabolic Control Analysis . . . . . . . . . . . . . . . . . . . 15
2 Liver TCA cycle model 18
2.1 Overview . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 18
2.2 Methods . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 19
2.2.1 Choice of model design . . . . . . . . . . . . . . . . . . . . . 19
2.2.2 Model definition . . . . . . . . . . . . . . . . . . . . . . . . . 21
2.2.3 Special Cases: Other model definitions . . . . . . . . . . . . 26
2.2.3.1 The [Pi] -variation of the updated model . . . . . . . . . 26
2.2.3.2 The apparent maximal activity of PC and the “PC
knock-down” model (PCkd) . . . . . . . . . . . . . . . . 28
2.2.3.3 Reduced liver TCA cycle model . . . . . . . . . . . . . . 30
2.2.3.4 Simple Test Models . . . . . . . . . . . . . . . . . . . . . 31
2.3 Results for the liver TCA cycle models . . . . . . . . . . . . . . 32
2.3.1 Elementary modes analysis of liver TCA cycle models . . . . 32
2.3.1.1 In detail: elementary modes of liver TCA cycle models . 35
2.3.2 Enzyme subset analysis of liver TCA cycle models . . . . . . 43
2.3.3 Steady-state analysis of the Liver TCA cycle kinetic models 46
2.3.4 Responses of the two models to the variations in enzyme activity 49
2.3.5 Metabolic Control Analysis of liver TCA cycle models . . . . 73
2.3.5.1 Flux control coefficients of liver TCA cycle models . . . 73
2.3.5.2 Complex pattern of Flux control coefficients in liver
TCA cycle models: Impact of kinetics . . . . . . . . . . 80
2.3.5.3 Complex pattern of Flux control coefficients in liver
TCA cycle models: Structural insights . . . . . . . . . . 88
2.3.5.4 Nearly-hyperbolic curves of Flux control coefficients in
liver TCA cycle models . . . . . . . . . . . . . . . . . . 94
2.3.5.5 Concentration control coefficients of liver TCA cycle models 100
2.3.5.6 Elasticity coefficients of liver TCA cycle models . . . . . 108
2.4 Discussion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 116
3 Heart TCA cycle prototype 122
3.1 Overview . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 122
3.2 Methods . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 123
3.3 Results for the heart TCA cycle prototype . . . . . . . . . . . . 124
3.3.1 Elementary modes analysis of heart TCA cycle prototype . . 124
3.3.2 Enzyme subset analysis of heart TCA cycle prototype . . . . 125
3.3.3 Steady-state analysis for the heart TCA cycle prototype . . . 126
3.3.4 Metabolic Control Analysis of the heart TCA cycle prototype 139
3.3.4.1 Flux control coefficients of heart TCA cycle prototype . 139
3.4 Discussion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 142
4 Heart TCA cycle model 144
4.1 Overview . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 144
4.2 Methods . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 145
4.2.1 Model definition . . . . . . . . . . . . . . . . . . . . . . . . . 145
4.3 Results for the heart TCA cycle model . . . . . . . . . . . . . . 150
4.3.1 Elementary modes analysis of the heart TCA cycle model . . 150
4.3.2 Enzyme subset analysis of the heart TCA cycle model . . . . 152
4.3.3 Steady-state analysis of the heart TCA cycle model . . . . . 153
4.3.4 Responses of the heart TCA cycle model to the variations
in enzyme activity . . . . . . . . . . . . . . . . . . . . . . . . 156
4.3.5 Metabolic Control Analysis of the heart TCA cycle model . 170
4.3.5.1 Flux control coefficients of the heart TCA cycle model . 170
4.3.5.2 Concentration control coefficients of the heart TCA
cycle model . . . . . . . . . . . . . . . . . . . . . . . . . 176
4.3.5.3 Elasticity coefficients of the heart TCA cycle model . . . 184
4.4 Discussion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 189
5 Malate-Aspartate shuttle model 194
5.1 Overview . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 194
5.2 Methods . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 195
5.2.1 Model definition . . . . . . . . . . . . . . . . . . . . . . . . . 195
5.3 Results for the Malate-Aspartate shuttle model . . . . . . . . . 197
5.3.1 Elementary modes analysis of the Malate-Aspartate shuttle
model . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 197
5.3.2 Flux control coefficients of the Malate-Aspartate shuttle model 199
5.4 Discussion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 200
6 Heart Glycolysis model 201
6.1 Overview . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 201
6.2 Methods . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 202
6.2.1 Model definition . . . . . . . . . . . . . . . . . . . . . . . . . 202
6.3 Results for the Heart Glycolysis model . . . . . . . . . . . . . . 206
6.3.1 Elementary modes analysis of the Heart Glycolysis model . . 206
6.3.2 Enzyme subset analysis of the Heart Glycolysis model . . . . 207
6.3.3 Flux control coefficients of the Heart Glycolysis model . . . . 208
6.4 Discussion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 209
7 Heart integrated model 210
7.1 Overview . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 210
7.2 Methods . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 210
7.2.1 Model definition . . . . . . . . . . . . . . . . . . . . . . . . . 210
7.3 Results for the Heart integrated model . . . . . . . . . . . . . . 212
7.3.1 Elementary modes analysis & Enzyme subset analysis of
the Heart integrated model . . . . . . . . . . . . . . . . . . . 212
7.3.2 Steady-state analysis of the Heart integrated model . . . . . 214
7.4 Discussion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 215
Appendices 220
A Liver TCA cycle model Differential Equations 220
B Liver TCA cycle Rate Equations 221
B.1 Pyruvate Carboxylase . . . . . . . . . . . . . . . . . . . . . . . 221
B.2 Pyruvate Dehydrogenase . . . . . . . . . . . . . . . . . . . . . . 223
B.3 Citrate Synthase . . . . . . . . . . . . . . . . . . . . . . . . . . 223
B.4 Aconitase . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 224
B.5 NAD+ -Dependent Isocitrate Dehydrogenase . . . . . . . . . . . 225
B.6 NADP+ -Dependent Isocitrate Dehydrogenase . . . . . . . . . . 226
B.7 α-Ketoglutarate Dehydrogenase . . . . . . . . . . . . . . . . . . 227
B.8 Succinyl-CoA Synthetase . . . . . . . . . . . . . . . . . . . . . . 228
B.9 Succinate Dehydrogenase . . . . . . . . . . . . . . . . . . . . . . 229
B.10 Fumarase . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 229
B.11 Malate Dehydrogenase . . . . . . . . . . . . . . . . . . . . . . . 230
B.12 Adenine-Nucleotide Translocase . . . . . . . . . . . . . . . . . . 230
B.13 Malate-Phosphate Exchange . . . . . . . . . . . . . . . . . . . . 231
B.14 ATP Synthesis . . . . . . . . . . . . . . . . . . . . . . . . . . . . 231
B.15 ATP Hydrolysis . . . . . . . . . . . . . . . . . . . . . . . . . . . 232
C ScrumPy code for the updated liver TCA cycle model 233
D A Python function to compute the variability in apparent
maximal activity of PC 237
E Differential and Rate equations: Heart TCA cycle model 240
E.1 Differential equations: Heart TCA cycle model . . . . . . . . . 240
E.2 Rate equations: Heart TCA cycle model . . . . . . . . . . . . . 240
E.2.1 alpha-Ketoglutarate transporter . . . . . . . . . . . . . . . . 240
F ScrumPy code for the Heart TCA cycle model 241
G ScrumPy code for the Malate-Aspartate shuttle model 244
H ScrumPy code for the Heart Glycolysis model 247
References i
Supplementary Data I
I Suppl. data: Liver TCA cycle models I
I.1 Suppl. data : Model definition for liver TCA model . . . . . . . I
I.2 Suppl. data : Steady-state analysis of liver model . . . . . . . . IX
I.3 Suppl. data : CJ’s for the liver TCA cycle model . . . . . . . . XVIII
I.4 Suppl. data : CS’s for the liver TCA cycle model . . . . . . . . XX
II Suppl. data : Heart TCA cycle prototype XXIII
II.1 Suppl. data : Steady-state analysis of PCko model . . . . . . . XXIII
III Suppl. data: Heart TCA cycle model XXVIII
III.1 Suppl. data : Model definition for heart TCA model . . . . . . XXVIII
Supplementary References XXXV
List of Figures
1. Introduction 1
1.1 A hypothetical reaction scheme illustrating elementary modes and
stoichiometry matrix . . . . . . . . . . . . . . . . . . . . . . . . . . . 12
2. Liver TCA cycle model 18
2.1 Schematic illustrating the TCA cycle reactions in the updated liver
TCA cycle model . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 21
2.2 Schematic illustrating the [Pi] -variation of the updated liver TCA
cycle model . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 27
2.3 Schematic illustrating the reduced version of the updated liver TCA
cycle model . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 30
2.4 Composition of the cyclical test model containing four reactions . . . 31
2.5 Infographics showing the stoichiometric account of net ATP produc-
tion in liver TCA cycle models for – ElMo[5], ElMo[4], ElMo[8], &
ElMo[7] . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 37
2.6 Infographics showing the stoichiometric account of net ATP produc-
tion in liver TCA cycle models for – ElMo[3] & ElMo[2] . . . . . . . . 38
2.7 Infographics showing the stoichiometric account of net ATP produc-
tion in liver TCA cycle models for – ElMo[1], ElMo[6], & ElMo[0] . . 38
2.8 Schematic showing the enzyme subsets for both the liver TCA cycle
models . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 43
2.9 Fluxes for the original & updated liver TCA cycle models, at initial
steady-state. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 46
2.10 A bar graph showing the metabolites for the original & updated
liver TCA cycle models, at initial steady-state . . . . . . . . . . . . . 47
2.11 Graph of ∆ Flux through the individual reaction fluxes between the
two liver TCA cycle models, at steady-state . . . . . . . . . . . . . . 47
2.12 Graph of ∆ Conc. through the individual metabolite concentrations
between the two liver TCA cycle models, at steady-state . . . . . . . 48
2.13 Metabolic status of CoA & its effects on CoA–related metabolites,
against the changes in maximal activities of PDH & ATPsynth . . . 50
2.14 Metabolic status of CoA & its effects on CoA–related metabolites,
against the changes in maximal activities of MC & PC . . . . . . . . 51
2.15 Metabolic status of CoA & its effects on CoA–related metabolites,
against the changes in concentrations of Pim & Pyrm . . . . . . . . . 52
2.16 Metabolic status of CoA & its effect on TCAi’s against the changes
in maximal activities of MC & PC . . . . . . . . . . . . . . . . . . . 55
2.17 Metabolic status of CoA & its effect on the liver TCA cycle fluxes
against the changes in maximal activities of MC & PC . . . . . . . . 56
2.18 A generalised flux distribution pattern observed for liver TCA cycle
models against the increasing maximal activities of MC or PC . . . . 59
2.19 Metabolic status of CoA & its effect on TCAi’s against change in
the concentrations of Pim & Pyrm . . . . . . . . . . . . . . . . . . . 63
2.20 Metabolic status of CoA & its effect on the liver TCA cycle fluxes
against change in the concentrations of Pim & Pyrm . . . . . . . . . 64
2.21 Metabolic status of CoA & its effect on the ATP/ADP-linked reac-
tion fluxes against change in the concentrations of Pim & Pyrm . . . 65
2.22 Variations in the ‘Energy status’ of the liver TCA cycle models:
[ATP/ADP] & [NADH/NAD+] ratios across the increasing maximal
activity of PC . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 68
2.23 Variations in the ‘Energy status’ of the liver TCA cycle models:
[ATP/ADP] & [NADH/NAD+] ratios across the increasing concen-
tration of Pim . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 69
2.24 Variations in the ‘Energy status’ of the liver TCA cycle models: [AT-
P/ADP] & [NADH/NAD+] ratios across increasing concentration
of Pyrm . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 70
2.25 Control of TCA cycle flux in the updated liver TCA cycle model:
against the changing activities of PDH & ATPsynth . . . . . . . . . 74
2.26 Control of flux through IDHa & PC, against the changing PDH
maximal activity . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 77
2.27 Control of flux through MDH & ANT, against the changing PDH
maximal activity . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 78
2.28 Effect of different PC activities on the flux control coefficient of
PDH: plotted against a fixed range of PDH maximal activity . . . . 81
[ a. ] CJ for PDH at different maximal activities of PC
[ b. ] CJ for PDH at PC Vmax = 0.045 mM/sec
[ c. ] CJ for PDH at PC Vmax = 0.45 mM/sec
[ d. ] CJ for PDH at PC Vmax = 4.53 mM/sec
2.29 Effect of different PDH activities on the flux control coefficient of
PDH: plotted against a fixed range of ATPsynth maximal activity . 82
[ a. ] CJ for PDH at different maximal activities of PDH
[b. ] CJ for PDH at PDH Vmax = 0.1 mM/sec
[ c. ] CJ for PDH at PDH Vmax = 0.5 mM/sec
[ d. ] CJ for PDH at PDH Vmax = 2.0 mM/sec
2.30 Effect of different ATPsynth activities on the flux control coefficient
of PDH: plotted against a fixed range of PDH maximal activity . . . 83
[ a. ] CJ for PDH at different maximal activities of ATPsynth
[ b. ] CJ for PDH at ATPsynth Vmax = 0.05 mM/sec
[ c. ] CJ for PDH at ATPsynth Vmax = 0.35 mM/sec
[ d. ] CJ for PDH at ATPsynth Vmax = 5.0 mM/sec
2.31 Dynamic nature of PC apparent maximal activity: against a fixed
range of change in the key enzyme activities or metabolite concs. . . 86
2.32 Control of TCA cycle flux in the PCkd model against the changing
maximal activities of PDH & ATPsynth . . . . . . . . . . . . . . . . 88
2.33 Control of TCA cycle flux in the reduced liver TCA cycle model:
effect of PDH substrate saturation changes . . . . . . . . . . . . . . 90
2.34 Distribution of flux control coefficients in a cyclical test model: effect
of ‘R4’ saturation variations, against the ‘R4’ maximal activity . . . 93
2.35 Distribution of flux control coefficients in a linear test model: effect
of ‘R4’ saturation variations, against the ‘R4’ maximal activity . . . 94
2.36 Flux control distribution for the control of TCA cycle flux, in the
full liver TCA cycle model: with & without the PDH substrate
saturation modifications . . . . . . . . . . . . . . . . . . . . . . . . . 95
2.37 Flux control coefficients for PDH & PC, in the full liver TCA cycle
model: with modifications in the substrate saturation for all enzymes 97
[ a. ] CJ with Kα variations
[ b. ] CJ with Kα,Kβ variations
2.38 Distribution of flux control coefficients calculated for the full liver
TCA cycle model, at a specific value of Kα & Kβ . . . . . . . . . . . 98
[ a. ] CJ with Kα = 1.6 mM
[ b. ] CJ with Kα,Kβ = 1.6 mM
2.39 Control of OAAm & Citm concentrations against the changing
maximal activity of PC . . . . . . . . . . . . . . . . . . . . . . . . . 101
2.40 Control of CoA- & NAD–related metabolites against the changing
maximal activity of PC . . . . . . . . . . . . . . . . . . . . . . . . . 102
2.41 Control of ATP–related metabolites against the changing maximal
activity of PC . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 103
2.42 An overview of the distribution of concentration control coefficients
in the updated liver TCA cycle model . . . . . . . . . . . . . . . . . 105
2.43 An overview of the distribution of elasticity coefficients for the
updated liver TCA cycle model . . . . . . . . . . . . . . . . . . . . . 109
2.44 The connectivity relationships in the updated liver TCA cycle model,
computed at initial steady-state . . . . . . . . . . . . . . . . . . . . . 110
2.45 An overview of the distribution of elasticity coefficients for the
updated liver TCA cycle model, at Kα,Kβ = 1.6 mM . . . . . . . . . 111
3. Heart TCA cycle prototype 122
3.1 Schematic illustrating the TCA cycle reactions in the PCko model . 123
3.2 Schematic showing enzyme subsets for the PCko model . . . . . . . . 125
3.3 Reaction fluxes of PCwt & PCko models, at initial steady-state . . . 126
3.4 TCAi concentrations of PCwt & PCko models, at initial steady-state 127
3.5 Key metabolite ratios in PCwt & PCko, at initial steady-state . . . . 129
3.6 Concentrations of TCAi’s : effect of PC knock-out in comparison
with the PC wild-type . . . . . . . . . . . . . . . . . . . . . . . . . . 131
3.7 TCA cycle fluxes against the changing concentration of Pim : effect
of PC knock-out in comparison with the PC wild-type . . . . . . . . 132
3.8 TCA cycle fluxes against the changing maximal activity of PDH :
effect of PC knock-out in comparison with the PC wild-type . . . . . 133
3.9 Concentrations of TCAi’s in PCko : as ‘percent of PCwt concentra-
tion’ for each metabolite, per dataset . . . . . . . . . . . . . . . . . . 135
3.10 PCko TCA cycle fluxes : as ‘percent of PCwt flux’ for each TCA
cycle reaction flux, per dataset . . . . . . . . . . . . . . . . . . . . . 136
3.11 Variations in the ‘Energy status’ of the liver TCA cycle models:
[ATP/ADP] & [NADH/NAD+] ratios across the increasing concen-
tration of Pim . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 137
3.12 Variations in the ‘Energy status’ of the liver TCA cycle models:
[ATP/ADP] & [NADH/NAD+] ratios across increasing maximal
activity of PDH . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 138
3.13 Control of TCA cycle flux in the ‘PC knock-out’ (PCko) model:
against the PDH maximal activity . . . . . . . . . . . . . . . . . . . 139
4. Heart TCA cycle model 144
4.1 Schematic illustrating the TCA cycle reactions participating in the
heart TCA cycle model . . . . . . . . . . . . . . . . . . . . . . . . . 145
4.3 Infographics showing the stoichiometric account of net ATP produc-
tion for the heart TCA cycle model elementary mode . . . . . . . . . 151
4.4 Graph for the HRTTCA fluxes, at initial steady-state . . . . . . . . . 153
4.5 Graph for the HRTTCA metabolites, at initial steady-state . . . . . . 153
4.6 Comparison of the liver, PCko & heart TCA cycle model TCAi, in
the form of ‘% change in initial values’, at initial steady-state . . . . 155
4.7 The effect of ATPhyd activity variations on the TCAi concentrations,
against the change in ANT maximal activity . . . . . . . . . . . . . 157
4.8 The effect of ATPhyd activity variations on the mitochondrial &
cytosolic adenine nucleotides, against the change in ANT maximal
activity . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 158
4.9 The effect of ATPhyd activity variations on the CoA– & NAD–
related metabolites, against the change in ANT maximal activity . . 159
4.10 The effect of ATPhyd activity variations on the enzyme subset
fluxes, against the change in ANT maximal activity . . . . . . . . . 160
4.11 The effect of PDH activity variations on the TCAi concentrations,
against the change in ANT maximal activity . . . . . . . . . . . . . 162
4.12 The effect of PDH activity variations on the mitochondrial & cy-
tosolic adenine nucleotides, against the change in ANT maximal
activity . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 163
4.13 The effect of PDH activity variations on the CoA– & NAD–related
metabolites, against the change in ANT maximal activity . . . . . . 164
4.14 The effect of pyruvate dehydrogenase activity variations on the
enzyme subset fluxes, against the change in ANT maximal activity . 165
4.15 Variations in the ‘Energy status’ of the heart TCA cycle model:
[ATP/ADP] & [NADH/NAD+] ratios against ATPhyd activity . . . 167
4.16 Variations in the ‘Energy status’ of the heart TCA cycle model:
[ATP/ADP] & [NADH/NAD+] ratios against PDH activity . . . . . 168
4.17 Control of TCA cycle flux in the heart TCA cycle model: against
the changing maximal activities of ANT & ATPhyd . . . . . . . . . 171
4.18 Control of TCA cycle flux in the heart TCA cycle model: against
changing PDH maximal activity & Pim concentration . . . . . . . . 172
4.19 Control of TCA cycle flux in the heart TCA cycle model: against
changing cAdNcsum total & αKGc concentration . . . . . . . . . . . 173
4.20 Distribution of concentration control coefficients calculated for OAA
& Citrate, against the changing maximal activity of ATPhyd . . . . 177
4.21 Distribution of concentration control coefficients calculated for Ac-
CoA & NADH, against the changing maximal activity of ATPhyd . 178
4.22 Distribution of concentration control coefficients calculated for
ATPm & ATPc, against the changing maximal activity of ATPhyd . 179
4.23 Distribution of concentration control coefficients calculated for
Malate, against the changing maximal activity of ATPhyd . . . . . . 180
4.24 An overview of concentration control coefficient distribution in the
heart TCA cycle model . . . . . . . . . . . . . . . . . . . . . . . . . 181
4.25 An overview of the distribution of elasticity coefficients in the heart
TCA cycle model . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 185
4.26 The connectivity relationships in the heart TCA cycle model, com-
puted at initial steady-state . . . . . . . . . . . . . . . . . . . . . . . 186
5. Malate-Aspartate shuttle model 194
5.1 Schematic illustrating the standlone malate-aspartate shuttle model 196
5.2 Schematic illustrating the elementary modes of Malate-Aspartate
shuttle model . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 197
5.3 Control of malate-aspartate shuttle flux in the malate-aspartate
shuttle model: against the changing NADHc concentration . . . . . . 199
6. Heart Glycolysis model 201
6.1 Schematic illustrating the standalone heart glycolysis model . . . . . 203
6.2 Schematic illustrating the enzyme subsets in heart glycolysis model . 207
6.3 Control of glyceraldehyde phosphate dehydrogenase flux in the heart
glycolysis model: against the changing hexokinase activity . . . . . . 209
7. Heart integrated model 210
7.1 Schematic illustrating the heart integrated TCA cycle model . . . . 211
7.2 Schematic illustrating the positive reaction directions heart inte-
grated TCA cycle model . . . . . . . . . . . . . . . . . . . . . . . . . 212
7.3 Schematic illustrating the heart integrated TCA cycle model enzyme
subsets . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 213
7.4 Schematic illustrating the ‘percentage response plot’ at the initial
steady-state of the heart integrated TCA cycle model . . . . . . . . 214
7.5 Schematic illustrating the ‘percentage response plot’ at steady-state,
at 10x ATPhyd activity in the heart integrated TCA cycle model . . 215
Suppl. I. Liver TCA cycle models I
I.1 Metabolic status of CoA & its effect on TCAi concentrations against
the change in maximal activities of MC & PC . . . . . . . . . . . . . IX
I.2 Metabolic status of CoA & its effect on ATP/ADP concentrations
against the change in maximal activities of MC & PC . . . . . . . . X
I.3 Metabolic status of CoA & its effect on NAD+/NADH concentra-
tions against the change in maximal activities of MC & PC . . . . . XI
I.4 Metabolic status of CoA & its effect on key Liver TCA cycle fluxes
against the change in maximal activities of MC & PC . . . . . . . . XII
I.5 Metabolic status of CoA & its effect on TCAi concentrations against
the change in concentrations of Pim & Pyrm . . . . . . . . . . . . . . XIII
I.6 Metabolic status of CoA & its effect on ATP/ ADP concentrations
against the change in concentrations of Pim & Pyrm . . . . . . . . . XIV
I.7 Metabolic status of CoA & its effect on NAD+/ NADH concentra-
tions against the change in concentrations of Pim & Pyrm . . . . . . XV
I.8 Metabolic status of CoA & its effect on key Liver TCA cycle fluxes
against the change in concentrations of Pim & Pyrm . . . . . . . . . XVI
I.9 Metabolic status of CoA & its effect on ATP/ADP-linked fluxes
against the change in concentrations of Pim & Pyrm . . . . . . . . . XVII
I.10 Control of the TCA cycle flux against the change in concentrations
of Pim & Pyrm . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . XVIII
I.11 Control of the TCA cycle flux against the change in maximal activi-
ties of PC & MC . . . . . . . . . . . . . . . . . . . . . . . . . . . . . XIX
I.12 Distribution of concentration control coefficients of αKG & Malate,
against the changing maximal activity of PC . . . . . . . . . . . . . XX
I.13 Distribution of concentration control coefficients of CoA & NAD+,
against the changing maximal activity of PC . . . . . . . . . . . . . XXI
I.14 Distribution of concentration control coefficients of ADPm & ADPc,
against the changing maximal activity of PC . . . . . . . . . . . . . XXII
Suppl. II. Heart TCA cycle prototype XXIII
II.1 Concentrations of TCAi’s: effect of PC knock-out (PCko) in com-
parison with the PC wild-type (PCwt) . . . . . . . . . . . . . . . . . XXIII
II.2 Concentrations of ATP–related metabolites: effect of PC knock-out
(PCko) in comparison with the PC wild-type (PCwt) . . . . . . . . . XXIV
II.3 Concentrations of NAD–related metabolites: effect of PC knock-out
(PCko) in comparison with the PC wild-type (PCwt) . . . . . . . . . XXV
II.4 Concentrations of CoA–related metabolites: effect of PC knock-out
(PCko) in comparison with the PC wild-type (PCwt) . . . . . . . . . XXVI
II.5 Liver TCA cycle fluxes in PCwt & PCko: against changes in Pim
conc. & PDH maximal activity . . . . . . . . . . . . . . . . . . . . . XXVII
List of Tables
2. Liver TCA cycle model 18
2.1 Overview of the liver TCA cycle reactions in the model . . . . . . 24
2.2 Values of TCA cycle variables in liver tissue . . . . . . . . . . . . . 25
2.3 A table showing elementary modes for liver TCA cycle models . . 33
2.4 Elementary mode stoichiometries for liver TCA cycle models . . . 33
2.5 Moiety conservation in liver TCA cycle models . . . . . . . . . . . 34
2.6 Resulting lengths of the elementary modes . . . . . . . . . . . . . 35
2.7 Moiety conservation in the [Pi] variant model . . . . . . . . . . . . 40
2.8 Elementary modes for (Pi) variation of the liver TCA cycle model 40
2.9 Elementary mode stoichiometries for (Pi) variation of the liver
TCA cycle model . . . . . . . . . . . . . . . . . . . . . . . . . . . . 40
2.10 Mapping the elementary modes between the existing and the [Pi]
variant model . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 41
3. Heart TCA cycle prototype 122
3.1 A table showing elementary modes for the PCko model . . . . . . 124
3.2 Elementary mode stoichiometries for the PCko model . . . . . . . 124
4. Heart TCA cycle model 144
4.1 Values of TCA cycle variables in heart tissue . . . . . . . . . . . . 149
4.2 A table showing elementary modes for heart TCA cycle model . . 150
4.3 Moiety conservation in heart TCA cycle model . . . . . . . . . . . 152
4.4 Flux control coefficients computed at the initial steady-state of
the heart TCA cycle model . . . . . . . . . . . . . . . . . . . . . . 185
6. Heart Glycolysis model 201
6.1 Elementary modes for the heart glycolysis model . . . . . . . . . . 206
Suppl. I. Liver TCA cycle models I
I.1 Values of TCA cycle variables in liver tissue . . . . . . . . . . . . . I
I.2 Parameter Values for the Liver TCA cycle model . . . . . . . . . . III
Suppl. III. Heart TCA cycle model XXVIII
III.1 Values of TCA cycle variables in heart tissue . . . . . . . . . . . . XXVIII
III.2 Parameter Values for the Heart TCA cycle model . . . . . . . . . XXIX

Acronyms
α-KGDH . . . . . . . . α-ketoglutarate dehydrogenase
AcCoA . . . . . . . . . Acetyl-CoA
ACS . . . . . . . . . . acetyl-CoA synthetase
ACO . . . . . . . . . . aconitate hydratase
AcCoAm . . . . . . . . . acetyl-CoA
ADP . . . . . . . . . . adenosine diphosphate
ADPc . . . . . . . . . . free cytosolic ADP
ADPm . . . . . . . . . . magnesium-bound mitochondrial ADP
ATPhyd . . . . . . . . . ATP hydrolysis
αKGc . . . . . . . . . . cytosolic α-ketoglutarate
α-KGDH . . . . . . . . α-ketoglutarate dehydrogenase
α-KG exp . . . . . . . . . α-ketoglutarate transporter
αKGm . . . . . . . . . . α-ketoglutarate
αKGm . . . . . . . . . . mitochondrial α-ketoglutarate
ALD . . . . . . . . . . aldolase
AMP . . . . . . . . . . adenosine monophosphate
ANT . . . . . . . . . . adenine-nucleotide translocase
Asp . . . . . . . . . . . aspartate
Aspc . . . . . . . . . . cytosolic aspartate
Aspm . . . . . . . . . . mitochondrial aspartate
ATPsynth . . . . . . . . ATP synthase
ATPc . . . . . . . . . . free cytosolic ATP
ATPm . . . . . . . . . . magnesium-bound mitochondrial ATP
HCO3– . . . . . . . . . bicarbonate
13BPG . . . . . . . . . 1,3-bisphosphoglycerate
Ca2+ . . . . . . . . . . mitochondrial free divalent calcium ions
CO2 . . . . . . . . . . carbon dioxide
CS . . . . . . . . . . . concentration control coefficient
εS . . . . . . . . . . . elasticity coefficient
C J . . . . . . . . . . . flux control coefficient
cGOT . . . . . . . . . . cytosolic glutamate-oxoglutarate transaminase
Citm . . . . . . . . . . citrate
— Ph.D. Thesis by Amar S. Ghaisas — Page A
cMDH . . . . . . . . . cytosolic malate dehydrogenase
CoAm . . . . . . . . . . coenzyme A
CoA . . . . . . . . . . external coenzyme A
CS . . . . . . . . . . . Citrate synthase
CS . . . . . . . . . . . citrate synthase
CSMG . . . . . . . . . Cell Systems Modelling Group
CSMG . . . . . . . . . Cell Systems Modelling Group
cAdNcsum . . . . . . . . conserved total of cytosolic adenine nucleotides
DHAP . . . . . . . . . dihydroxyacetone phosphate
ElMo . . . . . . . . . . elementary modes
ENO . . . . . . . . . . enolase
ESS . . . . . . . . . . . enzyme subsets
ETC . . . . . . . . . . electron transport chain
FAD . . . . . . . . . . flavin adenine dinucleotide (oxidized)
FADH2 . . . . . . . . . flavin adenine dinucleotide (reduced)
FFAs . . . . . . . . . . Free Fatty acids
FM . . . . . . . . . . . fumarate hydratase
F16BP . . . . . . . . . fructose 1,6-bisphosphate
F6P . . . . . . . . . . . fructose 6-phosphate
Fumm . . . . . . . . . . fumarate
GATx . . . . . . . . . . glutamate-aspartate transporter
Glc . . . . . . . . . . . glucose
GlcbL . . . . . . . . . . blood glucose
G6P exp . . . . . . . . . glucose 6-phosphate export
G6Px . . . . . . . . . . glucose 6-phosphate (external)
G6P . . . . . . . . . . glucose 6-phosphate
GLUT4 . . . . . . . . . glucose transporter type 4
Glut . . . . . . . . . . . glutamate
Glutc . . . . . . . . . . cytosolic glutamate
Glutm . . . . . . . . . . mitochondrial glutamate
GAPDH . . . . . . . . . glyceraldehyde phosphate dehydrogenase
GAP . . . . . . . . . . glyceraldehyde 3-phosphate
α-GLYp . . . . . . . . . α-glycerol 3-phosphate
cGPD1 . . . . . . . . . cytosolic α-glycerol phosphate dehydrogenase type 1
HRTGlc . . . . . . . . . heart glycolysis model
HRTTCA+ . . . . . . . . heart integrated TCA cycle model
HRTMAS . . . . . . . . malate-aspartate shuttle model
HRTTCA . . . . . . . . heart TCA cycle model
HK . . . . . . . . . . . hexokinase
OH - . . . . . . . . . . hydroxyl ion
IDH . . . . . . . . . . . Isocitrate dehydrogenase
IDH . . . . . . . . . . . isocitrate dehydrogenase
— Ph.D. Thesis by Amar S. Ghaisas — Page B
IDHa . . . . . . . . . . NAD+ -dependent isocitrate dehydrogenase
IDHb . . . . . . . . . . NADP+ -dependent isocitrate dehydrogenase
Isocitm . . . . . . . . . isocitrate
Lac . . . . . . . . . . . lactate
LacbL . . . . . . . . . . blood lactate
LDH . . . . . . . . . . lactate dehydrogenase
LVRTCA OGI . . . . . . . original liver TCA cycle model
PCkd . . . . . . . . . . “PC knock-down” model
PCko . . . . . . . . . . “PC knock-out” model
PCwt . . . . . . . . . . “PC wild-type” model
LVRTCA UPD . . . . . . . updated liver TCA cycle model
Mg 2+ . . . . . . . . . . mitochondrial free divalent magnesium ions
Malc . . . . . . . . . . cytosolic malate
Malm . . . . . . . . . . malate
Malm . . . . . . . . . . mitochondrial malate
MAS . . . . . . . . . . malate-aspartate shuttle
MC . . . . . . . . . . . malate carrier (malate-phosphate transporter)
MCA . . . . . . . . . . Metabolic Control Analysis
MDH . . . . . . . . . . mitochondrial malate dehydrogenase
mGOT . . . . . . . . . mitochondrial glutamate-oxoglutarate transaminase
mMDH . . . . . . . . . mitochondrial malate dehydrogenase
MCT1 . . . . . . . . . monocarboxylate transporter type 1
MCT1Pm . . . . . . . . monocarboxylate transporter type 1 (cell memb.)
MCT1Mm . . . . . . . . monocarboxylate transporter type 1 (mito. memb.)
MOTx . . . . . . . . . malate-oxoglutarate transporter
NADm+ . . . . . . . . . . nicotinamide adenine dinucleotide (oxidized)
NADc+ . . . . . . . . . . cytosolic nicotinamide adenine dinucleotide (oxidized)
NADm+ . . . . . . . . . . mitochondrial nicotinamide adenine dinucleotide (oxidized)
NADHm . . . . . . . . . nicotinamide adenine dinucleotide (reduced)
NADHc . . . . . . . . . cytosolic nicotinamide adenine dinucleotide (reduced)
NADHm . . . . . . . . . mitochondrial nicotinamide adenine dinucleotide (reduced)
NADP+ . . . . . . . . . nicotinamide adenine dinucleotide phosphate (oxidized)
NADPH . . . . . . . . . nicotinamide adenine dinucleotide phosphate (reduced)
OAAm . . . . . . . . . oxaloacetate
OAAc . . . . . . . . . . cytosolic oxaloacetate
OAAm . . . . . . . . . mitochondrial oxaloacetate
PC . . . . . . . . . . . pyruvate carboxylase
PDH . . . . . . . . . . Pyruvate dehydrogenase
PDH . . . . . . . . . . pyruvate dehydrogenase
PDHK . . . . . . . . . pyruvate dehydrogenase kinase
PDHP . . . . . . . . . pyruvate dehydrogenase phosphatase
PEP . . . . . . . . . . phosphoenolpyruvate
— Ph.D. Thesis by Amar S. Ghaisas — Page C
PFK . . . . . . . . . . phosphofructokinase
PGI . . . . . . . . . . . phosphoglucose isomerase
PGK . . . . . . . . . . phosphoglycerate kinase
PGM . . . . . . . . . . phosphoglycerate mutase
Pi . . . . . . . . . . . . inorganic phosphate
Pic . . . . . . . . . . . cytosolic inorganic phosphate
Pim . . . . . . . . . . . mitochondrial inorganic phosphate
PiHt . . . . . . . . . . Pi-H+ translocator
Pps . . . . . . . . . . . pyruvate, water dikinase (phosphoenolpyruvate synthase)
H+ . . . . . . . . . . . proton
Pyk . . . . . . . . . . . pyruvate kinase
Pyr . . . . . . . . . . . Pyruvate
Pyrm . . . . . . . . . . pyruvate
PyrbL . . . . . . . . . . blood pyruvate
Pyrc . . . . . . . . . . cytosolic pyruvate
PK . . . . . . . . . . . pyruvate kinase
SCoAm . . . . . . . . . succinyl-CoA
SCS . . . . . . . . . . . succinyl-CoA synthetase
SDH . . . . . . . . . . succinate dehydrogenase
Sucm . . . . . . . . . . succinate
TCA . . . . . . . . . . tricarboxylic acid cycle
TCAi . . . . . . . . . . TCA intermediate metabolites
TCAi . . . . . . . . . . TCA cycle intermediate metabolites
3PG . . . . . . . . . . 3-phosphoglycerate
TPI . . . . . . . . . . . triosephosphate isomerase
2PG . . . . . . . . . . 2-phosphoglycerate
QH2 . . . . . . . . . . ubiquinol (reduced)
Q . . . . . . . . . . . . ubiquinone (oxidized)
V PCapp . . . . . . . . . . . apparent maximal activity of PC
H2O . . . . . . . . . . water
— Ph.D. Thesis by Amar S. Ghaisas — Page D

Abstract
This project is in the area of “Computational Biology” or “Systems Biology”. Mathe-
matical modelling is a method to study a biological system using computer-aided tools.
A mathematical model of any biological system consists of a set of biochemical (or
other) reactions – complete with reaction mechanisms, substrate, product, and effector
concentrations, enzyme activities etc., specific to the system. Such models utilize relevant
experimental data as parameters and/or variables in the reaction equations.
In heart, mitochondrial energy metabolism involving utilization of dietary carbo-
hydrates and fats bears a crucial importance for the normal physiological function of
the cardiac muscle. The mammalian liver-specific tricarboxylic acid cycle (TCA) model
developed within the Cell Systems Modelling Group (CSMG) was used to study and
understand the basic functional properties of a tissue-specific TCA cycle model system
and to form a knowledge base. Based on this knowledge, we successfully constructed a
mammalian heart-specific TCA cycle model using heart-specific enzyme kinetics data
from published literature. Analysis of the heart TCA cycle model (HRTTCA) showed that
it needs an input from the malate-aspartate shuttle reactions and therefore a mammalian
heart-specific malate-aspartate shuttle model was built. Analysis of the malate-aspartate
shuttle model revealed that in order to supply the heart TCA cycle with anaplerotic input,
the cytosolic NADH/NAD+ couple must vary dynamically and therefore a glycolysis
model was built. Once, all the models were studied in detail, the three were combined
to form a fully extended model of heart TCA cycle. Structural analysis of the fully
extended model shows that there are more than 278 elementary modes in the extended
model that use different combinations of 37 reactions. Kinetic analysis of the model
shows significant findings that reveal its response to changes in various enzyme activities.
This project will lead to improved understanding of the responses of mammalian
heart mitochondrial metabolism to perturbations such as varying cellular demand for
energy (ATP) and substrates (e.g. Pyruvate (Pyr)). The invaluable addition of Malate
(Mal)-Aspartate (Asp) shuttle reactions as well as glucolysis reactions has hopefully
generated a more physiologically relevant model system. In future, we plan to adapt
the simulation to represent the dynamics of hyperpolarized 13C labelling, using the
experimental data generated with hyperpolarized 13C Pyr as a metabolic tracer. This
enables non-invasive, real-time visualization of the biochemical mechanisms under normal
as well as abnormal conditions.
Chapter 1
Introduction/ Literature Review
1.1 Metabolism
Mitochondria are sub-cellular membrane-enclosed organelles found in most eukaryotic
cells and are responsible for most of cellular energy production. In humans, mitochondria
found in different tissues vary in number and size. Many cells have only a single
mitochondrion, whereas others can contain several thousand mitochondria, e.g. muscle
cells. There are three major types of muscles in the human body – skeletal, smooth,
and cardiac. Skeletal is a voluntary muscle whereas smooth muscle and cardiac are
involuntary. Although functionally, all the three muscle types have significant differences,
all three use the movement of actin against myosin to generate contraction. In skeletal
and smooth muscles, contraction is stimulated by electrical impulses transmitted by
the motor nerves; whereas, in cardiac muscles, internal pacemaker cells initiate the
contractions and propagate the stimuli for contractions to the neighbouring cells they
are in contact with.
In muscle cells, mitochondrial function is vital as muscles require a constant supply
of ATP for their contractile activity (Williamson, 1979). In order to respond quickly to
the changes in stimulus levels, muscle cells effectively utilize the creatine-creatine kinase
(CK) shuttle to buffer the ATP content and this allows rapid regeneration of ATP when
demand spikes up. Muscles also store glucose in the form of glycogen and this enables
sufficient supply of substrates for oxidation when required. In the case of cardiac muscle,
the cellular energetics operates primarily by oxidation of carbohydrates and fatty acids
via the TCA cycle and β-oxidation, respectively (Bing, 1965).
The TCA cycle (also known as - citric acid cycle and Krebs cycle) – is a set of
reactions that is involved in the conversion of acetyl-CoA into CO2 and H2O to generate
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free chemical energy by transferring high-energy electrons to NAD+ to form NADH. In
most eukaryotic organisms, the TCA cycle is of central importance and it occurs in the
mitochondrial matrix. The TCA cycle is fuelled by AcCoAm derived from oxidation
of Free Fatty acids (FFAs) and oxidative decarboxylation of pyruvate. The NADH
produced in the TCA cycle contains high-energy electrons, that are passed on to the
electron acceptor, O2, through a series of redox reactions to generate ATP (Lehninger
et al., 1993).
β-oxidation is a catabolic process by which FFAs are broken down in mitochondria
to generate Acetyl-CoA, which can then enter the TCA cycle. β-oxidation of fatty acids
involves activation of fatty acids in cytosol, transport into mitochondria, and the actual
set of reactions converting fatty acyl-CoA esters to acetyl-CoA (AcCoA) in mitochondria.
Oxidation of fatty acids represents another important source for the generation of ATP
and NADH (Kiens, 2006; Rasmussen and Wolfe, 1999).
These redox reactions occur inside a series of closely associated protein complexes in
the inner mitochondrial membrane (IMM) that constitute the electron transport chain
(ETC). This entire process of generating energy-rich electrons from carbon substrates
by oxidation and passing them on to an electron acceptor through a series of coupled
redox reactions to generate ATP is known as oxidative phosphorylation. According to
the chemiosmotic hypothesis of oxidative phosphorylation proposed by Peter Mitchell in
1966, the energy produced by electrons flowing through the ETC protein complexes is
used to pump protons out of the mitochondria across the IMM and thereby generating
a pH gradient and electrical potential difference across IMM. This resultant electro-
chemical gradient (pH gradient and electrical potential difference) – also referred to
as the protonmotive force (PMF), is utilized by the Fo-F1–ATPase to pump H+ into
the mitochondria, generating ATP in the process through change in its conformation
(Lehninger et al., 1993).
Under certain conditions, protons can re-enter the mitochondrial matrix without
contributing to ATP synthesis. This process is known as proton leak and is due to the
facilitated diffusion of protons into the matrix. The process results in the unharnessed
potential energy of the proton electrochemical gradient being released as heat. In normal
physiology, this phenomenon is primarily found in brown adipose tissue, or brown fat
of new born babies and hibernating animals. The heat generated during this process is
dissipated throughout the body and helps to maintain the core temperature. In muscle
cells, under normal physiological conditions, the proton leak is negligible and can be
safely assumed to be equal to zero. Under certain disease conditions or with exposure to
certain respiratory inhibitors (e.g. 2,4-dinitrophenol), the mitochondrial proton leak may
increase, reducing the total yield of ATP generated under such conditions (Lehninger
et al., 1993).
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1.1.1 Heart mitochondrial metabolism
In this project, we propose to study the properties of mammalian heart mitochondrial
energy metabolism using a mathematical model.
The heart functions as a pump and requires energy to propel sufficient blood through
the vascular system to sustain life. The heart is capable of adjusting its pump performance
to meet various demands by adjusting its elastic and contractile properties and excitation-
contractile coupling. Myocardium is adapted to be highly resistant to fatigue by an
increased number of mitochondria per cell, enabling continuous aerobic respiration via
oxidative phosphorylation, and an enriched blood supply, which provides nutrients and
O2 (Opie, 1998).
Under basal aerobic conditions, 60% of total energy produced is derived from lipids,
35% from carbohydrates, and 5% from amino acids and ketone bodies. However, these
proportions vary widely according to the nutritional state. Since aerobic respiration is
the predominant mode in the myocardium, the total O2 consumption by the myocardium
is a good overall indicator of the metabolic rate. O2 consumption by an organ is usually
expressed as a volume of O2 consumed per 100 g of tissue per minute. During resting
conditions the O2 consumption of the heart is about 8 ml of O2 per 100 g of tissue*min-1
(Neely and Morgan, 1974; Stanley et al., 2005; Taegtmeyer et al., 2005).
The O2 consumption of the heart has implications for cardio-respiratory fitness
and it refers to the ability of the circulatory and respiratory systems to supply oxygen
to skeletal muscles during sustained physical activity. Sustained levels of sufficient O2
consumption can reduce the risk of heart disease, type 2 diabetes, stroke, and other
illnesses.
1.2 Control of TCA cycle
Four major mechanisms mediating regulation of TCA cycle reactions may be considered:
1. Regulation of the dehydrogenase reactions of the TCA cycle by ATP or ADP levels
(LaNoue et al., 1970),
2. Regulation of the dehydrogenase reactions of the TCA cycle by Ca2+ levels (Denton
et al., 1980),
3. Regulation by the oxidation-reduction state of the flavin and pyridine nucleotides
(LaNoue et al., 1970), and
4. Regulation of the transport of TCA intermediate metabolites (TCAi) across the
mitochondrial membrane (LaNoue et al., 1970).
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The major sites in the TCA cycle where feedback control from the respiratory
chain may be exerted are at Pyruvate dehydrogenase (PDH), Citrate synthase (CS),
Isocitrate dehydrogenase (IDH), and α-ketoglutarate dehydrogenase (α-KGDH) (LaNoue
et al., 1970). The feedback control at these reactions is imparted in through the
regulation of mitochondrial NAD+/NADH, ATP/ADP, and AcCoA/CoA ratios and the
concentrations of their substrate and products. Since there are a number of enzyme-
regulatory mechanisms, it is difficult to ascertain the relative contribution of each of
these mechanisms due to their large number and inter-dependence.
The transport of molecules across the inner membrane of mitochondria is controlled
by several small-molecule transporters and carriers. Also, the inner mitochondrial
membrane is impermeable to free carnitine, free CoA and their derivatives (Bremer, 1967;
Brosnan and Fritz, 1971; Garland et al., 1969; Haddock et al., 1970; Oram et al., 1973;
Parsons et al., 1966; Sottocasa et al., 1967; Yates and Garland, 1966), as well as other
low-molecular-weight solutes (Chappell, 1968; Klingenberg, 1970; Klingenberg and Pfaff,
1966; Pfaff et al., 1968; Williamson et al., 1968). In terms of transport of TCAi – adenine-
nucleotide translocase (ANT), malate carrier (malate-phosphate transporter) (MC),
OH --Pyr antiport carrier, Pi-H+ translocator (PiHt), malate-oxoglutarate transporter
(MOTx), and glutamate-aspartate transporter (GATx); are some of the important
transporters which may share a variable amount of control over the rate of TCA cycle,
depending on the physiological conditions (Stryer, 2002).
1.2.1 Anaplerotic reactions
Pyruvate carboxylase (PC) is an anaplerotic reaction in the liver TCA cycle model. The
term, ‘Anaplerosis’ refers to the entry of carbon into the TCA cycle, by routes other
than AcCoAm entry via the citrate synthase (CS) reaction. While, ‘Cataplerosis’ refers
to the exit of carbon from the TCA cycle by routes other than CO2 production (Bowtell
et al., 2007). The expression ‘anaplerotic sequences’ was a term used in biochemistry
by Sir Hans Kornberg (Kornberg, 1966) to describe a series of enzymatic reactions or
pathways that replenish the pools of metabolic intermediates in the TCA cycle (Gibala,
2003; Gibala et al., 2000; Owen et al., 2002). Ambient levels of TCA cycle intermediate
metabolites are controlled by various carboxylation and decarboxylation reactions which
regulate carbon flux into and out of the cycle (Lee and Davis, 1979). Under normal
conditions the cataplerotic removal of TCAi’s is counteracted by anaplerotic processes
so that the absolute concentration of TCAi’s remains constant (Gibala et al., 1997;
Lehninger et al., 1993).
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The first reaction of the TCA cycle, citrate synthase, catalyses the condensation of
oxaloacetate (OAAm) with AcCoAm; the oxaloacetate is subsequently regenerated by
the reactions of the cycle and condenses with another molecule of AcCoAm. However,
in gluconeogenic tissue like liver, TCA cycle also functions in biosynthetic processes
in which TCAi’s are removed from the cycle; which necessitates anaplerotic reactions
to replenish TCAi’s to ensure its continued function. Pyruvate carboxylase, which
synthesizes oxaloacetate from Pyruvate in the mitochondrial matrix, is the archetypical
anaplerotic enzyme. The activity of this enzyme is high in many tissues (e.g. 10–12
units/g of liver); AcCoAm is a positive allosteric regulator of the enzyme. Anaplerosis is
obligatory during both gluconeogenesis (hepatocytes in liver) and lipogenesis (adipocytes
in adipose tissue) when malate (gluconeogenesis) or citrate (lipogenesis) leaves the
mitochondria and is further metabolized to form glucose or fatty acids, respectively
(Owen et al., 2002).
1.2.2 TCA cycle unspanning
Although, the accumulation of TCA cycle intermediate metabolites (TCAi)’s is quite
extreme as seen in the results shown later (see, pg. 55), the peculiar divisioning of the
TCA cycle observed therein calls for a further discussion. In 1970, Randle, England, and
Denton observed a similar sort of division in rat heart TCA cycle, under conditions of
acetate perfusion and since then this property has been referred to as the “unspanning
of TCA cycle”. Owing to this finding, such a scheme of the TCA cycle, which is
physiologically relevant as well, appears to be the polar-opposite of the idealised ‘circular
pathway’ notion used throughout several leading biochemistry textbooks. Indeed, this
may only be of academic importance, but an essential aspect to point out, nonetheless.
Randle et al. suggested that the TCA cycle may operate as two ‘spans’: AcCoAm−→
αKGmit, controlled by citrate synthase, and αKGmit −→ OAAm, controlled by α-
ketoglutarate dehydrogenase. This proposal was brought on by the fact that they
observed accumulation of Citm & αKGm along with transient differences between the
rates of certain TCA cycle reactions during acetate perfusion of rat heart. They also
observed that since acetate increased the concentration of AcCoAm from 40 µM to 400
µM, changes in AcCoAm concentration along with that of CoAm & AMP, brought about
by acetyl-CoA synthetase (ACS), could act as the initiating factors for such unspanning
of the TCA cycle (Randle et al., 1970).
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Therefore, the “unspanning of TCA cycle” is a phenomenon wherein, different TCA
cycle reactions operate at distinctly different rates, in turn resulting in accumulation
of several of the TCAi’s. The unspanning phenomenon permits a redistribution of
carbons between TCAi’s during transition states of heart workload, which does happen
physiologically, and might be expected for other such changes (Achs and Garfinkel, 1977;
Ng et al., 1994; O’Donnell et al., 1998; Peuhkurinen et al., 1983; Randle et al., 1970;
Safer and Williamson, 1973). Furthermore, unspanning of the TCA cycle was shown
in isolated rat heart mitochondria (LaNoue and Williamson, 1971; LaNoue et al., 1970;
LaNoue et al., 1972), in perfused rat heart (Randle et al., 1970; Safer and Williamson,
1973; Safer et al., 1971; Williamson et al., 1973) and in vivo for liver (Jucker et al., 1998).
(LaNoue et al., 1973) Also, and more importantly, from Depre et al. (1999); Griffin
et al. (2000); O’Donnell et al. (1998); Russell and Taegtmeyer (1991), it appears that
anaplerotic reactions like the pyruvate carboxylase or transaminase reactions from the
malate-aspartate shuttle (MAS), may also play a pivotal role in mitochondrial carbon
metabolism by causing the unspanning of the TCA cycle at their respective intersection
points with the TCA cycle through competition for common pools of TCAi’s.
1.2.3 Metabolic homeostasis & TCA cycle
ATP synthesis is a consumer of NADH generated by the cycle, and as such also occupies
a unique position within the system. As discussed by Hofmeyr and Cornish-Bowden,
metabolism can be viewed as a network of functionally discrete supply and demand
blocks, which are linked by common intermediates (Hofmeyr and Cornish-Bowden, 2000).
Metabolic supply-demand analysis (Hofmeyr and Cornish-Bowden, 2000) shows that
in order for supply to efficiently meet changes in demand, while preserving common
intermediates at relatively constant levels far from equilibrium, the demand block controls
the flux through the system whereas the supply block is responsible for maintaining
intermediate concentrations. Furthermore, rather than feedback regulation of allosteric
enzymes being a means of controlling flux, as is often believed to be the case, the
analysis instead indicates that this brings about homeostasis of metabolites. Within the
TCA cycle model, ATP synthesis forms the demand block, whereas the supply block is
represented by the reactions of the cycle. As shown later in the results (see, pg. 74),
the relatively high flux control coefficient of ATP synthesis and minimal coefficients
of enzymes within the cycle, even though some (e.g. IDH and α-KGDH) are highly
regulated and commonly viewed as key rate-controlling enzymes, are therefore in keeping
with this view of metabolic control and regulation.
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1.3 Mathematical modelling
In the Cell Systems Modelling Group, we use ScrumPy, a modelling software written in
the Python programming language and developed in the group (Poolman, 2006). Python
(http://www.python.org/) is a general-purpose, high-level programming language whose
design philosophy emphasizes code readability. ScrumPy provides tools for model
definition, model interrogation as well as data analysis. ScrumPy model files are plain
ASCII files with an extension “.spy".
Using a programming language for the above mentioned activities offers flexibility
in data handling. The model definition and data analysis can be maintained separately
and it yields an easily manageable data structure. It becomes easy to create, append,
modify and read the datasets without having to use any other special tools.
1.3.1 Need for mathematical models
At the system level, the responsiveness of ATP producing reactions is a result of the
total sum of effects caused by several factors, internal as well as external. In effect,
the emergent behaviour of any metabolic system is a function of manifold interactions
between its individual components. Such emergent behaviour is subject to change with
change in the environmental conditions. In order to study the local as well as systemic
effects caused by several factors simultaneously, a well defined quantitative description
of such a system is required. Conventional experimental approaches are often limited
to studying the local effects and prove difficult to be used for studying and analysing
multiple effects simultaneously. Therefore, if a comprehensive view of the quantitative
kinetic behaviour of any metabolic system is to be achieved, reliable mathematical models
representing such a system are essential.
The process of constructing quantitative models of metabolism can help in several
ways:
(i) It can help identify whether the individual components of a system have been
adequately characterized and whether available data are complete and consistent.
(ii) It can be used to qualitatively investigate and compare the model results with that
of the observed behaviour exhibited by the real system.
(iii) It can be utilized to assess the validity of the experimental values for the components’
properties based on whether one can make accurate predictions of the system’s
in vivo responses using those values.
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1.3.2 Model definition and formulation
A detailed mathematical description of any dynamic biological system is called a model.
In a metabolic context, a metabolic model would include a set of balanced biochemical
reactions with details about the proportions of reactants and products in each reaction,
concentrations and constants. A metabolic model is a simplified mathematical represen-
tation of the observed system or process. The term modelling refers to establishing a
formal representation of the system under observation, and the term simulation refers to
the numerical calculations performed using the model. Heinrich and Schuster discuss the
aspects of modelling and theory in biochemistry in great detail (Heinrich and Schuster,
1996).
1.3.2.1 Stoichiometry
The stoichiometry of a reaction expresses the proportions of changes in mole numbers
of the reactants and products involved. Metabolic models consist of more than one
biochemical reaction. A concise way of representing the stoichiometric coefficients is
to compile them in a matrix. In this matrix, the rows correspond to metabolites and
columns correspond to reactions. Such a matrix is called a Stoichiometry matrix. Using
such a model, metabolic pathways can be found, if any, within a metabolic network.
Then, if the routes exist, it is possible to calculate the overall stoichiometries for each
metabolic conversion and to find the most efficient route to produce a certain metabolite.
This has a potential application in genetic engineering, e.g. Genetically modified crops
or genetically modified bacteria producing ethanol.
1.3.2.2 Classification of metabolites
In order to apply the principles of mass conservation in a meaningful way, the distinction
is made between two types of metabolites. Internal metabolites are those metabolites that
are internal to the model and their dynamics can be explained based on the restriction
imposed by the mass conservation relationship. That is, the concentration of an internal
metabolite depends on the difference between the rates of formation and utilization. On
the other hand, External metabolites are those that form the boundaries of the system,
i.e. they participate both in reactions involved in the model and in additional (external)
reactions that are outside the scope of the model. External metabolites are sometimes
also known as source and sink, as they define the points in the system that remain
constant over time acting as a source to generate a metabolite or as a sink to destroy
one.
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1.3.2.3 Rate equations
The rate equation for a chemical reaction is an equation that links the reaction rate with
concentrations of reactants and constant parameters (e.g. rate coefficients and equilibrium
constants). The rate equation is a differential equation, and it can be integrated to obtain
an integrated rate equation that links concentrations of reactants or products with time.
In metabolic models, the rate equations take different forms depending on the nature of
enzyme mechanism. Widely used forms of the rate equations include first order mass
balance rate equations, Michaelis-Menton enzyme kinetics, modified Michaelis-Menton
enzyme kinetics etc.
Equation 1.2 shows a simplified, generic, reversible bi-substrate equation (Chassagnole
et al., 2001b; Rohwer et al., 2006), modified where necessary to account for more than
two substrates and/ or products. Equation 1.2 shows an example of such a simplified
bi-substrate equation for a generic reaction (see, eq. 1.1). Equations of this form are
simple enough to include a limited number of parameters that are easily determined, and
do not require additional explicit assumptions to be made, yet adequately describe the
response of an enzyme to changes in both substrate and product concentrations within
the physiological range (Chassagnole et al., 2001b).
A + B−−⇀↽− P + Q (1.1)
ν =
Vf
[A] · [B]− ( [P] · [Q]Keq
)
KA
(
1 + [P]KP
)
+ [A]
KB
(
1 + [Q]KQ
)
+ [B]
 (1.2)
By default, this equation assumes competitive product inhibition with respect to
the corresponding substrate (e.g. ADP competitive with ATP), and non-competitive
inhibition for unrelated substrate-product pairs in multi-substrate reactions. Additional
effector interactions are also considered when necessary. In all cases, the simplest
expression that adequately represents the key kinetic properties of the enzyme is used.
Throughout the models described in this work, nearly all rate equations are based
on such a simplified bi-substrate equation, as it allowed us to maintain the model
complexity to a bare minimum, while making the models neither too complicated nor
overly simplified.
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1.3.3 Models of TCA cycle
Over the years, several research groups have attempted modelling different aspects of
TCA cycle. Kohn et al. built a TCA cycle model for pyruvate perfused rat heart (Kohn
et al., 1979a,b). Cortassa et al. attempted to study an integrated model of cardiac
mitochondrial energy metabolism that included regulation of TCA cycle dehydrogenases
by calcium (Cortassa et al., 2003). Mogilevskaya et al. studied a kinetic model of the
TCA cycle for the salicylate hepatotoxic effects (Mogilevskaya et al., 2006). Wu et al.
built a TCA cycle model integrated with oxidative phosphorylation and metabolite
transport and also included the aspects of electrophysiology (Wu et al., 2007). Nazaret
et al. investigated the properties of a simplified model of TCA cycle with ATP production
(Nazaret et al., 2009). In CSMG, we are trying to build a heart-specific model of TCA
cycle that attempts to address certain limitations posed by these earlier published models.
1.3.4 Different types of model analyses
Model analysis involves exploring the mathematical model and its response to varying
conditions using mathematical and computer programming tools. Model analysis is
categorized as Structural and Kinetic analysis. The distinction is made at the level of
analysis and not the model because it is the type of analysis and tools used to characterize
the model responses that changes according to aim of study and not the model itself.
1. Structural analysis: The models used for this type of analysis are comparatively
simple in their construction and do not need no more than a reaction list. Such
models require all the metabolic intermediates to be exactly balanced with respect
to their respective rates of formation and utilization at metabolic steady state. In
other words, at steady state, these types of models require all of their intermediate
metabolites to be stoichiometrically balanced and therefore emphasize on stoichiometry.
Apart from the stoichiometry, the other important aspect in these models are the
mass conservation relationships between metabolites. The conservation relationships
between metabolites imply that the temporal change in the concentration of each
metabolite equals the sum of all reaction rates producing that metabolite minus all
reaction rates consuming it. In fact, it is because of the restrictions imposed by the
mass conservation of metabolites that we can express them in terms of meaningful
equations that make the mathematical modelling of metabolic systems possible.
2. Kinetic analysis: A model used for kinetic analysis requires a full kinetic description
of each enzyme or step of the reaction list. Therefore, essentially, all kinetic models
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are structural models containing kinetic details of every reaction. This means that
these models will comprise detailed reaction equations representing the enzyme
reaction mechanism observed in physiology. Such equations consider the effects of
all the substrates, the products, the reverse reaction and any effectors, with all the
corresponding parameters such as the limiting rate and Km values. These kinetic
details are subject to change depending on the experimental conditions, species of
the organism used for experiments, methods etc. Although, obtaining such large
array of information is often a cumbersome task, once utilized appropriately, it can
lead to important predictions with respect to time courses and steady states, as
well as the control distribution, for a wide range of different conditions. In time
course simulations, dynamic changes in concentrations of metabolites are monitored
against time. Time course simulations can help in understanding temporal effects of
perturbations to the system. Steady state simulations show the information related
to the reaction rate and metabolite concentrations, when there is no net flow of
mass in the system. Steady state simulations help in determining the structural
properties of the system. Models used for the kinetic analysis can also be used for
Metabolic Control Analysis (MCA) of the system for determining the different types
of sensitivities associated with individual enzymes, concentrations, and fluxes in the
system.
1.3.4.1 Discussion on the identicalness of elementary modes
For the sake of clarity in this discussion, let us briefly consider a hypothetical system
with r reactions (say, j in number), as shown in fig. 1.1 (see Schuster et al., 2002a, fig.
2.1).
This system comprises internal metabolites (i and k in number), that have variable
concentrations and external metabolites (X and p in number) with fixed concentrations
(i.e. they can act as sinks or sources), for example due to regulated supply. As seen in
fig. 1.1, N denotes the stoichiometry matrix of the system. Many biochemical systems
achieve an asymptotically stable steady-state, in such a way that the vector of reaction
rates, V, fulfils the condition (Reder, 1988; Schilling et al., 1999; Schuster and Hilgetag,
1994; Schuster et al., 2002a; Trinh et al., 2009):
N.V = 0 (1.3)
As shown in the fig. 1.1, rows of N represent the internal metabolite s (ik) only,
as the steady-state condition (eq. 1.3) applies only to the internal metabolite s (Reder,
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X1
X3
r1 r2 r3
r4
i1 i2 X2
em1
em3
em2
( (0     1     -1     01     -1     0     -1N = i1i2
r2 r3 r4r1
• Figure 1.1.
A hypothetical reaction scheme showing elementary modes and stoichiometry matrix.
ik: internal metabolites; Xp: external metabolites; rj: reactions. The reaction with double arrowheads is
assumed to be reversible. Dashed lines denote elementary modes. Let N denote the stoichiometry matrix
of the system. In N, column j denotes reaction j (rj) and row k denotes internal metabolite k (ik).
The value at N(k,j) is a stoichiometric coefficient (α) of ik in reaction rj.
For α:
if, α = +α, reaction rj produces α molecules of ik;
if, α = –α, reaction rj consumes α molecules of ik; and
if, α = 0, reaction rj neither produces nor consumes ik.
1988; Schilling et al., 1999; Schuster and Hilgetag, 1994; Schuster et al., 2002a; Trinh
et al., 2009). This means that the stoichiometry matrix N is independent of the status of
external metabolite s (X). In that case, if we were to internalise, say external metabolite-
X3, then the value of α at N(k,j) is likely to vary due to the change in topology of said
metabolic network∗ and also the elementary mode (em3) would disappear; but the length
of N (total number of rows & columns) would remain constant.
While discussing how the elementary modes could behave if additional reactions are
included, Schuster et al. say that the invariance in elementary modes after additional
reactions are included, only holds, if the status of the metabolites (internal or external)
remains unchanged. If the metabolite status is indeed changed, the modes could vary
in a complicated way (Schuster et al., 2000). Furthermore, Schuster et al. state that
sometimes in simple systems, however, the number of modes does not increase but
some of the modes are increased in length (Schuster et al., 2000). For example, if in an
∗Topology of a metabolic network: Set of enzymes and metabolites, their connections and the
stoichiometry and directionality of the reactions. (see Schuster et al., 1999, Glossary on pg. 2)
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unbranched reaction chain, a reaction removing the product is added and the former
product if now considered as an internal metabolite, the mode representing this pathway
is simply enlarged by one reaction. The system shown in fig. 1.1, is a branched reaction
chain, so although we may not be able to comment on how its modes could behave if an
additional reaction was included, but we can give an example of an additional reaction
removing the product from this system. Reaction r3 and r4 (in forward direction, from
i1 to X3) are two examples of reactions removing the product from the system.
In the study of biochemical systems, generally, such reactions are differentiated from
internal reactions and termed as ‘boundary reactions’. Schuster and Hilgetag, discuss the
properties of boundary reactions, in detail (Schuster and Hilgetag, 1994). They mention
that it is the property of boundary reactions that all the reactants utilised or all the
products formed by such reactions are external (i.e. their concentrations are fixed). In the
example shown in fig. 1.1, reactions r1, r3, and r4 are boundary reactions, while reaction
r2 is internal. Schuster and Hilgetag also mention that this distinction between boundary
reactions & internal reactions can be made by investigating the stoichiometry matrix. In
the stoichiometry matrix, boundary reactions are represented by those columns that only
contain elements of the same sign or zeros, while internal reactions are represented by
columns that contain elements of opposite sign. From the corresponding stoichiometry
matrix of the system shown in fig. 1.1, we can conclude that columns 1, 3, and 4 represent
boundary reactions and 2 represents the only internal reactions in this system.
In theory, it is possible to have same length for two modes and correspondingly,
different overall (net) stoichiometries. From Schuster et al. (2000), consider the case
of inclusion of pyruvate, water dikinase (phosphoenolpyruvate synthase) (Pps) to the
reaction scheme representing a part of monosaccharide metabolism (see, Fig. 1 & Table
1 from Schuster et al.). When this (reversible) enzyme is considered in addition to the
other E.coli enzymes, all the 13 modes, plus eight additional modes are obtained (see
Schuster et al., 2000, Table 2). These eight modes comprise seven modes that coincide
with the seven modes producing pyruvate except that pyruvate kinase (Pyk) is replaced
by Pps in the reverse direction and in the overall stoichiometry, ADP is partially replaced
by AMP plus inorganic phosphate. The eighth additional mode is the futile cycle made
up of Pyk and Pps.
1.3.4.2 Physiological relevance of elementary modes
Before we discuss each elementary modes (ElMo) in detail later on in the results section,
we must keep in mind that they represent idealised situations and a single ElMo may
therefore, represent the cellular physiology, at given initial conditions, in part. Usually,
in living cells, demands are mixed so that the flux distribution specific to that state of
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cellular physiology is a superposition∗ of several modes. However, cellular metabolism
can sustain potentially different flux distributions in response to different environmental
stimuli (Stephanopoulos and Vallino, 1991). For instance, in muscle tissue, post rigorous
exercise, aerobic metabolism is noticeably repressed. This indicates a switch between
markedly different metabolic modes, which are likely to be superpositions of a limited
number of elementary modes. Specific metabolic pathways dominate in certain stress
conditions. For example, catabolic modes predominate during prolonged starvation.
(Schuster et al., 1999, 2000)
1.4 Concepts in metabolic regulation
The ‘regulation’ of an enzyme in a set of reactions is how its activity is increased or
decreased in response to a change in stimulus. Regulation refers to a biological phenomena
of specific alteration of enzyme activity by other molecules or their properties. Enzymes
can be regulated by altering the level of gene transcripts, compartmentalization, effectors,
post-translational modification. Therefore, it can be said that ‘regulation’ implies a
qualitative relationship between enzymes and effectors.
Control, as used in a biological context, is a vague term and unless defined ap-
propriately, may lead to false interpretations. ‘Control’ should be distinguished from
‘regulation’. For example, ‘X controls respiration’, in this report, only means that the
change in the level of X will cause a change in the rate of respiration, and does not
necessarily imply that respiration is regulated by X in vivo. According to Kacser and
Burns, control implies simply a quantitative relationship between components of a system.
To say A controls B means that altering the amount or activity of A causes a change
in the amount or activity of B (Kacser and Burns, 1973). We will follow the same
distinction between these two terms in the discussion to follow.
Metabolic regulation allows the organism to respond optimally to change in its
environment and variations in stimuli levels. Metabolic regulation can be divided further
into intrinsic regulation and extrinsic regulation. In intrinsic regulation, metabolic
pathways appear to self-regulate to respond to changes in levels of substrates and
products, often by means of allosteric regulation of enzyme activities in the pathway.
Extrinsic regulation involves a cell in a multicellular organism altering its metabolism
in response to stimuli from the neighbouring cells. Regulation of glucose metabolism by
insulin is a very well studied example for the extrinsic regulation. Enzyme activity can
∗Linear combination (superposition): Sum of several terms, each of which may be weighted by
an appropriate coefficient. (see Schuster et al., 1999, Glossary on pg. 2)
— Ph.D. Thesis by Amar S. Ghaisas — Page 14
1. Introduction 1.4. Metabolic regulation
also be altered by reversible covalent modification of the enzyme and this mechanism
represents another level of metabolic regulation. The catalytic properties of many
enzymes are markedly altered by the covalent attachment of a modifying moiety, most
commonly a phosphoryl group. ATP serves as the phosphoryl donor in these reactions,
which are catalyzed by protein kinases and on the other hand the removal of the
phosphoryl group is catalyzed by protein phosphatases, thereby altering the enzyme
between active and inactive states. The covalent attachment or removal of the phosphoryl
group causes a conformational change in the enzyme structure and thereby altering its
activity. Activation of PDH by pyruvate dehydrogenase phosphatase (PDP)-mediated
dephosphorylation and inactivation by pyruvate dehydrogenase kinase (PDK)-mediated
phosphorylation is a well understood example of reversible covalent modification of
enzyme activity.
Allosteric regulation is the regulation of an enzyme activity by an effector molecule
binding to the enzyme. Effector molecules that enhance enzyme activity are referred to as
allosteric activators, whereas those that decrease the enzyme activity are called allosteric
inhibitors. Ca2+, Mg2+ are some of the important examples of allosteric activators of
metabolic enzyme activity.
1.4.1 Metabolic Control Analysis
In an attempt to provide a reliable quantitative description of control of metabolic
flux, the theory of ‘Metabolic Control Analysis’ (MCA) arose from two independent
approaches by Kacser and Burns (1973) and Heinrich and Rapoport (1974). MCA is
a form of sensitivity analysis; that is, the magnitude of the effect of small change in a
parameter (such as an enzyme activity) on a metabolic system property (such as the
flux or the concentration of a metabolite) is mathematically related to the properties of
the components of the system (Fell, 1997).
Metabolic Control Analysis attempts to relate the systemic properties of a metabolic
system to the properties of its component parts, in particular, the enzymes. Control
coefficients are the system properties that are at the centre of this theory. These describe
how a variable or property of the system, typically a metabolic flux or the concentration
of a metabolite, will respond to variation of a parameter, typically enzyme concentration.
Thus, MCA defines four types of control coefficients, viz.– flux control coefficient (CJ),
response coefficient, concentration control coefficient (CS) and elasticity coefficient (εS).
For further explanation of control coefficients let us consider the following specimen
pathway:
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X0
xase−−−→
Jxase
S1 → · · ·Y
ydh−−−→
Jydh
S6 · · · → X1
1. Flux Control Coefficient (CJ) : Suppose that if a small change, δExase, is made in
the amount of enzyme Exase, and that this produces a small change, δJydh, in the
steady state pathway flux, J, measured at the step catalyzed by ydh, then the flux
control coefficient, CJydhxase , is defined as:
C
Jydh
xase =
δJydh
δExase
· Exase
Jydh
2. Elasticity Coefficient (εS): Unlike control coefficients, elasticities are properties
of individual enzymes and not of the metabolic system. The elasticity coefficient
for the effect of metabolite S on the velocity υ of enzyme xase is the fractional
change in rate of the isolated enzyme for a fractional change in substrate S, with
all other effectors of the enzyme held constant at their respective values:
εxaseS =
δυxase
δS
· S
υxase
Elasticities have positive values for metabolites that stimulate the rate of a reaction
(substrates, activators) and negative values for those, like products and inhibitors,
that slow the reaction.
3. The summation theorem: When Kacser and Burns first developed MCA, they
found that, if all the enzymes that can affect a particular metabolic flux in a cell
or a metabolic system are taken and the values of their control coefficients on that
flux added up, the sum comes to 1. Thus if we number all the enzymes involved
from 1 to n, then:
CJ1 + CJ2 + · · ·+ CJn = 1
This relationship is known as the summation theorem for flux control coefficients,
and in mathematical notation can be expressed as:
n∑
i=1
CJi = 1
Therefore, the summation theorem shows that the enzymes of the pathway can
share the control of flux. The summation theorem also shows that the flux control
coefficient of an enzyme is a system property. Therefore, the value of a flux control
coefficient cannot be determined by considering the properties of the enzyme in
isolation; the characteristics and amounts of the other enzymes in the metabolic
system will affect the result.
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4. The connectivity theorem: Suppose we choose one pathway metabolite S and find
all the enzymes in the given metabolic system whose rates respond to it; further
suppose that we find there are three and let us lable these enzymes i, j, and k.
The connectivity theorem states that, for each of these enzymes, if we form a term
by taking its flux control coefficient on a particular flux J and multiplying by its
elasticity with respect to S, then the sum of the terms is zero, i.e. :
CJi ε
i
S + CJj ε
j
S + C
J
k ε
k
S = 0
In mathematical notation can be expressed as:
n∑
i=1
CJi ε
i
S = 0
Metabolic Control Analysis shows that neither the degree of displacement of a
reaction from equillibrium nor the relative value of the limiting rate of an enzyme is
a reliable guide to the degree of control an enzyme can exert on a flux and therefore
quantifying these effects in terms of control coefficients is essential for reliable analysis.
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Modification of the existing liver
TCA cycle model
2.1 Overview
The biochemical background of mitochondrial carbon metabolism in mammalian cells
was reviewed in the introductory chapter. Furthermore, the basic techniques involved
in the construction and analysis of kinetic metabolic models were also described in
the introductory chapter. A major objective of this study is to investigate the basic
functional characteristics of the tricarboxylic acid cycle (TCA) and its interactions
with other mitochondrial metabolic pathways, in response to changes in cellular energy
demand at the systemic level, in specific mammalian tissues such as the cardiac or
skeletal muscle; using kinetic as well as structural modelling and analysis techniques.
However, before defining a heart or skeletal muscle-specific TCA cycle model, at the
beginning stages of this project, it was essential to study an existing tissue-specific model,
to understand the basic functional properties of a tissue-specific TCA cycle, as well as
to learn the processes involved in properly defining and analysing such a model. The
mammalian liver-specific tricarboxylic acid cycle model developed within the Cell Systems
Modelling Group (CSMG) was used for this purpose (Brightman et al., 2010, unpublished
manuscript). This model was developed using COPASI (A COmplex PAthway SImulator;
see, http://www.copasi.org/; Hoops et al., 2006), as part of a larger-scale project,
to investigate the systemic consequences of molecular defects in mitochondrial energy
metabolism. For the work described here, the COPASI -based model was manually
converted into a ScrumPy -based model, henceforth referred to as the – Original liver
TCA cycle model (LVRTCAOGI). ScrumPy is a metabolic modelling tool written in
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Python (see, Poolman 2006; also, Poolman et al. 2003, Modelling software, pg.3 ; and
http://www.python.org).
Detailed analysis of this model revealed that CoA–related metabolites were not
conserved within this system, because coenzyme A (CoAm) was defined as a fixed
parameter of the model (external metabolite), instead of being defined as a model
variable (internal metabolite), the value of which would be determined dynamically
at model simulation. Therefore, the ScrumPy -based original liver TCA cycle model
was developed further to include the conservation relationship involving CoAm, acetyl-
CoA (AcCoAm), & succinyl-CoA (SCoAm), by redefining CoAm as a model variable.
Henceforth, this updated model will be referred to as – Updated liver TCA cycle
model (LVRTCAUPD). Just to reiterate, the ‘original’ & the ‘updated’ liver TCA
cycle models differ from each other only in terms of the model definition of coenzyme A;
otherwise, the two models are identical with respect to their individual model definitions.
Although, upon model simulation, such a change in the model definition might cause
some alteration in its dynamic properties; for the purposes of discussing how these models
are defined in terms of their individual reaction rate equations etc., there is absolutely
no need to treat them separately. Therefore, in the following section, we shall discuss
the definition & construction of updated liver TCA cycle model, as a common example.
Section 2.3: Results for the liver TCA cycle models on pg. 32, describes an in-depth
analysis of the plausible differences in the dynamic properties of the two models.
2.2 Methods: Model design and definition
As mentioned earlier, the updated liver TCA cycle model (LVRTCAUPD) representing
the operation of mammalian liver-specific TCA cycle was manually constructed using
ScrumPy. The model in ScrumPy format is available in Appendix C (see, pg. 233) and
is illustrated in fig. 2.1 (see, pg. 21). The final version of the updated model contains 15
reactions and 28 metabolites.
2.2.1 Choice of model design
For any particular mathematical model, its design choices and other design-related
requirements are mainly determined by the specific questions that it aims to address.
The original large-scale project for which the liver TCA cycle model was developed,
required a model of mitochondrial carbon metabolism in a specific mammalian tissue,
in which the individual enzyme rate equations exhibit certain key properties, such as –
enzyme saturation, product inhibition and reversibility (where appropriate); since all
— Ph.D. Thesis by Amar S. Ghaisas — Page 19
2. Liver TCA cycle model 2.2. Methods
of these specific enzyme characteristics are known a priori for their potential effects
on the overall distribution of control in a given metabolic system (Cornish-Bowden
and Cárdenas, 2001; Fell and Sauro, 1985). There are a number of existing models
of mitochondrial energy metabolism that include varying representations of the TCA
cycle (Bazil et al., 2010; Cortassa et al., 2003; Kohn et al., 1979a; Mogilevskaya et al.,
2006; Nazaret et al., 2009; Stucki and Walter, 1972; Tran-Dinh et al., 1997; Wu et al.,
2007; Yugi and Tomita, 2004). However, none of these models both exhibit the scope
and properties required, and operate at appropriate concentrations of mitochondrial
metabolites; which prompted the development of this novel, mammalian liver-specific
model of the TCA cycle in our group. We continued to follow the same modelling strategy
for the development of other models presented as a part of this work.
The liver TCA cycle model is constructed using saturable kinetics to represent 14
out of 15 reactions in the model and most of these processes are assumed to be reversible.
All of these 15 enzyme-catalysed reactions, including those considered to be effectively
irreversible, are modelled considering the effects of product inhibition as well as other
additional effector interactions, as appropriate. Except one reaction, all of the single
substrate/ product processes are assumed to follow a simple uni-uni kinetic model (Segel,
1993). The remaining reactions are represented using the simplified, generic, reversible
bi-substrate equation (Chassagnole et al., 2001b; Rohwer et al., 2006), modified where
necessary to account for more than two substrates and/ or products. Equation 2.2 shows
an example of such a simplified bi-substrate equation for a generic reaction (see, eq. 2.1).
Equations of this form are simple enough to include a limited number of parameters that
are easily determined, and do not require additional explicit assumptions to be made, yet
adequately describe the response of an enzyme to changes in both substrate and product
concentrations within the physiological range (Chassagnole et al., 2001b).
A + B−−⇀↽− P + Q (2.1)
ν =
Vf
[A] · [B]− ( [P] · [Q]Keq
)
KA
(
1 + [P]KP
)
+ [A]
KB
(
1 + [Q]KQ
)
+ [B]
 (2.2)
By default, this equation assumes competitive product inhibition with respect to
the corresponding substrate (e.g. ADP competitive with ATP), and non-competitive
inhibition for unrelated substrate-product pairs in multi-substrate reactions. Additional
effector interactions are also considered when necessary. In all cases, the simplest
expression that adequately represents the key kinetic properties of the enzyme is used.
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2.2.2 Model definition
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• Figure 2.1.
Schematic illustrating the TCA cycle reactions in the updated liver TCA cycle model.
• The original liver TCA cycle model is also defined as illustrated in the above shown schematic, with
the exception of CoAm; which is a fixed parameter (external metabolite) in the original model.
• Internal metabolites: in Black; external metabolites: in Blue; reaction/ enzyme names: in Red .
• Reaction with double arrowheads is assumed to be reversible and reaction with single arrowhead is
assumed to be irreversible.
As illustrated in Figure 2.1, the model includes nine canonical (non-tissue-specific)
TCA cycle reactions including the reaction catalysed by pyruvate dehydrogenase (PDH),
two liver tissue-specific reactions (malate carrier (malate-phosphate transporter) (MC)
& pyruvate carboxylase (PC)), a reaction catalysed by the NADP+ -dependent isocitrate
dehydrogenase (IDHb), and three ATP/ADP–linked reactions that include an abstracted
representation of oxidative phosphorylation, cytosolic ATP hydrolysis (ATPhyd), along
with an adenine-nucleotide exchange with the cytosol catalysed by ANT. The major
outflow from the TCA cycle in liver mitochondria is via malate (Baranyai and Blum, 1989;
Des Rosiers et al., 1995; Rabkin and Blum, 1985) and despite the existence of several
mitochondrial metabolite transporters in liver cells, malate carrier (malate-phosphate
transporter) is the only transporter considered in the model to represent this outflow
(Lehninger, 1977); since other transporter systems, such as the Malate-Aspartate shuttle,
do not achieve a net export of carbon from the cycle.
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In this model , except pyruvate dehydrogenase, NAD+ -dependent isocitrate dehydro-
genase, α-ketoglutarate dehydrogenase, & ATP hydrolysis, all other enzyme-catalysed
steps are modelled using reversible form of the simplified, generic, saturable rate equation.
While, the aforementioned reactions (except ATPhyd) are modelled using the irreversible
form. The ATP hydrolysis reaction is represented using an irreversible, first-order flux.
All other single substrate/ product reactions are assumed to follow a simple uni-uni
kinetic model (Segel, 1993). Table 2.1 (see, pg. 24) gives a brief overview of the liver TCA
cycle reactions. Also, complete details regarding net stoichiometric equations as well as
enzyme rate equations used in the liver TCA cycle model are included in Appendix B
(see eqs. B.1 to B.38 on pgs. 221 to 232, respectively).
The liver TCA cycle model comprises 16 variables that describe the concentrations
of TCA cycle intermediates, and of acetyl-CoA, CoAm, adenine nucleotides, NADm+, &
NADHm. In other words, these 16 metabolites are ‘internal’ to the system described by
the liver TCA cycle model and their respective values are computed at model simulation.
Each of these variables in the model is assigned an initial value, based on literature data.
Also, this model includes 12 parameters that describe fixed quantities of model inputs
(pyruvate & HCO3–), enzyme cofactors (Q/ QH2, NADP+, & NADPH), effectors (Ca2+
& Mg2+), inorganic phosphates (Pim & Pic), and system outputs (CO2 & Malc); i.e.
they are ‘external’ to the system under consideration, since the in vivo processes that
determine these concentrations are beyond its scope.
The updated liver TCA cycle model (LVRTCAUPD) consists of a system of 12 non-
linear ordinary differential equations, each of which describes the evolution of one of the
model variables (concentrations of internal metabolites) over time, from their respective
initial model values. This system also contains 4 algebraic expressions that define the
concentrations of conserved moieties in terms of their total quantities, whereby the total
is a sum all concentrations in a given conservation relationship (e.g. in eq. A.14 on
pg. 220, [ NTot ] is a conserved total of
[
NAD+m
]
& [ NADHm ]). The decision to include
such algebraic expressions in the original COPASI -based model, might have been made
in light of certain limitations in COPASI ∗.
In ScrumPy however, an internal, global parameter (in the form: CSUM_<name>) is
assigned to each of the conserved totals in the model, by default, at model simulation.
∗In COPASI, moieties are the result of stoichiometric analysis and the result of this analysis is not
unique, as it depends on the algorithm chosen (e.g. the Householder reduction method described by
Vallabhajosyula et al., 2006). Therefore, in order to compute the conserved totals in an algorithm-
independent manner, COPASI requires the declaration of a global quantity of type ‘assignment’ (COPASI
project, 2009a). Global quantities with assignment require a mathematical expression to be specified
(which can involve other variable or parameter values from the model) and their value is always the
value of this expression. These assigned quantities could be used as model input/ output only or both
(COPASI project, 2009b). The 4 algebraic expressions in the liver TCA cycle model are actually such
‘globally assigned quantities’ that originated in the COPASI -based version of the model.
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For instance, every conservation relationship described in Results (see tbl. 2.5 on pg. 34)
points to a unique internal parameter generated at model simulation, with a constant
value, for a given conserved total (e.g. CSUM_NAD = 2.1). During model analysis, it is
possible to change the value of these internally generated parameters, without applying
any permanent changes to the model, since they are generated by default at model
simulation. However, the respective algebraic function/ expression for a given conservation
relationship, can not be changed manually in ScrumPy, since it is a direct result of the
structural definition of a given mathematical model. Nonetheless, these manually defined
algebraic expressions (see, eqs. A.13 to A.16 on pg. 220) have been maintained even in
the ScrumPy -based model, since they are more accessible than the internal parameters,
and their value as well as the mathematical expression can both be changed, if necessary.
This model also includes a function that dynamically calculates the apparent maximal
activity of PC (see, eqs. B.3 to B.5 on pg. 222). The non-linear ordinary differential
equations as well as the algebraic expressions used in the liver TCA cycle model are
described in Appendix A (see, eqs. A.1 to A.16 on pg. 220).
The values of the model parameters (kinetic and thermodynamic constants, plus
concentrations of external metabolites and constants describing the total quantities of the
conserved moieties), and the initial concentrations of the variables, were derived almost
exclusively from experimental studies reported in the literature. The main exceptions are
the activities of adenine-nucleotide translocase (ANT), malate carrier (malate-phosphate
transporter) (MC), ATP synthase and ATP hydrolysis, for which satisfactory estimates
were not available. These quantities were fitted to the representative experimental data
taken from a number of sources, using the genetic algorithm for parameter estimation in
COPASI 4.5. Briefly, the representative experimental data was obtained by extensively
surveying the literature for experimental measurements of TCA cycle flux (flux through
CS) and mitochondrial metabolite concentrations in mammalian tissues. For most
metabolites, a range of values, largely from rat liver tissue, were found. However,
fumarate was the only metabolite for which mitochondrial concentration data were not
available. Table 2.2 (see, pg. 25) shows the values of TCA cycle variables (internal
metabolites & key fluxes) in liver tissue taken from the literature and compares them to
corresponding values predicted by the model at initial steady-state. The values of all
the model parameters (external metabolites & kinetic/ thermodynamic constants) are
provided in the supplementary material, in Table I.2 (see, pg. III).
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• Table 2.1. Overview of the liver TCA cycle reactions in the model a
Eqn.
No. Enzyme Inhibitors
h Additional
effectors
Reversibility
in the model
No. of
substrates
B.11 ACO b Isocit –
Reversible
1
B.24 FM b Mal –
B.9 CS c Citrate SCoA i & ATP i
2
B.16 IDHb c αKG & NADPH CO2 l
B.22 SDH d Fum & QH2 OAA p
B.26 MDH d OAA & NADH –
B.28 ANT d ADP & ATPc –
B.34 MC d Pim & Malc –
B.2 PC c OAA, ADP, & Pim AcCoA g & Mg2+ g 3
B.20 SCS c Suc & CoA GTP o & Pim o
B.38 ATPhyd e – –
Irreversible
1
B.13 IDHa f NADH & ATP j ADP k & Ca2+ k 2
B.7 PDH f AcCoA & NADH –
3B.18 α-KGDH f ATPm, SCoA, & NADH n ADP k & Ca2+ k
B.36 ATPsynth f NAD & ATP ATP & Pim
a For further details regarding each enzyme-catalysed reaction, please refer to the detailed account
given in the Appendix B (see, pg. 221).
b A reversible uni-uni rate law is used to represent this step (Segel, 1993).
c The extended, reversible form of the generic rate equation is used to represent this step.
d The simplified, generic, reversible bi-substrate rate equation (see, Equation 2.2 on pg. 20) is used to
represent this step.
e This step is modelled as a simple first-order flux.
f The extended, irreversible form of the generic rate equation is used to represent this step.
g Apparent maximal activity of PC is a function of AcCoA & Mg2+.
h Product inhibition, competitive with respect to corresponding substrate(s); unless stated otherwise.
i Inhibitor, competitive with respect to AcCoA (Shepherd and Garland, 1969; Smith and Williamson,
1971).
j Inhibitor, competitive with respect to NADm+ (Chen and Plaut, 1963; Plaut and Aogaichi, 1968).
k Activator.
l Inhibitor, non-competitive.
m Inhibitor, competitive with respect to αKG (McCormack and Denton, 1979).
n Mixed inhibition with respect to NADm+.
o Competitive binding between GTP & Pi has been reported (Cha and Parks, 1964). Also, ADP and
ATP are substituted for GDP and GTP in the expression, according to (Alberty, 2003b).
p Inhibitor, competitive with respect to succinate (Hatefi and Stiggall, 1976).
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• Table 2.2. Values of TCA
cycle variables in liver tissue taken from the literature and predicted by the model d,e
Fluxes are in units of mmol/sec and concentrations in mM.
Literature Values
Variable
Range Median
Model Values
TCA cycle (CS) flux 0.04 – 0.48 0.24 0.27
PC flux 0.05 – 4.5 0.70 0.82
MDH flux −0.63 – −4.0e-04 −0.07 −0.55
MC flux 0.03 – 1.0 0.34 0.82
[
CoAm
]a 0.31 – 1.93 1.92 1.67[
AcCoAm
]
0.14 – 0.49 0.25 0.35[
Citm
]
1.7 – 5.5 3.73 3.57[
Isocitm
]
0.14 – 0.62 0.15 0.19[
αKGm
]
0.38 – 2.8 1.3 1.34[
Sucm
]
1.5 – b 1.64[
SCoAm
]
0.30 – 1.4 – b 0.68[
Fumm
]
– – b 0.34[
Malm
]
0.23 – 2.5 1.26 1.41[
OAAm
]
4.0e-05 – 2.71e-02 2.26e-03 4.05e-04[
NAD+m
]
0.41 – 1.93 1.25 1.22[
NADHm
]
0.20 – 1.25 0.51 0.88[
ADPm
]
3.11 – 9.0 6.12 3.06[
ATPm
]
3.19 – 13.65 7.64 7.34
Free c
[
ADPc
]
0.04 – 0.20 0.17 0.14
Free c
[
ATPc
]
2.62 – 7.4 4.76 4.67
a In the original liver TCA cycle model, CoAm was a fixed parameter. In the updated liver TCA cycle
model, it has been correctly re-defined as a model variable.
b Fewer than three reported values, hence a median value was not determined.
c Not bound to fixed sites.
d The predicted model values are obtained at steady-state, upon simulating the updated liver TCA
cycle model. These are the same values shown in the analysis of initial steady-state of the model, in
the results section.
e An expanded version of this table, containing details of the source references for the literature data, is
provided in the supplementary material (see, Table I.1 on pg. I).
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2.2.3 Special Cases: Alternative model definitions & other models
Later on, as the different analyses evolved, we were required to construct alternative
variations of the updated liver TCA cycle model, as well as other simple models for
testing purposes. Here, we shall discuss the respective definitions of these custom-built
models. Further details regarding each of these different analyses can be found in the
Section 2.3: Results for the liver TCA cycle models on pg. 32.
2.2.3.1 The [Pi] -variation of the updated liver TCA cycle model
During the elementary modes analysis, we needed to experiment with the the basic
structure of the updated model to validate or reject a specific hypothesis regarding the
possibility of an alternative outcome of this analysis. Here, we describe the specifically
altered structure of the existing updated liver TCA cycle model and full details of its
elementary modes analysis can be found in Results (see, pgs. 39 to 42).
As illustrated in Figure 2.1 (see, pg. 21), the inorganic phosphate metabolites (Pim
& Pic) are defined as ‘external metabolites’ in the existing updated liver TCA cycle
model. From fig. 2.1, we may also note that both these metabolites are involved in at
least two reactions in the model, either as co-substrate(s) or co-product(s) and that these
reactions represent key enzyme-catalysed processes in this system. Our investigation
with the existing model structure revealed that a desired, alternative outcome of the
elementary modes analysis is a distinct possibility if the existing boundary conditions of
the model are extended to include the external inorganic phosphate metabolites (Pim &
Pic) as internal species. Originally, from a modelling standpoint, they were defined as
external metabolites to avoid the additional complexity involved in balancing the total
phosphate content of the system, as well as to maintain the simplified framework of the
model by holding off on all such dynamic interactions that are secondary to the central
liver TCA cycle dynamics (e.g. the effect of mitochondrial free divalent calcium ions
(Ca2+) on TCA cycle dehydrogenases).
From the literature, we know that the total phosphate content of an intact cell
is held essentially constant in a “metabolic homoeostasis” in relation with the varying
energy demands of the cell (Balaban, 2002; Bose et al., 2003; Connett, 1988; From et al.,
1990; Katz et al., 1989a; Korzeniewski et al., 2008). Therefore, to generate this new
structural model, the inorganic phosphate metabolites (Pim & Pic) were redefined as
‘internal metabolites’, as illustrated in Figure 2.2 (see, pg. 27). Internalisation of inorganic
phosphates in this model, forms a new conservation relationship involving the inorganic
phosphates, as shown in tbl. 2.7 (see, pg. 40) from Results.
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Also, for the scope of this experiment, a reaction representing the cytosolic inorganic
phosphate (Pic) influx into the mitochondria via the Pi-H+ translocator (PiHt) was
introduced in the liver TCA cycle model. Cytosolic inorganic phosphate is believed to
enter the mitochondria via a neutral phosphate transporter (PiHt) in exchange for a
hydroxyl ion (OH -) or by co-transport with a proton (H+) (Bose et al., 2003; Chappell
and Crofts, 1966; Chappell and Haarhoff, 1967; Greenbaum and Wilson, 1985; Hoek
et al., 1971; Wohlrab, 1986). However, the OH - efflux or the H+ influx part of the PiHt
reaction was excluded from the model; since in these models, it is implicitly assumed
that water (H2O) and thereby its ionised products (OH - & H+) are present in excess.
Moreover, the OH - & H+ dynamics has not been considered in any of the other liver
TCA cycle reactions as well.
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• Figure 2.2.
Schematic illustrating the [Pi] -variation of the updated liver TCA cycle model.
• Newly added Pi-H+ translocator (PiHt) is shown here against a bluish background.
• #, in Red : Protons (H+) are implicitly assumed to be in excess and therefore their co-transport
via PiHt has not been included in the model.
• ∗, in Red : In this [Pi] variant model, the inorganic phosphate metabolites (Pim & Pic) were
redefined as internal metabolites and therefore shown in Black.
• Other conditions as shown in fig. 2.1 on pg. 21.
However, later on this [Pi] variant model appeared to be kinetically unstable and
could not be readily stabilised. Therefore, due to its kinetic instability, any changes
made to this variation of the updated liver TCA cycle model, were not implemented
during further development towards the Heart TCA cycle model.
— Ph.D. Thesis by Amar S. Ghaisas — Page 27
2. Liver TCA cycle model 2.2. Methods
2.2.3.2 The apparent maximal activity of PC and evolution of the
“PC knock-down” model (PCkd)
As shown in eqs. B.2 to B.5 (see, pg. 222), we know that the updated liver TCA cycle
model comprises a separate algebraic expression that dynamically calculates the apparent
maximal activity of PC, at model simulation. As shown in eq. B.3 (see, pg. 222), the
apparent maximal activity of PC (V PCapp) is modelled as a function of acetyl-CoA & Mg2+
concentrations; where, α is an acetyl-CoA dependent activation term; and β is a Mg2+
dependent activation term. At model simulation, this algebraic expression is evaluated
dynamically and substituted into the rate equation. In other words, unlike the maximal
activity parameters of other enzyme catalysed reactions, V PCapp is a ‘variable’ of the model.
In liver TCA cycle models, Mg2+ is an external metabolite and therefore in the context
of this function, its effect is a constant. The other effector in this function, acetyl-CoA,
is an internal metabolite and its concentration varies significantly with change in enzyme
maximal activity, as shown using the steady-state analysis data in Results (see figs. 2.13
to 2.15 on pgs. 50 to 52, respectively). Therefore, compared to the constant effect of
Mg2+, change in acetyl-CoA concentration could significantly affect the resultant variable
value of PC apparent maximal activity, as well as the net flux through PC.
In Results, the steady-state analysis data shows the dynamically changing concen-
tration of acetyl-CoA against increasing maximal activity of PDH, across consecutive
steady-state solutions of the updated liver TCA cycle model (see fig. 2.13b on pg. 50).
In such a situation, the value of α from eq. B.3 would vary, with respect to a change in
steady-state concentration of acetyl-CoA. As a result, the value of V PCapp would change
as well, thereby causing a change in the pyruvate carboxylase flux. In other words, if a
change in enzyme activity alters the acetyl-CoA concentration, then the activity of that
enzyme is also likely to change the value of V PCapp.
While analysing the complex patterns of flux control coefficient distribution in the
updated liver TCA cycle model (see sec. 2.3.5.2 on pg. 80), we wanted to evaluate the
impact of such dynamic variability in pyruvate carboxylase activity on the distribution
of flux control in liver TCA cycle models. However, before proceeding with any such
analysis, we first had to determine the possible range of V PCapp variability, when key
enzyme activities/ metabolite concentrations are changed in liver TCA cycle models.
Ideally, we wanted to generate a single plot containing all computed variations in the
apparent maximal activity of PC against change in key TCA cycle enzyme activities/
metabolite concentrations. Therefore, in order to generate such a plot, we designed a
specifically-modified Python function, which allowed us to combine all possible variations
of the V PCapp value in a single dataset. In Appendix D (see, pg. 237), we have described
the working of this function in brief, along with the actual code written in Python (see
listing D.1 on pg. 238).
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Negative control condition for the V PCapp variability analysis
Furthermore, to provide a valid negative control for the V PCapp variability analysis, as
well as to show that the value of V PCapp stays constant in the absence of variability in
the acetyl-CoA concentration, we computed the value of PC apparent maximal activity
using a specific control condition.
In this control condition, the updated liver TCA cycle model was modified by redefin-
ing all three CoA–related metabolites (i.e., CoAm, AcCoAm, & SCoAm), as external
metabolites. In this modified control condition model, the CoA–related metabolites
are no longer conserved and their respective concentrations remain constant over time.
Therefore, using this modified system, if the V PCapp value is computed in response to
changes in key enzyme activities/ metabolite concentrations, we expect its value to
remain constant regardless of any perturbation in this system.
As the final output shown in the Results section shows, the V PCapp value computed
under these control conditions, serves as a ‘control value’ against which, the V PCapp
variability seen in the updated liver TCA cycle model can be compared (see, pg. 86).
The “PC knock-down” model (PCkd)
Thus, the V PCapp variability analysis raised an interesting question — does the CJ distri-
bution pattern in the updated liver TCA cycle model differ when the V PCapp value is a
constant against when it is a variable? In order to answer this question, we required a
model system which is nearly identical to the existing one, except for the definition of
V PCapp. The modified control condition model described above, in which all 3 CoA–related
metabolites are defined as external, did not fit these requirements, due to its significantly
altered structural properties.
Hence, as a minor variation of the existing model, we created a test model system,
in which the original algebraic expression describing the V PCapp (see, pg. 222) was replaced
with a constant value of 2.26 mM/sec. This particular value was chosen based on the
following — (a.) in the modified control condition model described above, wherein the
respective concentrations of CoA–related metabolites are kept constant, V PCapp is equal
to 2.26 mM/sec; and (b.) in the existing updated liver TCA cycle model, at initial
conditions, the V PCapp algebraic expression equates to the exact same value and also at
initial steady-state conditions, the V PCapp value is nearly the same (i.e. 2.28 mM/sec).
Therefore in this altered system, apart from this one minor change, everything else,
including the model’s structural properties, remains identical to the updated liver TCA
cycle model system.
Thus, for this altered model, also known as the “PC knock-down” model (PCkd), the
flux control coefficients were computed and subsequently compared with the corresponding
coefficients from the existing updated model (see pgs. 86 to 88).
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2.2.3.3 A reduced version of the updated liver TCA cycle model
While analysing the complex patterns of flux control coefficient distribution in the updated
liver TCA cycle model (see, pg. 88), we wanted to determine which features of these
control distribution patterns might be due to kinetic or thermodynamic characteristics of
the model and which are influenced by the model’s structural characteristics. However,
since the structure of the updated liver TCA cycle model involves branching of the TCA
cycle (see, pgs. 32 and 43), it proved to be quite a complex problem to solve.
Therefore, to eliminate possible effects due to the structural properties of the model,
the control distribution patterns were studied using a reduced version of the model,
consisting of only the 9 canonical TCA cycle reactions, plus PDH (see fig. 2.1 on pg. 21).
In this reduced version, all adenine and nicotinamide nucleotide concentrations (i.e.
ATPm, ADPm, NADm+, & NADHm) were redefined as external metabolites, i.e. their
respective quantities were fixed. By virtue of these modifications, we were able to reduce
this system to contain only two conservation relationships, one involving the 3 CoA–
related metabolites and the other involving all TCA cycle intermediates, except SCoAm.
Thus, the full version of the liver TCA cycle model was successfully scaled down to a
canonical, textbook version of the TCA cycle, which includes PDH as an input reaction.
Figure 2.3 illustrates this reduced version of the updated liver TCA cycle model.
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• Figure 2.3.
Schematic illustrating the reduced version of the updated liver TCA cycle model.
• Other conditions as shown in fig. 2.1 on pg. 21.
• Please note that in this reduced model, all adenine and nicotinamide nucleotide concentrations
are redefined as external metabolites and therefore are shown in Blue.
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2.2.3.4 Simple Test Models
While analysing the complex patterns of flux control coefficient distribution in the updated
liver TCA cycle model (see sec. 2.3.5.3 on pg. 88), we discovered that the substrate-
dependent enzyme saturation is likely to be the most important factor responsible for
the characteristic sigmoidal CJ distribution curves in metabolic systems with saturable
enzyme kinetics. However, we still needed to show whether it is a general property of
all saturable metabolic systems and not just the system described by the updated liver
TCA cycle model.
Therefore, to explore the control properties of some simple models, we built 4-
step simple test models, both linear and cyclical, and containing four reactions in
series, that are based on the simplest, reversible Michaelis-Menton kinetic equations. In
addition, except the input & output reactions comprising the external ‘source’ and ‘sink’
metabolites, all other reactions involve a single substrate/ product interconversions. All
internal as well as external metabolites (‘source’ and ‘sink’ metabolites) are set to unity.
The schematic in fig. 2.4, shows a general composition of a 4-step cyclical model. Using
both the test models, flux control coefficients were computed at different levels of enzyme
saturation. Please refer to Results for further information (see sec. 2.3.5.3 on pg. 88).
S2
R4
S1
S3S4
X4
X3
X1 X2
R1
R2
R3
• Figure 2.4. Composition of the cyclical
test model containing four reactions
• Reactions are: R1 to R4;
• Internal metabolites are: S1 to S4;
• External metabolites are: X1 to X4
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2.3 Results for the liver TCA cycle models
Earlier, in Methods (see, pg. 19), we described the ‘model design & definitions’ for a
couple of liver TCA cycle models as well as other accessory models. In this section,
various kinetic as well as structural properties of the liver TCA cycle models are studied
using various methods of analysis, such as – ‘Elementary modes analysis’, ‘Enzyme
subset analysis’, ‘Steady-state analysis’, ‘Metabolic Control Analysis’, etc. Due to the
large volume of data available for each model, in this section, we will primarily focus on
physiologically significant key findings, in order to present a more thorough discussion of
the presented data.
As shown earlier in Methods (see, pg. 19), there are two liver TCA cycle models,
one that comprises CoA as an external metabolite (original liver TCA cycle model –
LVRTCAOGI) and the other which includes CoA as an internal metabolite (updated liver
TCA cycle model – LVRTCAUPD). Here, we shall present, compare and analyse the
results for both these models. Due to the difference in their respective definitions, the
two models could possibly exhibit different properties and therefore comparing the two
sets of data, could prove beneficial towards the overall understanding of similar dynamic
systems.
Briefly, the following types of results will be presented for each model:
1. Elementary modes analysis (see sec. 2.3.1 on pg. 32)
2. Enzyme subset analysis (see sec. 2.3.2 on pg. 43)
3. Initial steady-state data & Steady-state analysis (see sec. 2.3.3 on pg. 46)
4. Metabolic Control Analysis (MCA) results (see sec. 2.3.5 on pg. 73)
2.3.1 Elementary modes analysis of liver TCA cycle models
Both liver TCA cycle models have 9 possible elementary modes that are identical in
terms of their composition. Elementary modes (ElMo) are presented in tbl. 2.3 (see,
pg. 33) and corresponding elementary mode stoichiometries are presented in tbl. 2.4 (see,
pg. 33); both of which are common between the two models. So, why are the two models
identical with respect to their structural properties?
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Liver TCA cycle reactions ATP/ ADP- linked reactions
Modes PDH CS ACO IDHa IDHb SCS SDH FM MDH MC PC ATPsynth ATPhyd ANT
0 0 0 1.4 -1.4 0 0 0 0 -1 1 1 0.1 0 0
0 0 0 0 0 0 0 0 0 1 -1 -1 0.25 3.5 3.5
1 1 1 0 1 1 1 1 1 1 0 0 0.75 8.5 8.5
1 1 1 1 0 1 1 1 1 1 0 0 1 11 11
1 1 1 0 1 1 1 1 1 0 1 1 0.5 5 5
1 1 1 1 0 1 1 1 1 0 1 1 0.75 7.5 7.5
0 0 0 1 -1 0 0 0 0 0 0 0 0.25 2.5 2.5
0.7 0.7 0.7 0 0.7 0.7 0.7 0.7 0.7 -1 1.7 1.7 0.1 0 0
0.35 0.35 0.35 0.35 0 0.35 0.35 0.35 0.35 -0.75 1.1 1.1 0.075 0 0
α-KGDH
ElMo 0
ElMo 1
ElMo 2
ElMo 3
ElMo 4
ElMo 5
ElMo 6
ElMo 7
ElMo 8
• Table 2.3. A table showing elementary modes for liver TCA cycle models.
• For each mode, fractions have been converted to decimals. • Key: NAD+ -dependent isocitrate
dehydrogenase (IDHa), NADP+ -dependent isocitrate dehydrogenase (IDHb), and malate carrier (MC).
Reactants Products
ElMo2 12 : HCO3
-2 +2 4.52Pic2 +2 Pyrm 820Malc2 +2 4.52Pim
ElMo2 32 : 32CO22 +2 QH22 +2 112Pic 840112Pim2 +2 Pyrm2 +2 Q
ElMo2 62 : NADP+2 +2 2.52Pic 8702.52Pim2 +2 NADPH
ElMo2 72 : 880
2.12CO22 +2 1.72Malc2 +2 1.72Pim
+2 0.72QH22 +2 0.72NADPH
1.72HCO3
-2 +2 0.72NADP+
+2 1.72Pic2 +2 2.42Pyrm2 +2 0.72Q
ElMo2 82 : 890
1.052CO22 +2 1.12Malc
+2 1.12Pim2 +2 0.352QH2
1.12HCO3
-2 +2 1.12Pic
+2 1.452Pyrm2 +2 0.352Q
ElMo2 42 : 850
32CO22 +2 Malc2 +2 QH2
+2 42Pic2 +2 NADPH
42Pim2 +2 HCO3
-2 +2 22Pyrm
+2 NADP+2 +2 Q
ElMo2 02 : Malc2 +2 Pim2 +2 1.42NADP
+ 810
HCO3
-2 +2 1.42NADPH
+2 Pic2 +2 Pyrm
ElMo2 22 : 830
32CO22 +2 NADPH
+2 QH22 +2 8.52Pic
8.52Pim2 +2 Pyrm
+2 NADP+2 +2 Q
ElMo2 52 : 860
6.52Pim2 +2 HCO3
-
+2 22Pyrm2 +2 Q
32CO22 +2 Malc
+2 QH22 +2 6.52Pic
• Table 2.4. Net stoichiometries for elementary modes presented in tbl. 2.3.
• Since the elementary modes for both liver TCA cycle models are identical, a common list of elementary
mode stoichiometries is presented here.
• All metabolites in this table are, by necessity, external in the modelling sense.
• For each net stoichiometric equation, fractions have been converted to decimals.
As seen earlier in the introductory chapter, we know that the stoichiometry matrix
(N) is independent of the status of external metabolites (X) (Reder, 1988; Schilling
et al., 1999; Schuster and Hilgetag, 1994; Schuster et al., 2002a; Trinh et al., 2009).
Moreover, in both liver TCA cycle models, there are equal number of reactions that
either produce (citrate synthase (CS) & succinyl-CoA synthetase (SCS)) or consume
(pyruvate dehydrogenase (PDH) & α-ketoglutarate dehydrogenase (α-KGDH)) CoAm
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and all of these reactions are part of a common “enzyme subset” ∗. We also know that in
resulting elementary modes, all reactions of a given enzyme subset exist in “all-or-none”
fashion (Klamt and Gilles, 2004; Pfeiffer et al., 1999). Therefore, irrespective of whether
CoAm is defined as an internal or an external metabolite in liver TCA cycle models, any
change in the length of the stoichiometry matrix, elementary mode lengths, or mode
stoichiometries between the two models is not feasible.
Having said that, the change in the metabolic status of CoA in liver TCA cycle models
does however affect an important structural property of metabolic systems – the property
of “moiety conservation”. With internalisation of CoA, an additional but necessary
conservation relationship involving CoAm, AcCoAm, & SCoAm is introduced in the
LVRTCAUPD model. Apart from their structural significance, conservation relationships
also affect the kinetic properties of a metabolic system, as they form an inherent
relationship between the constituent metabolite concentrations. Table 2.5 shows the
individual conservation relationships that exist in liver TCA cycle models.
1
2
3
4 --- N.A. ---
Original liver TCA cycle 
model
Updated liver TCA cycle 
model
ATP
c
  :  ADP
c
ATP
c
  :  ADP
c
ATP
m
  :  ADP
m
ATP
m
  :  ADP
m
NADH
m
  :  NAD
m
NADH
m
  :  NAD
m
AcCoA
m
  :  (SCoA
m 
, CoA
m
)
• Table 2.5. Moiety conservation in liver TCA cycle models
Thus, elementary modes analysis of the two liver TCA cycle models shows that
irrespective of the metabolic status of CoA in these models, there is no significant
structural difference between the two; indeed apart from the change in the moiety
conservation of CoA–related metabolites. Hence, the significance may lie in the kinetics
and metabolite concentrations; which shall be discussed later in Section 2.3.3 : Steady-
state analysis of the Liver TCA cycle kinetic models on pg. 46.
∗Enzyme subset analysis results for liver TCA cycle models are discussed on pg. 43.
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2.3.1.1 Properties of the elementary modes for Liver TCA cycle models
Length Modes Non-participating reactions
13 Mode 5
13 Mode 4
12 Mode 8
12 Mode 7
12 Mode 3
12 Mode 2
6 Mode 1
6 Mode 6
6 Mode 0
IDHb & MDH
IDHa & MDH
IDHb, ATPhyd & ANT
IDHa, ATPhyd & ANT
IDHb, MC & PC
IDHa, MC & PC
PDH, CS, ACO, IDHa, IDHb, α-KGDH, SCS, SDH, & FM
PDH, CS, ACO, α-KGDH, SCS, SDH, FM, MDH, MC, & PC
PDH, CS, ACO, α-KGDH, SCS, SDH, FM, ATPhyd, & ANT
• Table 2.6. Resulting lengths of the elementary modes presented in tbl. 2.3.
1st column : total no. of reactions in each ElMo; 3rd column : non-participating reactions in each ElMo.
1. In liver TCA cycle models there are 15 reactions in total. 9 canonical (non-tissue-
specific) reactions, 3 ATP/ADP–linked reactions, 2 liver tissue-specific reactions
(MC & pyruvate carboxylase (PC)), and NADP+ -dependent isocitrate dehydrogenase.
From tbl. 2.6, we can observe that in any given ElMo, the total number of participating
reactions is always less than 15.
2. Except for three ElMos (i.e. ElMo[0], ElMo[6] & ElMo[1]), IDHa & IDHb function in a
mutually exclusive manner (see, tbl. 2.3). In ElMo[0] & ElMo[6], both these reactions
participate and they balance each other by carrying fluxes in opposite directions;
wherein, IDHa works in its forward direction and IDHb acts in its reverse direction.
Whereas, in ElMo[1] both reactions are absent along with most other canonical TCA
cycle reactions.
3. Due to the mutual exclusivity of IDHa & IDHb in liver TCA cycle models, the
remaining six elementary modes can be divided into modes that comprise IDHa
and those that contain IDHb, instead. ElMo[3], ElMo[5] & ElMo[8] are IDHa -
based and ElMo[2], ElMo[4] & ElMo[7] are their respective IDHb -based counterparts.
Functionally, elementary modes that comprise only IDHb produce 2.5 ATPm molecules
fewer than the modes that contain only IDHa; provided that mitochondrial malate
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dehydrogenase (MDH) functions in its respective forward direction. ElMo[7] & ElMo[8]
are two such modes that are inconsistent with this observation as they contain MDH
in its reverse direction.
4. As explained earlier in Methods (see, pg. 19), the mammalian liver-specific TCA cycle
includes additional reactions such as PC & MC; whereas, in mammalian heart as well
as skeletal muscle-specific TCA cycle, the anaplerotic contribution of PC to the total
TCA cycle flux is disputable (Gibala, 2003; Gibala et al., 2000; Owen et al., 2002;
Scrutton and Utter, 1968). Therefore, we may classify the 9 elementary modes of
liver TCA cycle models into 3 separate categories as follows:
4.(a.) ElMo[4], ElMo[5], ElMo[7], & ElMo[8]: Modes that contain all the
canonical TCA cycle reactions along with mammalian liver-specific reactions
(viz.– PC & MC). These modes describe the complete structural aspect of
mammalian liver-specific TCA cycle (see fig. 2.5 on pg. 37).
4.(b.) ElMo[2], & ElMo[3]: Modes that contain only the canonical TCA cycle
reactions and lack the mammalian liver-specific reactions. These modes can
be assumed to describe the structural framework of mammalian heart or
skeletal muscle-specific TCA cycle (see fig. 2.6 on pg. 38).
4.(c.) ElMo[0], ElMo[1], & ElMo[6]: Modes that contain a partial list of reactions,
in this case, only 6 out of possible 15 reactions. These modes describe either
the internal cycles within a system or a particular span of TCA cycle (see
fig. 2.7 on pg. 38).
5. Having said that, we must remember that elementary modes represent certain idealised
situations and therefore, a single elementary mode is only a partial representation
of the cellular physiology, under a given set of initial conditions. Most often, a
superposition of several elementary modes is required to adequately describe the flux
distribution in a specific state of cellular physiology; due to mixed energy demands in
living cells (Schuster et al., 1999, 2000; Stephanopoulos and Vallino, 1991). Therefore
in mathematical models, it is possible that a combination of several elementary modes
is required to explain the kinetic behaviour of a specific steady-state.
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Key:
# of NADH 
produced
Reaction represented in its 
reverse direction
Reaction that does not participate 
in a given elementary mode
1.0
1.0
# of ATPmit 
produced
Mode 5
PDH
PC1.0
CS
IDHa
α-KGDH
SCS
FM
MC
1.0
1.0
1.0
1.0
1.0
1.0
1.0
1.0-1.0
1.0
1.0
1.0
ATPsynth
ATPhyd
ANT7.5
7.5
7.5
7.5
7.5
0.75
MDH0.0
0.0
0.0
Net NADH = 3 Net ATPmit = 7.5
Mode 4
α-KGDH
1.0
PC1.0
PDH
1.0
CS
1.0
SCS
1.0
MDH0.0
0.0
FM
1.0
MC
1.0
IDHb 1.0
-1.0 1.0
0.0
1.0
1.0
5.0
ATPsynth
0.5
ANT5.0
ATPhyd
5.0
5.0
5.0
Net NADH = 2 Net ATPmit = 5
Mode 8
SCS
0.35
FM
0.35
α-KGDH
0.35
IDHa 0.35
CS
0.35
MC
1.1
PC1.1
PDH
0.35
0.35-1.1
0.35
0.35
0.35
MDH0.7
5
-0.75
0.75
ATPsynth
0.075
ANT0.0
ATPhyd
0.0
0.0
0.0
Net NADH = 0.3 Net ATPmit = 0
Mode 7
SCS
0.7
FM
0.7
α-KGDH
0.7
IDHb 0.7
CS
0.7
MC
1.7
PC1.7
PDH
0.7
0.7-1.7
0.0
0.7
0.7
MDH1.0
-1.0
1.0
ATPsynth
0.1
ANT0.0
ATPhyd
0.0
0.0
0.0
Net NADH = 0.4 Net ATPmit = 0
• Figure 2.5.
Infographics showing the stoichiometric account of the net mitochondrial ATPm and
NADHm production for elementary modes of group (a) — the TCA cycle with PC & MC.
• All the liver TCA cycle model reactions are represented in their minimal form. Only the absolutely
essential metabolites & co-factors are included in this diagram.
• In this figure, the arrowheads point towards the respective forward or reverse directions of the
participating reactions, specific to each elementary mode.
• Reactions shown in Red, function in their respective reverse directions. Also, those shown in Grey,
do not participate in that elementary mode. Whereas, reactions shown in light Blue, function in their
respective forward directions.
• For a given elementary mode, numbers within the arrows represent the respective reaction strengths
(see tbl. 2.3 on pg. 33). Also, all reactions that act in the reverse direction are shown using positive
numbers; since, the arrowheads point towards their true direction.
• ATPm is represented by a small Yellow circle and NADHm by a small Orange circle. Numbers within
these circles represent the number of molecules produced by the corresponding reaction. For any reaction,
the production of a metabolite is shown using a positive number and the consumption using a negative
number. For IDHb containing modes, the NADHm production for IDHb is shown to be zero; since, it is a
NADP+ -dependent enzyme.
• Net NADHm production = NADHmPDH + NADHmIDHa + NADHmα-KGDH + NADHmMDH
• Net ATPm production = ATPmATPsynth + ATPmSCS + ATPmPC
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Modes2
NetsNADHs=s3 NetsATPmits=s8.5
α-KGDH
1.0
PC0.0
PDH
1.0
CS
1.0
SCS
1.0
MDH1.0
1.0
FM
1.0
MC
0.0
IDHb 1.0
0.0 1.0
0.0
1.0
1.0
7.5
ATPsynth
0.75
ANT8.5
ATPhyd
8.5
8.5
8.5
Modes3
NetsNADHs=s4 NetsATPmits=s11
α-KGDH
1.0
PC0.0
PDH
1.0
CS
1.0
SCS
1.0
MDH1.0
1.0
FM
1.0
MC
0.0
IDHa 1.0
0.0 1.0
1.0
1.0
1.0
10.0
ATPsynth
1.0
ANT11.0
ATPhyd
11.0
11.0
11.0
• Figure 2.6.
Infographics showing the stoichiometric account of the net mitochondrial ATPm and
NADHm production for elementary modes of group (b) — the canonical TCA cycle.
• Key, symbols and representation as shown in fig. 2.5 on pg. 37.
Moden1
NetnNADHn=n1 NetnATPmitn=n3.5
CS
0.0
α-KGDH
0.0
PC
PDH
0.0
SCS
0.0
MDH1.0
1.0
FM
0.0
MC
IDHa 0.0
0.0
0.0
0.0
0.0
2.5
ATPsynth
0.25
ANT3.5
ATPhyd
3.5
3.5
3.5
1.0
1.0
1.0
Moden6
NetnNADHn=n1 NetnATPmitn=n2.5
α-KGDH
0.0
PC0.0
PDH
0.0
CS
0.0
SCS
0.0
MDH0.0
0.0
FM
0.0
MC
0.0
IDHa 1.0
0.0 0.0
1.0
0.0
0.0
2.5
ATPsynth
0.25
ANT2.5
ATPhyd
2.5
2.5
2.5
IDHb
1.0
Moden0
NetnNADHn=n0.4 NetnATPmitn=n0
1.0
ATPsynth
0.1
ANT0.0
ATPhyd
0.0
0.0
0.0α-KGDH
0.0
PC1.0
PDH
0.0
CS
0.0
SCS
0.0
FM
0.0
MC
1.0
IDHa 1.4
-1.0 0.0
1.4
0.0
0.0
IDHb
1.4
MDH1.0
-1.0
• Figure 2.7. Infographics showing
the stoichiometric account of the net mitochondrial ATPm and NADHm production for
elementary modes of group (c) — subsets of the full set of liver TCA cycle reactions.
• Key, symbols and representation as shown in fig. 2.5 on pg. 37.
As seen in fig. 2.5 (see, pg. 37), ElMo[4] & ElMo[5] lack MDH; whereas, ElMo[7] &
ElMo[8] lack adenine-nucleotide translocase (ANT) & ATP hydrolysis (ATPhyd) but
include MDH, albeit in reverse direction. It means that in liver TCA cycle models, MDH
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can function either in its reverse direction or not at all, provided that PC & MC both
act in their respective forward directions. Other modes of liver TCA cycle models (viz.–
ElMo[1], ElMo[2], & ElMo[3]) show that the converse is also true; that is, for MDH to
function in its forward direction, both PC & MC must act in their respective reverse
directions or not at all. Also, though ElMo[1] shows the possibility of producing external
pyruvate (Pyrm) from external cytosolic malate (Malc); only the net forward reaction of
PC is likely to occur in cells, at physiological concentrations of reactants & products
(Keq = 10.98 unitless; Wood et al., 1966).
In an ideal and physiologically correct representation of the liver TCA cycle, the
required combination of elementary modes must exist in such a fashion, so that the
resultant state of the model should include MDH (in either direction) and PC/ MC
in their respective forward directions. As shown later in fig. 2.18 (see, pg. 59), the
steady-state data for these models show that MDH operates in its reverse direction, PC
& MC in their respective forward directions, and IDHa/ IDHb function as an internal
cycle, balancing each other by carrying fluxes in opposite directions; wherein, IDHa works
in its forward direction and IDHb acts in its reverse direction. Logically, it points towards
2 possible sets of superpositions of individual elementary modes – a set containing ElMo[0]
& ElMo[5]; and another containing ElMo[6] & ElMo[8] (see figs. 2.5 to 2.7 on pgs. 37 to 38,
respectively).
Table 2.6 (see, pg. 35) shows that in liver TCA cycle models, the maximum number of
participating reactions is 13. Thus raising the question that whether the same liver TCA
cycle model can exist in such a way that one or more of its resultant elementary modes
include 14 or even all (i.e. 15) of its possible reactions; where, PC & MC act in their
respective forward directions and MDH functions in either forward or reverse direction?
In other words, could the existing structure of this model be altered in order to meet
all the requirements mentioned earlier? Further investigation with the [Pi] -variation of
the updated liver TCA cycle model described in Methods (see, pg. 26), revealed that
such a structure is a distinct possibility if the existing boundary conditions of the model
are extended to include the external inorganic phosphate metabolites (Pim & Pic) as
internal species.
At least structurally, such a variation of the liver TCA cycle model is worth looking
into; however, later it appeared to be kinetically unstable and could not be readily
stabilised. Internalisation of inorganic phosphates in the model, forms a new conservation
relationship involving the inorganic phosphates (see tbl. 2.7 on pg. 40); which, in effect,
maintains the total phosphate content of the system constant. Table 2.8 (see, pg. 40)
shows the 9 possible elementary modes for such a structural variation of the liver TCA
cycle model and tbl. 2.9 (see, pg. 40) shows the corresponding overall (net) stoichiometries
for the same.
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1
2
3
4
5 --- N.A. ---
Updated liver TCA cycle 
model
[ Pi ] variation of the updated 
model
ATP
c
  :  ADP
c
ATP
c
  :  ADP
c
ATP
m
  :  ADP
m
ATP
m
  :  ADP
m
NADH
m
  :  NAD
m
NAD
m
  :  NADH
m
AcCoA
m
  :  (SCoA
m 
, CoA
m
) CoA
m
  :  (AcCoA
m 
, SCoA
m
)
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m
  :  (ADP
m 
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c 
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c
)
• Table 2.7. Moiety conservation in the [Pi] variant model
Table 2.8 shows that in liver TCA cycle models, if indeed the inorganic phosphate
metabolites (Pim & Pic) are made internal, then 2 out of 9 resulting elementary modes
satisfy the earlier mentioned requirements for an ideal and physiologically correct repre-
sentation of the liver TCA cycle function. Both these modes, viz.– ElMo[0] & ElMo[7],
include 14 out of 16 possible reactions from the [Pi] variation of the liver TCA cycle
model: PC & MC in their respective forward directions, MDH in its respective reverse
direction and all the other 9 canonical TCA cycle reactions along with the 3 ATP/ADP–
linked reactions.
Liver TCA cycle reactions ATP/ ADP- linked reactions
Modes PDH CS ACO IDHa IDHb SCS SDH FM MDH MC PC ATPsynth ATPhyd ANT
4.5 4.5 4.5 4.5 0 4.5 4.5 4.5 4.5 -6.5 11 11 0 1.75 11 11
1 1 1 0 1 1 1 1 1 0 1 1 4 0.5 5 5
0 0 0 1 -1 0 0 0 0 0 0 0 2.5 0.25 2.5 2.5
1 1 1 0 1 1 1 1 1 1 0 0 8.5 0.75 8.5 8.5
1 1 1 1 0 1 1 1 1 0 1 1 6.5 0.75 7.5 7.5
0 0 0 0 0 0 0 0 0 1 -1 -1 4.5 0.25 3.5 3.5
0 0 0 1.8 -1.8 0 0 0 0 -1 1 1 0 0.2 1 1
4.5 4.5 4.5 0 4.5 4.5 4.5 4.5 4.5 -4 8.5 8.5 0 1.25 8.5 8.5
1 1 1 1 0 1 1 1 1 1 0 0 11 1 11 11
α-KGDH PiHt
ElMo 0
ElMo 1
ElMo 2
ElMo 3
ElMo 4
ElMo 5
ElMo 6
ElMo 7
ElMo 8
• Table 2.8. Elementary modes for the [Pi] variation of the liver TCA cycle model.
• Other conditions as shown in tbl. 2.3 on pg. 33. • Key: Pi-H+ translocator (PiHt).
Reactants Products
ElMoA 6A : 970HCO3
-A +A 1.8ANADPHA +A Pyrm MalcA +A 1.8ANADP
+
ElMoA 5A : 960Malc HCO3
-A +A Pyrm
ElMoA 3A : 940PyrmA +A NADP
+A +A Q 3ACO2A +A NADPHA +A QH2
ElMoA 8A : 990PyrmA +A Q 3ACO2A +A QH2
ElMoA 4A : 950HCO3
-A +A 2APyrmA +A Q 3ACO2A +A MalcA +A QH2
ElMoA 2A : 930NADPH NADP+
ElMoA 7A : 980
13.5ACO2A +A 8.5AMalc
+A 4.5AQH2A +A 4.5ANADPH
8.5AHCO3
-A +A 4.5ANADP+
+A13APyrmA +A 4.5AQ
ElMoA 0A : 910
13.5ACO2A +A 11AMalc
+A 4.5AQH2
11AHCO3
-A +A 15.5APyrm
+A 4.5AQ
ElMoA 1A : 920
3ACO2A +A Malc
+A QH2A +A NADPH
HCO3
-A +A 2APyrm
+A NADP+A +A Q
• Table 2.9. Net stoichiometries for elementary modes presented in tbl. 2.8.
• Other conditions as shown in tbl. 2.4 on pg. 33.
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In fact, the 9 resultant elementary modes for the [Pi] variant model shown in tbl. 2.8
are quite similar to the 9 modes of the existing liver TCA cycle model shown in tbl. 2.3
(see, pg. 33), barring a few exceptions. Table 2.10 shows how the two sets of elementary
modes map with reference to each other.
Models Group A Group B
Existing Liver TCA cycle 
model
ElMo 1 ElMo 2 ElMo 3 ElMo 4 ElMo 5 ElMo 6 ElMo 0 ElMo 7 ElMo 8
[Pi] variant of the Liver 
TCA cycle model
ElMo 5 ElMo 3 ElMo 8 ElMo 1 ElMo 4 ElMo 2 ElMo 6 ElMo 7 ElMo 0
• Table 2.10. Mapping the ElMo’s between the existing and the [Pi] variant model.
This table maps out the elementary modes between tbl. 2.3 (see, pg. 33) and tbl. 2.8 (see, pg. 40).
As shown in Table 2.10, all the Group A elementary modes are exactly the same,
except for the inclusion of PiHt, in the [Pi] variant model. Also, all the Group B
elementary modes are exactly the same, except that modes corresponding to the [Pi]
variant model include the involvement of ATPhyd & ANT, with comparatively higher
stoichiometric coefficients than that of the existing model.
In the case of [Pi] variant model, 6 elementary modes that belong to Group A (ElMo[1],
ElMo[2], ElMo[3], ElMo[4], ElMo[5], ElMo[8]), include the PiHt reaction; which in turn
indicates that in these modes, PiHt recycles the additional cytosolic inorganic phosphate
back to the mitochondria. If both MC & PiHt are present in a given mode, as seen in
ElMo[1], ElMo[4] & ElMo[5], then PiHt would import the remaining cytosolic inorganic
phosphate generated by ATPhyd into the mitochondria; since, stoichiometrically, MC
can only exchange a single molecule of cytosolic inorganic phosphate for a molecule of
Malm.
The 3Group B elementary modes of the [Pi] variant model (ElMo[0], ElMo[6], ElMo[7]),
generate approx. 2 to 2.5 times more NADHm & ATPm, compared to corresponding
modes of the existing liver TCA cycle model. This comparison shows that the [Pi]
variant model is capable of producing sufficient ATPm to be transported into cytosol
using ANT and subsequently hydrolysed to ADPc & Pic via ATPhyd; whereas, the
existing liver TCA cycle model produces just enough ATPm to be consumed by PC in
the mitochondria. We believe that this could be a direct effect of the internalisation of
inorganic phosphate metabolites in the [Pi] variant model, since the additional recycling
of inorganic phosphates via PiHt does not occur in these three modes. Although, most
classical hypotheses concerning the regulation of oxidative phosphorylation have now
been proven to be inadequate; the present experimental observations strongly suggest
that among other regulatory factors, the rate of oxidative phosphorylation is kinetically
regulated by the availability of its substrates, NADH, ADP, and Pi in the presence of
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abundant O2 (Balaban, 2002; Erecinska et al., 1977, 1978; From et al., 1990; Katz et al.,
1989a). In this context, as a result of the internalisation of inorganic phosphates in liver
TCA cycle models, a relative increase in the capacity of NADHm & ATPm synthesis, is
therefore a significant structural outcome in the right direction.
Also, from the corresponding stoichiometries shown in tbl. 2.9 (see, pg. 40) we can
observe that external inorganic phosphate metabolites are absent from the net equations
due to their internalisation in the [Pi] variant model, compared to those from tbl. 2.4 (see,
pg. 33). Whereas, tbl. 2.4 shows the lack of recycling for cytosolic inorganic phosphate
in the existing liver TCA cycle model; since it tends to accumulate in the model, in
response to the consumption of its mitochondrial counterpart during ATP synthesis.
Internalisation of inorganic phosphates and the inclusion of PiHt in the [Pi] variant model,
addresses such apparent inconsistencies in the existing liver TCA cycle model by allowing
the excess cytosolic inorganic phosphate to be recycled back to the mitochondria.
Having said that, as already mentioned, due to kinetic instability of the [Pi] variant
model, we decided to consider the existing updated Liver TCA cycle model as a starting
point for further development towards the Heart TCA cycle model.
Table 2.6 (see, pg. 35) shows that in the updated liver TCA cycle model, ElMo[2] &
ElMo[3] lack the mammalian liver-specific reactions and only contain 9 canonical TCA
cycle reactions along with 3 ATP/ADP–linked reactions. In mammalian heart as well as
skeletal muscle tissue, evidence suggests that the anaplerotic contribution of PC to the
total flux through the TCA cycle is insignificant as compared to that in liver (for refs.,
please see earlier). Also, there is very little evidence that would suggest any significant
activity of MC in heart or skeletal muscle tissue (Chappell, 1968; Fiermonte et al., 1999;
Klingenberg, 1970; LaNoue and Schoolwerth, 1979; Palmieri, 1994; Sluse et al., 1971).
Therefore, if we were to isolate these 12 reactions, the resulting structural framework
would appropriately define a mammalian heart or skeletal muscle-specific TCA cycle
model.
ElMo[0] & ElMo[6] contain only a partial list of liver TCA cycle reactions and mostly
describe an internal substrate cycle in which α-ketoglutarate (αKGm) generated by IDHa
is converted back to isocitrate by IDHb. In fact, as we already know from Methods
(see, pg. 19), the NADP+ -dependent isocitrate dehydrogenase was introduced in the
model for the same purpose. This idea is supported based on the original proposal
put forward by Sazanov and Jackson (1994, 1995). Furthermore, conclusive evidence
for the existence of such a cycle has been provided by several studies in both heart
and liver (Ernster and Navazio, 1957; Huang and Colman, 2005; Londesborough and
Dalziel, 1968; McCormack and Denton, 1981; Rutter and Denton, 1988; Sazanov and
Jackson, 1993). Also, Comte et al. (1997, 2002) observed a reverse flux through NADP+
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-dependent isocitrate dehydrogenase under normoxia as well as ischemia in perfused rat
hearts. Therefore, existence of such a substrate cycle in these liver TCA cycle models is
a significant structural outcome.
2.3.2 Enzyme subset analysis of liver TCA cycle models
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Malm
Sucm
Fumm
CS
α-KGDH
MDH
SCS
SDH
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CoAm
CO2
NADHm
NADm
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+
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Q
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• Figure 2.8. Schematic showing the enzyme subsets for both the liver TCA cycle models.
• Internal metabolites: in Black; external metabolites: in Blue; reaction/ enzyme names: in Red .
• Reversible reactions: double arrowheads and irreversible reactions: single arrowhead.
Figure 2.8 shows a common theme for “Enzyme subsets (ESS)” of the two liver
TCA cycle models. Since, the elementary modes (Heinrich and Schuster, 1998; Schilling
et al., 1999; Schuster and Hilgetag, 1994; Schuster et al., 2000, 2002a) as well as enzyme
subsets (Pfeiffer et al., 1999; Poolman et al., 2007; Schuster et al., 2002b) can be readily
calculated from the stoichiometry matrix of a model, it is not entirely unexpected that
the two liver TCA cycle models share identical elementary modes as well as enzyme
subsets.
From Figure 2.8, the following observations can be made to elaborate the significance
of identifying the enzyme subsets of a mathematical model:
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1. ESS #2:
This subset comprises most of the canonical TCA cycle reactions from liver TCA
cycle models, viz.– PDH, CS, aconitate hydratase (ACO), α-KGDH, SCS, succinate
dehydrogenase (SDH), and fumarate hydratase (FM); except for MDH, IDHa, and
IDHb. The latter three act as “independent reactions” and break the subset into
two halves; with the top/ upper-half containing PDH, CS, & ACO and the bottom/
lower-half containing α-KGDH, SCS, SDH, & FM. ‘ESS #2’ can be viewed as a set
of reactions that along with both the independent reactions, allow for the complete
functioning of a generic (tissue non-specific) TCA cycle.
2. ESS #1:
This subset comprises two distant reactions, PC & MC, interrupted by MDH that
acts as an independent reaction.
As seen earlier (see, pgs. 37 and 38), this subset is functional in the forward direction
in ElMo[0], ElMo[4], ElMo[5], ElMo[7] & ElMo[8]; in the reverse direction in ElMo[1];
and is completely absent in ElMo[2], ElMo[3] & ElMo[6].
We have already discussed ElMo[1] earlier at length. In ElMo[0], ElMo[7] & ElMo[8]
‘ESS #1’ operates in the forward direction and MDH acts in its reverse direction,
thus separating PC & MC within ‘ESS #1’. Their net stoichiometries (see, pg. 33)
suggest that ‘ESS #1’ along with MDH working in its reverse direction, futilely adds
anaplerotic carbon into the TCA cycle, only to remove most of it in the form of Malc.
Also, these 3 elementary modes result in zero net production of mitochondrial ATP
(see, pgs. 37 and 38). The significance of ‘ESS #1’, MDH, & ElMo[8] is discussed in
further detail with respect to the steady-state analysis results (see, pgs. 58 to 60).
In contrast, in ElMo[4] & ElMo[5], ‘ESS #1’ participates in the absence of MDH
and thus provides sufficient oxaloacetate (OAAm) for the system to produce the
theoretically maximal amount of mitochondrial ATP possible under these conditions.
As noted earlier, whether we consider the original system represented by liver TCA
cycle models or the [Pi] variant model, it appears that the two reactions that comprise
‘ESS #1’ and the independent reaction – MDH, can not all simultaneously operate in
their respective forward directions in any given elementary mode of the liver TCA
cycle models presented here.
Thus, for the system represented by liver TCA cycle models, structurally, there are 3
viable modes of operation in terms of the combination of ‘ESS #1’ and MDH:
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2.(a.) Futilely add anaplerotic carbon into the TCA cycle via PC and later remove
most of it via MC and reverse acting MDH; as well as effect a suboptimal
production of mitochondrial ATP, as seen in ElMo[7] & ElMo[8] (see fig. 2.5
on pg. 37).
2.(b.) Allow ‘ESS #1’ to function in absence of MDH and consequently result in
the near-to-optimal production of mitochondrial ATP, as seen in ElMo[4] &
ElMo[5] (see fig. 2.5 on pg. 37).
2.(c.) Completely remove the anaplerotic component of the system via deletion
of ‘ESS #1’, thereby converting the system back to its canonical form and
consequently effect a theoretically optimal production of mitochondrial ATP,
as seen in ElMo[2] & ElMo[3] (see fig. 2.6 on pg. 38).
Hence, in liver TCA cycle models, depending on the exact flux distribution of a given
steady-state, a specific superposition (linear combination) of suitable elementary
modes may exist and in that resultant superposition of elementary modes, MDH and
the two ‘ESS #1’ reactions are likely to be operational in one of these 3 possible ways,
as described above.
3. ESS #3:
This enzyme subset includes ANT & ATPhyd, two reactions that share most of their
reactants & products (i.e. ATPm, ADPm, ADPc & ATPc), except of course, Pic, which
is external to the system. Curiously, ATP synthase (ATPsynth), another ATP/ADP–
linked reaction, is excluded from this subset; perhaps, due to its tight coupling with
the 4 NADH -producing dehydrogenases of the TCA cycle.
‘ESS #3’ remains absent in ElMo[0], ElMo[7] & ElMo[8], since their net mitochondrial
ATP production is zero. As seen earlier (see, pg. 45), these are the same modes that
operate with MDH in its reverse direction. On the other hand, corresponding modes
of the [Pi] variant model (ElMo[6], ElMo[7] & ElMo[0]; see tbl. 2.10 on pg. 41), show
both ‘ESS #3’ reactions to be functional, due to the near-to-optimal production
of mitochondrial ATP via ATPsynth, which could be a direct consequence of the
internalisation of the inorganic phosphate metabolites in the system. Interestingly,
such relative increase in the net production of mitochondrial ATP is observed despite
the reversal of MDH in these modes.
In the following sections, we look at the kinetic/ dynamic properties of liver TCA
cycle models and in some cases establish appropriate links with its structural properties
as well.
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2.3.3 Steady-state analysis of the Liver TCA cycle kinetic models
To compare the steady-states of the two liver TCA cycle models, both were solved with
the ‘initially defined’ values of all the parameters & variables presented in Methods (see
tbl. 2.2 on pg. 25 & tbl. I.2 on pg. III in supplementary material).
At first, let us begin by comparing the compositions of “Initial steady-states” for the
two liver TCA cycle models. The reaction fluxes are shown in fig. 2.9 and metabolite
concentrations in fig. 2.10 (see, pg. 47), respectively.
Figures 2.11 and 2.12 (see, pgs. 47 and 48) show the comparison of individual reaction
fluxes (∆ Flux) and metabolite concentrations (∆ Conc.) between the two liver TCA
cycle models at steady-state; with reactions & metabolites arranged in the descending
order of ∆ Flux & ∆ Conc, respectively.
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• Figure 2.9. Fluxes for the LVRTCAOGI & LVRTCAUPD models, at initial steady-state.
• Dark Grey: LVRTCA OGI data; • Red: LVRTCA UPD data
• The difference through the individual reaction fluxes between the two models (∆ Flux) is shown separately
in fig. 2.11 (see, pg. 47).
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• Figure 2.10. A bar graph
showing the metabolites for the LVRTCAOGI & LVRTCAUPD models, at initial steady-state.
• Dark Grey: LVRTCA OGI data; • Blue: LVRTCA UPD data
• In liver TCA cycle models, [oxaloacetate] is in submicromolar range and therefore it is particularly mentioned
in this figure.
• The difference through the individual metabolite concentrations between the two models (∆ Conc.) is
shown separately in fig. 2.12 (see, pg. 48).
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• Figure 2.11. ∆ Flux
through the individual reaction fluxes between the two liver TCA cycle models, at steady-state.
• ∆ Flux, at steady-state = [Value in LVRTCA OGI] − [Value in LVRTCA UPD]
• ‘ESS #1’: Sea Blue; • ‘ESS #3’: Deep Blue; • ‘ESS #2’: Yellow
— Ph.D. Thesis by Amar S. Ghaisas — Page 47
2. Liver TCA cycle model 2.3. Results for the liver TCA cycle . . .
-6E-2  
-4E-2  
-2E-2  
0E+0  
2E-2  
4E-2  
6E-2  
8E-2  
1E-1  
9E-2  
6E-2  
-5E-2  
5E-2  
4E-2  
3E-2  
2E-2  
6E-3  4E-3  
-4E-3  -4E-3  
4E-3  3E-3  2E-3  5E-6  
Δ
 C
o
n
c
. 
(O
ri
g
in
a
l 
–
 U
p
d
a
te
d
) 
(m
M
)
In descending 
order of Δ Conc.
NADHm
SCoAm NADm
+
OAAm
Citm
IsoCitmα-KGmSucm
FummMalmADPm ADPc
ATPcATPm
AcCoAm
• Figure 2.12. ∆ Conc. through the
individual metabolite concentrations between the two liver TCA cycle models, at steady-state.
• CoAm is not included in this figure; since, it is an external metabolite in LVRTCA OGI.
• ∆ Conc., at steady-state = [Value in LVRTCA OGI] − [Value in LVRTCA UPD]
• All metabolites are shown in Blue; except for the conserved pairs. ATPm & ADPm are shown in Yellow;
NADm+ & NADHm are shown in Orange; and ATPc & ADPc are shown in Green.
From figs. 2.9 to 2.12 (see, pgs. 46 to 48), we can observe the following:
1. Between the steady-states of two liver TCA cycle models, the difference in fluxes
(∆ Flux, in mmol/sec) ranges from 3.0e-05 to 6.0e-03; whereas, the difference in
metabolite concentrations (∆ Conc., in mM) ranges from 5.0e-06 to 9.0e-02.
2. The ∆ Flux for 11 out of 15 reactions falls in the range of 2.0e-03 to 6.0e-03 and the
remaining 4 reactions are within a much lower range of 3.0e-05 to 4.0e-04. All ‘ESS
#1’, ‘ESS #2’ reactions, IDHa, & MDH fall under the earlier category; whereas the
‘ESS #3’ reactions, IDHb, & ATPsynth are in the latter category. Since the enzyme
subsets are common between the two liver TCA cycle models, all respective subset
reactions necessarily exhibit the same ∆ Flux value.
3. Three reactions with the largest changes in their fluxes between the two models are –
PC, MC, & MDH. PC & MC have a comparatively larger flux in the original liver
TCA cycle model; whereas, MDH carries a relatively greater flux in the updated
model.
4. The ∆ Conc. for 7 out of 15 metabolites falls in the range of 2.0e-02 to 9.0e-02 and
remaining 8 metabolites are within a lower range of 5.0e-06 to 6.0e-03. SCoAm,
citrate (Citm), ATPm, ADPm, succinate (Sucm), AcCoAm, & αKGm fall under the
earlier category; whereas, malate (Malm), NADm+, NADHm, ATPc, ADPc, isocitrate
(Isocitm), fumarate (Fumm), & OAAm are in the latter category.
5. In the original liver TCA cycle model, relatively higher concentrations of TCA cycle
intermediate metabolites (TCAi) such as, Citm, Sucm, & αKGm, could result from
the continuous supply of external CoA and a comparatively higher flux through PC.
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In the updated liver TCA cycle model, a conserved CoA content and a much lower
flux through PC is likely to limit such increases in TCAi’s.
6. In the updated liver TCA cycle model, a relatively higher flux through MDH translates
to a slightly higher concentration of NADHm, which in turn causes a comparatively
higher concentration of ATPm. Thus, the updated model could possibly produce a
comparatively higher mitochondrial ATP than the original model.
7. As shown earlier in fig. 2.9 (see, pg. 46), MDH functions in its reverse direction in
both models. Also, in both models, IDHa is in the forward direction; whereas, IDHb
in the reverse direction.
8. From the literature, we know that in liver mitochondria, Pyruvate carboxylase flux
apparently ranges from 1.3 to 9.4 times the TCA cycle flux (flux through CS), and is
on average around 3 times the TCA cycle flux (Baranyai and Blum, 1989; Beylot et al.,
1995; Des Rosiers et al., 1995; Di Donato et al., 1993; Magnusson et al., 1991; Rabkin
and Blum, 1985). At steady-state, both liver TCA cycle models are in agreement
with this average value (see, fig. 2.9).
9. Overall, the respective compositions of initial steady-states for the two liver TCA cycle
models are very similar and yet, not identical, unlike their corresponding elementary
modes. Sizeable differences in 2–3 out of 15 possible fluxes give rise to substantial
differences in 6–7 out of 15 possible metabolite concentrations, between the two
models. Therefore, it would be particularly interesting to study whether, across
several different steady-states, such differences in fluxes and metabolite concentrations
between the two models actually translate to significant differences in, for example,
the net ATPm production or the net anaplerotic contribution by PC.
2.3.4 Dynamic responses of the two liver TCA cycle models to the
variations in TCA cycle enzyme activities
Observations made earlier regarding the differences between initial steady-states of the
two liver TCA cycle models, suggest a further analysis of these models to determine
whether these differences are genuine or just an isolated consequence of a particular
set of parameters used. Therefore, in response to variations in the TCA cycle enzyme
activities, successive steady-states of both liver TCA cycle models are analysed in detail.
From this analysis, data for the specific reaction fluxes & metabolite concentrations is
presented here, with an emphasis on the two key aspects that emerge entirely due to the
change in metabolic status of CoA between the two liver TCA cycle models. They are
as follows:
1. Conservation of CoAm, SCoAm, & AcCoAm.
2. Effect of CoAm conservation relationship on rest of the liver TCA cycle system.
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• Figure 2.13. Change in the
metabolic status of CoA between the two liver TCA cycle models: Effect on [AcCoA],
[SCoA] & [CoA] of changes in the maximal activities of PDH & ATPsynth, respectively.
AcCoAm ; CoAm ; SCoAm ; Total CoA content
• The vertical black line represents the initial model value. At this point, in figs. 2.13a and 2.13b,
V PDHmax = 0.648 mM/sec and in figs. 2.13c and 2.13d, V
ATPsynth
max = 0.886637 mM/sec, respectively.
• Total CoA content for LVRTCA OGI = [AcCoAm] + [SCoAm] = variable; & for
LVRTCA UPD = [AcCoAm] + [SCoAm] + [CoAm] = constant = 2.7 mM.
• Since, CoAm is an external metabolite in LVRTCA OGI, it is absent from figs. 2.13a and 2.13c,
unlike in corresponding plots for LVRTCA UPD.
• Note the different Y-axis scales between figs. 2.13a and 2.13c compared with figs. 2.13b and 2.13d,
respectively.
— Ph.D. Thesis by Amar S. Ghaisas — Page 50
2. Liver TCA cycle model 2.3. Results for the liver TCA cycle . . .
-2
 0
 2
 4
 6
 8
 10
 12
 5  10  15  20  25  30  35  40  45  50
C
o
n
ce
n
tr
at
io
n
 (
m
M
)
Malate carrier maximal activity (mM/sec)
Original Liver TCA cycle model - LVRTCA
OGI
2.14.a
-0.5
 0
 0.5
 1
 1.5
 2
 2.5
 3
 5  10  15  20  25  30  35  40  45  50
C
o
n
ce
n
tr
at
io
n
 (
m
M
)
Malate carrier maximal activity (mM/sec)
Updated Liver TCA cycle model - LVRTCA
UPD
2.14.b
-10
 0
 10
 20
 30
 40
 50
 60
 70
 1  2  3  4  5  6  7  8  9  10
C
o
n
ce
n
tr
at
io
n
 (
m
M
)
PC maximal activity (mM/sec)
Original Liver TCA cycle model - LVRTCA
OGI
2.14.c
-0.5
 0
 0.5
 1
 1.5
 2
 2.5
 3
 1  2  3  4  5  6  7  8  9  10
C
o
n
ce
n
tr
at
io
n
 (
m
M
)
PC maximal activity (mM/sec)
Updated Liver TCA cycle model - LVRTCA
UPD
2.14.d
• Figure 2.14. Change
in the metabolic status of CoA between the two liver TCA cycle models: Effect on
[AcCoA], [SCoA] & [CoA] of change in the maximal activities of MC & PC, respectively.
AcCoAm ; CoAm ; SCoAm ; Total CoA content
• The vertical black line represents the initial model value. At this point, in figs. 2.14a and 2.14b,
V MCmax = 23.2574 mM/sec and in figs. 2.14c and 2.14d, V PCmax = 2.26234 mM/sec (apparent velocity),
respectively.
• Note the substantially different Y-axis scales between figs. 2.14a and 2.14c compared with figs. 2.14b
and 2.14d, respectively.
• Other conditions as shown in fig. 2.13 on pg. 50.
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• Figure 2.15. Change
in the metabolic status of CoA between the two liver TCA cycle models: Effect on
[AcCoA], [SCoA] & [CoA] of change in the concentrations of Pim & Pyrm, respectively.
AcCoAm ; CoAm ; SCoAm ; Total CoA content
• The vertical black line represents the initial model value. At this point, in figs. 2.15a and 2.15b,
[Pim] = 8.9 mM and in figs. 2.15c and 2.15d, [Pyrm] = 0.2 mM, respectively.
• Note the substantially different Y-axis scales between figs. 2.15a and 2.15c compared with figs. 2.15b
and 2.15d, respectively.
• Other conditions as shown in fig. 2.13 on pg. 50.
Figures 2.13 to 2.15 (see, pgs. 50 to 52), describe the effect of CoA internalisation on
the steady-state concentrations of CoA–related metabolites against a change in enzyme
activity (Vmax) or metabolite concentration. These figures clearly show a significant
difference in total CoA content of the two liver TCA cycle models. In the original liver
TCA cycle model, which contains CoA as an external metabolite, total CoA content
is a ‘variable’ and varies with the AcCoAm & SCoAm concentrations (see figures, a.
& c. from figs. 2.13 to 2.15). Moreover, in the original model, total CoA content can
vary within a wide range of values due to a constant supply of an external CoA in this
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model. For example, in figs. 2.13a and 2.13c, total CoA content varies between 0.0–7.0
mM; whereas, in fig. 2.14a its value decreases from approx. 8.0 mM to 2.0 mM and in
fig. 2.14c its value drops from almost 65.0 mM to 2.0 mM. On the other hand, in the
updated liver TCA cycle model, which contains CoAm as an internal metabolite, total
CoA content is a ‘constant’ at 2.7 mM; which is due to the conservation relationship
involving CoAm, AcCoAm & SCoAm that arises as a result of the change in metabolic
status of CoA (external) to CoAm (internal).
Therefore, based on the following reasons, we believe that behaviour exhibited by
the Updated liver TCA cycle model is more realistic —
1. Due to the conservation relationship involving CoAm, SCoAm, & AcCoAm, total
CoA content in the updated model remains constant at 2.7 mM; whereas in the
original model, in the absence of such a moiety conservation, it increases to unlikely
levels. In rat liver mitochondria, CoA ranges from 0.3 mM to 2.0 mM (Hansford and
Johnson, 1975; Mogilevskaya et al., 2006; Williamson and Brosnan, 1974; Williamson
and Corkey, 1969; Williamson et al., 1968), AcCoA from 0.1 mM to 1.0 mM (Garland
et al., 1965; McClure and Lardy, 1971; Williamson, 1969; Williamson et al., 1968,
1972), and SCoA from 0.3 mM to 1.4 mM (Hansford and Johnson, 1975; LaNoue et al.,
1972; Mogilevskaya et al., 2006; Smith and Williamson, 1971; Williamson et al., 1972).
Also, the inner mitochondrial membrane is impermeable to free carnitine, free CoA
and their derivatives (Bremer, 1967; Brosnan and Fritz, 1971; Garland et al., 1969;
Haddock et al., 1970; Oram et al., 1973; Parsons et al., 1966; Sottocasa et al., 1967;
Yates and Garland, 1966), as well as other low-molecular-weight solutes (Chappell,
1968; Klingenberg, 1970; Klingenberg and Pfaff, 1966; Pfaff et al., 1968; Williamson
et al., 1968). It means that in vivo, the total mitochondrial CoA content is in limited
supply and remains fairly constant, which is appropriately shown in the updated liver
TCA cycle model by the internalisation of CoA.
2. Although the variation in enzyme activity (Vmax) or metabolite concentration shown
here is above the physiological range, in vivo, it would be particularly unusual for
metabolites such as AcCoAm to vary to the extent it does in the original liver
TCA cycle model. On the other hand, in the updated liver TCA cycle model, such
variations in the CoA–related metabolites are within physiological range, considering
the concentration of AcCoAm in rat liver mitochondria and the fact that the inner
mitochondrial membrane is impermeable to CoA–related metabolites.
Now, let us look at how the internalisation of CoA affects other metabolites and
reaction fluxes.
Note: The relative change in TCAi’s and fluxes is mostly quantitative in nature and
hence presented here as bar graphs. The original steady-state analysis plots are included
in the supplementary material. Details are given in the figures.
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2.16.a. TCA cycle intermediate metabolites (TCAi)
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2.16.b. ATP–related metabolites
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2.16.c. NAD- & CoA–related metabolites
• Figure 2.16. Change in
the metabolic status of CoA between the two liver TCA cycle models: Effect on the
TCAi concentrations against the change in the maximal activities of MC & PC, respectively.
• Combined bar graphs against the change in maximal activities of MC (V MCmax) & PC (V PCmax), for the
change in concentrations of — (a.) TCAi’s, (b.) ATP–related metabolites, and (c.) NAD & CoA–
related metabolites, respectively. 4 different bars represent 4 separate piece of data from 2 liver TCA
cycle models – 2 each for MC & PC.
• Red bars represent the steady-state data for change in V PCmax; whereas, Blue bars show the data for change
in V MCmax. In both colours, darker bars represent the Original liver TCA cycle model (LVRTCA OGI) and lighter
bars represent the Updated liver TCA cycle model (LVRTCA UPD), respectively.
• An average concentration value was calculated for each metabolite from all consecutive steady-state values
per dataset. These were then used in the form of log10 values to generate the actual bar graph. For each
common parameter, i.e., MC or PC; a fold difference was calculated as –
[(avg. conc. in updated model)/(avg. conc. in original model)]
and represented in the graph as –
log10[(avg. conc. in updated model)/(avg. conc. in original model)].
• Blue points represents the log10[Fold difference] w.r.t. the change in V MCmax and Black points represents the
log10[Fold difference] w.r.t. the change in V PCmax. Points in both colours are drawn aligned to the ‘Secondary
Y-axis’.
• Lines in both colours are drawn only to connect two consecutive points, otherwise they do not hold
any significance to the data presented here.
• In each subfigure, the metabolites are arranged in a descending order of log10[Fold difference] values,
calculated for the change in V MCmax.
• Supplementary data for figs. 2.16a, 2.16b and 2.16c is shown in figs. I.1, I.2 and I.3 on pgs. IX
to XI, respectively.
• Figure 2.16c includes the same CoA/ AcCoA/ SCoA data presented earlier in fig. 2.14 on pg. 51.
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• Figure 2.17. Change in the metabolic
status of CoA between the two liver TCA cycle models: Effect on the key liver TCA
cycle reaction fluxes against change in the maximal activities of MC & PC, respectively.
• This is a combined bar graph for change in key liver TCA cycle reaction fluxes against the change
in maximal activities of MC (V MCmax) & PC (V PCmax), respectively. 4 different bars represent 4 separate
piece of data from 2 liver TCA cycle models, 2 each for MC & PC.
• Red bars represent the steady-state data for change in V PCmax; whereas, Blue bars show the data for change
in V MCmax. In both colours, darker bars represent the Original liver TCA cycle model (LVRTCA OGI) and lighter
bars represent the Updated liver TCA cycle model (LVRTCA UPD), respectively.
• An average flux value was calculated for each reaction from all consecutive steady-state values per dataset.
These were then used to generate the actual bar graph. For each common parameter, i.e., MC or PC; a
difference of respective average flux values was calculated between the two liver TCA cycle models and was
termed as ∆ Flux Average (Original − Updated).
• Since, in the case of a reaction flux, the negative sign signifies only the direction taken by a reaction in a
steady-state; in this graph, the average flux value was considered as a positive number for those reactions
that function in their respective reverse directions. All such reactions are denoted by ± .
• X-axis: Key liver TCA cycle reaction fluxes as data categories. These 7 reactions were chosen as
representatives of three enzyme subsets as well as all the independent reactions from liver TCA cycle models.
• Yellow points represents the ∆ Flux Average (Original − Updated) w.r.t. the change in V MCmax and Black
points represents the ∆ Flux Average (Original − Updated) w.r.t. the change in V PCmax. Points in both colours
are drawn aligned to the ‘Secondary Y-axis’. Actual lines are inconsequential.
• Supplementary data shown in fig. I.4 on pg. XII.
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From figs. 2.16 and 2.17 (see, pgs. 55 and 56) following observations can be made:
1. In the updated model, across increasing maximal activity of MC (V MCmax scan), respec-
tive average concentrations of αKGm, Citm, & Isocitm show the largest fold change
in the range of approx. 15 to 40 folds, when compared to the original model (see,
fig. 2.16a). Whereas, other TCAi concentrations show only a moderate increase in
the range of approx. 2 to 6–folds. Noticeably, NADm+ & NADHm levels remain fairly
stable between the two models (see, fig. 2.16c). Compared to the original, ATPc,
ATPm, & SCoAm show a slight decrease (by approx. 0.5–fold) in the updated model
(see, figs. 2.16b and 2.16c). Across the V MCmax scan, the average fold change in all
TCAi concentrations is approx. 7.0–fold w.r.t. the original model. On the other hand,
across increasing maximal activity of PC (V PCmax scan), most TCAi concentrations
in the updated model decrease significantly compared to the original; except for
an increase in ATPc by approx. 3.0–folds (see, fig. 2.16b). As a result, the overall
variation observed in all TCAi’s is quite moderate (approx. 0.75–fold) compared to
that seen in the V MCmax scan.
Across the V MCmax scan, most liver TCA cycle fluxes in the updated model increase
significantly in the range of approx. 3.0 to 6.0–folds relative to the original model;
except for a slight drop in the ATPhyd flux (see, fig. 2.17). The overall fold change
in TCA cycle fluxes is approx. 3.4–fold w.r.t. the original model. On the other hand,
across increasing maximal activity of PC, key liver TCA cycle fluxes in the updated
model decrease significantly compared to the original model; similar to the trend
displayed by most TCAi concentrations. However, in this scan, CS, & ATPsynth
remain nearly constant between the two models. For this scan, similar to TCAi’s,
the average fold change in all TCA cycle fluxes is quite moderate as well (approx.
1.3–fold) compared to that seen in the MC scan.
The log10[Fold difference] values included in these graphs provide a clear indication
of the comparative course taken by the metabolite concentrations and reaction fluxes
between the two liver TCA cycle models.
2. In the case of V PCmax scan, a significant reduction in most TCAi concentrations shows
that the internalisation of CoA brings about a desired change in the updated liver
TCA cycle model, in such a way that the overall TCA cycle metabolite content is
kept relatively close to the physiological range. In this model, the newly established
conservation relationship between CoA–related metabolites forces the system to
maintain its total metabolite content within physiological range, in accordance with
a set of constraints imposed by mass conservation and available external ‘sources’,
in the absence of CoA as an external metabolite. As a result, this model is able to
maintain the total CoA content at a constant value, as well as limit the degree of
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variation in the overall metabolite content of the TCA cycle. Such reduction in the
metabolite concentrations is a result of lower flux through the TCA cycle reactions
and a relatively higher flux through ‘ESS #1’ that constitutes PC & MC. In both
liver TCA cycle models, the flux through ‘ESS #1’ is at least 4 times more than
the TCA cycle flux (flux through CS), as shown in fig. 2.17 (see, pg. 56). In the
updated liver TCA cycle model, for V PCmax scan, most reaction fluxes drop by approx.
0.4–0.9 mmol/sec compared to the original model; except CS & ATPhyd, which tend
to compensate by increasing their flux slightly, especially ATPhyd.
The role of ‘ESS #1’ in varying the overall TCA cycle metabolic content is discussed
at length in the following point.
3. In the case of V MCmax scan, most TCAi concentrations increase significantly in the
updated model as compared to that of the original. In liver TCA cycle models,
although MC & PC constitute ‘ESS #1’; intrinsically their roles differ in that, PC
introduces the anaplerotic carbon into the TCA cycle and MC transports that carbon
into the cytosol in a 1:1 exchange with Pic to the mitochondria. More importantly,
there are 2 reactions in these models that introduce carbon into the TCA cycle, viz.–
PDH & PC; whereas, only a single reaction, i.e. MC, which removes that carbon
from the TCA cycle. Therefore, increase in V MCmax causes the MC flux to increase, thus
removing the TCA cycle carbon at a higher rate and imposing an enhanced demand
on the two input reactions (viz.– PDH & PC) to maintain TCA cycle homoeostasis
by increasing their flux.
As seen earlier, fig. 2.17 (see, pg. 56) shows that in liver TCA cycle models, the TCA
cycle flux is approx. 1/4th the flux through PC. Also, MDH functions in its reverse
direction and is approx. 3 times the TCA cycle flux; which means that a large portion
of the TCA cycle carbon is routed via: PC→ MDH (reverse)→ MC ; and only a smaller
fraction of the TCA cycle carbon comes from the rest of TCA cycle to MC. This
idea is supported further on the basis of elasticity coefficients of the updated liver
TCA cycle model (see, pg. 108). It is likely that both these factors along with the
conservation of CoA–related metabolites, would cause the observed build-up of most
TCAi’s in the updated liver TCA cycle model, despite the increased demand set by
MC. Figure 2.18 (see, pg. 59) describes the aforementioned flux distribution pattern
using the approximated flux data from fig. 2.17 and the enzyme subsets from fig. 2.8
(see, pg. 43).
4. When we compare the individual flux values from both liver TCA cycle models, at
initial steady-state (see fig. 2.9 on pg. 46), to the values across consecutive steady-
states (see, fig. 2.17), the relative impact of increasing V MCmax or V PCmax becomes more
evident.
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5. In fig. 2.16a (see, pg. 55), we can also observe that regardless of the model version or
the scanning parameter, Citm, αKGm & Isocitm (to some extent), tend to accumulate
in the system compared to other TCAi’s. The following factors could be responsible
for such a selective accumulation of TCA cycle metabolites in liver TCA cycle models:
a) As shown earlier (see, fig. 2.8), ‘ESS #2’ is divided into two halves (top/ upper-
half & bottom/ lower-half) as the 3 independent reactions (MDH, IDHa, & IDHb)
break this subset at different junctions. It means that isocitrate is at a junction
between the top-half of ‘ESS #2’ and IDHa/ IDHb; whereas, α-ketoglutarate is
at a junction between IDHa/ IDHb and the bottom-half of ‘ESS #2’.
Reaction
Strength
Ess-u-2
Ess-u-1
Independent
reactions
Pyrm
AcCoAm
CoAm
OAAm
Citm
PDH
CS
Isocitm
ACO
αKGm
SCoAm
α-KGDH
Malm
Sucm
Fumm
SCS
SDH
FM
PC
Malc
MC
MDH
IDHb
IDHa
• Figure 2.18. A generalised flux distribution pattern observed for liver
TCA cycle models against the increasing maximal activities of MC (V MCmax) or PC (V PCmax).
• Since, in this schematic the flux information of ATP/ADP–linked reactions is of little importance, ATPsynth,
ANT, & ATPhyd are excluded. Also, all reactions are shown in their minimal form. Only the absolutely
essential metabolites & co-factors are included in this diagram.
• The arrow-line thickness varies according to the respective strength of every flux.
• In this figure, the arrowheads point towards the respective forward or reverse directions of the participating
reactions, specific to the flux data. For actual reaction definitions, please refer to fig. 2.1 from Methods (see,
pg. 21).
• internal metabolites: in Black; external metabolites: in Blue; reaction/ enzyme names: in Red ;
“Independent reactions”: in Grey.
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b) From figs. 2.17 and 2.18, we know that the flux through IDHa is approx. 0.8–2.5
times greater than the TCA cycle flux and that in most situations IDHb op-
erates in its reverse direction, thereby producing isocitrate at the expense of
α-ketoglutarate, CO2 & NADPH.
Therefore, in demanding situations such as represented by the V MCmax or V PCmax scans;
there are 2 input reactions (PC & PDH) that can push the Citm concentration
upward via OAAm & AcCoAm; whereas, there is only one reaction (IDHa) that
can directly reduce the Citm concentration by producing Isocitm. On the other
hand, the reverse acting IDHb could effectively counteract any such reduction in
Citm by partially replenishing the Isocitm concentration. Moreover, aconitate
hydratase (ACO) is assumed to be operating reversibly at equilibrium, (Cortassa
et al., 2003; Kohn et al., 1979a) characterised by an equilibrium constant (Keq)
of 0.0685 (dimensionless) (Alberty, 2003a).
c) Also, in such situations, it is now evident that the accumulation of αKGm could
be a direct result of it being produced faster by the independent reaction (IDHa)
and consumed at a slower rate by the reactions constituting the bottom-half of
‘ESS #2’, especially α-KGDH.
d) From Methods (see, pg. 223), we know that the activity of citrate synthase
is inhibited by physiological concentrations of SCoAm (Smith and Williamson,
1971) and ATP (Shepherd and Garland, 1969). Whereas, PDH is allosterically
inhibited by increase in mitochondrial ATP/ADP, NADH/NAD+ & AcCoA/CoA
ratios (Lehninger et al., 1993; Tsai et al., 1973). We also know that α-KGDH is
inhibited by SCoAm, NADH, & ATP and activated by ADP (Smith et al., 1974).
Also, IDHa is activated by ADP and inhibited by ATP as well as its products,
αKGm, NADH & CO2 (Colman, 1975). Since, the allosteric interactions of all
TCA cycle enzymes are described in detail in the Methods section (see Appendix B
on pg. 221), please refer to it for further details as well as references.
Also, Williamson and Cooper, observed an energy-dependent link between CS,
α-KGDH, & SCS, via succinyl-CoA & ATP/ADP -mediated inhibition and based
on such a link, suggested a concerted regulation of these enzymes (Williamson and
Cooper, 1980). In liver TCA cycle models, all of the above effector interactions are
considered, alongside the substitution of GDP & GTP with ATP & ADP in the
SCS rate equation (Alberty, 2003a). Therefore, in liver TCA cycle models, such
inhibitory interactions are likely to cause an accumulation of citrate, isocitrate,
& α-ketoglutarate, due to reductions in consuming fluxes, particularly when
either of the ATP/ADP, AcCoA/SCoA, or NADH/NAD+ ratios are significantly
altered; which is the case, against change in PC or MC maximal activity (see,
fig. 2.14d for AcCoA/SCoA on pg. 51 and figs. 2.22a and 2.22c for ATP/ADP &
NADH/NAD+ on pg. 68).
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Once again, Williamson and Cooper, observed that the mitochondrial citrate
concentration in turn is dependent on the IDHa activity and the effect of this
interaction is to allow an increase of flux despite a fall in the isocitrate concen-
tration. As the citrate is converted to isocitrate, falling citrate concentration
lowers the apparent Km of CS for oxaloacetate; which together with the direct
effect of rising oxaloacetate levels (see fig. 2.39b on pg. 101) that result from the
adjustment of malate/oxaloacetate ratio due to the falling NADH/NAD+ (see
fig. 2.22c on pg. 68), permits increased flux through CS, thereby increasing the cit-
rate concentration further (Williamson and Cooper, 1980; and in supplementary
material, see figs. I.1d and I.11c on pg. IX & pg. XIX, respectively).
Therefore, in liver TCA cycle models, as a consequence of the combined effect of
all or some of the aforementioned regulatory interactions involving key ‘ESS #2’
enzymes, an average increase in the respective concentrations of citrate, isocitrate,
and α-ketoglutarate appears distinctly possible, especially in the absence of mono-
, di-, tricarboxylate transporter reactions; which when present, could possibly
reduce the mitochondrial metabolite concentrations (Chappell, 1968; Klingenberg,
1970; LaNoue and Schoolwerth, 1979; Passarella et al., 2003; Williamson et al.,
1968, 1969a).
Thus, in conclusion, along with the contribution of regulatory effector interactions
of TCA cycle enzymes, the difference between respective fluxes of different TCA
cycle ‘spans’ and that of the independent reactions is responsible for such a bipartite
response; wherein, some TCAi’s decrease while others accumulate.
In the introductory chapter we have already discussed the unspanning of TCA cycle
in detail along with several examples from the literature. Here, in the case of liver TCA
cycle models, the unspanning is somewhat similar to the suggestion made by Randle
et al. in that, the bottom half of liver TCA cycle, from α-KGDH to FM, forms a single
‘span’ (Randle et al., 1970). The exclusion of MDH, IDHa, and IDHb from the enzyme
subsets is very specific to the structure of the models described here and as such can not
be held against the aforementioned claim.
Now, we’ll see the effect of increasing the TCA cycle inputs, such as Pyrm & Pim, on
various metabolite concentrations & reaction fluxes and whether the change in metabolic
status of CoA (external) causes any variation in behaviour between the two models.
Note: As seen earlier, the relative change in TCAi’s and fluxes is mostly quantitative
in nature and hence presented here as bar graphs. The original steady-state analysis plots
are included in the supplementary material. Details are given in the figures.
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2.19.a. TCA cycle intermediate metabolites (TCAi)
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2.19.b. ATP–related metabolites
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2.19.c. NAD- & CoA–related metabolites
• Figure 2.19. Change
in the metabolic status of CoA between the two liver TCA cycle models: Effect on
the TCAi concentrations against change in the concentrations of Pim & Pyrm, respectively.
• Combined bar graphs against the increasing concentrations of [Pim] & [Pyrm] respectively, for the
change in concentrations of — (a.) TCAi’s, (b.) ATP–related metabolites, and (c.) NAD & CoA–
related metabolites. 4 different bars represent 4 separate piece of data from 2 liver TCA cycle models,
2 each for [Pim] & [Pyrm].
• Red bars represent the steady-state data for change in [Pyrm]; whereas, Blue bars show the data for
change in [Pim]. In both colours, darker bars represent the Original liver TCA cycle model (LVRTCA OGI) and
lighter bars represent the Updated liver TCA cycle model (LVRTCA UPD), respectively.
• An average concentration value was calculated for each metabolite from all consecutive steady-state values
per dataset. These were then used in the form of log10 values to generate the actual bar graph. For each
common parameter, i.e., [Pim] or [Pyrm]; a fold difference was calculated as –
[(avg. conc. in updated model)/(avg. conc. in original model)]
and represented in the graph as –
log10[(avg. conc. in updated model)/(avg. conc. in original model)].
• Blue points represents the log10[Fold difference] w.r.t. the change in [Pim] and Black points represents the
log10[Fold difference] w.r.t. the change in [Pyrm]. Points in both colours are drawn aligned to the ‘Secondary
Y-axis’.
• Lines in both colours are drawn only to connect two consecutive points, otherwise they do not hold
any significance to the data presented here.
• In each subfigure, the metabolites are arranged in a descending order of log10[Fold difference] values,
calculated for the change in V MCmax.
• Supplementary data for figs. 2.19a, 2.19b and 2.19c is shown in figs. I.5, I.6 and I.7 on pgs. XIII
to XV, respectively.
• Figure 2.19c includes the same CoA/ AcCoA/ SCoA data presented earlier in fig. 2.15 on pg. 52.
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• Figure 2.20. Change in the metabolic
status of CoA between the two liver TCA cycle models: Effect on the key liver TCA
cycle reaction fluxes against change in the concentrations of Pim & Pyrm, respectively.
• This is a combined bar graph for change in key liver TCA cycle reaction fluxes against the change
in respective concentrations of [Pim] & [Pyrm]. 4 different bars represent 4 separate piece of data
from 2 liver TCA cycle models, 2 each for [Pim] & [Pyrm].
• Red bars represent the steady-state data for change in [Pyrm]; whereas, Blue bars show the data for
change in [Pim]. In both colours, darker bars represent the Original liver TCA cycle model (LVRTCA OGI) and
lighter bars represent the Updated liver TCA cycle model (LVRTCA UPD), respectively.
• An average flux value was calculated for each reaction from all consecutive steady-state values per dataset.
These were then used to generate the actual bar graph. For each common parameter, i.e., MC or PC; a
difference of respective average flux values was calculated between the two liver TCA cycle models and was
termed as ∆ Flux Average (Original − Updated).
• Since, in the case of a reaction flux, the negative sign signifies only the direction taken by a reaction in a
steady-state; in this graph, the average flux value was considered as a positive number for those reactions
that function in their respective reverse directions. All such reactions are denoted by ± .
• X-axis: Key liver TCA cycle reaction fluxes as data categories. These 7 reactions were chosen as
representatives of three enzyme subsets as well as all the independent reactions from liver TCA cycle models.
• Yellow points represents the ∆ Flux Average (Original − Updated) w.r.t. the change in [Pim] and Black
points represents the ∆ Flux Average (Original − Updated) w.r.t. the change in [Pyrm]. Points in both
colours are drawn aligned to the ‘Secondary Y-axis’.
• Lines in both colours are drawn only to connect two consecutive points, otherwise they do not hold
any significance to the data presented here.
• Supplementary data shown in fig. I.8 on pg. XVI.
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• Figure 2.21. Change in the metabolic
status of CoA between the two liver TCA cycle models: Effect on the ATP/ADP-
linked reaction fluxes against change in the concentrations of Pim & Pyrm, respectively.
• This is a combined bar graph for change in the ATP/ADP-linked reaction fluxes against the change
in respective concentrations of [Pim] & [Pyrm]. 4 different bars represent 4 separate piece of data
from 2 liver TCA cycle models, 2 each for [Pim] & [Pyrm].
• Red bars represent the steady-state data for change in [Pyrm]; whereas, Blue bars show the data for
change in [Pim]. In both colours, darker bars represent the Original liver TCA cycle model (LVRTCA OGI) and
lighter bars represent the Updated liver TCA cycle model (LVRTCA UPD), respectively.
• An average flux value was calculated for each reaction from all consecutive steady-state values per dataset.
These were then used to generate the actual bar graph. For each common parameter, i.e., Pim or Pyrm; a
difference of respective average flux values was calculated between the two liver TCA cycle models and was
termed as ∆ Flux Average (Original − Updated).
• In this graph, a set of hatched bars in the same colour key show the total ATPm production or consumption
by the respective liver TCA cycle models, for respective scans.
• X-axis: pyruvate carboxylase (PC) is included alongside other ATP/ADP–linked reactions to maintain the
balance between ATP-consuming reactions (ATPhyd & PC) and ATP-producing reactions (ATPsynth & SCS).
• Yellow points represents the ∆ Flux Average (Original − Updated) w.r.t. the change in [Pim] and Black
points represents the ∆ Flux Average (Original − Updated) w.r.t. the change in [Pyrm]. Points in both
colours are drawn aligned to the ‘Secondary Y-axis’.
• Lines in both colours are drawn only to connect two consecutive points, otherwise they do not hold
any significance to the data presented here.
• ¶ : In this figure, the average values for ATP synthase (ATPsynth) flux have been scaled by a factor of 10;
due to the difference in respective reaction stoichiometries between ATPsynth (in mitochondria) and ATPhyd
(in cytosol).
• Supplementary data shown in fig. I.9 on pg. XVII.
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From figs. 2.19 to 2.21 (see, pgs. 63 to 65) following observations can be made:
1. Across increasing [Pim], compared to the original model, the TCA cycle flux increases
by approx. 0.5–fold in the updated model; whereas, across increasing [Pyrm], it
increases by approx. 3–fold. Increase in IDHa flux is nearly the same in both scans
(by about 6–fold). MDH, PC, & ATPsynth are approx. twice the original in the
[Pim] scan; whereas, across increasing [Pyrm], these fluxes increase by approx. 4–fold
compared to the original model. In both scans, IDHb operates in its reverse direction.
Its flux remains virtually unaffected across increasing [Pim]; whereas, it increases by
approx. 35–fold across increasing [Pyrm].
As seen earlier in the case of MC/ PC scans, flux data for both these scans suggest
the same flux distribution pattern as shown in fig. 2.18 (see, pg. 59).
2. Across increasing [Pyrm], the overall flux carrying capacity of the updated liver TCA
cycle model is on an average 5 times the original; whereas, it is about thrice the
original across increasing [Pim]. Original plots given in the supplementary material
clearly show that even within a physiological range of Pim/ Pyrm concentrations,
such an increase in the overall flux carrying capacity is quite plausible for liver TCA
cycle models (see figs. I.8 and I.9 on pg. XVI and pg. XVII, respectively).
In systems built using saturable kinetics, the responsiveness of a system to an increase
or decrease in its primary inputs (in this case, Pyrm & Pim) depends on the substrate
saturation of enzymes. A substrate present at a concentration greater than the
corresponding Km is generally considered to be saturating. However, in the case of
liver TCA cycle models, since the effects of competitive product inhibition are also
factored in for several enzymes; the overall reaction rate can still be responsive to
changes in substrate concentration, regardless of the extent of substrate saturation
(i.e. Km,S  [substrate]). In such systems, calculation of enzyme elasticities can
help to study the sensitivity of a reaction rate to a change in substrate concentration.
In the updated liver TCA cycle model, some of the elasticity coefficients of PDH &
PC, calculated for pyruvate (0.05 & 0.41, respectively) and those of SCS & ATPsynth
for Pim (−3.35 & 0.61, respectively) were found to be high enough to conclude that
the observed increase in the total flux carrying capacity is due to the responsiveness of
some of these reactions towards the primary inputs to the TCA cycle. Subsequently,
the elasticities of remaining liver TCA cycle enzymes towards other metabolites could
also play a role in increasing the overall flux capacity (e.g. elasticity coefficients of
citrate synthase : 0.95 for oxaloacetate & 0.70 for acetyl-CoA). For further discussion
on elasticities, please see, pg. 108.
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Compared to the original model, fold increase in the total flux carrying capacity
is significantly more in the updated model; which could primarily be due to the
internalisation of CoA. As seen earlier, reassignment of external CoA as an internal
metabolite, maintains the total metabolite content of a system within physiological
range. Figure 2.19c (see, pg. 63) shows that the average concentration of SCoAm is
reduced by about 55% across [Pim] and by about 36% across [Pyrm] compared to the
original model. Also, AcCoAm is reduced by approx. 90% across increasing [Pim], but
remains nearly unchanged across increasing [Pyrm].
As mentioned earlier on pg. 61, the allosteric inhibitory interactions of PDH, CS,
IDHa, & α-KGDH are appropriately considered while defining the respective rate
equations in liver TCA cycle models. Since, the allosteric interactions of all TCA
cycle enzymes are described in detail in the Methods section (see Appendix B on
pg. 221), please refer to it for further details as well as references.
Therefore, compared to the original liver TCA cycle model, significantly reduced
SCoAm concentration in the updated model lowers its CS and α-KGDH inhibition,
thereby contributing towards the higher flux carrying capacity of the model. Also,
across increasing [Pim], a significant 90% reduction in AcCoAm concentration could
play a role as well, by lowering its inhibition of PDH via a possible decrease in the
AcCoA/CoA ratio. Moreover, across increasing [Pim] as well as [Pyrm], a significantly
lower [ATP/ADP]m ratio also helps to increase the flux carrying capacity by reducing
the ATP-induced inhibition of CS, IDHa, & α-KGDH. The individual ratio profiles
are presented later in figs. 2.23 and 2.24 (see, pgs. 69 and 70).
3. Across increasing [Pim], compared to the original model, most TCAi concentrations
from the bottom-half of ‘ESS #2’ show a significant increase in the range of 1.5
to 5.0–folds. α-ketoglutarate increases by approx. 30–fold than that in the original
model, due to the same flux distribution pattern explained earlier in the case of
MC/ PC scans (see fig. 2.18 on pg. 59). Increase in Sucm and decrease in SCoAm are
as a result of 1.5–fold increase in the substrate-level phosphorylation via SCS, as the
availability of its co-substrate (Pim) increases. Whereas, across increasing [Pyrm], the
relative change in TCAi concentrations is spread throughout ‘ESS #2’, perhaps due
to the significant increases in key TCA cycle fluxes as well as the reversal of IDHb.
In the updated liver TCA cycle model, although the actual scale of relative change in
TCA metabolite concentrations is very large, original plots provided in the supplemen-
tary material suggest that qualitatively such changes in TCAi levels are valid to some
extent within a much smaller range that includes the physiological concentrations of
Pim/ Pyrm (see fig. I.5 on pg. XIII).
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• Figure 2.22. Variations in the ‘Energy status’ of liver TCA cycle models:
[ATP/ADP] & [NADH/NAD+] ratios across the increasing maximal activity of PC (V PCmax).
• Key for figs. 2.22a to 2.22c is as follows :
• [ATP/ADP]m : Original model ; Updated model
• [ATP/ADP]c : Original model ; Updated model
• [NADH/NAD+]m : Original model ; Updated model
For figs. 2.22a to 2.22c :
• X-axis : log10[VPCmax] – PC maximal activity in logarithmic scale.
• Y-axis : Ratio of concentrations (dimensionless).
• The vertical black line represents the initial model value. At this point on the X-axis,
V PCmax = 2.26234 mM/sec (apparent velocity) in logarithmic scale.
• A dotted, black, horizontal line represents the “zero-axis” in each figure.
• Supplementary data for figs. 2.22a, 2.22b and 2.22c is shown in figs. I.2c, I.2d, I.3c and I.3d on
pg. X & pg. XI, respectively.
— Ph.D. Thesis by Amar S. Ghaisas — Page 68
2. Liver TCA cycle model 2.3. Results for the liver TCA cycle . . .
 0
 1
 2
 3
 4
 5
 6
 1  10
[A
T
P
m
it
o
] 
: 
[A
D
P
m
it
o
] 
(d
im
en
si
o
n
le
ss
)
log10[Pimito concentration]
Original v Updated Liver TCA cycle model data
2.23.a. [ATP/ADP]m
 0
 1
 2
 3
 4
 5
 6
 1  10
[A
T
P
cy
to
] 
: 
[A
D
P
cy
to
] 
(d
im
en
si
o
n
le
ss
)
log10[Pimito concentration]
Original v Updated Liver TCA cycle model data
2.23.b. [ATP/ADP]c
 0
 0.5
 1
 1.5
 2
 2.5
 3
 3.5
 4
 1  10
[N
A
D
H
m
it
o
] 
: 
[N
A
D
m
it
o
] 
(d
im
en
si
o
n
le
ss
)
log10[Pimito concentration]
Original v Updated Liver TCA cycle model data
2.23.c. [NADH/NAD+]m
Median values
Updated model 0.3
Original model 0.2
Updated model 0.4
Original model 3.5
Updated model 0.4
Original model 2.2
NADH
m 
/ NAD
m
ATPm / ADPm
ATP
c 
/ ADP
c
2.23.d. Median values
• Figure 2.23. Variations in the ‘Energy status’ of liver TCA cycle
models: [ATP/ADP] & [NADH/NAD+] ratios across the increasing concentration of [Pim].
• Key for figs. 2.23a to 2.23c is as follows :
• [ATP/ADP]m : Original model ; Updated model
• [ATP/ADP]c : Original model ; Updated model
• [NADH/NAD+]m : Original model ; Updated model
For figs. 2.23a to 2.23c :
• X-axis : log10[Pim] – concentration of mitochondrial inorganic phosphate (Pim) in logarithmic scale.
• Y-axis : Ratio of concentrations (dimensionless).
• The vertical black line represents the initial model value. At this point on the X-axis,
[Pim] = 8.9 mM in logarithmic scale.
• A dotted, black, horizontal line represents the “zero-axis” in each figure.
• Supplementary data for figs. 2.23a, 2.23b and 2.23c is shown in figs. I.6a, I.6b, I.7a and I.7b on
pg. XIV & pg. XV, respectively.
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• Figure 2.24. Variations in the ‘Energy status’ of liver TCA cycle
models: [ATP/ADP] & [NADH/NAD+] ratios across increasing concentration of [Pyrm].
• Key for figs. 2.24a to 2.24c is as follows :
• [ATP/ADP]m : Original model ; Updated model
• [ATP/ADP]c : Original model ; Updated model
• [NADH/NAD+]m : Original model ; Updated model
For figs. 2.24a to 2.24c :
• X-axis : log10[Pyrm] – concentration of pyruvate (Pyrm) in logarithmic scale.
• Y-axis : Ratio of concentrations (dimensionless).
• The vertical black line represents the initial model value. At this point on the X-axis,
[Pyrm] = 0.2 mM in logarithmic scale.
• A dotted, black, horizontal line represents the “zero-axis” in each figure.
• Supplementary data for figs. 2.24a, 2.24b and 2.24c is shown in figs. I.6c, I.6d, I.7c and I.7d on
pg. XIV & pg. XV, respectively.
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Figures 2.22 to 2.24 (see, pgs. 68 to 70) describe the ‘energy status’ of liver TCA
cycle models in terms of key ratios like – [ATP/ADP]m, [ATP/ADP]c & [NADH/NAD+]
m, across increasing maximal activity of PC and across increasing concentrations of Pim
& Pyrm, respectively. Figures 2.22d, 2.23d and 2.24d provide a list of median values for
these ratios. Before we inspect the differences in ratio profiles between the two models,
it is important to note that the initial concentrations of ADPm, ATPm, ADPc, ATPc,
NADHm, & NADm+ are identical in both models. Moreover, the individual conservation
relationships among these metabolites between the two models are identical as well.
Although, both liver TCA cycle models appear to follow a similar course qualitatively,
there is a distinct quantitative gap between their respective ratio profiles, as shown by
their corresponding median values.
Across increasing [Pyrm], the [NADH/NAD+]m ratio between the two models is
noticeably different (see fig. 2.24c on pg. 70) in that, the original model appears to be
more reduced (median = 0.6) than the updated model (median = 0.3). Whereas, across
increasing maximal activity of PC (see fig. 2.22c on pg. 68) and across increasing [Pim]
(see fig. 2.23c on pg. 69), the median redox ratio values for the two models are relatively
similar. The respective redox states between the two models are quantitatively similar
even within a much narrower range of a given scanning parameter, where the given range
includes its initial model value; with the exception of [Pyrm] scan.
The mitochondrial redox ratio reported for control rat livers varies from 0.01 (Siess
et al., 1976, 1982b; Soboll et al., 1978; von Glutz and Walter, 1975; Williamson et al.,
1969a,b) to 0.1 (Krebs and Veech, 1969; Stubbs et al., 1972; Veech et al., 1969; Williamson
et al., 1967a), depending on the experimental conditions, diet, etc. In livers from rats
that are starved for 48 hrs., the mitochondrial redox ratio is 0.2 (Krebs and Veech,
1969; Veech et al., 1969; Williamson et al., 1967a). In rats fed on a high-sucrose diet
for 3–5 days, the ratio is 0.15–0.2 and in rats fed on low-carbohydrate diet for 3–5 days,
it is 0.2–0.3 (Krebs and Veech, 1969; Veech et al., 1969). In ethanol treated rat livers
the mitochondrial redox ratio is 0.4; whereas, in L-ethionine treated livers it is 0.15
(Stubbs et al., 1972). On the other hand, in isolated rat hepatocytes, depending on the
experimental conditions, the mitochondrial redox ratio varies between 0.2 to 0.65, upon
the direct estimation of mitochondrial NAD & NADH (Tischler et al., 1977). Therefore,
it appears that within physiological range, the redox ratios for both models are in good
agreement with the published data and that the two models differ only qualitatively, in
terms of their respective [NADH/NAD+]m profiles. The mitochondrial redox ratios are
discussed further with respect to elasticity coefficients on pg. 108.
Across all 3 scanning parameters, the mitochondrial as well as cytosolic ATP/ADP
ratios are distinctly different between the two models. Even within physiological range,
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a qualitative difference between the two ATP/ADP ratio profiles is quite noticeable.
Across V PCmax, both the mitochondrial as well as cytosolic ATP/ADP ratio median values
are significantly higher in the updated model (1.0 & 2.3, respectively), compared to the
original model (0.6 & 0.2, respectively). On the other hand, across increasing [Pim] as
well as [Pyrm], both ratio medians are significantly lower in the updated model than the
original.
Qualitatively, the ATP/ADP ratio can be seen as a preliminary indicator of system’s
‘energy-yielding readiness’ in energy demanding situations. Whether a high or a low
ATP/ADP ratio is preferable, depends entirely on the given metabolic state of a cell.
For example, from in vitro studies, we know that pyruvate dehydrogenase is inhibited
by a high ATP/ADP ratio (Siess and Wieland, 1975); whereas, pyruvate carboxylase
is activated by a high ATP/ADP ratio (Stucki et al., 1972; von Glutz and Walter,
1976). Therefore, pyruvate oxidation in the fed state would require an active PDH and
low ATP/ADP ratios; whereas, gluconeogenesis in the starved state would require an
activation of PC and an inactivation of PDH favoured by high ATP/ADP ratios (Soboll
et al., 1978). Therefore, it appears that the ATP/ADP ratios in the updated liver TCA
cycle model are in good agreement with this observation.
The ATP/ADP ratios in isolated mitochondria, under control conditions, vary
between 0.4 (von Glutz and Walter, 1975) to 0.6 (Stucki and Walter, 1972). In rat
liver in situ, the mitochondrial ATP/ADP ratio is 0.9 in fed rats and 1.0 in starved
rats; whereas, the cytosolic ATP/ADP ratio is 6.9 in fed rats and 5.9 in starved rats
(Schwenke et al., 1981). In perfused rat livers, the mitochondrial ATP/ADP ratio is
0.2 in fed rats and 0.7 in starved rats; whereas, the cytosolic ATP/ADP ratio is 10.3
in fed rats and 2.6 in starved rats (Soboll et al., 1978). In isolated hepatocytes, the
mitochondrial ATP/ADP ratio is 2.3 in fed rats and 1.5 in starved rats; whereas, the
cytosolic ATP/ADP ratio is between 5–12 in fed rats and 9.1 in starved rats (Akerboom
et al., 1978; Siess and Wieland, 1976; Soboll et al., 1980). Within physiological range,
the ATP/ADP ratios are well inside the reported range; except across increasing V PCmax.
In conclusion, key metabolic ratios between the two models show significant qualita-
tive differences. The significance of their quantitative differences, if any, is subjective to
the available experimental data and therefore, as such, can not be properly assessed, at
present.
Now, in the following sections, we shall discuss the control properties of the two
models, in terms of the flux control coefficients, concentration control coefficients, &
elasticity coefficients. Also, in these sections we shall revisit some of the special cases we
have seen so far and discuss them with respect to the emergent control properties of the
two liver TCA cycle models.
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2.3.5 Metabolic Control Analysis (MCA) of the Liver TCA cycle
models
In the introductory chapter, we discussed the theory of “Metabolic Control Analysis
(MCA)”, at length. In this section, we’ll see the results of such analysis, when applied
to liver TCA cycle models by observing the distribution of flux control coefficient (CJ),
concentration control coefficient (CS) and elasticity coefficient (εS).
‘Flux control coefficient scans’, a method of obtaining the flux control coefficient
data, is already explained in the global Methods chapter.
2.3.5.1 Flux control coefficient analysis for Liver TCA cycle models
In this section, we will first analyse the control of flux through citrate synthase (CS),
using the flux control coefficients of all liver TCA cycle enzymes. Later, we’ll also
analyse the control of flux through other liver TCA cycle reactions, such as – independent
reactions (e.g. IDHa) & other enzyme subset reactions (e.g. PC). Since, we have already
established that the updated liver TCA cycle model is a qualitatively better version of
the liver TCA cycle, going forward, we will only focus on the updated model. Between
two parameter datasets, if required, one of the qualitatively similar flux control coefficient
plots are included in the supplementary material .
As the enzyme activities or metabolite concentrations vary, their corresponding
degree of control varies as well. Hence, we examined how the pattern of control changed
as these parameters were varied over a fixed range. Figure 2.25 (see, pg. 74) and figs. I.10
and I.11 in supplementary material (see, pg. XVIII & pg. XIX) show the flux control
coefficients calculated with respect to TCA cycle flux (flux through CS), for all enzymes
in the liver TCA cycle model, across a fixed range of increasing maximal activities
(ATPsynth, PDH, PC & MC) or metabolite concentrations (Pim & Pyrm). These CJ
plots are presented alongside a corresponding steady-state plot of citrate synthase (CS)
flux across the same fixed range of a given parameter (here, CS is the reaction ‘J’ on
which the flux control coefficient, ‘CJ’ is calculated). In each plot, result of the summation
theorem is also included using a dotted line. In these plots, the flux control coefficients
are distributed between the range of −0.6 to 1.2 (unitless).
A plot of CJ against the enzyme maximal activity or concentration would normally be
expected to be hyperbolic however, for ATPsynth (see, fig. 2.25a), PDH (see, fig. 2.25b),
PC (see, fig. I.11a), and Pim (see, fig. I.10a), a complex pattern of CJ variation can be
observed. For Pyrm (see, fig. I.10b) and MC (see, fig. I.11b) however, the observed CJ
pattern is comparatively more simpler. The emergence of complex pattern of variation
in flux control coefficients is discussed later, on pg. 80.
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2.25.a. CJ, Updated model
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2.25.b. CJ, Updated model
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2.25.c. CS flux, Updated model
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2.25.d. CS flux, Updated model
• Figure 2.25. Control of TCA cycle flux in
the updated liver TCA cycle model: against the changing activities of ATPsynth & PDH.
• Key for figs. 2.25a and 2.25b is as follows :
PDH ; CS ; ACO ; IDHa ; α-KGDH ; SCS;
SDH ; FM ; MDH ; ATPsynth ; ANT ; ATPhyd;
PC ; MC ; IDHb ; Total Sum (dotted line)
• The vertical black line represents the initial model value. At this point, in figs. 2.25a and 2.25c,
V ATPsynthmax = 0.886637 mM/sec and in figs. 2.25b and 2.25d, V PDHmax = 0.648 mM/sec, respectively.
• Orange dotted line shows the Summation theorem result across the entire range.
• Corresponding flux control coefficient plots for the original liver TCA cycle model are both qualita-
tively as well as quantitatively similar to the data shown above and therefore not included here.
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From fig. 2.25 and figs. I.10 and I.11 in supplementary material, it is evident that
pyruvate dehydrogenase has a relatively greater control of the TCA cycle flux; however,
the control is also distributed between PDH and two other enzymes: pyruvate carboxylase
& ATP synthase. While the popular notion of a single ‘rate limiting’ step in a pathway
has been shown both theoretically as well as experimentally to be erroneous (Fell, 1997),
the first enzyme in a linear pathway often does possess a higher degree of control of the
pathway flux, with declining extent of control for the consecutive enzyme reactions along
the rest of the pathway length. This can be explained on the basis of the relationship
between individual flux control coefficients and the disequilibrium ratio (ρ) of each
enzyme reaction (Kacser and Burns, 1973). The liver TCA cycle model represents a
cyclical, branched metabolic system and the actual factors that affect the distribution of
control in such a system are more complex than the theoretical linear pathway considered
by Kacser and Burns, 1973. However, PDH & PC, two of the most controlling enzymes,
are a set of connected reactions in the initial linear portion of the liver TCA cycle
pathway, and therefore can be expected to exhibit a relatively higher degree of control,
particularly in the absence of any feedback regulation (or ‘closed’ regulatory sequences,
see Crabtree and Newsholme, 1987) other than a direct product inhibition.
Based on the concepts – ‘organisation of metabolic networks as functionally discrete
supply & demand blocks’ and ‘supply-demand analysis’, put forward by Hofmeyr and
Cornish-Bowden (2000), we may say that ATP synthase forms a demand block within
liver TCA cycle, whereas other reactions of the cycle represent the supply block and they
are linked via a common intermediate, NADHm, which is produced by the TCA cycle
dehydrogenases and consumed by ATPsynth. Therefore, a comparatively high CJ of
ATPsynth and minimal coefficients of enzymes within the cycle, for the control of TCA
cycle flux, is in good agreement with the ‘molecular economy’ –based view of Hofmeyr
and Cornish-Bowden (2000). Although, PDH is in fact a part of the supply block, its
position in the initial linear portion of the pathway automatically tends to allow a higher
CJ than the successive reactions.
A small but notable negative flux control coefficient for IDHa indicates that an
increase in the IDHa activity causes a modest decrease in the TCA cycle flux. This may
initially seem counter-intuitive, but an increase in the IDHa activity increases the α-
ketoglutarate concentration and thus its availability for the IDHb; which in turn increases
the IDHb reverse flux, thereby counteracting and occasionally, even over-compensating
for the greater IDHa activity. SDH is one of the four dehydrogenase reactions within
liver TCA cycle and yet it shares a relatively high degree of control for the TCA cycle
flux along with ATPsynth. Although, initially it may appear to contradict with our
earlier view of the distribution of control, it can be explained as follows:
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1. We know that in liver TCA cycle models, ‘ESS #2’ is broken into two halves by
the presence of independent reactions on both ends. In these halves, α-KGDH, SCS,
SDH form a linear portion; whereas, due to the reverse direction of MDH, FM, MC
& MDH form a branched reaction sequence.
2. Within this linear reaction sequence, α-KGDH & SCS are – (a.) highly regulated and
(b.) share their co-substrate/ co-product – CoAm, with PDH & CS, two enzymes
from the top/ upper-half of ‘ESS #2’; thereby adding onto their existing level of
complexity.
3. On the other hand, SDH is regulated by a direct product inhibition by Fumm & QH2
and an inhibition by OAAm (competitive to Sucm).
Therefore, a high CJ for SDH does not seem to be counter-intuitive after all.
Moreover, in situations where MDH acts in its respective forward direction, SDH is likely
to exhibit a minimal coefficient value.
Also, CJ for SDH is transiently negative just before the respective initial model value
of a given scanning parameter, as well as it mirrors the complex pattern of variation in
CJ for PDH. This pattern is also shared to some degree by ATPsynth, and mirrored by
other enzymes as well, most notably α-KGDH and IDHa. A transiently negative CJ
for SDH translates to a transient & modest decrease in the TCA cycle flux, effectively
reducing the efflux of TCA cycle carbon via MC. This view is further supported by
fig. I.11b (see, pg. XIX), which shows that at activities higher than the initial model
value of V MCmax (23.3 mM/sec), the system attempts to restrict the efflux of TCA cycle
carbon by limiting the TCA cycle flux through a negative CJ for SDH. Interestingly, the
negative coefficient of SDH never exceeds the negative value of CJ for IDHa, thereby
limiting its reductive effect on the TCA cycle flux within the upper (negative) bound set
by the transiently negative CJ for IDHa. α-KGDH, despite being highly regulated, shares
a small but notable flux control coefficient with SDH and follows the SDH coefficient
pattern throughout the given parameter range. Therefore, in the liver TCA cycle model,
the transiently negative flux control coefficients for enzymes within the cycle, such as –
IDHa, α-KGDH, & SDH, together can be considered as a mechanism to limit the extent
TCA cycle carbon efflux, under demanding situations.
Here, we have been able to reproduce, both qualitatively as well as quantitatively, the
same distribution pattern of flux control coefficients for the liver TCA cycle model that was
originally developed within our group using COPASI (see, http://www.copasi.org/).
These original results are a part of the unpublished manuscript (Brightman et al., 2010).
In particular, the complex distribution pattern of CJ against the PDH maximal activity
(see fig. 2.25b on pg. 74), matches exactly with that shown in Brightman et al., see figure
3A.
— Ph.D. Thesis by Amar S. Ghaisas — Page 76
2. Liver TCA cycle model 2.3. Results for the liver TCA cycle . . .
Figure 2.25 showed the distribution of control for the overall TCA cycle flux (flux
through CS) or the flux through ‘ESS #2’. Now, let us investigate the distribution of
control for the flux through other enzyme subsets and independent reactions in the
updated liver TCA cycle model. Figure 2.26 (see, pg. 77) shows the distribution of control
for the flux through IDHa and PC (‘ESS #1’), against the change in PDH maximal
activity. Figure 2.27 (see, pg. 78) shows the distribution of control for the flux through
MDH and ANT (‘ESS #3’), against the change in PDH maximal activity.
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2.26.b. CPC, Updated model
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2.26.c. IDHa flux, Updated model
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2.26.d. PC flux, Updated model
• Figure 2.26. Control of flux through
IDHa & PC in the updated liver TCA cycle model: against the PDH maximal activity.
• Key for figs. 2.26a and 2.26b is as follows :
PDH ; CS ; ACO ; IDHa ; α-KGDH ; SCS;
SDH ; FM ; MDH ; ATPsynth ; ANT ; ATPhyd;
PC ; MC ; IDHb ; Total Sum (dotted line)
• The vertical black line represents the initial model value. At this point, in figs. 2.26a to 2.26d,
V PDHmax = 0.648 mM/sec.
• Orange dotted line shows the Summation theorem result across the entire range.
• Corresponding flux control coefficient plots for the original liver TCA cycle model are both qualita-
tively as well as quantitatively similar to the data shown above and therefore not included here.
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2.27.a. CMDH, Updated model
-1.5
-1
-0.5
 0
 0.5
 1
 1.5
 0.5  1  1.5  2
C
J  
(J
 =
 f
lu
x
 t
h
ro
u
g
h
 A
N
T
)
PDH maximal activity (mM/sec)
Updated Liver TCA cycle model - LVRTCA
UPD
2.27.b. CANT, Updated model
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2.27.c. MDH flux, Updated model
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2.27.d. ANT flux, Updated model
• Figure 2.27. Control of flux through
MDH & ANT in the updated liver TCA cycle model: Distribution of flux control
coefficients calculated for the flux through MDH & ANT, against the PDH maximal activity.
• Key and other conditions are as shown in fig. 2.26 on pg. 77.
Figures 2.26 and 2.27 (see, pgs. 77 and 78) show a complex pattern of control
distribution for the flux through IDHa, PC & MDH, similar to that shown in fig. 2.25
(see, pg. 74), for the control of TCA cycle flux. On the other hand, control distribution
for the flux through ANT (see, fig. 2.27b) is distinctly simple and shows signs of sigmoidal
CJ transition curves.
From figs. 2.26 and 2.27 it is evident that at lower PDH activities, PDH has a
relatively greater control of flux; whereas, at higher activities, the control is rapidly
exchanged and distributed between PDH and other TCA cycle enzymes, similar to that
observed in fig. 2.25. However, for the control of IDHa flux (see, fig. 2.26a), the control is
more widely distributed between PDH and other TCA cycle enzymes and the exchange
phase is notably different than that observed in other cases.
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In fig. 2.26a, the control of IDHa flux is evenly distributed between PDH, ATPsynth,
IDHa, PC, α-KGDH, & SDH throughout the given range of PDH maximal activity,
except at very low activity values. In this case, IDHa has a majority of the control of
its own flux and CJ for IDHa is positive throughout the given range, unlike in fig. 2.25,
where it is negative. Also in this case, the respective coefficients for α-KGDH & SDH
remain negative throughout the given range, whereas in fig. 2.25 they are positive for the
most part and become transiently negative near the initial model value of PDH maximal
activity. Therefore, for the control of IDHa flux, IDHa, PC, ATPsynth, & PDH are the
most-controlling enzymes that would increase the flux through IDHa as their individual
activities are increased; whereas, α-KGDH & SDH would decrease its flux moderately
with any increase in their individual activities.
The CJ distribution patterns for the flux through PC (see, fig. 2.26b) & MDH (see,
fig. 2.27a) are almost identical to each other and closely resemble the control distribution
pattern for the TCA cycle flux (see, fig. 2.25). In both cases, PDH has most of the
control, before it is rapidly exchanged and distributed between PC, ATPsynth, SDH,
IDHa, & α-KGDH. CJ for IDHa is distinctly positive in both these cases, whereas it is
distinctly negative for the control of TCA cycle flux; which means that while an increase
in the IDHa activity causes a moderate decrease in the TCA cycle flux, it would also
increase the MDH & PC fluxes moderately.
Figure 2.27b shows the control distribution pattern for the flux through ANT and it
stands out due to its distinctively simple CJ transition curves. The rapid exchange of
control between two enzymes seems to be a central feature of the control distribution in
liver TCA cycle models, as it exists even in this comparatively uncomplicated pattern
of control distribution. In this case, the flux through ANT is controlled mostly by
ATPhyd and to a small extent by PC, after a rapid exchange of control with PDH & SCS.
Therefore, for PDH maximal activity values between 0.3 to 2.0 mM/sec, an increase in
the ATPhyd activity will increase the flux through ANT; whereas, any increase in the
PC activity will marginally decrease the ANT flux. ANT carries out a 1:1 exchange of
mitochondrial ATP and cytosolic ADP. ATPhyd in the cytosol and pyruvate carboxylase
in the mitochondria both compete for the mitochondrial ATP. Therefore, the control
distribution for ANT flux suggests that ATPhyd ensures an efficient ANT mediated
transfer of mitochondrial ATP to cytosol, by gaining maximal control of the ANT flux;
whereas, a small negative CJ for PC reduces the ANT flux fractionally with any increase
in the PC activity, in order to maintain a sufficient supply of mitochondrial ATP that is
required for the carboxylation of pyruvate.
Therefore, figs. 2.26 and 2.27 show that in the updated liver TCA cycle model,
reactions that were classified as structurally distinct, are also discrete in terms of their
kinetic control properties. This observation provides further support to the ‘unspanning’
of TCA cycle, as seen earlier in pg. 59 and suggested by Randle et al., 1970.
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2.3.5.2 The complex pattern of variation in flux control coefficients of Liver
TCA cycle models: Impact of enzyme kinetics
A plot of CJ against the enzyme maximal activity or concentration is expected to be
hyperbolic; instead, in fig. 2.25, fig. I.10 & fig. I.11, the emerging pattern of variation in
CJ is mostly ‘multiphasic’.
In literature, there are known examples of ‘biphasic’ CJ curves. For example, in rat
liver mitochondria, for the control of oxidative phosphorylation and respiration (Brand
et al., 1993; Brown, 1992; Fell, 1997; Groen et al., 1982b; Hafner et al., 1990; Korzeniewski
and Mazat, 1996a); also, for control of glycolysis in T. brucei (Bakker et al., 1999), &
S. cerevisiae (Pritchard and Kell, 2002). Whereas, specific examples of ‘multiphasic’ CJ
curves are rare (Chassagnole et al., 2001a; Giersch, 1995a; Liguzinski and Korzeniewski,
2006) ∗. It could be due to the fact that in most studies, a single CJ value per enzyme
is computed; which corresponds to either a unique physiological state (Fritzen et al.,
2007; Giersch, 1995b; Kashiwaya et al., 1994; Moreno-Sánchez et al., 2008; Torres et al.,
1986, 1989) or a unique steady-state solution of a mathematical model (Albe and Wright,
1992; Cortassa et al., 2003, 2009; Dzbek and Korzeniewski, 2007, 2008; Korzeniewski and
Froncisz, 1991; Moreno-Sánchez et al., 2008; Rohwer and Botha, 2001).
As a representative case of the complex pattern, let’s focus on fig. 2.25b (see, pg. 74),
which shows the variation in CJ against PDH activity. Although these patterns are not
easy to interpret, it is clear that within a very narrow range of activities around the
initial model value (0.65 mM/sec), the distribution of control shifts abruptly between
PDH and the other enzymes. Thus, CJ for PDH varies from almost unity to approaching
zero, between 0.6 to 1.0 mM/sec, i.e. with a less than 25% change in PDH activity. The
initial model value of PDH Vmax (0.65 mM/sec; Fahien and Teller, 1992 †) is assumed
to represent the PDH active fraction under physiological conditions, which has been
reported to be between 50% and 100% in perfused rat heart (Dennis et al., 1979; Olson
et al., 1978; Reed et al., 1972). Therefore, it suggests that the abrupt shift in the
distribution of CJ across a fixed range of PDH activity, apparently occurs within the
physiological range of PDH activation. However, fig. 2.25d (see, pg. 74) shows that large
increases in PDH activity, particularly between 0.6 to 1.0 mM/sec and beyond, cause
only a minimal net increase in the TCA cycle flux (flux through CS).
Figure 2.25, fig. I.10 & fig. I.11 show that the model is poised in such a way that
control over the TCA cycle flux is distributed largely between PDH, PC & ATPsynth;
wherein the system is maximally responsive to the activity changes in each of these
∗In Giersch 1995a, the CJ curves are against simulated time and comparatively simpler and in
Chassagnole et al. 2001a, the CJ curves are across successive steady-states and comparatively simpler.
†Calculated from the reported mitochondrial concentration and specific activity, taking into account
the number of active sites within the holoenzyme.
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key enzymes with minimal influence of the liver TCA cycle reactions (with the notable
exceptions of SDH, IDHa & α-KGDH). Therefore, we investigated the effect of changing
respective initial model values of PDH, PC & ATPsynth Vmax’s, on the complex pattern
of CJ distribution against enzyme maximal activities. Figures 2.28 to 2.30 (see, pgs. 81
to 83) show this effect on CJ for PDH, against a fixed range of PDH & ATPsynth
activities.
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2.28.a. CJ for PDH at different maximal activities of PC
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2.28.b. at PC Vmax = 0.045 mM/sec
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2.28.c. at PC Vmax = 0.45 mM/sec
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2.28.d. at PC Vmax = 4.53 mM/sec
• Figure 2.28. Effect of different PC activities on the
flux control coefficient of PDH: plotted against a fixed range of PDH maximal activity.
• Key for figs. 2.28b to 2.28d (only for enzymes with most control; for the rest, refer to: pg. 74) :
PDH ; CS ; IDHa ; α-KGDH ; SDH ; PC ; ATPsynth ; ATPhyd
• Figure 2.28a is a result of 8 simulations at different PC activities. Figures 2.28b to 2.28d describe the
complete flux control distribution at specific values of PC activities used in fig. 2.28a.
• Figure 2.28b includes C J for PDH shown in fig. 2.28a using at V PCmax = 0.045 mM/sec
• Figure 2.28c includes C J for PDH shown in fig. 2.28a using at V PCmax = 0.45 mM/sec
• Figure 2.28d includes C J for PDH shown in fig. 2.28a using at V PCmax = 4.53 mM/sec
• X & Y-axes for figs. 2.28b to 2.28d : Range of PDH maximal activity: 0.0 – 2.0 mM/sec and flux control
coefficient for the flux through CS (CCS) (unitless), respectively.
• The vertical black line represents the initial model value. At this point, in figs. 2.28b to 2.28d,
V PDHmax = 0.648 mM/sec.
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2.29.a. CJ for PDH at different maximal activities of PDH
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2.29.c.
at PDH Vmax = 0.5 mM/sec
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2.29.d.
at PDH Vmax = 2.0 mM/sec
• Figure 2.29. Effect of different PDH activities on the flux
control coefficient of PDH: plotted against a fixed range of ATPsynth maximal activity.
• Key for figs. 2.29b to 2.29d (only for enzymes with most control; for the rest, refer to: pg. 74) :
PDH ; CS ; IDHa ; α-KGDH ; SDH ; PC ; ATPsynth ; ATPhyd
• Figure 2.29a is a result of 7 simulations at different PDH activities. Figures 2.29b to 2.29d describe the
complete flux control distribution at specific activities of PDH used in fig. 2.29a.
• Figure 2.29b includes C J for PDH shown in fig. 2.29a using at V PDHmax = 0.1 mM/sec
• Figure 2.29c includes C J for PDH shown in fig. 2.29a using at V PDHmax = 0.5 mM/sec
• Figure 2.29d includes C J for PDH shown in fig. 2.29a using at V PDHmax = 2.0 mM/sec
• X & Y-axes for figs. 2.29b to 2.29d : Range of ATPsynth maximal activity: 0.0 – 5.0 mM/sec and flux
control coefficient for the flux through CS (CCS) (unitless), respectively.
• The vertical black line represents the initial model value. At this point, in figs. 2.29b to 2.29d,
V ATPsynthmax = 0.886637 mM/sec.
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• Figure 2.30. Effect of different ATPsynth activities on the
flux control coefficient of PDH: plotted against a fixed range of PDH maximal activity.
• Key for figs. 2.30b to 2.30d (only for enzymes with most control; for the rest, refer to: pg. 74) :
PDH ; CS ; IDHa ; α-KGDH ; SDH ; PC ; ATPsynth ; ATPhyd
• Figure 2.30a is a result of 10 simulations at different ATPsynth activities. Figures 2.30b to 2.30d describe
the complete flux control distribution at specific activities of ATPsynth used in fig. 2.30a.
• Figure 2.30b includes C J for PDH shown in fig. 2.30a using at V ATPsynthmax = 0.05 mM/sec
• Figure 2.30c includes C J for PDH shown in fig. 2.30a using at V ATPsynthmax = 0.35 mM/sec
• Figure 2.30d includes C J for PDH shown in fig. 2.30a using at V ATPsynthmax = 5.0 mM/sec
• X & Y-axes for figs. 2.30b to 2.30d : Range of PDH maximal activity: 0.0 – 2.0 mM/sec and flux control
coefficient for the flux through CS (CCS) (unitless), respectively.
• The vertical black line represents the initial model value. At this point, in figs. 2.30b to 2.30d,
V PDHmax = 0.648 mM/sec.
Figures 2.28 to 2.30 (see, pgs. 81 to 83) and observations made earlier on pg. 80
concerning the PDH maximal activity, indicate the importance of choosing physiologically
relevant values for key model parameters such as enzyme activities. Figures 2.28a, 2.29a
and 2.30a show that the complex pattern of CJ distribution observed earlier can become
nearly hyperbolic, but only at significantly lower values of enzyme activities than those
used in the model. For example, the CJ curve can become nearly hyperbolic when —
(a.) V PCmax is at least 10 times lower (0.23 mM/sec) than its initial model value (2.26
mM/sec; see fig. 2.28a) or (b.) V PDHmax is at least 6 times lower (0.1 mM/sec) than its
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initial model value (0.65 mM/sec; see fig. 2.29a) or (c.) V ATPsynthmax is at least 4 times
lower (0.225 mM/sec) than its initial model value (0.9 mM/sec; see fig. 2.30a). More
importantly, these figures show that the rapid transfer of control between PDH and other
TCA cycle enzymes changes with change in the initial model values of enzyme activity
parameters. For example, at very low V ATPsynthmax values (0.05 mM/sec; see fig. 2.30b), the
rapid exchange of control is between PDH & ATPsynth; at 0.35 mM/sec, the exchange is
between PDH & SDH plus α-KGDH (see, fig. 2.30c); and at 5.0 mM/sec, the exchange is
between PDH & PC, SDH, plus α-KGDH (see, fig. 2.30d). These figures also show that
the slope of CJ transition curve increases with an increase in the initial model value and
vice versa. For example, in fig. 2.28a, as V PCmax is increased from 1.13 to 4.53 mM/sec or
in fig. 2.30a as the V ATPsynthmax is increased from 0.25 to 5.0 mM/sec, the steepness (slope)
of the CJ curve for PDH increases.
In the case PC activity, the lower value at which the CJ curve is nearly hyperbolic
(0.23 mM/sec), is at least 400% lower than the basal PC activity (1.02 mM/sec) reported
in literature; which is shown to be approx. 20% of activity for maximally activated
enzyme (Ashman et al., 1972; Fahien and Teller, 1992; Scrutton, 1974; Scrutton and
White, 1972). Incidentally, fig. 2.28a includes CJ curves near to the reported values
of both basal (1.02 mM/sec; shown in ) as well as maximal activities (5.1 mM/sec;
shown in ; Fahien and Teller, 1992) and shows that the complex CJ pattern exists
even at the physiologically relevant PC activities. For PDH activity, the lower value at
which the CJ curve is nearly hyperbolic (0.1 mM/sec), is in fact within close range of the
reported PDH activity in rat heart mitochondria (Kerbey et al., 1976; Kohn et al., 1979b).
Therefore, at this level of PDH activity, though the observed CJ curve is hyperbolic (see,
figs. 2.29a and 2.29b), the resulting flux control distribution does not correctly represent
the normal physiological state of the mammalian liver-specific TCA cycle.
For ATPsynth activity, the initial model value used in the model (0.9 mM/sec), is
a fitted estimate of the ATP synthase rate constant. The unidirectional rate constant
(k fwd) of ATP synthase (rate of Pi −→ ATP incorporation) calculated by 31P NMR
saturation-transfer measurements under varying cardiac performance conditions using
Langendorff-perfused rat hearts, is seen to vary from 0.2 to 0.8 mM/sec between the
data presented in Bittl and Ingwall (1985); Kingsley-Hickman et al. (1986); Spencer et al.
(1988) ∗. Although Kingsley-Hickman et al. report this rate constant to be twice as large
than the actual net rate of ATP synthase in intact rat hearts, this range gives us a good
enough approximation of k fwd for ATPsynth. Also, in pig hearts, k fwd for ATPsynth
varies between a much wider range, from 0.04 to 1.2 mM/sec (originally reported in
sec-1; Zweier and Jacobus, 1987). Thus, our fitted estimate for the initial model value of
∗In these reports, the unidirectional rate constants (k fwd) of ATP synthase are originally shown
in units: sec-1. The values shown here are a product of the rate constant and the concentration of
F1F0-ATPase, in mM. Concentration of F1F0-ATPase was taken from Cortassa et al. (2003), originally
reported by Magnus (1995); Magnus and Keizer (1997). Here, a median value of the reported range is
used for these calculations.
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V ATPsynthmax (0.9 mM/sec) appears to be within close range of the reported physiological
values. For ATPsynth activity, although the lower value at which the CJ curve is nearly
hyperbolic is within the reported range of k fwd for ATPsynth, it is very close to the lower
limit of the range (0.225 mM/sec; shown in ).
However, the steady-state data at such lower values of ATPsynth activity, shows
that the previously observed dynamic behaviour of this model is significantly altered at
this rate of ATP synthase (data not shown). For instance, at this lower rate of ATPsynth
activity, the ‘redox state’ (NADH/NAD+) of this model shifts from oxidised (≈ 0.6 – 0.7)
to reduced (≈ 4.0 – 5.0) and its ‘energy state’ (mitochondrial ATP/ADP) shifts from being
‘ATP-rich’ (≈ 2.0 – 3.0) to ‘ADP-rich’ (≈ 0.7 – 0.8). These observations confirm that
although less complex, the CJ distribution at such lower values of ATPsynth activity,
describes a metabolic state which is dynamically distinct from the normal physiological
state of the mammalian liver-specific TCA cycle.
In liver TCA cycle models, two of the most controlling enzymes, PDH & PC, share
pyruvate as a common primary substrate and acetyl-CoA as a common allosteric effector.
From Methods (see pg. 223 in Appendix B), we know that pyruvate dehydrogenase is
competitively inhibited by acetyl-CoA with respect to CoAm (Bremer, 1969); whereas,
for pyruvate carboxylase, acetyl-CoA is an effective allosteric activator (Scrutton and
Utter, 1967; see pg. 221 in Appendix B). Therefore, in liver TCA cycle models, if the
mitochondrial AcCoA/CoA ratio is increased, it would inhibit PDH and lower its flux
and activate PC, thereby increasing the flux through it. It would be interesting to find
out if the acetyl-CoA -induced activation of pyruvate carboxylase affects the distribution
of flux control and whether it is significant enough to change the presently observed
pattern of distribution.
In the liver TCA cycle model, the apparent maximal activity of PC (V PCapp) is modelled
as a function of acetyl-CoA & Mg2+ concentrations, which is evaluated dynamically
through a separate algebraic expression (see pg. 222 in Appendix B) and substituted into
the rate equation during model simulation. For further details regarding the PC rate
equation, please refer to pg. 221 in Appendix B. Therefore, given the model definition
of V PCapp and the significantly changing AcCoAm concentration (as shown in, figs. 2.13
to 2.15 on pgs. 50 to 52, respectively), it is probable that the ‘variable’ V PCapp value causes
the PC flux to change and thereby affects the distribution of flux control in liver TCA
cycle models to some degree. However, before analysing the flux control data any further,
we must determine the possible extent of V PCapp variability in the liver TCA cycle model,
as key enzyme activities/ metabolite concentrations are varied. Therefore, the limits of
V PCapp variability in the liver TCA cycle model was evaluated using a specifically-modified
Python function, described earlier in Methods (see Appendix D on pg. 237 and Listing D.1
on pg. 238). Figure 2.31 shows the limits of V PCapp variability in the liver TCA cycle
model, in response to changes in key enzyme activities/ metabolite concentrations.
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Figure 2.31 also includes the V PCapp value for a control condition, where it was
computed using a model containing all CoA–related metabolites as external metabolites.
A (negative) control value of V PCapp, constant at 2.26 mM/sec (shown using ∗, in Red)
provides a baseline variation against which the liver TCA cycle model data can be
compared. Please refer to Methods for further details of this control condition model
(see, pg. 29).
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• Figure 2.31. Dynamic nature of PC apparent maximal activity (V PCapp):
against a fixed range of change in the key enzyme activities or metabolite concentrations.
• Key for variation in V PCapp value against a change in maximal activity or concentration of :
PC ; MDH ; PDH ; ATPsynth ; Pim ; Mg 2+ ; Pyrm
• The plot shown above is a combined result of 7 different simulations, one for each enzyme activity or
metabolite concentration selected.
• Each plot line, shown in different colours, represents the variation in V PCapp value against a change in maximal
activities of key TCA cycle enzymes or metabolite concentrations. e.g. line shown in Red represents variation
against PDH maximal activity.
• Line plotted using ∗, in Red: represents the V PCapp value under control conditions, computed by defining
all CoA–related metabolites in the model as ‘external’. Also, this value was computed by varying the PDH
maximal activity and since in this control model, all CoA–related metabolites are external, the computed
value remains constant (at 2.26 mM/sec; ∗; in red); unlike the variation seen in the existing model (solid line
in red), where all CoA–related metabolites are internal.
• The vertical black line represents the position of the respective initial model values for every selected
parameter on the combined X-axis. At this point,
• V PCmax = 2.26234 mM/sec (apparent velocity) • V MDHmax = 26.752 mM/sec • V PDHmax = 0.648 mM/sec
• V ATPsynthmax = 0.886637 mM/sec • Pim, Mg 2+ & Pyrm conc. = 8.9, 0.37 & 0.2 mM, respectively.
• In the plot shown above, though all lines appear to pass through a common point, it is simply an artefact
introduced by the respective scales chosen for both axes. When the same data is observed at a higher scale,
the artefact disappears to show that none of these lines pass through a common point.
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Overall, fig. 2.31 shows that in the liver TCA cycle model, the V PCapp value can vary
between 1.0 to 3.0 mM/sec, when the initial conditions are perturbed either by changing
enzyme activities or metabolite concentrations. It also means that in the liver TCA cycle
model, the pyruvate carboxylase flux is likely to vary similarly under these conditions, as
shown in figs. 2.17 and 2.20 & also in fig. I.4 and fig. I.8 in supplementary material (see
pgs. 56 and 64 & pg. XII and pg. XVI, respectively). This unique dynamic characteristic
of the PC kinetics could act as one of the factors responsible for the complex nature
of flux control distribution in liver TCA cycle models. Therefore, examining a direct
causality between V PCapp and the emergent complexity of flux control distributions in
the updated model is essential and can be achieved by modifying the existing model
definition of V PCapp from a ‘variable’ to a ‘constant’. Thus, in yet another variation of the
existing updated model, the separate V PCapp algebraic expression (see eq. B.3 on pg. 222)
was replaced by a parameter with a value of 2.26 mM/sec and the corresponding flux
control coefficients were computed using this variant model — “PC knock-down” model
(PCkd). Please refer to Methods for further details of the PCkd model (see, pg. 29).
Figure 2.32 (see, pg. 88) shows the distribution of flux control coefficients in the
PCkd model, against the change in maximal activities of ATPsynth & PDH, respectively.
Figures 2.32a and 2.32b are comparable to figs. 2.25a and 2.25b (see, pg. 74) respectively,
that are computed using the updated liver TCA cycle model; wherein, V PCapp is a variable.
Figure 2.32 shows that a deviation from the dynamic definition of V PCapp to a constant
value does significantly affect the earlier seen pattern of CJ distribution in the updated
liver TCA cycle model. It is evident that the complex pattern of CJ distribution seen in
fig. 2.25 becomes relatively less complex in fig. 2.32. And yet the CJ transition curves
shown in fig. 2.32 are not exactly hyperbolic; which suggests that the dynamic definition
of V PCapp is only partially responsible for the emergence of such complex CJ distribution
patterns in liver TCA cycle models.
In PCkd, a constant value of V PCapp also affects the TCA cycle flux and the sharing
of control between key enzymes, quantitatively. Against the change in PDH activity,
the PCkd TCA cycle flux is increased by nearly 2–folds (see, fig. 2.32d), compared to
that in the updated model (see, fig. 2.25d; please note the different Y-axis scales between
the two plots). Also, in the PCkd model, the sharing of control between key enzymes is
comparatively more in favour of pyruvate carboxylase (see, figs. 2.32a and 2.32b) than
that in the updated model (see, figs. 2.25a and 2.25b).
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• Figure 2.32. Control of TCA cycle flux in the PCkd model:
Distribution of flux control coefficients, against the ATPsynth & PDH activities, respectively.
• Key for figs. 2.32a and 2.32b is as follows :
PDH ; CS ; ACO ; IDHa ; α-KGDH ; SCS;
SDH ; FM ; MDH ; ATPsynth ; ANT ; ATPhyd;
PC ; MC ; IDHb ; Total Sum (dotted line)
• In the PCkd model, V PCapp is a constant, at 2.26 mM/sec.
• Other conditions as shown in fig. 2.25 on pg. 74.
2.3.5.3 The complex pattern of variation in flux control coefficients of Liver
TCA cycle models: Insights from structural properties
As seen earlier, the updated liver TCA cycle model exhibits branching of the TCA cycle
at various junctions. In such a systems, it is often difficult to separate between the effects
caused by the kinetic or thermodynamic characteristics and those that are influenced by
the structural features of the system. The evolution of complex flux control distribution
patterns in the updated liver TCA cycle model is one such phenomenon. The evidence
presented so far, suggests that the dynamic properties of this model do not fully explain
the emergence of these complex patterns and therefore can not be deemed conclusive,
unless the possible effects of the structural properties are ruled out.
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Therefore, to eliminate possible effects due to the structural properties of the model,
the control distribution patterns were studied using a reduced version of the model, as
described in Methods (see, pg. 30). This reduced liver TCA cycle model contains a total
of 10 reactions. It comprises a single enzyme subset that contains 8 out of 10 possible
TCA cycle reactions, except IDHa & IDHb; which act as independent reactions. This
model also results in fewer elementary modes (3 modes) compared to the full version
(9 modes); where, 2 modes describe the complete TCA cycle function in this model,
dependent on either IDHa or IDHb. The remaining mode is an internal cycle between
IDHa (forward flux) and IDHb (reverse flux).
Figure 2.33 (see, pg. 90) describes the flux control distribution for TCA cycle flux in
the reduced liver TCA cycle model, against the maximal activity of PDH.
Figure 2.33a shows that even in the reduced version of the liver TCA cycle model, a
rapid exchange of control between key TCA cycle enzymes over a short range of enzyme
activity, is a central feature of the evolved pattern of control distribution. In fig. 2.33a,
CJ for PDH dominates and after a rapid exchange, the extent of control lost from PDH
is picked up mostly by α-KGDH & SDH; which is quite similar to the distribution of
control observed in the full model (see, fig. 2.25). Furthermore, fig. 2.33a shows that CJ
transition curves for the reduced model are clearly sigmoidal, rather than hyperbolic.
Figure 2.25b provides an indication of the sigmoidal nature of CJ transition curves in
the full version of the model; however, it is partially obscured by artefacts which result
from the additional structural as well as kinetic complexities that prevail in this model.
Similar rapid transfer of control between key enzymes, characterised by sigmoidal
transition curves, has been observed in the Calvin cycle model (Fell et al., 1999) with
experimental validations for two key enzymes involved: rubisco (Stitt et al., 1991) and
sedoheptulose bisphosphatase (Poolman et al., 2001). The same phenomenon was observed
in a simple model of a linear, two-step pathway (Letellier et al., 1994), as well as in more
complex models of oxidative phosphorylation (Korzeniewski and Mazat, 1996b; Liguzinski
and Korzeniewski, 2006), and therefore in theory, it is not limited to cyclical systems.
In all cases, the effect was associated with saturating substrate concentrations (i.e. at
Km,S  [substrate]). Comparison of the liver TCA cycle intermediate concentrations
in liver mitochondria and respective Km values of the liver TCA cycle enzymes suggests
that most of these enzymes are apparently saturated with respect to their substrate(s).
Hence, we studied how the saturation level of key enzymes affects the emergence of
complex control distribution pattern in this system, in further detail ∗.
∗On pg. 67, we have already clarified the actual meaning of the term ‘saturated’ in the context of
liver TCA cycle models. Please refer to the 2nd paragraph of itm. 2 on that page.
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• Figure 2.33. Control of TCA cycle flux in the reduced liver
TCA cycle model: effect of PDH substrate saturation changes, against the PDH activity.
• Key is as follows :
PDH ; CS ; α-KGDH ; SDH ; MDH
• In fig. 2.33a, the flux control coefficients are calculated with the reduced model as is; wherein, the respective
substrate concentrations for PDH far exceed their corresponding Km values, i.e. at Km,S  [substrate].
• Whereas, in figs. 2.33b and 2.33c, the flux control coefficients are calculated with a modified reduced
model; wherein, the respective Km values for PDH substrates are set equal to their corresponding substrate
concentrations, i.e. Km,S = [substrate].
• X-axis: Range of PDH maximal activity for figs. 2.33a and 2.33b: 0.0 – 2.0 mM/sec (approx. 3 times the
initial model value of PDH maximal activity, 0.65 mM/sec).
• X-axis: Range of PDH maximal activity for fig. 2.33c: 0.0 – 100.0 mM/sec (approx. 150 times the initial
model value of PDH maximal activity, 0.65 mM/sec).
• The vertical black line represents the initial model value. At this point, in figs. 2.33a and 2.33b,
V PDHmax = 0.648 mM/sec, respectively.
• Orange dotted line shows the Summation theorem result across the entire range.
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Figure 2.33b (see, pg. 90) shows the distribution of flux control coefficients against
PDH maximal activity, when PDH is no longer saturated with respect to its substrates
(i.e. Km,S = [substrate]). The range of PDH maximal activity displayed in this plot
is exactly the same as shown in fig. 2.33a — 0.0 – 2.0 mM/sec (i.e. approx. 3 times
(3X) the initial model value of V PDHmax (X); where, X = 0.65 mM/sec). Within this
range of PDH activity, the steep CJ transition curves seen earlier in fig. 2.33a, are
eliminated and the CJ for PDH remains close to unity. Therefore, the rapid transfer
of control between key enzymes, characterised by sigmoidal transition curves, observed
at saturating conditions for PDH (i.e. Km,S  [substrate]; fig. 2.33a), is completely
lost with desaturation of PDH with respect to its substrates (i.e. Km,S = [substrate];
fig. 2.33b). At these conditions, flux through the system is now controlled by PDH alone,
and has become virtually insensitive to changes in other enzyme activities.
As shown in fig. 2.33c (see, pg. 90), some of the central features of flux control
distribution are restored even at ‘non-saturating’ conditions for PDH, but only over a
much wider range of PDH activity, between 0.0 – 100.0 mM/sec (i.e. approx. 150 times
(150X) the initial model value of V PDHmax (X); where, X = 0.65 mM/sec). In fig. 2.33c,
majority of the control is eventually transferred to α-KGDH, SDH and CS; when the
PDH activity is around 30 – 60 times its initial model value (i.e. between 20.0 – 40.0
mM/sec). Nevertheless, such a large hypothetical increase in the PDH maximal activity
is unlikely to have any physiological relevance; since, in rat heart mitochondria, increases
in PDH activation apparently result in at most a 5–fold increase in the total PDH activity
(Dennis et al., 1979; Hutson et al., 1978).
Thus, analysis of the reduced version of liver TCA cycle model shows that the
phenomenon of rapid exchange of flux control between key enzymes is independent of the
structural as well as kinetic or thermodynamic complexities of liver TCA cycle models.
It also suggests that the specific features of flux control transition curves, such as the
slope or exact trajectory of these curves, are sensitive to change in the structural as well
as kinetic properties of liver TCA cycle models; while the underlying central property
of rapid exchange of control remains unaffected. Furthermore, our studies with the
enzyme saturation kinetics indicate the possibility of it being the only determining factor
responsible for the characteristic sigmoidal CJ distribution curves in metabolic systems
with saturable enzyme kinetics. However, as a general property of all saturable metabolic
systems, the enzyme saturation dependence of sigmoidal CJ curves, is still disputable,
until tested against other generic, saturable metabolic systems.
Therefore, to explore the control properties of some simple models, we built 4-step
simple test models, both linear and cyclical, as described in Methods (see, pg. 31). In
this four-reaction cyclical test model, when at least one of the controlling enzymes is
saturated with respect to its substrates, the same flux control distribution properties
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are observed, as seen earlier in the reduced version of the liver TCA cycle model (see,
fig. 2.33). Figure 2.34 (see, pg. 93) describes the flux control coefficient curves for a
four-reaction cyclical test model.
Figure 2.34a shows that in a 4-step cyclical test model, when only one of the
rate-controlling enzymes (‘R4’) is saturated with respect to its substrate (‘S4’) (i.e.
at KR4S4m  [S4]), the distinctive sigmoidal CJ transition curves emerge; wherein, the
sharing of control between key enzymes shifts abruptly, against the ‘R4’ activity. Also, it
shows that as the degree of saturation is reduced, these characteristically sigmoidal CJ
transition curves become increasingly more hyperbolic. On the other hand, fig. 2.34b
shows that if more than a single enzyme is saturated with respect to its substrate (i.e.
KR4S4m  [S4] & KR1S1m  [S1]), the same CJ transition curves become progressively less
steep as the value of KR4S4m is increased (and as the value of KR1S1m is kept as is). However,
in this case, these curves continue to be sigmoidal in form, since the other enzymes in
this system remain saturated (i.e. KR1S1m  [S1]). This is quite similar to the situation in
the reduced liver TCA cycle model. As shown earlier, at ‘non-saturating’ conditions for
PDH, over a narrow range, the rapid exchange of control between the key enzymes is
eliminated entirely (see, fig. 2.33b); however, over a much wider range, the characteristic
exchange of control between key components is restored (see, fig. 2.33c), since at least
one of the remaining TCA cycle enzymes is saturated with respect to its substrates.
Therefore, if all enzyme-saturation is eliminated across the entire liver TCA cycle system,
the resultant CJ transition curves can be expected to be hyperbolic.
Furthermore, fig. 2.35 (see, pg. 94) shows that this phenomenon is not limited to
the cyclical models, but can also exist in linear systems, as exemplified by the 4-step
linear test model in this plot. Thus, our analysis of both the full and reduced versions of
liver TCA cycle models, as well as the 4-step cyclical & linear test models, suggests that
in saturable metabolic systems such as these, the emergence of sigmoidal CJ transition
curves is symptomatic of the prevalence of enzyme saturation with respect to substrates
in the system and vice versa. In such systems, the enzyme saturation can even be
considered as the only prerequisite for the characteristic CJ patterns we have seen so
far; as well as being independent of any other additional kinetic, thermodynamic or
structural aspects.
— Ph.D. Thesis by Amar S. Ghaisas — Page 92
2. Liver TCA cycle model 2.3. Results for the liver TCA cycle . . .
 0
 0.2
 0.4
 0.6
 0.8
 1
 0.5  1  1.5  2  2.5  3  3.5  4
C
J  
(J
 =
 f
lu
x
 t
h
ro
u
g
h
 R
2
)
R4 maximal activity (mM/sec)
4 Reaction Cyclic Test Model
2.34.a. at KR4S4m  [S4]
 0
 0.2
 0.4
 0.6
 0.8
 1
 0.5  1  1.5  2  2.5  3  3.5  4
C
J  
(J
 =
 f
lu
x
 t
h
ro
u
g
h
 R
2
)
R4 maximal activity (mM/sec)
4 Reaction Cyclic Test Model
2.34.b. at KR4S4m 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 [S1]
• Figure 2.34. Distribution of flux control coefficients in a
cyclical test model: effect of ‘R4’ saturation variations, against the ‘R4’ maximal activity.
• Plotted here are the C J curves for ‘R1’ & ‘R4’, two reactions that share majority of control in this 4-step
cyclical test model, against the ‘R4’ maximal activity.
• Key is as follows : ‘R4’ ; ‘R1’
• In this figure the flux control coefficients are calculated with variations in the KR4S4m value; when :
• Figure 2.34a : ‘S4’ concentration far exceeds its corresponding Km value (i.e. at KR4S4m  [S4]); and
• Figure 2.34b : The respective concentrations of ‘S4’ & ‘S1’, far exceed their corresponding Km values
(i.e. at KR4S4m  [S4] & at KR1S1m  [S1])
• In this 4-step cyclical test model, the initial concentrations of ‘S4’ & ‘S1’ are set equal to 1.0 mM and
their respective initial Km values are set equal to :
• Figure 2.34a : KR4S4m = 0.1 mM & KR1S1m = 1.0 mM; and
• Figure 2.34b : KR4S4m = 0.1 mM & KR1S1m = 0.1 mM.
• The flux control coefficients are calculated within a wide range of KR4S4m values, from 0.001 to 10.0 mM.
• In these plots, matching line-types correspond to the same KR4S4m value within the given range and the
shallowest curves correspond to the highest value in that range.
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• Figure 2.35. Distribution of flux control coefficients in
a linear test model: effect of ‘R4’ saturation variations, against the ‘R4’ maximal activity.
• Plotted here are the C J curves for ‘R1’ & ‘R4’, two reactions that share majority of control in this 4-step
linear test model, against the ‘R4’ maximal activity.
• Key is as follows : ‘R4’ ; ‘R1’
• In this figure the flux control coefficients are calculated with variations in the KR4S4m value; when the
respective concentrations of ‘S4’ & ‘S1’, far exceed their corresponding Km values, i.e. KR4S4m  [S4] &
KR1S1m  [S1], respectively.
• In this 4-step linear test model, the initial concentrations of ‘S4’ & ‘S1’ are set equal to 1.0 mM and their
respective initial Km values are set equal to 0.1 mM.
• The flux control coefficients are calculated at several different values of KR4S4m , within a wide range of
values from 0.001 mM to 10.0 mM.
2.3.5.4 Distribution of flux control coefficients in the Liver TCA cycle
models: Emergence of nearly-hyperbolic curves
As a further validation of our hypothesis, full version of the liver TCA cycle model was
tested for the elimination of characteristic CJ transition curves by reducing the enzyme
substrate saturation, similar to the analysis of reduced models. However, as a preliminary
test, only PDH substrate saturation was eliminated gradually by increasing the Km value
corresponding to its primary substrate, pyruvate (i.e. KPDHPyrm ). Figure 2.36 (see, pg. 95)
describes the respective CJ curves for PDH, PC, SDH & ATPsynth, against V PDHmax , at
increasing values of KPDHPyrm .
Figure 2.36 shows that reducing the substrate saturation of PDH alone is clearly
not sufficient to render hyperbolic flux control curves in the full liver TCA cycle model,
unless the value of KPDHPyrm is extremely high (KPDHPyrm  1.0 mM). However, at this value,
CJ for PDH is close to unity and gains nearly all control of the TCA cycle flux, rendering
it insensitive to changes in the activities of other TCA cycle enzymes. At KPDHPyrm = 1.0
mM, although PDH is completely desaturated with respect to pyruvate (since, its
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initial concentration is 0.2 mM), the resultant CJ transition curves are characteristically
sigmoidal. Even a simultaneous reduction in the saturation of PDH primary as well
as co-substrates (Pyrm, CoAm & NADm+), fails to show any significant improvement in
these sigmoidal curves (data not shown); since, the other TCA cycle enzymes are still
saturated with respect to their corresponding substrate(s). Therefore, fig. 2.36 confirms
our earlier conclusions and suggests a system-wide reduction in the substrate saturation
of TCA cycle enzymes, at least with respect to key primary substrates, in order to render
nearly-hyperbolic CJ transition curves in the updated liver TCA cycle model.
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• Figure 2.36. Flux control distribution for the control
of TCA cycle flux in the full liver TCA cycle model: against the maximal activity of
PDH, with & without substrate saturation modifications in the PDH kinetics w.r.t. pyruvate.
• This plot is a result of 4 simulations at different values of KPDHPyrm , viz.– 0.01, 0.1, 1.0 & 5.0 mM; where,
KPDHPyrm = 0.01 is the initial model value.
• In liver TCA cycle models, the initial concentration of pyruvate (Pyrm) is 0.2 mM.
• X-axis: Note that the range of PDH maximal activity is exactly the same as used earlier in figs. 2.25b,
2.33a and 2.33b on pgs. 74 and 90, respectively (i.e. 0.0 – 2.0 mM/sec).
• The vertical black line represents the initial model value. At this point, V PDHmax = 0.648 mM/sec.
Therefore, this test analysis was followed up by investigating the effect of a simul-
taneous, system-wide reduction in the substrate saturation of enzymes in the updated
model, with respect to:
1. All corresponding primary substrates:
For this part of the analysis, corresponding Km parameters for all primary substrates
were replaced with a common parameter, Kα; which was then varied within a wide
range between 1.0 to 10.0 mM and at each new value of Kα, the flux control coefficients
were calculated for PDH & PC, two most-controlling enzymes in this model, against
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the PDH maximal activity. Figure 2.37a (see, pg. 97) shows the effect of different
values of Kα on CJ for PDH & PC, respectively. Figure 2.38a (see, pg. 98) shows
a complete flux control distribution for all enzymes in the updated model, against
the PDH maximal activity, for a specific Kα value (Kα = 1.6 mM), from the earlier
given range of values.
2. All corresponding primary substrates as well as key co-substrates:
For this part, corresponding Km parameters for selected key co-substrates were
replaced with a common parameter, Kβ. These key co-substrates were selected by the
process of elimination, based on their degree of impact on the elimination of sigmoidal
CJ transition curves. The Kα,Kβ values were varied simultaneously, within a short
range between 1.0 to 3.0 mM and the flux control coefficients were calculated for each
new value ∗. Figure 2.37b (see, pg. 97) shows the effect of simultaneous change in the
Kα,Kβ values, on the PDH & PC coefficients, against the PDH maximal activity.
Figure 2.38b (see, pg. 98) shows a complete flux control distribution for all enzymes
in the updated model, against the PDH maximal activity, for a specific Kα,Kβ value
(Kα,Kβ = 1.6 mM), from the earlier given range of values.
In the updated liver TCA cycle model, comparing all metabolite concentrations to
their respective Km values shows that 13 out of 15 TCA cycle enzymes are saturated with
respect to their primary as well as co-substrates; with the exceptions of ATP synthase
& ATP hydrolysis. ATPsynth is functional at nearly non-saturating conditions; while
ATPhyd is modelled as a simple first-order mass-action reaction. Figures 2.37a and 2.38a
(see, pgs. 97 and 98, respectively) exhibit sigmoidal CJ transition curves, as a result of
varying Kα for 13 key TCA cycle enzymes. These figures also show that such a significant,
system-wide reduction in the primary substrate saturation of enzymes is still insufficient
to eliminate the sigmoidal CJ transition curves in the updated model and suggest that
at least some of these key enzymes should be concurrently desaturated with respect to
their corresponding co-substrates, as well.
A simultaneous, system-wide reduction in the saturation of all primary as well as
co-substrates for all 13 enzymes in the updated liver TCA cycle model was ruled out
immediately, due to the kinetic instability introduced by such system-wide changes in the
model. Therefore, through the process of elimination, 9 out of 15 possible co-substrates
were finalised, based on their moderate-to-high impact on the elimination of sigmoidal
CJ transition curves in the updated liver TCA cycle model.
∗Due to kinetic instability of the updated liver TCA cycle model for Kα,Kβ values beyond 3.0 mM,
a much shorter range (1.0 to 3.0 mM) was selected for their concurrent variation in the model, compared
to that for the variation of Kα alone (1.0 to 10.0 mM). However, it must be noted that finding a region
of kinetic instability in a model this size is not entirely unexpected, especially when the said analysis
involves simultaneous variations in 22 enzyme saturation parameters of the model.
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• Figure 2.37. Flux control
coefficients for PDH & PC, in the full liver TCA cycle model, against the change in
PDH activity: with modifications in the substrate saturation for all liver TCA cycle enzymes.
• Key is as follows : PDH ; PC
• Figure 2.37a: This plot is a result of 6 simulations at different values of Kα, viz.– 1.0, 1.6, 2.5, 4.5, 8.0 &
10.0 mM.
• Figure 2.37b: This plot is a result of 5 simulations at different values of Kα & Kβ, viz.– 1.0, 1.6, 2.0, 2.5,
& 3.0 mM; so that, for every simulation, Kα = Kβ.
• Kα: a common Km parameter for all primary substrates; Kβ: a common Km parameter for selected key
co-substrates. For further details, please see pg. 96.
• X-axis: Note that the range of PDH maximal activity is exactly the same as used earlier in figs. 2.25b,
2.33a and 2.33b on pgs. 74 and 90, respectively (i.e. 0.0 – 2.0 mM/sec).
• The vertical black line represents the initial model value. At this point, V PDHmax = 0.648 mM/sec.
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• Figure 2.38. Control of the
TCA cycle flux at a specific value of Kα & Kβ: Distribution of flux control coefficients
calculated for the full liver TCA cycle model, against the change in PDH maximal activity.
• Key is as follows (only for enzymes with most control; for the rest, refer to: pg. 74) :
PDH ; CS ; IDHa ; α-KGDH ; SDH ; PC ; ATPsynth ; ATPhyd
• Kα: a common Km parameter for all primary substrates; Kβ: a common Km parameter for selected key
co-substrates. For further details, please see pg. 96.
• X-axis: Note that the range of PDH maximal activity is exactly the same as used earlier in figs. 2.25b,
2.33a and 2.33b on pgs. 74 and 90, respectively (i.e. 0.0 – 2.0 mM/sec).
• The vertical black line represents the initial model value. At this point, V PDHmax = 0.648 mM/sec.
• Orange dotted line shows the Summation theorem result across the entire range.
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Figures 2.37b and 2.38b (see, pgs. 97 and 98) exhibit nearly-hyperbolic flux control
curves, as a result of 4 enzymes being desaturated with respect to primary substrates
alone (Kα), as well as 9 enzymes being desaturated with respect to primary as well as
co-substrates (Kα,Kβ), simultaneously. Therefore, within a given range of change (1.0 to
3.0 mM), using an optimal degree of system-wide enzyme desaturation in the updated
liver TCA cycle model, we have successfully eliminated the sigmoidal CJ transition
curves to render an overall distribution of nearly-hyperbolic CJ curves, without affecting
the underlying central property of rapid exchange of control between key liver TCA cycle
enzymes. (see, fig. 2.38b).
In fig. 2.38, in either case, majority of the control is shared by PDH & PC; while
the remaining control is uniformly shared between ATPsynth, CS & IDHb. Also, the
rapid exchange of control between key enzymes is much more gradual compared to that
in fig. 2.25b (see, pg. 74). In fact, at initial conditions (i.e. V PDHmax = 0.65 mM/sec), the
gradual exchange of control between key enzymes is such that, in fig. 2.38a, PDH has
majority of the control; whereas in fig. 2.38b, PC has majority of the control. Moreover,
fig. 2.38 shows that a system-wide enzyme desaturation in the updated model completely
destroys the significant extent of control shared by SDH, α-KGDH & IDHa in the original
and far more saturated liver TCA cycle system, as seen earlier in fig. 2.25b. Instead,
as seen in fig. 2.38b, CS and IDHb appear to acquire a small share of control, post
system-wide enzyme desaturation.
Therefore, this analysis not only confirms that the phenomenon of rapid exchange of
flux control between key enzymes is independent of the structural as well as kinetic or
thermodynamic complexities of the liver TCA cycle model, it also supports our earlier
hypothesis that in liver TCA cycle models, if substrate saturation for all enzymes is
eliminated across the system, the resultant CJ transition curves can be expected to be
hyperbolic. Also, through such comprehensive set of analyses, we have accumulated
sufficient evidence to confirm that the dependence of sigmoidal flux control coefficient
curves on the extent of substrate saturation of enzymes is a general property of metabolic
systems with saturable enzyme kinetics.
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2.3.5.5 Concentration control coefficient analysis for Liver TCA cycle
models
In this section, we shall analyse the concentration control coefficients (CS) of TCA cycle
intermediate metabolites, calculated with respect to all enzymes in the model. For the
concentration control coefficients, we will only focus on the updated liver TCA cycle
model data, as mentioned earlier in the case of flux control coefficients. Liver TCA
cycle models contain 16 internal metabolites, all of which can be analysed using the
concentration control coefficients. However, in this section, we have presented data for
only a selected group of metabolites. These metabolites were selected as follows —
• Citrate :
• Since, it is produced by citrate synthase; which represents the TCA cycle flux.
• Since, Citm, along with αKGm, tends to accumulate in the system (see, pg. 59).
• Oxaloacetate :
• Since, it is produced by pyruvate carboxylase; which has a high degree of flux
control and it is a point of entry for the anaplerotic carbon into the cycle.
• Since, [OAAm] is often a limiting factor for citrate synthesis (Olson and Williamson,
1971; Shepherd and Garland, 1969; Williamson et al., 1967a,b, 1972).
• Acetyl-CoA :
• Since, it represents a point of entry for the TCA cycle carbon and acts as CS a
substrate; the rate of which, represents the overall TCA cycle flux.
• Since, V PCapp is defined as a function of [AcCoAm] (see eq. B.3 on pg. 222).
• NADHm, ATPm, & ATPc :
• Since, among other factors, they comprise the ‘energy status’ of a cell.
Figures 2.39 to 2.41 (see pgs. 101 to 103, respectively) show the distribution of
concentration control coefficients for the aforementioned TCA cycle intermediate metabo-
lites, against the change in PC maximal activity. Also, fig. 2.42 (see, pg. 105), gives
a qualitative overview of the control distribution for all 16 internal metabolites in the
updated liver TCA cycle model, against the change in PC maximal activity. Moreover,
other qualitatively similar concentration control coefficient plots are included in the
supplementary material, in figs. I.12 to I.14 (see pgs. XX to XXII, respectively).
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• Figure 2.39. Control of TCA cycle
intermediate metabolites: Distribution of concentration control coefficients calculated for
the respective concentrations of OAA & Citrate, against the changing maximal activity of PC.
• Key for figs. 2.39a and 2.39c is as follows :
PDH ; CS ; ACO ; IDHa ; α-KGDH ; SCS;
SDH ; FM ; MDH ; ATPsynth ; ANT ; ATPhyd;
PC ; MC ; IDHb ; Total Sum (dotted line)
• The vertical black line represents the initial model value. At this point, in figs. 2.39a to 2.39d,
V PCmax = 2.26234 mM/sec (apparent velocity).
• Orange dotted line shows the Summation theorem result across the entire range. For concentration
control coefficients, since the sum is equal to zero, the dotted line is not easily visible.
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• Figure 2.40. Control of CoA- & NAD–
related metabolites: Distribution of concentration control coefficients calculated for the
respective concentrations of AcCoA, & NADH, against the changing maximal activity of PC.
• Key for figs. 2.40a and 2.40c is as follows :
PDH ; CS ; ACO ; IDHa ; α-KGDH ; SCS;
SDH ; FM ; MDH ; ATPsynth ; ANT ; ATPhyd;
PC ; MC ; IDHb ; Total Sum (dotted line)
• The vertical black line represents the initial model value. At this point, in figs. 2.40a to 2.40d,
V PCmax = 2.26234 mM/sec (apparent velocity).
• Orange dotted line shows the Summation theorem result across the entire range. For concentration
control coefficients, since the sum is equal to zero, the dotted line is not easily visible.
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• Figure 2.41. Control
of ATP–related metabolites: Distribution of concentration control coefficients calculated
for the respective concentrations of ATPm & ATPc, the changing maximal activity of PC.
• Other conditions as shown in fig. 2.39 on pg. 101.
Figures 2.39, 2.40 and 2.41 (see pgs. 101, 102 and 103, respectively), show the
concentration control coefficients (CS) of OAAm, Citm, AcCoAm, NADHm, ATPm, &
ATPc against the change in PC maximal activity. These concentration control coefficient
plots are presented alongside a steady-state plot of the corresponding metabolite concen-
tration, across the same parameter range (the metabolite concentration ‘S’ for which
the coefficient, ‘CS’ is calculated). In these plots, concentration control coefficients are
distributed between the overall range of −1.5 to 2.0 (unitless). In each plot, a summation
theorem result is also shown using a dotted line; however, for concentration control
coefficients, since the sum is equal to zero, the dotted line coincides with the zero-axis
and hence may not be easily visible.
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As shown in figs. 2.39 to 2.41, the pattern of distribution for concentration control
coefficients is distinctively sigmoidal in most cases and is not as complex as the pattern
observed in the case of flux control coefficients. Also, the phenomenon of rapid exchange
of control between key enzymes, is not a prominent feature of the CS distributions, unlike
that seen in the case of CJ distributions.
From these plots, it is evident that the overall control of TCA cycle intermediates
is uniformly distributed between PC, ATPsynth, IDHa, SDH, & α-KGDH. Unlike in
the case of flux control coefficients, PDH controls only a few TCA cycle intermediates.
Figure 2.42 (see, pg. 105) provides a qualitative overview of the concentration control
distribution across all 16 TCA cycle intermediate metabolites, against the change in PC
maximal activity. From fig. 2.42 we may observe that, PC, ATPsynth, IDHa, SDH, &
α-KGDH share a high degree of concentration control for most TCA cycle intermediates;
whereas, ATPhyd, ANT, MC, & PDH share a moderate-to-high degree of control for
only a few metabolites and the remaining TCA cycle enzymes control only up to 4 out
of 16 TCA cycle intermediates. Later, we shall discuss this schematic in further detail.
Figure 2.39a (see, pg. 101) shows that as the PC maximal activity increases, a
majority of control for oxaloacetate concentration ([OAAm]) is transferred from PC to
ATPsynth. To some degree, the control of [OAAm] is also distributed between IDHa,
α-KGDH, SDH, MDH, & MC. In this case, PC & ATPsynth have positive CS values;
whereas, most of the other enzymes have negative CS values. It means that any increase in
the respective activities of PC & ATPsynth, would cause an increase in [OAAm]; whereas,
increasing the respective activities of, e.g. MDH & MC, would reduce its concentration.
Therefore, the control distribution for oxaloacetate agrees well with the observation made
by Williamson and Cooper, that the mitochondrial oxaloacetate concentration is expected
to be determined by the malate concentration and the NAD+/NADH ratio (Williamson
and Cooper, 1980). Figure 2.39c shows the concentration control distribution for citrate;
which, apart from its qualitative similarities to the oxaloacetate control distribution, also
includes positive coefficients for CS & PDH, along with a large negative coefficient for
SDH.
Figure I.12a (see, pg. XX), shows the control distribution for α-ketoglutarate concen-
tration ([αKGm]) and apart from its qualitative similarities with the control distributions
for Citm & OAAm (see, figs. 2.39a and 2.39c), it shows a positive coefficient for IDHa
as well as includes coefficients for ACO & IDHb. Figure I.12c shows the concentration
control distribution for malate; where, a large negative CS for MC counteracts a group
of positive coefficients for IDHa, SDH, ATPsynth, & PC.
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• Figure 2.42. Control of TCA cycle intermediate metabolites:
An overview of the distribution of concentration control coefficients in the updated liver TCA
cycle model; against the changing maximal activity of pyruvate carboxylase.
• This figure shows the overall distribution of concentration control coefficients for all TCA cycle intermediate
metabolites, with respect to all enzymes that share a moderate-to-high degree of control of the respective
concentrations; against the change in PC maximal activity.
• Enzymes shaded in grey have either no control of the respective metabolite concentrations, or an
infinitesimally small share of the overall control.
• This figure is based on the qualitative nature of the coefficient values (i.e. < 0, > 0, or ≈ 0) and does not
reflect the actual quantitative data.
As mentioned earlier, ATPsynth shares a relatively high degree of control for most
TCA cycle intermediates, which can be explained based on its demand for the efficient
supply of NADH from TCA cycle dehydrogenases, as discussed earlier on pg. 75. Similarly,
PC & PDH share a fairly high degree of control for most TCA cycle intermediates, which
can be explained on the basis that these reactions form the initial linear portion of the
TCA cycle pathway and therefore more likely to exhibit a higher degree of control, as
discussed earlier on pg. 75. Also, a high coefficient value for citrate synthase, for the
control of Citm, Isocitm, & αKGm, is to be expected; since, citrate is produced by CS,
which is the first 6-carbon compound to be formed in the cycle and since, there are no
alternative reactions in the model that can produce any of these three metabolites.
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IDHa, α-KGDH, & SDH comprise the latter part of ‘ESS #2’, leading to the conver-
sion of isocitrate to malate, thereby reducing the TCA cycle intermediate metabolite
concentrations; which is reflected in terms of their negative coefficients for metabolites
from the span between oxaloacetate to succinate. In the case of αKGm, a positive CS
for IDHa is an exception and it arises because αKGm is produced solely by IDHa. Also
in this case, a negative CS for IDHb can be explained based on its reverse flux in liver
TCA cycle models, which converts α-ketoglutarate back to isocitrate.
Malate dehydrogenase (MDH) shows a noticeably negative coefficient for metabolites
from the span between OAAm to αKGm; because in liver TCA cycle models, it operates
in its reverse direction, thereby reducing the concentrations of oxaloacetate -dependent
TCA cycle intermediates. Also, as shown earlier in fig. 2.18 (see, pg. 59), the role of
MC as an exporter of TCA cycle carbon in liver TCA cycle models, is also reflected
here in terms of its negative coefficient for all TCA cycle intermediate metabolites.
Figure 2.42 shows that CS for MC is negative for metabolites from the entire span
between oxaloacetate to malate, which basically covers all TCA cycle intermediates.
Figures 2.40 and 2.41 (see, pgs. 102 and 103, respectively), show the distribution of
concentration control coefficients for conserved metabolites in the updated liver TCA
cycle model, against the change in PC maximal activity. Figure I.13 & fig. I.14 in
supplementary material (see, pg. XXI & pg. XXII, respectively) show the distribution of
concentration control coefficients for their corresponding counterparts from the respective
conservation relationships. In fig. 2.40a & fig. I.13a, both acetyl-CoA & CoA show
similar distributions of concentration control, except for the reversal of PDH & SDH
coefficients. PDH produces acetyl-CoA and therefore its positive coefficient dominates
the control of AcCoAm concentration ([AcCoAm]); whereas, it consumes CoAm and
thus, shows a negative coefficient for the control of CoAm concentration ([CoAm]). On
the other hand, any increase in the SDH activity would reduce [AcCoAm] as well as
[SCoAm], thereby restoring the concentration of CoAm via CS & SCS; which reflects
in its corresponding coefficients for AcCoAm (negative) & CoAm (positive). Overall,
the control of CoA–related metabolites is uniformly distributed between PDH, PC,
ATPsynth, IDHa, α-KGDH, & SDH.
The distribution of control for the conserved metabolite pairs of, viz.–
NADm+/NADHm, ATPm/ADPm, & ATPc/ADPc, is a clear reflection of their counterbal-
ancing steady-state behaviour. For NADHm (see, fig. 2.40c) & ATPm (see, fig. 2.41a), the
control is largely distributed between PC, ATPsynth, IDHa, α-KGDH, & SDH. Whereas,
for ATPc (see, fig. 2.41c), the control distributions comprise ATPhyd & ANT; plus PC,
ATPsynth, IDHa, & SDH.
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Pyruvate carboxylase utilises ATPm during the carboxylation of pyruvate, thus
decreasing its availability for the ANT -mediated export to cytosol and therefore, for
the control of ATPm & ATPc concentrations, PC shows a strong negative coefficient. A
large positive coefficient for SDH in this case can be explained on the basis that, any
increase in the SDH activity would require a proportional increase in the ‘ESS #2’ flux
(i.e. CS flux), which would ultimately increase the respective concentrations of NADHm,
ATPm, & ATPc. Also, positive coefficients for IDHa & ATPsynth can be explained in
terms of the supply & demand blocks of the TCA cycle, as discussed earlier on pg. 75.
The control distribution of ATPc concentration (see, fig. 2.41c), shows that ATPhyd
& ANT share a large portion of control in opposite directions, with a negative CS for
ATPhyd and a positive CS for ANT; which is due to the fact that ATPc is produced by
ANT and consumed by ATPhyd alone. Figure 2.40c, shows the distribution of control for
NADHm concentration ([NADHm]); where, a strong negative coefficient for ATPsynth is
due to its dependence on NADHm as its substrate and indicates a key role of ATPsynth
in controlling the TCA cycle dehydrogenases, via the control of NADHm concentration.
As mentioned earlier, the control distributions for NADm+ (see, fig. I.13c), ADPm (see,
fig. I.14a), & ADPc (see, fig. I.14c) in supplementary material, show control properties
that are exactly opposite to those observed for NADHm (see, fig. 2.40c), ATPm (see,
fig. 2.41a), & ATPc (see, fig. 2.41c), respectively. For example, the control distribution
of ATPc shows positive coefficients for ATPsynth, SDH, IDHa, & ANT and negative
coefficients for PC & ATPhyd; whereas, the control distribution of ADPc shows positive
coefficients for PC & ATPhyd and negative coefficients for ATPsynth, SDH, IDHa, &
ANT.
Figure 2.42 (see, pg. 105) shows the overall distribution of concentration control
coefficients across all 16 TCA cycle intermediate metabolites in the form of a ‘heat-map’,
by considering all TCA cycle enzymes, for which the corresponding coefficient values are:
> 0 or < 0; and not 1 or ≈ 0. Therefore, for a given metabolite, all enzymes that have
positive coefficients (> 0) are shaded in green and those that have negative coefficients
(< 0) are shaded in red; whereas, enzymes with infinitesimally small coefficients ( 1 or
≈ 0) are shaded in grey.
From fig. 2.42, we may notice that the concentration control of Citm, Isocitm, &
αKGm is shared by almost 12–13 TCA cycle enzymes, which suggests their significant role
in the liver TCA cycle pathway. Oxaloacetate is controlled by 9 enzymes, out of which, 7
enzymes have negative coefficients; which suggests the crucial role of anaplerotic reactions
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like pyruvate carboxylase, in maintaining an optimal level of oxaloacetate, sufficient enough
to sustain the physiological rates of citrate synthesis; since, the availability of substrates,
particularly, oxaloacetate, is a major regulatory factor that limits the citrate synthase
activity in liver mitochondria (Garland et al., 1969; LaNoue et al., 1970; Olson and
Williamson, 1971; Shepherd and Garland, 1969; Srere, 1974; Williamson and Olson, 1968;
Williamson et al., 1967b, 1969a, 1972; Wojtczak, 1968). Furthermore, it indicates the
need for including Malate-Aspartate shuttle reactions, particularly in the absence of PC;
which is the case in mammalian heart as well as skeletal muscle (for refs., please see
earlier). This schematic also highlights the prominent role played by PC & ATPsynth,
in controlling the respective concentrations of all 16 TCA cycle intermediates; which
suggests the importance of expanding the ATP synthase reaction kinetics to include an
adequately detailed description of the electron transport chain (ETC) reactions.
Although, fig. 2.42 does not include data for changes in other enzyme activities,
comparing such data with the data presented here (in this case, against the change in PC
maximal activity), reveals that the overall distribution of concentration control against
other enzyme activities, is qualitatively similar and therefore, we may conclude that
fig. 2.42 shows a qualitative overview of the concentration control distribution against
all enzyme activities in liver TCA cycle models.
2.3.5.6 Elasticity coefficient analysis for Liver TCA cycle models
In this section, we shall analyse the elasticity coefficients (εS) of liver TCA cycle models,
calculated for all enzymes, with respect to all internal as well as external metabolites in
the model. Similar to the calculation of flux control coefficients, we will only focus on
elasticity coefficients of the updated liver TCA cycle model. Figure 2.43 (see, pg. 109)
shows the distribution of elasticity coefficients for the updated liver TCA cycle model,
for all 15 enzymes in the model, calculated with respect to 28 metabolites that include
internal as well as external metabolites. Figure 2.45 (see, pg. 111) shows the distribution
of elasticity coefficients, when most TCA cycle enzymes are desaturated with respect to
primary substrates as well as co-substrates, as demonstrated earlier for the distribution of
flux control coefficients using Kα,Kβ = 1.6 mM (see fig. 2.38b on pg. 98). Figure 2.44 (see,
pg. 110) shows the connectivity theorem result that links the elasticity coefficients (εxaseS )
shown in fig. 2.43 and flux control coefficients (CJxase) computed at initial steady-state of
the updated liver TCA cycle model.
— Ph.D. Thesis by Amar S. Ghaisas — Page 108
2. Liver TCA cycle model 2.3. Results for the liver TCA cycle . . .
• Figure 2.43. Local properties of the liver TCA cycle enzymes:
The distribution of elasticity coefficients in the updated liver TCA cycle model.
• In this figure, positive εS values are shown in green and negative εS values are shown in red.
• Enzymes that are not affected by a given metabolite (‘S’), have elasticity values equal to zero and
in this figure, they are shaded in grey.
• All internal metabolites are shown in black and external metabolites are shown in blue.
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• Figure 2.44. Connectivity relationships in the updated liver TCA cycle model:
Connectivity theorem result involving the elasticity coefficients (εxaseS ) shown in fig. 2.43
(see, pg. 109) and flux control coefficients (C Jxase) computed at initial steady-state, such
that for a given metabolite ‘S’, the total sum of all products of εxaseS & C Jxase , calculated
for each enzyme, should be equal to zero.
• ¶ : These metabolites are conserved within this system, which means their connectivity equations are
more complicated compared to the other metabolites in the system. For further explanation, please see
pg. 113. These rows represent combined connectivity equations of conserved metabolites in the liver TCA
cycle models; which also means that number of individual equations are reduced compared to the total number
of metabolites in the model.
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• Figure 2.45. Local properties of the liver TCA cycle enzymes:
Elasticity coefficients of the updated liver TCA cycle model, when most enzymes are
desaturated w.r.t. primary substrates as well as co-substrates, using Kα,Kβ = 1.6 mM,
as shown in fig. 2.38b (see, pg. 98).
• Other conditions as shown in fig. 2.43 on pg. 109.
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From fig. 2.43, following observations can be made:
1. Link between elasticity coefficients & flux control coefficients:
Unlike control coefficients, elasticities represent properties of individual enzymes and
not of the entire metabolic system. At the ‘local’ level of individual enzymes, elasticity
coefficients are a quantitative measure of how metabolite concentrations affect the
enzyme activities; whereas, at the systemic level, elasticities provide a link between
the kinetic properties of enzymes & their effect on the pathway flux (flux control
coefficients) known as the connectivity theorem (Kacser and Burns, 1973). According
to the connectivity theorem, flux control coefficients on a particular pathway flux
(‘J’), and elasticity coefficients on a given metabolite (‘S’), calculated for each enzyme
affected by ‘S’, are inversely proportional to each other (Fell, 1997); which means
that enzymes with high flux control coefficient values have smaller elasticities and
vice versa.
As seen earlier (see, pg. 73), the control of TCA cycle flux is distributed between PC,
SDH, ATPsynth, PDH, IDHa, & α-KGDH. From fig. 2.43 (see, pg. 109), it is evident
that most of these enzymes show smaller εS values with respect to their corresponding
substrates. For example, pyruvate dehydrogenase, which shows relatively high flux
control coefficient values, has elasticity coefficients of 0.05, 0.07, & 0.5 for pyruvate,
CoA, & NAD+, respectively. Whereas, citrate synthase, which shows a minimal
control of the TCA cycle flux, has elasticity coefficients of 0.7 & 0.9 for acetyl-
CoA & oxaloacetate, respectively. Therefore, fig. 2.43 shows that in the absence
of any information about the control of pathway flux, it is possible to predict the
most-controlling pathway enzymes based on their elasticities.
Figure 2.44 (see, pg. 110) shows the result of connectivity theorem equations for
the elasticities given in fig. 2.43. This result was obtained by multiplying flux
control coefficients calculated at initial steady-state, by individual enzyme elasticities
calculated for all metabolites in the model and ultimately adding all such products to
get a sum total. For example, fig. 2.43 shows that oxaloacetate affects 4 enzymes –
CS, PC, SDH, & MDH. For oxaloacetate, the connectivity equation would be:
CJCS · εCSOAA + CJPC · εPCOAA + CJSDH · εSDHOAA + CJMDH · εMDHOAA = 0 ; where, J = CS
For other enzymes that remain unaffected by a change in the oxaloacetate concen-
tration, the product of εxaseS & CJxase would be zero and therefore would not affect
the total sum. Figure 2.44 shows a connectivity theorem result of zero for several
metabolites and non-zero for others (shown in blue). Most of these non-zero sums
are actually quite close to zero, which suggests that they might be due to numerical
errors during model simulation.
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In liver TCA cycle models, there are 4 conservation relationships, one involving 3 CoA
–related metabolites, one each for mitochondrial ATP & NAD–related metabolites
and one for cytosolic ATP metabolites (see tbl. 2.5 on pg. 34). For a conserved pair
of metabolites, such as NAD+ & NADH, there is a complication in the connectivity
theorem (Fell, 1997; Fell and Sauro, 1985). Essentially, for any one of these single
metabolites, the net result of the connectivity equation is no longer zero, but the
equations can be combined in pairs to give a zero result, causing a reduction in the
number of connectivity equations (Fell and Sauro, 1985). In liver TCA cycle models, a
combined connectivity equation for each of the 4 conservation relationships causes the
total number of equations to reduce by 5, thus resulting in 23 connectivity equations
for 28 metabolites. In fig. 2.44, corresponding results of the combined connectivity
equations are marked using ¶ (in red).
2. Elasticities as the effector impact indicators:
Elasticities have positive values for metabolites that stimulate the rate of a reaction
(substrates, activators) and negative values for those that lower the reaction rate
(products, inhibitors) (Fell, 1997). For example, PDH, which consumes pyruvate,
CoA, & NAD+ to generate AcCoA & NADH; shows positive values for the former
and negative values for the latter. Also, for a given enzyme, based on the relative
values of its positive & negative effectors, it is possible to differentiate between them,
in terms of their corresponding effector strengths. For example, in the case of PDH,
product inhibition by acetyl-CoA and NADH, competitive with respect to CoA &
NAD+, respectively (Tsai et al., 1973) is considered in the model. From fig. 2.43, it is
clear that the elasticity of PDH for AcCoA (−0.07) is much smaller than its elasticity
for NADH (−0.5); which suggests that in this model, the inhibited rate of pyruvate
dehydrogenase is substantially more responsive to changes in the concentration of
NADH than that of acetyl-CoA.
During a study of the kinetic properties of pig heart and kidney pyruvate dehydroge-
nases, it was found that PDH is only moderately inhibited by a high AcCoA/CoA
ratio; whereas, it is strongly inhibited by a high NADH/NAD+ ratio (Bremer, 1969;
Strumiło, 2005; Wieland, 1983). Also, based on the increase in liver mitochondrial
NADH/NAD+ ratio in fasted animals, as well as, a lowered NADH/NAD+ ratio
(Williamson et al., 1967a) and an extremely high AcCoA/CoA ratio (Bremer and
Aas, 1969) in the ketotic state of diabetic animals, Bremer suggested that in general,
variations in the NADH/NAD+ ratio might prove to be a more direct regulator of
the PDH activity than the AcCoA/CoA ratio and that during the diabetic ketotic
state, the latter ratio is likely to be more important (Bremer, 1969).
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3. Elasticities of enzymes competing for a common substrate:
In situations where two enzymes compete for a common substrate, their responsiveness
to changes in the concentration of that substrate can be assessed and differentiated
using corresponding elasticities. For instance, in liver TCA cycle models, pyruvate
dehydrogenase and pyruvate carboxylase compete for pyruvate as their primary
substrate. For pyruvate, PDH has an elasticity coefficient of 0.05; whereas, elasticity
of PC is 0.4 (see, fig. 2.43). It means that compared to PDH, pyruvate carboxylase is
35% more responsive to changes in mitochondrial pyruvate availability. This result
agrees well with the observation made by Siess et al., that the PDH flux should be
much less sensitive to changes in mitochondrial pyruvate availability, since the Km of
pyruvate dehydrogenase for pyruvate is much lower than that of pyruvate carboxylase
(Siess et al., 1982a).
Additionally, we also know that in liver mitochondria, pyruvate carboxylase flux
apparently ranges from 1.3 to 9.4 times the TCA cycle flux (flux through CS), and is
on average around 3 times the TCA cycle flux (Baranyai and Blum, 1989; Beylot et al.,
1995; Des Rosiers et al., 1995; Di Donato et al., 1993; Magnusson et al., 1991; Rabkin
and Blum, 1985). In fact, in liver TCA cycle models, ‘ESS #2’ (which comprises
PDH) or the TCA cycle flux is approx. 1/4th the flux through ‘ESS #1’ (which
includes PC) (see figs. 2.9 and 2.17 on pgs. 46 and 56, respectively).
In fig. 2.18 (see, pg. 59), we showed that since MDH operates in its reverse di-
rection, a large fraction of the anaplerotic carbon introduced by PC is routed via:
PC→ MDH (reverse) → MC. Therefore, in liver TCA cycle models, Malate Dehydro-
genase & citrate synthase compete for the oxaloacetate availability. Figure 2.43 shows
that the elasticity of CS for OAAm is nearly 1 (0.9) and that of MDH is 3; which
not only shows the MDH reversibility in this model, but also provides an additional
support to the flux distribution pattern given in fig. 2.18.
4. Elasticities of near-equilibrium reactions:
In fig. 2.43, 6 enzymes show elasticity coefficients that are greater than 1, viz.– ACO,
SCS, IDHb, MDH, FM, & MC. In liver TCA cycle models, these enzymes represent
reactions that are close to equilibrium and for such reactions, the elasticities with
respect to substrate and product are mostly determined by the degree of displacement
of the reaction from equilibrium (or the disequilibrium ratio (ρ)) rather than by
their kinetic details, which can lead to much larger elasticity values than that of the
non-equilibrium reactions (Fell, 1997; Groen et al., 1982a; Kacser and Burns, 1973;
Westerhoff et al., 1984).
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5. Seemingly inconsistent elasticity values:
From fig. 2.43, the corresponding elasticities of IDHb & SCS appear inconsistent
compared to their earlier observed steady-state behaviour. According to fig. 2.43, IDHb
and SCS appear to be operating in their forward and reverse directions, respectively.
However, at steady-state, IDHb mostly functions in its reverse direction and SCS has
a positive flux. In fact, the elasticities are calculated instantaneously (i.e. without
simulating the model), unlike other control coefficients, which are calculated by
simulating the model for a steady-state solution. In liver TCA cycle models, when the
individual reaction rates are computed instantaneously, IDHb and SCS show positive
(forward) and negative (reverse) fluxes, respectively.
Also in fig. 2.43, εPCOAA is shown in red with a value of zero; whereas, εIDHaαKG is shown in
grey with a value of zero. In fact, for PC, εPCOAA ≈ 0 (i.e. = −2.4e-04); which means
that it has a weak product inhibition by oxaloacetate and thus its representation in
the figure appears to be valid.
On the other hand, since α-ketoglutarate is a product of IDHa and this reaction is in
principal reversible, one might have expected α-ketoglutarate to have some influence
on reaction rate and therefore, εIDHaαKG be shown in red, like other products of the
reaction. However, in liver TCA cycle models, IDHa kinetics are modelled using a
modified, irreversible form of the generic rate equation, while considering the product
inhibition by NADHm alone. In practice, the reversibility of IDHa has not been
observed, possibly due to insufficient binding of both α-ketoglutarate & CO2 (Plaut,
1970), and hence for the purposes of modelling, α-ketoglutarate & CO2 are assumed
to have no influence on reaction rate (Chen and Plaut, 1963; Plaut and Aogaichi,
1968), thereby making it irreversible.
The system-wide enzyme desaturation analysis performed using Kα,Kβ = 1.6 mM,
when most enzymes are desaturated with respect to primary substrates as well as co-
substrates (see, fig. 2.38b on pg. 98), presents a perfect example to demonstrate the link
between elasticity coefficients and flux control coefficients. Figure 2.45 (see, pg. 111)
shows the distribution of elasticity coefficients in the updated liver TCA cycle model for
this analysis.
As a result of a system-wide reduction in enzyme saturation, fig. 2.45 shows significant
changes in the elasticities of CS, α-KGDH, IDHa, PDH, SDH, MDH, FM, & MC, when
compared to those shown in fig. 2.43. These alterations are correspondingly reflected in
the distribution of flux control coefficients shown in fig. 2.38b (see, pg. 98), where the
control of TCA cycle flux is shared between PDH, PC, ATPsynth, CS, & IDHb; which is
significantly different from that of the saturated model (see fig. 2.25b on pg. 74).
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2.4 Discussion & Conclusions
The study of liver TCA cycle model was initiated at the beginning of this project in
order to gain better understanding of the modelling process as well as to understand
the basic functional properties of a tissue-specific TCA cycle. Moreover, further analysis
of this model showed that if modified slightly by removing pyruvate carboxylase, the
resultant model is a metabolic system similar to the mammalian heart TCA cycle and
the analysis of which can provide valuable insight into its dynamic properties, before
actually building a proper heart-specific TCA cycle model.
The liver TCA cycle model analysis presented earlier has provided an in-depth
perspective of the dynamic properties as well as the distribution of control in a tissue-
specific TCA cycle model and some key aspects of this valuable analysis are as follows:
1. This model demonstrates the need of constructing simplified mathematical models
that are capable of representing the fundamental physiological characteristics of
real metabolic systems. The complex pattern of control distribution in this model
highlights the fact that a mathematical model must not be overloaded with kinetic
information and should be defined based on the criticality of a given process with
respect to the overall biochemical function. This applies particularly well to the
kinetic/ dynamic modelling of biochemical pathways. In kinetic metabolic models,
model complexity can arise roughly due to the number of included reactions as well
as the excessive enzyme kinetics data for a given process.
The mammalian liver mitochondrial carbon metabolism is a much larger network of
several biochemical processes and involves a number of smaller biochemical subsystems,
such as the TCA cycle. Therefore, while modelling the mammalian liver-specific TCA
cycle metabolism, embedded as it is, as a part of a much larger metabolic network,
the modeller must determine which reactions or processes can be ignored based on
their criticality within the network and which processes are absolutely essential for
the overall biochemical function of that larger network. For example, in the case of
liver TCA cycle models presented in this study, several metabolite transport reactions
have been excluded (except two, i.e. MC & ANT), based on their criticality with
respect to the overall liver TCA cycle function.
Also, to avoid the excess use of enzyme kinetics data, most of the enzyme rate equations
in liver TCA cycle models are defined using the simplified, generic, reversible bi-
substrate equation (Chassagnole et al., 2001b; Rohwer et al., 2006), modified where
necessary to account for more than two substrates and/ or products. In all cases,
the simplest expression that adequately represents the key kinetic properties of the
enzyme is used.
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2. Overall, current analysis of the two liver TCA cycle models shows that a seemingly
minor change, such as the metabolic status of CoA, can lead to significant quantitative
effects in some aspects; whilst in others, it has relatively minor qualitative effects.
For instance, the steady-state analysis data shows significant quantitative differences
in metabolite concentrations as well as TCA cycle fluxes between the two liver TCA
cycle models. On the other hand, Metabolic Control Analysis reveals that the control
of TCA cycle flux between key TCA cycle enzymes is qualitatively similar between
the two models.
Furthermore, this study highlights the importance of defining the model boundary
conditions in a precise and non-conflicting manner. It shows the full extent of
impact on the dynamic properties of a mathematical model caused by an ill-defined
metabolite in the system (i.e. CoA), as a result of a simple oversight on modeller’s
part. More importantly, this study corrects such a significant error in the already
established mammalian liver-specific TCA cycle model developed within the Cell
Systems Modelling Group (CSMG) (Brightman et al., 2010, unpublished manuscript)
and analyses the corrected/ updated model in full detail.
3. The elementary modes analysis shows that the dynamic properties of this model
can arise as a result of possible linear combinations of nine elementary modes in the
model. Also, the elementary modes analysis shows that we can arrive at a rough
structural framework of the mammalian heart- or skeletal muscle-specific TCA cycle
model, if a particular elementary mode containing only the heart-specific reactions is
isolated from the model.
It also suggests that the internal substrate cycle between the NAD+ -dependent
isocitrate dehydrogenase and the NADP+ -dependent isocitrate dehydrogenase that
operates in the updated liver TCA cycle model is likely to exist in a mammalian heart-
specific TCA cycle model as well, provided it follows a similar structural definition as
that of the isolated elementary mode. There is sufficient literature evidence to support
the existence of such a cycle in heart tissue (Huang and Colman, 2005; Londesborough
and Dalziel, 1968; McCormack and Denton, 1981; Rutter and Denton, 1988; Sazanov
and Jackson, 1993).
Moreover, this analysis indicates that a theoretically ideal version of TCA cycle,
often described in biochemistry textbooks, that produces 11 molecules of ATPm &
3 molecules of CO2 per pyruvate, is a distinct possibility. PC, MC, & IDHb would
be removed from the resulting model, to isolate ElMo[3] described in tbs. 2.3 and 2.4
(see, pg. 33). This TCA cycle model would then contain only a single elementary
mode (ElMo[3]), which would also be the only enzyme subset that comprises all 12
reactions of this model.
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4. During the steady-state analysis, comparing the reported and model-predicted values
of all variables for which it was possible to carry out a comparison, except fumarate
(since, no literature value for its mitochondrial concentration was available) shows
that the model-predicted values are all within reported ranges. This is to be expected,
since four of the model parameters (see, Methods) were fitted to the in vivo TCA
cycle intermediate concentration data.
Also, the updated liver TCA cycle model independently reproduces the behaviour
observed in studies reporting TCA cycle fluxes in liver, in which the radiolabel incor-
poration from 13C- or 14C- labelled substrates into the TCA cycle intermediates was
measured. Thus, PC flux is around three times the TCA cycle flux, and mitochondrial
malate dehydrogenase is found to be operating in an opposite direction compared to
the direction of TCA cycle flux, with PC influx into the cycle being balanced to a
greater or lesser degree by an efflux via malate carrier (malate-phosphate transporter),
out of the mitochondria at the level of malate (Baranyai and Blum, 1989; Beylot
et al., 1995; Des Rosiers et al., 1995; Di Donato et al., 1993; Magnusson et al., 1991;
Rabkin and Blum, 1985). Also, the model-predicted estimate of PC flux in relation to
the overall TCA cycle flux, agrees with an average range of PC flux being 2–4 times
the TCA cycle flux in liver, as reported by some of the experimental as well as model
simulation studies (Nazaret et al., 2009; Stucki and Walter, 1972; Williamson et al.,
1969a).
The steady-state analysis data shows that the respective magnitudes of reverse flux
through MDH and the MC/ PC flux (i.e. ‘ESS #1’ flux) are rather higher in the
model than would be expected, given the overall TCA cycle flux. It must be noted
that the model is an abstracted representation of the real system, and that several
processes have been omitted for the purposes of simplification. Amongst these are
other transport processes through which material leaves the TCA cycle at the level
of citrate, oxaloacetate and α-ketoglutarate, such as the mono-, di-, tricarboxylate
transporters (Chappell, 1968; Klingenberg, 1970; LaNoue and Schoolwerth, 1979;
Passarella et al., 2003; Williamson et al., 1968, 1969a); which, in combination with the
MC efflux, balance the influx via PC into the cycle (Baranyai and Blum, 1989; Beylot
et al., 1995; Des Rosiers et al., 1995; Di Donato et al., 1993; Magnusson et al., 1991;
Rabkin and Blum, 1985). The model-predicted magnitude of fluxes through MDH
& MC thus represent a degree of compensation for such processes absent from the
liver TCA cycle model in addition to the reported estimates, and are hence greater in
relation to the TCA cycle flux than reported experimentally.
5. In this study, we have analysed how flux in the mammalian liver tricarboxylic acid
cycle varies with changes in the activity of its enzymes. Through the application of
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Metabolic Control Analysis (MCA) to liver TCA cycle models, and also to a suite
of test models, we show that the control of flux in systems containing one or more
enzymes that are saturated with respect to substrate(s) displays a characteristic
pattern of sharp, sigmoidal transitions between two or more key processes, with only
relatively small changes in enzyme maximal activity. However, for the variation in
flux control coefficients in response to a change in enzyme activity, a hyperbolic
relationship would normally be expected, under ideal conditions. This characteristic
pattern of sigmoidal CJ distribution is observed in both cyclical and linear systems.
Moreover, although this phenomenon can allow control within the system to be
dominated by a single process when maximal activity is low, MCA of the liver TCA
cycle model suggests that the TCA cycle could be poised at a point where control
is shared evenly between several processes. Our findings are in agreement with a
theoretical analysis of another compartmentalized metabolic cycle, the Calvin cycle
(Fell et al., 1999; Letellier et al., 1994). Consequently, existence of such a relationship
between the control of flux and enzyme activity, establishes a strict limitation on the
achievable increase in flux by activating any single enzyme; since such single-point
activation results in a rapid loss of influence over flux by the given enzyme. Therefore,
in order to increase the overall flux significantly, control mechanisms must act at
multiple sites within the system (Fell, 1997; Fell and Thomas, 1995; Korzeniewski
et al., 1995). In fact, there is indeed evidence for control mechanisms acting at
multiple sites within the TCA cycle, e.g. through Ca2+-mediated enzyme activation
(Denton and McCormack, 1995) and via lysine acetylation (Zhao et al., 2010). As
mentioned by Kacser and Burns, for a given metabolic system, an even distribution
of flux control serves as the obvious advantage that global fluxes become relatively
insensitive to large variations in enzyme concentrations (Kacser and Burns, 1981).
However, it must be noted that the liver TCA cycle models investigated in this study
do not reflect the true complexity of real systems and it is possible that the properties
demonstrated by these models could be suppressed in vivo; to our knowledge, these
properties have not yet been reported in any experimental system. Indirect evidence
can be found in a recent study conducted by Bennett et al.; which suggests that
the potential for generating observed flux control behaviour may also exist in vivo,
by demonstrating that the metabolite concentrations can in fact be considerably in
excess of the Km values (Bennett et al., 2009). Although, this study also implies that
the TCA cycle enzymes tend not to be saturated in prokaryotes, it is not necessarily
true for eukaryotic cells, due to the mitochondrial localisation of TCA cycle. Also, a
comprehensive literature survey showed that several metabolite concentrations may be
up to ten times higher within mammalian mitochondria than in the cytosol (or when
averaged across the total cell volume), and are often found to be considerably in excess
of the corresponding Km values. For instance, a high mitochondrial concentration of
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acetyl-CoA (from 0.2 to 2 mM) compared to the PC Ka value (0.06 mM) and the
resulting prospect that pyruvate carboxylase is therefore likely to be saturated under
mitochondrial conditions, has been noted previously (Kimmich and Rasmussen, 1969;
McClure and Lardy, 1971).
Furthermore, we speculate that conserved cycles, particularly when compartmental-
ized, may routinely operate at near-saturation conditions; under other circumstances
this situation would in fact be potentially disastrous (e.g. linear systems) (Cornish-
Bowden, 2012). But, in a cyclical system such as the TCA cycle or the Calvin cycle,
the evolution of regulatory mechanisms to prevent saturation would be redundant in
the face of obligatory mass conservation imposed by the structure of the system.
Lastly, it must be noted that the saturation-dependent properties identified in the
liver TCA cycle models, highlight the importance of using saturable enzyme kinetics
in a mathematical model to represent the individual rate equations.
6. During the flux control analysis of liver TCA cycle models, we observed a rapid
exchange of control between PDH and other key TCA cycle enzymes, as the PDH
maximal activity increases. It highlights not only the importance of accurately
reflecting PDH maximal activity in the model, but also has implications when
considering the significance of many regulatory interactions of pyruvate dehydrogenase.
For modelling purposes, we have assumed a constant PDH activity and regulation
only by product inhibition. Yet, the current analysis indicates that including the PDH
regulation by covalent modification in this model would be beneficial, particularly
since the model variables (i.e., pyruvate, acetyl-CoA, & NADH) act as allosteric
effectors of pyruvate dehydrogenase kinase (PDHK) (Holness and Sugden, 2003).
Moreover, if these observations are also true in the case of a real system, they could
provide a slightly different perspective on the physiological significance of various
PDH regulatory mechanisms. However, it is interesting to note that the liver TCA
cycle model is poised at a point where the control over flux is distributed largely
between PDH, PC, & ATP synthase, in such a way that the system is maximally
responsive to changes in the activity of each of these key enzymes, while minimizing
the influence of other TCA cycle reactions. Provided the same behaviour is also
observed in vivo, such a phenomenon may reflect the functional organization of the
system and facilitate a dynamic balance between the demands of gluconeogenesis and
ATP production.
7. A high degree of control shared by SDH in liver TCA cycle models, indicates the
importance of expanding the succinate dehydrogenase reaction to include the FAD/
FADH2 dynamics; that is to include a comprehensive representation of Complex II or
— Ph.D. Thesis by Amar S. Ghaisas — Page 120
2. Liver TCA cycle model 2.4. Discussion
succinate-CoQ reductase (EC 1.3.5.1), an integral component of the Electron transport
chain (ETC). Also, a high degree of control shared by ATP synthase indicates the
importance of including fully developed modules of electron transport chain as well as
ATP synthase. Such expansion would also include the oxygen consumption reaction in
the form of an appropriately expanded representation of Complex IV or cytochrome
c oxidase (EC 1.9.3.1); which would make the mammalian liver-specific model further
aligned with the experimental observations. Moreover, including the fully developed
ETC as well as ATPsynth modules has an additional significance with respect to a
possible expansion of PDH kinetics that reflects its regulation by covalent modification
is considered. Since, as shown earlier, ATPsynth is one of the highly controlling
enzymes in the model, which acquires most of the control lost by PDH.
Therefore, this study of the liver TCA cycle models proved to be instrumental in
enhancing our understanding of certain modelling fundamentals that are essential for
building kinetic/ dynamic models of cellular metabolism, such as — modelling strategy,
model design, choice of rate equations, parameter selection, model boundary conditions
etc. Moreover, it informed us not only about the approximate structural aspects, but
also the rough dynamic behaviour for the proposed and soon-to-be-built mammalian
heart- or skeletal muscle-specificTCA cycle model. Accordingly, we followed the same
modelling strategy to construct a ‘consensus’ kinetic model of TCA cycle in mammalian
heart or skeletal muscle mitochondria, which is neither over-simplified nor too complex
in terms of rate equations, reversibility of reactions and regulatory interactions.
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Chapter 3
Heart TCA cycle prototype: a
“PC knock-out” model (PCko)
3.1 Overview
In this chapter we will look at a prototype of the heart TCA cycle model, which is actually
a derivative of the updated liver TCA cycle model. We started studying the existing
liver TCA cycle model to understand the basic functional properties of a tissue-specific
TCA cycle and it provided a strong knowledge base for building a heart or skeletal
muscle-specific TCA cycle model. Moreover, if modified slightly, the existing model
provides an opportunity to glance at the rough qualitative nature of a heart-specific
TCA cycle model, prior to building one.
As mentioned earlier in the previous chapter (see, pg. 18), in mammalian heart as well
as skeletal muscle tissue, literature evidence suggests that the anaplerotic contribution
of PC to the total flux through the TCA cycle is insignificant as compared to that in
liver (Gibala, 2003; Gibala et al., 2000; Owen et al., 2002; Scrutton and Utter, 1968).
Therefore, in order to construct a heart TCA cycle model prototype, the liver TCA
cycle model needs to be modified by removing the anaplerotic contribution of pyruvate
carboxylase, so that the resultant ‘derivative’ system would be somewhat similar to the
physiological description of a heart or skeletal muscle-specific TCA cycle model.
In Section 3.2, we shall discuss the definition & construction of a heart TCA cycle
model prototype in further detail. Section 3.3 (see, pg. 124), describes an in-depth
analysis of the emergent dynamic properties of this heart TCA cycle model prototype.
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3.2 Methods: Model construction and definition
In a separate copy of the existing updated liver TCA cycle model, the pyruvate carboxylase
(PC) reaction was “switched off” (i.e. deleted) to form a heart TCA cycle model prototype;
henceforth be referred to as - “PC knock-out” model (PCko). Likewise, the existing
liver TCA cycle model will be referred to as - “PC wild-type” model (PCwt). The
heart TCA cycle model prototype or the PCko model is illustrated in fig. 3.1.
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• Figure 3.1. Schematic illustrating the TCA cycle reactions in the PCko model.
• Internal metabolites: in Black; external metabolites: in Blue; reaction/ enzyme names: in Red .
• Reaction with double arrowheads is assumed to be reversible and reaction with single arrowhead is
assumed to be irreversible.
• Pyruvate carboxylase (PC) reaction is deleted from the PCko model and is shown here against a red
background and as a consequence, the malate carrier (malate-phosphate transporter) (MC) reaction
carries infinitesimally small amount of flux and is therefore a “dead reaction” which is shown here
against a grey background.
As illustrated in Figure 3.1, the PCko model only includes the heart or skeletal
muscle-specific TCA cycle reactions as a result of the modifications described here.
However, in spite of these modifications, PCko model is still essentially the updated liver
TCA cycle model, albeit with zero pyruvate carboxylase activity. Also worth noting is
that these changes do not affect the existing conservation relationships described in the
earlier chapter on liver TCA cycle model (see tbl. 2.5 on pg. 34). Apart from the changes
shown here, no other reactions, variables, or parameters were modified while constructing
the PCko model.
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3.3 Results for the heart TCA cycle prototype
In this section, we will take a quick look at the kinetic as well as structural properties of
the PCko model in comparison with that of the PCwt model. Briefly, following types of
results will be presented:
1. Elementary modes analysis & Enzyme subset analysis (see, pgs. 124 and 125)
2. Initial steady-state data & Steady-state analysis (see, pg. 126)
3. Metabolic Control Analysis (MCA) results (see, pg. 139)
To begin with, in the following section, we shall establish the possible differences in
structural properties between the two models.
3.3.1 Elementary modes analysis of the heart TCA cycle prototype
Since, the pyruvate carboxylase reaction is absent in the “PC knock-out” model, the
PC containing elementary modes present in the PCwt model, are no longer functional in
this model. As a result, the PCko model contains only 3 elementary modes that are PC
-independent and exactly identical to the corresponding modes of the PCwt model (see
tbs. 2.3 and 2.4 on pg. 33). The PCko elementary modes are presented in tbl. 3.1 and
corresponding elementary mode stoichiometries are presented in tbl. 3.2.
Heart TCA cycle prototype - reactions ATP/ ADP- linked reactions
Modes PDH CS ACO IDHa IDHb SCS SDH FM MDH ATPsynth ATPhyd ANT
ElMo 0 0 0 0 1 -1 0 0 0 0 0 0.25 2.5 2.5
ElMo 1 1 1 1 0 1 1 1 1 1 1 0.75 8.5 8.5
ElMo 2 1 1 1 1 0 1 1 1 1 1 1 11 11
α-KGDH
• Table 3.1. A table showing elementary modes for the PCko model.
• For each mode, fractions have been converted decimals.
Reactants Products
ElMoN 2N : 3NCO2N +N QH2N +N 11NPic (3)11NPimN +N PyrmN +N Q
ElMoN 0N : NADP+N +N 2.5NPic (1)2.5NPimN +N NADPH
ElMoN 1N : (2)
3NCO2N +N NADPH
+N QH2N +N 8.5NPic
8.5NPimN +N Pyrm
+N NADP+N +N Q
• Table 3.2. Net stoichiometries for elementary modes presented in tbl. 3.1.
• All metabolites in this table are, by necessity, external in the modelling sense.
• For each net stoichiometric equation, fractions have been converted decimals.
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ElMo[1] & ElMo[2] describe the structural framework of a mammalian heart or skeletal
muscle-specific TCA cycle, as seen in the earlier chapter on liver TCA cycle model (see
fig. 2.6 on pg. 38). These two elementary modes are actually the same mode with different
isocitrate dehydrogenase (IDH) activity, where ElMo[1] is IDHb -dependent and ElMo[2]
is IDHa -dependent. Due to the participation of different isocitrate dehydrogenases, these
two modes also differ in terms of total amount of ATPm produced via ATP synthase
reaction. For instance, the IDHb -dependent mode (ElMo[1]) produces a total of 2.5
fewer ATPm molecules than the IDHa -dependent mode (ElMo[2]), as it lacks one of
the NADH -producing dehydrogenases (IDHa). The substrate-level phosphorylation via
succinyl-CoA synthetase (SCS) accounts for the additional ATPm molecule produced by
these modes.
ElMo[0] describes the internal substrate cycle in which α-ketoglutarate generated by
IDHa is converted back to isocitrate by IDHb. In fact, literature suggests that not only
such a cycle exists in both heart and liver (Huang and Colman, 2005; Londesborough
and Dalziel, 1968; McCormack and Denton, 1981; Rutter and Denton, 1988; Sazanov
and Jackson, 1993), but also that IDHb carries a reverse flux in perfused rat hearts
under normoxia as well as ischemia (Comte et al., 1997, 2002). Further details regarding
ElMo[0] can be seen in the earlier chapter on liver TCA cycle model (see fig. 2.7 on
pg. 38).
3.3.2 Enzyme subset analysis of the heart TCA cycle prototype
The PCko enzyme subsets (ESS) are shown in fig. 3.2.
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• Figure 3.2. Schematic showing enzyme subsets for the PCko model.
• Internal metabolites: in Black; external metabolites: in Blue; reaction/ enzyme names: in Red .
• Reversible reactions: double arrowheads and irreversible reactions: single arrowhead.
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In the PCko model, similar to the effect observed in the case of elementary modes,
the deletion or “switching-off” of pyruvate carboxylase reaction completely eliminates
the ‘ESS #1’; which is an enzyme subset originally present in the PCwt model that
comprised PC & MC. As a result, as illustrated in fig. 3.2 (see, pg. 125), the PCko model
contains only two enzyme subsets.
‘ESS #1’ from the PCko model includes 8 out of 9 canonical TCA cycle reactions
and is interrupted by IDHa & IDHb, which act as independent reactions. Whereas, ‘ESS
#2’ includes ANT & ATPhyd. Also, as seen earlier in PCwt, IDHa, IDHb and ATPsynth
remain as independent reactions in the PCko model, as well.
Furthermore, the removal of PC, turns MC into a “dead reaction”, which carries
an infinitesimally small amount of flux and also causes MDH to become a constituent
reaction of ‘ESS #1’ in the PCko model. Originally, in the PCwt model, MDH operated
as an ‘independent reaction’ along with IDHa, IDHb and ATPsynth.
3.3.3 Steady-state analysis for the heart TCA cycle prototype
In order to analyse the emergent dynamic properties of the PCko model, we begin by
comparing its “initial steady-state” composition with that of the PCwt model. The
reaction fluxes are shown in fig. 3.3 and metabolite concentrations in fig. 3.4, respectively.
Note: Both the PCwt & PCko models are essentially liver TCA cycle models, with
different pyruvate carboxylase (PC) activities; which means that all the enzyme kinetics
and metabolite concentration data applied to the PCko model is still liver tissue-specific.
It is possible that in the skeletal or cardiac muscle tissue, the resting metabolite concen-
trations as well as the kinetics data for these same TCA cycle enzymes could differ from
that in the liver tissue. Therefore, it is important to view the PCko results from
a qualitative perspective only.
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• Figure 3.3. Reaction fluxes of PCwt & PCko models, at initial steady-state.
• Blue line : PCwt flux data; Red line : PCko flux data.
• Primary Y-axis: PCwt data; Secondary Y-axis: PCko data.
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• Figure 3.4. TCAi concentrations of PCwt & PCko models, at initial steady-state.
• Green line : PCwt concentration data; Orange line : PCko concentration data.
• Y-axis: log10[metabolite concentration] – metabolite concentration in logarithmic scale.
From figs. 3.3 and 3.4, we can observe the following:
1. Removal of PC from the PCko model causes the the flux through malate carrier (MC)
to reduce significantly to an infinitesimally small amount when compared to the PCwt
initial steady-state MC flux. For instance, in PCko, the MC flux equals to 3.5e-10
mmol/sec, at initial steady-state. Whereas, in the PCwt model, it is nearly 3 times
the TCA cycle flux. Possible factors causing MC to become a “dead reaction” in
PCko, could be as follows —
(A) Complete removal of the enzyme subset that comprised PC & MC, due to the
deletion of pyruvate carboxylase reaction from PCwt; which essentially makes the
malate carrier reaction structurally extraneous or “dead”;
(B) As shown in the earlier chapter on liver TCA cycle model (see fig. 2.18 on pg. 59),
some amount of oxaloacetate produced by PC flows directly out of the TCA cycle
via MC; since in PCwt, MDH is an ‘independent reaction’ that works in a reverse
direction and at a higher rate than that of the TCA cycle flux. However, in the PCko
model, malate dehydrogenase functions in its forward direction, producing OAAm
from Malm and it also constitutes the TCA cycle enzyme subset (‘ESS #1’); which
means that the malate concentration is highly constrained to flow out of the TCA
cycle via MC ; and
(C) In the absence of pyruvate carboxylase, the PCko TCA cycle flux is significantly
reduced; which means that the TCA cycle probably produces just enough malate to
help sustain that same level of flux through the cycle.
Moreover, in the PCko model, if the malate carrier (MC) would have been knocked
out along with PC, then all the TCA cycle intermediates would have formed a
conservation relationship; wherein, the total TCAi content would have remained
constant at the start of model simulation. However, since the malate carrier was not
removed from the PCko model, the conservation relationship of TCAi does not exist
and the malate carrier reaches equilibrium with the cytosolic malate concentration in
such a way that at steady-state, the malate carrier reaction becomes ‘dead’ (as it is
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structurally required to be). However, the infinitesimally small amount of flux can
be observed because the malate carrier reaction allows the TCA cycle intermediates
to ‘equilibrate’ by exchange with the cytosolic malate pool. Physiologically, in the
absence of PC, it is assumed that the cytosolic malate concentration is buffered by
the amino acid metabolism and uptake of amino acids from the blood. Also, as shown
in eq. B.34 from Appendix B (see, pg. 231), the malate carrier reaction comprises
a single internal metabolite (mitochondrial malate) and three external metabolites
of fixed concentrations (cytosolic malate & inorganic phosphate; and mitochondrial
inorganic phosphate); due to which the malate carrier flux could become zero, given
the right set of conditions.
2. “Switching-off” PC in the PCko model causes the TCA cycle flux (flux through CS)
to reduce by approx. 89-fold, as compared to that in the PCwt model. In mammalian
liver tissue, literature suggests that the PC flux is on average around 3 times the TCA
cycle flux (Baranyai and Blum, 1989; Beylot et al., 1995; Des Rosiers et al., 1995; Di
Donato et al., 1993; Magnusson et al., 1991; Rabkin and Blum, 1985). Therefore, it
is possible that in the absence of PC as well as any other anaplerotic mechanism, the
TCA cycle flux in mammalian skeletal or cardiac muscle tissue is significantly lower
than that in the hepatic tissue.
3. In the PCko model, IDHa & IDHb are reduced by approx. 54- & 15-fold, respectively,
in comparison to the PCwt model. Also, in the PCko model, IDHb acts in the reverse
direction; whereas, it works in the forward direction in PCwt.
4. Between the two models, the ‘ESS #2’ reactions, ANT & ATPhyd remain virtually
unchanged. In the PCwt model, PC & ATPhyd are both ATP-hydrolysing reactions;
with PC hydrolysing ATPm during the carboxylation of Pyrm to OAAm and ATPhyd
hydrolysing ATPc in to ADPc & Pic. In the PCko model, in the absence of PC,
ATPhyd is the only ATP-hydrolysing reaction. Since, the mitochondrial energy
metabolism in skeletal and cardiac muscle tissues is highly demand-driven; the role of
ATPhyd in a metabolic system like the one described by PCko thus becomes more
important.
5. In the initial steady-state of the PCko model, OAAm concentration decreases the
most by approx. 335-fold, as compared to that in PCwt. Among all TCAi’s, succinate
shows the next largest decrease, by approx. 10-fold. Whereas the remaining TCAi’s,
such as – Citm, Isocitm, αKGm, Fumm, & Malm, all show relatively small reductions
in their respective concentrations by approx. 1.5–2.0 -fold.
Figure 3.5 shows the differences in key metabolite ratios between PCwt & PCko
models, at initial steady-state.
NADm+ (by approx. 27-fold), ADPm (by approx. 52-fold), ADPc (by approx. 11-fold), &
CoAm (by approx. 5-fold) – all show moderate to large reductions in the PCko model,
— Ph.D. Thesis by Amar S. Ghaisas — Page 128
3. Heart TCA cycle prototype 3.3. Results for the heart TCA cycle . . .
in comparison with the PCwt model. Since, these 4 metabolites form 4 separate con-
servation relationships in the PCko (as well as, PCwt) model, corresponding members
of these conservation relationships show increase in their respective concentrations.
As a result, key ratios involving these metabolites change significantly between the
PCwt & PCko models and fig. 3.5 shows these changes in detail.
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• Figure 3.5. Key metabolite ratios in PCwt & PCko, at initial steady-state.
• Blue bars : PCwt data; Red bars : PCko data. • Black line : log10[Fold difference] between the two
models. The fold difference was calculated as – [(Metabolite ratio in PCko) / (Metabolite ratio in PCwt)].
In fig. 3.5, difference in the [NADH/NAD+]m ratio between the two models suggests
a crucial qualitative switch in the initial redox state of these systems. PCwt is an
oxidised system with [NADH/NAD+]m = approx. 0.7; whereas, PCko is a highly
reduced system with [NADH/NAD+]m = approx. 46.0. Although, in the case of
mammalian skeletal or cardiac muscle mitochondria, the actual ratio may not be
as high, it is still qualitatively significant; since, literature suggests that the muscle
mitochondria are comparatively more reduced than the liver mitochondria (Kobayashi
and Neely, 1979). Significant improvement in the [ATP/ADP]m & [ATP/ADP]c
ratios in the PCko model, could be due to the PC removal and MDH operating in the
forward direction, thereby producing more NADHm than that in the PCwt model.
Now, for the PCwt & PCko models, let’s look at the specific flux & concentration
profiles using steady-state scans across a fixed range of increasing maximal activity
of PDH (V PDHmax scan) and Pim concentration, respectively. Figure 3.6 (see, pg. 131)
describes the dynamic response of TCAi’s from PCwt as well as PCko to changes in V PDHmax
& Pim concentration. Figures 3.7 and 3.8 (see, pgs. 132 and 133) show the dynamic
response of key TCA cycle reaction fluxes from PCwt as well as PCko to changes in Pim
concentration & V PDHmax , respectively.
Note: The relative change in TCAi’s and reaction fluxes is mostly quantitative in
nature and hence presented here as bar graphs. The original steady-state analysis plots
are included in the supplementary material. Details are given in the respective graphs.
— Ph.D. Thesis by Amar S. Ghaisas — Page 129
3. Heart TCA cycle prototype 3.3. Results for the heart TCA cycle . . .
Mal Fum α-KG IsoCit Cit Suc OAA
-6
-5
-4
-3
-2
-1
0
1
2
3
-2.9
-2.3
-1.7
-1.1
-0.5
0.1
0.7
1.3
1.9
-0.617 -0.656
-0.665
-0.460
-0.619
-1.454
-2.791
0.034
0.014
-0.362
-0.380
-0.481
-0.628
-2.291
Pi (mito) scan:  PC (WT) model
PDH (Vmax) scan:  PC (WT) model
Pi (mito) scan:  PC (KO) model
PDH (Vmax) scan:  PC (KO) model
Pi (mito) scan:  log10 (KO / WT)
PDH (Vmax) scan:  log10 (KO / WT)
lo
g
10 [ P
C
K
O  / P
C
W
T  ]  (F
o
ld
 C
h
an
g
e in
 co
n
ce
n
tra
tio
n
)
lo
g
10
 [
A
v
e
ra
g
e
 C
o
n
c
e
n
tr
at
io
n
]
3.6.a. TCA cycle intermediate metabolites (TCAi)
ADPm ADPc ATPc ATPm
-1.8
-1.5
-1.2
-0.9
-0.6
-0.3
0
0.3
0.6
0.9
1.2
-2.5
-1.3
0.0
1.3
2.5
3.8
5.0
-1.656
-1.969
0.541 0.599
-2.008
-1.367
0.023
0.185
Pi (mito) scan:  PC (WT) model PDH (Vmax) scan:  PC (WT) model
Pi (mito) scan:  PC (KO) model PDH (Vmax) scan:  PC (KO) model
Pi (mito) scan:  log10 (KO / WT) PDH (Vmax) scan:  log10 (KO / WT)
lo
g
10 [ P
C
K
O  / P
C
W
T  ]  (F
o
ld
 C
h
an
g
e
 in
 co
n
c
en
tra
tio
n
)
lo
g
10
 [
A
ve
ra
g
e
 C
o
n
ce
n
tr
a
ti
o
n
]
3.6.b. ATP–related metabolites
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3.6.c. NAD- & CoA–related metabolites
• Figure 3.6. Concentrations of TCAi’s : effect
of PC ‘knock-out’ (PCko) in comparison with the PC ‘wild-type’ (PCwt i.e. LVRTCAUPD).
• This is a combined bar graph for the dynamic response of TCAi concentrations from PCwt as well
as PCko to changes in Pim concentration & the maximal activity of PDH (V PDHmax ), respectively. Four
different bars represent four separate piece of data for the two liver TCA cycle models (i.e. PCwt &
PCko, respectively) – two each for [Pim] & V PDHmax .
• Red bars represent the steady-state data for change in V PDHmax ; whereas, Blue bars show the data for change
in [Pim]. In both colours, darker bars represent the PCwt data and lighter bars represent the PCko data,
respectively.
• An average concentration value was calculated for each metabolite from all consecutive steady-state values
per dataset. These were then used in the form of log10 values to generate the actual bar graph. For each
common parameter, i.e. – [Pim] or V PDHmax ; a fold difference was calculated as –
[(avg. conc. in PCko model)/(avg. conc. in PCwt model)] and was represented in the graph as –
log10[(avg. conc. in PCko model)/(avg. conc. in PCwt model)]
• Primary Y-axis (left) : log10[average concentration] of TCAi’s in logarithmic scale.
• Secondary Y-axis (right) : log10[(avg. conc. in PCko model)/(avg. conc. in PCwt model)] –
fold difference of [(avg. conc. in PCko model)/(avg. conc. in PCwt model)] in logarithmic scale.
• Blue line represents the log10[Fold difference] w.r.t. the change in [Pim] and Black line represents the
log10[Fold difference] w.r.t. the change in V PDHmax . Both lines are drawn aligned to the ‘Secondary Y-axis’.
• Supplementary data for figs. 3.6a, 3.6b and 3.6c is shown in figs. II.1, II.2, II.3 and II.4 on pgs. XXIII
to XXVI, respectively.
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• Figure 3.7. TCA cycle fluxes against increasing conc. of [Pim] :
effect of PC ‘knock-out’ (PCko) in comparison with PC ‘wild-type’ (PCwt i.e. LVRTCAUPD).
• This is a combined bar graph showing the dynamic response of key TCA cycle reaction fluxes from
PCwt as well as PCko to changes in Pim concentration.
• Dark Blue bars represent the PCwt steady-state data and the Light Blue bars represent the PCko
steady-state data.
• An average flux value was calculated for each reaction from all consecutive steady-state values per dataset.
These were then used to generate the actual bar graph. A difference of respective average flux values between
the PCwt & PCko models was calculated as – ∆ Flux Average (PCwt - PCko).
• Since, in the case of a reaction flux, the negative sign signifies only the direction taken by a reaction in a
steady-state; in this graph, the average flux value was considered as a positive number for those reactions
that function in their respective reverse directions. All such reactions are denoted by ± .
• Primary Y-axis (left) : Average Flux & ∆ Flux Average (PCwt - PCko), mmol/sec.
• Secondary Y-axis (right) : Average Flux, mmol/sec.
• Dark Blue bars for the PCwt model are aligned to the Primary Y-axis (left); whereas, Light Blue bars
for the PCko model are aligned to the Secondary Y-axis (right).
• Red line represents the ∆ Flux Average (PCwt - PCko) and is drawn aligned to the Primary Y-axis (left).
• Supplementary data shown in fig. II.5 on pg. XXVII.
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• Figure 3.8.
TCA cycle fluxes against the increasing maximal activity of PDH : effect of
PC ‘knock-out’ (PCko) in comparison with PC ‘wild-type’ (PCwt i.e. LVRTCAUPD).
• This is a combined bar graph showing the dynamic response of key TCA cycle reaction
fluxes from PCwt as well as PCko to changes in V PDHmax .
• Dark Green bars represent the PCwt steady-state data and the Light Green bars represent the
PCko steady-state data.
• An average flux value was calculated for each reaction from all consecutive steady-state values
per dataset. These were then used to generate the actual bar graph. A difference of respective
average flux values between the PCwt & PCko models was calculated as – ∆ Flux Average (PCwt
- PCko).
• Since, in the case of a reaction flux, the negative sign signifies only the direction taken by a
reaction in a steady-state; in this graph, the average flux value was considered as a positive number
for those reactions that function in their respective reverse direction s. All such reactions are
denoted by ± .
• Primary Y-axis (left) : Average Flux & ∆ Flux Average (PCwt - PCko), mmol/sec.
• Secondary Y-axis (right) : Average Flux, mmol/sec.
• Dark Green bars for the PCwt model are aligned to the Primary Y-axis (left); whereas, Light
Green bars for the PCko model are aligned to the Secondary Y-axis (right).
• Black line represents the ∆ Flux Average (PCwt - PCko) and is drawn aligned to the Primary
Y-axis (left).
• Supplementary data shown in fig. II.5 on pg. XXVII.
From figs. 3.6 to 3.8 (see, pgs. 131 to 133), following observations can be made:
1. In PCwt as well as PCko, excluding the 9 metabolites involved in 4 conservation
relationships described in the earlier chapter (see tbl. 2.5 on pg. 34), remaining 7
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TCAi’s are not conserved within the system and act as free variables. In the PCwt
model, PC & MC together represent a large influx–outflux subsystem (see fig. 2.18 on
pg. 59); which in theory, allows for relatively large variations in TCAi’s compared to
that in PCko. However, whether a particular metabolite concentration exhibits such
variations is entirely dependent on how the control of a given metabolite concentration
(i.e., concentration control coefficient (CS)) is shared between all TCA cycle enzymes.
In the PCko model, in absence of PC and a virtually non-existent MC, the allowable
variability in metabolite concentrations is significantly reduced compared to the PCwt
model. Moreover, the TCA cycle flux (flux through CS) in PCko is significantly
smaller compared to that in PCwt; which could potentially translate to relatively
lower steady-state concentrations of individual TCA cycle intermediates. Therefore,
mostly as a consequence of the altered structural properties, the difference in relative
variations of individual metabolite concentrations between the two models is likely to
be substantial in certain cases.
For instance, if we consider the average concentration value of a given metabolite in
PCwt as 100% for each steady-state scan dataset (i.e., against the increasing [Pim]
or V PDHmax , as represented in figs. 3.6 to 3.8), then the average concentration of any
PCko metabolite can be expressed in terms of – ‘percent of PCwt concentration’.
PCko fluxes as well as the total metabolite content (sum of all internal metabolite
concentrations) can be expressed similarly. Figures 3.9 and 3.10 (see, pgs. 135 and 136)
illustrate the individual PCko concentrations and fluxes as ‘% PCwt concentration/
flux’, respectively, for the same datasets represented earlier (see, figs. 3.6 to 3.8 on
pgs. 131 to 133, respectively).
2. From fig. 3.9, we can observe that for a given parameter scan (across [Pim] or PDH
activity), the average total metabolite content of PCko is reduced by a factor of 25 to
50 % of that in the PCwt model. In fact, even when the two models are simulated at
their respective initial conditions, the resultant total metabolite content of PCko, at
initial steady-state , shows a 17% decrease compared to that in PCwt (i.e., if we add
and compare all TCAi concentrations shown in fig. 3.4 on pg. 127, between the two
models); which means that the relative difference in respective TCAi concentrations
between these two models exists independent of any further changes in their respective
initial conditions and could be due to the factors explained earlier.
3. From this graph, we can also observe that [oxaloacetate] shows the highest percentage
reduction in PCko and considering its initial model value (4.05e-04 mM) as well as
the absence of PC in this model, it doesn’t seem so unreasonable.
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• Figure 3.9. Concentrations of TCAi’s in PCko : as
‘percent of PCwt concentration’ for each metabolite, per dataset (i.e., against [Pim] or V PDHmax ).
• This is a combined graph for the dynamic response of PCko TCAi concentrations to changes in
[Pim] & V PDHmax , respectively.
• This graph includes only 7 out of 16 TCAi’s that are not conserved within the system and act as free
variables. Also, this graph shows the same data presented earlier in fig. 3.6 (see, pg. 131), in terms of
percentage changes.
• Red line & Red bar : V PDHmax scan data; and Blue line & Blue bar : [Pim] scan data.
• The bars in the background represent the ‘Total TCAi content’ calculated for each dataset. The total
TCAi content is calculated as a sum total of average concentration values for all PCko TCAi’s and not just
the 7 TCAi’s shown here. The total TCAi content is then represented as ‘% PCwt concentration’ per dataset,
same as rest of the data included in this graph.
• Primary Y-axis (left) : PCko average conc. values, in percent (as % PCwt conc.).
• Secondary Y-axis (right) : PCko total TCAi content, in percent (as % PCwt conc.).
4. Between the V PDHmax & [Pim] scans, metabolites from the first half of the TCA cycle
(i.e., Citm, Isocitm, & αKGm) show the percentage concentration values within a
short range of 20 to 40%; whereas, metabolites from the latter half of the cycle (i.e.,
Fumm & Malm) show the percentage concentration values within a much larger range
of 20 to 110%. The overall reduction in PCko metabolites is significantly larger for
the [Pim] scan in comparison with the V PDHmax scan; which can be explained based on
the fact that increase in [Pim] causes the rate of ATP synthase to increase, thereby
increasing the TCA cycle substrate utilization and the percentage flux values given
in fig. 3.10 (see, pg. 136) agree with this reasoning.
5. The PCko % flux values described in fig. 3.10, show a significantly larger reduction in
almost all fluxes, by nearly 90 – 99% that of the respective PCwt fluxes; except in the
case of ATPhyd, which actually increases by 6% against V PDHmax and by 244% against
[Pim]. In the absence of PC, PCko contains a single ATP hydrolysing reaction in the
form of ATPhyd and therefore, in this PCko system, its flux is increased in response
to the change in ATP demand.
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• Figure 3.10. PCko TCA cycle fluxes : as ‘percent
of PCwt flux’ for each TCA cycle reaction flux, per dataset (i.e., against [Pim] or V PDHmax ).
• This is a combined graph for the dynamic response of PCko fluxes to changes in [Pim] & V PDHmax ,
respectively. Also, it shows the same data presented earlier in figs. 3.7 and 3.8, as percentage changes.
• Since, in the case of a reaction flux, a negative sign signifies only the steady-state direction of a reaction;
therefore, in this graph, the average flux value was considered as a positive number for those reactions that
function in their respective reverse directions, before calculating the percentage values. Please refer to figs. 3.7
and 3.8; wherein, all such reactions are denoted by ± .
• Red line : V PDHmax scan data; and Blue line : [Pim] scan data.
• Y-axis : PCko average flux values, in percent (as % PCwt flux), in logarithmic scale.
6. As shown in fig. 3.10, the TCA cycle flux in PCko is only 1.3% of that in the PCwt
model and thus strongly supports the observations made earlier regarding the relative
percentage reduction in PCko metabolite concentrations.
7. From these graphs, we can observe that MDH shows the highest difference in flux
between the two models. In fact, the PCko MDH flux is only 0.5–0.6% that of the
PCwt MDH flux in both scans (see, fig. 3.10). However, it is mostly because of the
structural difference between these models. Since, MDH acts in the forward direction
in PCko and at a same rate as the TCA cycle flux or ‘ESS #1’; whereas in PCwt, it
acts as an independent reaction that operates in its reverse direction and at a rate
higher than the TCA cycle flux.
Despite such detailed analysis, it is important to note that the quantitative aspect of
the data shown here essentially highlights the broad qualitative differences between these
models; since, they are basically the same model (see, note on pg. 126). Qualitatively,
this analysis shows the effects of zero pyruvate carboxylase activity on liver TCA cycle
metabolites & fluxes, as well as points towards the urgent need for an alternative
anaplerotic mechanism in the heart TCA cycle prototype, based on the significantly
reduced [oxaloacetate] in PCko, as shown in fig. 3.9.
— Ph.D. Thesis by Amar S. Ghaisas — Page 136
3. Heart TCA cycle prototype 3.3. Results for the heart TCA cycle . . .
-50
 0
 50
 100
 150
 200
 250
 300
 1  10
[A
T
P
m
it
o
] 
: 
[A
D
P
m
it
o
] 
(d
im
en
si
o
n
le
ss
)
log10[Pimito concentration]
PCwt v PCko Liver TCA cycle model data
3.11.a. [ATP/ADP]m
-50
 0
 50
 100
 150
 200
 250
 1  10
[A
T
P
cy
to
] 
: 
[A
D
P
cy
to
] 
(d
im
en
si
o
n
le
ss
)
log10[Pimito concentration]
PCwt v PCko Liver TCA cycle model data
3.11.b. [ATP/ADP]c
-5
 0
 5
 10
 15
 20
 1  10
[N
A
D
H
m
it
o
] 
: 
[N
A
D
m
it
o
] 
(d
im
en
si
o
n
le
ss
)
log10[Pimito concentration]
PCwt v PCko Liver TCA cycle model data
3.11.c. [NADH/NAD+]m
Median values
Updated model 0.3
Original model 0.2
Updated model 0.4
Original model 3.5
Updated model 0.4
Original model 2.2
NADH
m 
/ NAD
m
ATPm / ADPm
ATP
c 
/ ADP
c
3.11.d. Median values
• Figure 3.11. Variations in the ‘Energy status’ of the liver TCA cycle
models: [ATP/ADP] & [NADH/NAD+] ratios across the increasing concentration of [Pim].
• Key for figs. 3.11a to 3.11c is as follows :
• [ATP/ADP]m : PC ‘wild-type’ (PCwt) ; PC ‘knock-out’ (PCko)
• [ATP/ADP]c : PC ‘wild-type’ (PCwt) ; PC ‘knock-out’ (PCko)
• [NADH/NAD+]m : PC ‘wild-type’ (PCwt) ; PC ‘knock-out’ (PCko)
For figs. 3.11a to 3.11c :
• X-axis : log10[Pim] – concentration of mitochondrial inorganic phosphate (Pim) in logarithmic scale.
• Y-axis : Ratio of concentrations (dimensionless).
• The vertical black line represents the initial model value. At this point on the X-axis, [Pim] = 8.9 mM.
• A dotted, black, horizontal line represents the “zero-axis” in each figure.
• Supplementary data for figs. 3.11a, 3.11b and 3.11c is shown in figs. II.2c, II.2d, II.3c and II.3d on
pgs. XXIV to XXV, respectively.
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• Figure 3.12. Variations in the ‘Energy status’ of the liver TCA cycle models:
[ATP/ADP] & [NADH/NAD+] ratios across increasing maximal activity of PDH (V PDHmax ).
• Key for figs. 3.12a to 3.12c is as follows :
• [ATP/ADP]m : PC ‘wild-type’ (PCwt) ; PC ‘knock-out’ (PCko)
• [ATP/ADP]c : PC ‘wild-type’ (PCwt) ; PC ‘knock-out’ (PCko)
• [NADH/NAD+]m : PC ‘wild-type’ (PCwt) ; PC ‘knock-out’ (PCko)
For figs. 3.12a to 3.12c : • X-axis : log10[VPDHmax ] – PDH maximal activity in logarithmic scale.
• Y-axis : Ratio of concentrations (dimensionless). • The vertical black line represents the initial model
value. At this point on the X-axis, V PDHmax = 0.648 mM/sec. • A dotted, black, horizontal line represents the
“zero-axis” in each figure. • Supplementary data for figs. 3.12a, 3.12b and 3.12c is shown in
figs. II.2a, II.2b, II.3a and II.3b on pgs. XXIV to XXV, respectively.
The variation in the ‘energy status’ of the two models, as seen in figs. 3.11 and 3.12
(see, pgs. 137 and 138), is in agreement with earlier made observations for the respective
initial steady-states of these models on pg. 129.
Across [Pim] as well as V PDHmax , the [NADH/NAD+]m ratio between the PCwt &
PCko, shows a qualitative switch in the redox states. Across both parameters, the PCko
model becomes further reduced; whereas, the PCwt model exists in a comparatively more
oxidised state.
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Also, the [ATP/ADP]m & [ATP/ADP]c ratios for the PCko model show that there
is significantly more ATP in the system, as compared to that in the PCwt model. As
mentioned earlier in the discussion for the initial steady-states, such a qualitative shift
in the ATP/ADP ratios could be due to the PC removal and MDH operating in the
forward direction in the PCko model.
Thus, identifying the properties of the PCko model and its differences with the PCwt
model, has been helpful to learn about the overall qualitative nature of the structural as
well as kinetic properties of a mammalian heart- or skeletal muscle- specific TCA cycle
model.
3.3.4 Metabolic Control Analysis (MCA) of the heart TCA cycle
prototype
In this section, we’ll see the results of Metabolic Control Analysis (MCA), when
applied to heart TCA cycle model prototype by observing the distribution of flux control
coefficient (CJ).
3.3.4.1 Flux control coefficient analysis of the heart TCA cycle prototype
Figure 3.13, describes the control of flux through citrate synthase (CS), using the
flux control coefficients (CJ) of all the PCko enzymes.
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• Figure 3.13. Control of
TCA cycle flux in the ‘PC knock-out’ (PCko) model: against the PDH maximal activity.
• Key for fig. 3.13a is as follows :
PDH ; CS ; ACO ; IDHa ; α-KGDH ; SCS;
SDH ; FM ; MDH ; ATPsynth ; ANT ; ATPhyd;
IDHb ; Total Sum (dotted line)
• The vertical black line represents the initial model value. At this point, in figs. 3.13a and 3.13b,
V PDHmax = 0.648 mM/sec, respectively. • Orange dotted line shows the Summation theorem result.
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Figure 3.13 (see, pg. 139) shows the distribution of flux control coefficients (CJ)
calculated for the control of TCA cycle flux (flux through CS), for all enzymes of the
PCko model, across the increasing maximal activity of PDH (V PDHmax ). These flux control
coefficient plots are presented alongside a corresponding steady-state plot of citrate
synthase (CS) flux (the reaction ‘J’ on which the coefficient, ‘CJ’ is calculated) across
the same parameter range. In fig. 3.13, the flux control coefficients are distributed
between the range of −0.5 to 1.2 (unitless). In these plots, result of the summation
theorem is also included using a dotted line. For the corresponding flux control coefficient
plot computed for the PCwt model (i.e. updated liver TCA cycle model), please refer to
fig. 2.25b (see, pg. 74) of the previous chapter on liver TCA cycle models.
The comparison of these two flux control coefficient plots reveals that the removal of
PC from the PCko model, has nearly eliminated the complex pattern of CJ variation
that was observed in the PCwt model (see, fig. 2.25b). In PCwt model, the control of
TCA cycle flux is largely distributed between PDH, PC, ATPsynth, SDH, α-KGDH, &
IDHa, with a rapid exchange of the majority of control between PDH and the other key
enzymes. However, in the PCko model (see, fig. 3.13), the CJ distribution against V PDHmax
is fairly linear, without any rapid exchange between enzymes and distributed between
ATPhyd, α-KGDH, ATPsynth, & IDHa, with ATPhyd sharing the majority of control.
Citrate synthase (CS) also shares a minute amount of control in PCko (with an average
CJ value of 0.07–0.08). Also, in PCko, IDHa & ATPsynth have a moderate but notable
negative flux control coefficients, as shown in fig. 3.13.
The negative CJ value for IDHa indicates that an increase in the IDHa activity
causes a modest decrease in the TCA cycle flux. This may initially seem counter-intuitive,
but an increase in the IDHa activity increases the α-ketoglutarate concentration and
thus its availability for the IDHb; which in turn increases the IDHb reverse flux, thereby
counteracting and occasionally, even over-compensating for the greater IDHa activity.
Also, the negative CJ value of ATPsynth in fig. 3.13 may appear counter-intuitive,
as well. In fact, in the liver TCA cycle model it shares a strongly positive value, as
seen in fig. 2.25b (see, pg. 74). As described in the earlier chapter on liver TCA cycle
models (see, pg. 75), based on the Supply-demand analysis put forward by Hofmeyr
and Cornish-Bowden (2000), we may say that ATP synthase & ATP hydrolysis form
a demand block within the heart TCA cycle prototype, whereas other reactions of the
cycle represent the supply block. Accordingly, we may also expect that the flux control
coefficient of ATPsynth for the control of TCA cycle flux to be on the positive side.
However, with the notable exception of PCwt results, flux control distribution in the
PCko model doesn’t agree with this observation and we believe that the reason for these
counter-intuitive results lies in the supply block of the heart TCA cycle prototype.
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The negative CJ value for ATPsynth indicates that an increase in the ATPsynth
activity causes a modest decrease in the TCA cycle flux. In the PCko model, considering
the absence of PC & extremely limited supply of oxaloacetate (with an initial model
value of 4.05e-04 mM & an initial steady-state value of 1.2e-06 mM), the TCA cycle flux
can increase only within a limited range and soon hits a plateau within a short range of
change in enzyme activity, as seen in figs. II.5b, II.5d and 3.13b (see, pg. XXVII & pg. 139,
respectively). Any significant increase in the ATPsynth activity also means a substantial
increase in NADHm demand. Since, 3 out of 4 NAD- dependent dehydrogenases in
PCko constitute ‘ESS #1’ along with CS (since, IDHa is an independent reaction), the
NADHm supply is subjected to the same restrictions as that of the TCA cycle flux. Such
limitations on the supply of reduced substrate for the synthesis of ATP is likely to impact
the TCA cycle flux negatively, resulting into a negative CJ value of ATPsynth for the
control of PCko TCA cycle flux.
Since, PC is absent in the heart TCA cycle prototype, ATPhyd becomes the only
ATP-hydrolysing reaction in the model and therefore the only reaction that sets the
ATP-demand in this system. From literature, we already know that in mammalian
tissues such as heart and skeletal-muscle, the mitochondrial carbon metabolism is highly
demand-driven and the high share of control exhibited by ATPhyd for the control of
PCko TCA cycle flux, is in good agreement with the published data.
In the liver TCA cycle model, SDH shared a prominent share of control after the
‘rapid-exchange phase’, along with ATPsynth, PC, & α-KGDH. In the heart TCA cycle
prototype however, it shares no discernible share of control. In fact in fig. 3.13, the
average CJ value for SDH is as low as −0.002. As explained in the chapter on liver TCA
cycle models (see, pg. 76), one of the major factors influencing the amount of control
shared by SDH, was the interruption of its enzyme subset (‘ESS #2’) by the independent
reactions (MDH, IDHa, and IDHb), causing the two halves of the subset to form a linear
and a branched reaction sequence, respectively. The branched reaction sequence included
FM, MC & MDH and it was formed due to MDH operating in its reverse direction. In
the heart TCA cycle prototype, since PC was deleted and since, MC is essentially a dead
reaction (against increasing V PDHmax , its average steady-state value is 2.0e-12 mmol/sec),
the branched reaction sequence from PCwt is no longer operational in PCko, thereby
causing SDH to lose its prominent share of control in this system.
Overall, even in response to change in other enzyme activities or metabolite concen-
trations, the distribution of flux control between the PCko TCA cycle enzymes is found
to be roughly within the same range as that seen in fig. 3.13 and displays a qualitatively
similar pattern of CJ distribution.
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3.4 Discussion & Conclusions
The idea of a “PC knock-out” model was first born during the Metabolic Control Analysis
of liver TCA cycle models as a simple yet elegant way to study the dynamic properties
of a metabolic system that is more akin to the mammalian heart TCA cycle, a priori.
So far, the structural as well as kinetic analysis of the “PC knock-out” model or the
heart TCA cycle prototype has already provided valuable insights regarding the plausible
behaviour of a mammalian heart or skeletal muscle-specific TCA cycle and they are as
follows:
1. The “PC knock-out” model demonstrates that by removing the most influential,
mammalian liver-specific anaplerotic reaction (i.e., pyruvate carboxylase) from the
updated liver TCA cycle model, we can isolate only those elementary modes that
describe the core structural aspects of a mammalian heart or skeletal muscle-specific
TCA cycle model and thereby transforming the liver-specific model into an archetypical
heart-specific TCA cycle model. From a novice modeller’s perspective, it is an
important lesson in understanding how to isolate a desired subsystem that exists as
an integral part of a larger system by simply analysing the model using structural
analysis tools.
2. The elementary modes analysis of the PCko model suggests that the internal substrate
cycle between the NAD+ -dependent isocitrate dehydrogenase and the NADP+ -
dependent isocitrate dehydrogenase that operates in the updated liver TCA cycle
model is likely to exist in a mammalian heart-specific TCA cycle model as well,
provided it follows a similar structural definition as that of the PCko model. In fact,
there is enough literature evidence to support the existence of such a cycle in heart
tissue (Huang and Colman, 2005; Londesborough and Dalziel, 1968; McCormack and
Denton, 1981; Rutter and Denton, 1988; Sazanov and Jackson, 1993).
3. The elementary modes analysis of the PCko model also shows that a theoretically
ideal version of TCA cycle, often described in biochemistry textbooks, that produces
11 molecules of ATPm & 3 molecules of CO2 per pyruvate, can be built from this
model by removing the NADP+ -dependent isocitrate dehydrogenase from PCko to
further isolate ElMo[2] described in tbs. 3.1 and 3.2 (see, pg. 124). This TCA cycle
model would then contain only a single elementary mode (ElMo[2]), which would also
be the only enzyme subset that comprises all 12 reactions of this model.
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4. As mentioned in the earlier chapter, the moderate degree of control shared by
ATPsynth in this model, indicates the importance of including a fully developed
module of the Electron transport chain (ETC). The possible inclusion of an expanded
ETC module would also include the oxygen consumption reaction; which would make
the heart-specific model further aligned with the experimental observations.
5. The high degree of control shared by ATPhyd in this model, indicates the importance
of ATP-demanding reactions such as ATPhyd in a heart-specific TCA cycle model.
Currently, it is defined as an irreversible, simple first-order reaction flux. Considering
its importance in this system, it might be appropriate to include a further detailed
description of ATP hydrolysis. For instance, currently, both ATPc & ADPc represent
an example of poorly constrained concentrations in a metabolic model and are likely
to cause locally confined mathematical anomalies in certain special cases.
6. As mentioned in the earlier chapter, expanding the model to reflect PDH regulation
by covalent modification would be a worthwhile addition to the heart-specific TCA
cycle model, as it may help to facilitate a dynamic balance between the demands of
gluconeogenesis and ATP production.
7. The absence of pyruvate carboxylase and the extremely low steady-state concentra-
tion of oxaloacetate in the PCko model, points towards an alternative anaplerotic
mechanism that, at least in theory, is expected to provide additional routes into and
out of the mitochondrial TCAi pool and the ‘Malate-aspartate shuttle (MAS)’ is one
such mechanism that operates in mammalian heart or skeletal-muscle mitochondria.
Possible inclusion of malate-aspartate shuttle in the heart-specific TCA cycle model,
would be another useful modification to align this model further in agreement with
the published data.
8. Overall analysis of the “PC knock-out” model, highlights the qualitative realignment of
structural as well as dynamic properties of liver TCA cycle model towards a metabolic
system that roughly describes a specific subset of metabolic characteristics that are
in agreement with general experimental observations of a heart or skeletal muscle-
specific TCA cycle. More importantly, obtaining an abstract picture for plausible
metabolic characteristics of a heart-specific TCA cycle model, during the early stages
of model development is extremely useful in optimising the entire development process,
particularly the phase of ‘data collection’, for collecting the relevant enzyme kinetics
data.
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Chapter 4
The Heart TCA cycle model
4.1 Overview
In the previous chapter, dynamic properties of the mammalian liver-specific tricarboxylic
acid cycle model developed within the Cell Systems Modelling Group (CSMG) (Brightman
et al., 2010, unpublished manuscript) were studied extensively. The understanding and
the knowledge of various modelling processes as well as the tissue-specific TCA cycle
model itself, acquired during this study proved to be most helpful at the beginning stages
of this project and formed the core base of all future development. In this chapter, we
will be studying the modification of the existing liver TCA cycle model to a heart or
skeletal muscle-specific TCA cycle model, as well as the resultant properties of the newly
created system.
The structure of the existing liver TCA cycle model was modified in terms of
reactions to be included in the resultant heart-specific model. Moreover, for the selected
set of reactions, the mammalian heart-specific enzyme kinetics data was collected from
published literature and applied to the model. Also, as mentioned in the earlier chapter,
we have followed the same modelling strategy used to define individual reactions of
the liver TCA cycle model, to construct a ‘consensus’ kinetic model of TCA cycle in
mammalian heart or skeletal muscle mitochondria, which is neither over-simplified nor too
complex in terms of rate equations, reversibility of reactions and regulatory interactions.
In Section 4.2, we shall discuss the definition & construction of heart TCA cycle
model (HRTTCA) in further detail. Section 4.3: Results for the heart TCA cycle model
on pg. 150, describes an in-depth analysis of the emergent dynamic properties of this
model.
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4.2 Methods: Model design and definition
As mentioned earlier, the Heart TCA cycle model (HRTTCA) representing the operation
of heart or skeletal muscle-specific TCA cycle was manually constructed by modifying
the existing liver TCA cycle model using ScrumPy. The model in ScrumPy format is
available in Appendix F (see, pg. 241) and is illustrated in fig. 4.1 (see, pg. 145). The
final version of the updated model contains 13 reactions and 24 metabolites.
4.2.1 Model definition
Since, this model is based on the liver TCA cycle model, it follows the same design
choices in terms of individual enzyme rate equations that are represented using the
simplified, generic, reversible bi-substrate equation (Chassagnole et al., 2001b; Rohwer
et al., 2006), as explained in the earlier chapter (see, pg. 19).
CS
AcCoAm
NADHmNADm
+
CoAm CO2
Pyrm
PDH
OAAm
Citm
SCoAm
Malm
Sucm
Fumm
α-KGDH
MDH
SDH
FM
CoAm
CO2
NADHm
NADm
+
NADHm
NADm
+
SCS
CoAm Pim
ADPm
ATPm
Q
QH2
ACO
Mitochondria
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α-KGm
Cytoplasm
ANT
ATPm
ADPm ATPc
ADPc
ATPhyd
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Pim
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+
NADHm
• Figure 4.1. Schematic
illustrating the TCA cycle reactions participating in the heart TCA cycle model.
• Internal metabolites: in Black; external metabolites: in Blue; reaction/ enzyme names: in Red .
• Reaction with double arrowheads is assumed to be reversible and reaction with single arrowhead
is assumed to be irreversible.
— Ph.D. Thesis by Amar S. Ghaisas — Page 145
4. Heart TCA cycle model 4.2. Methods
As illustrated in Figure 4.1, the model includes eight canonical (non-tissue-specific)
TCA cycle reactions including the reaction catalysed by pyruvate dehydrogenase (PDH),
a hypothetical, reversible transport reaction that transports α-ketoglutarate in and out
of the mitochondria and three ATP/ADP–linked reactions that include an abstracted
representation of oxidative phosphorylation, cytosolic ATP hydrolysis (ATPhyd), along
with an adenine-nucleotide exchange with the cytosol catalysed by ANT. The two liver
tissue-specific reactions (MC & PC) are absent in this model, since in mammalian
heart as well as skeletal muscle tissue, literature evidence suggests that the anaplerotic
contribution of PC to the total flux through the TCA cycle is insignificant as compared
to that in liver (Gibala, 2003; Gibala et al., 2000; Owen et al., 2002; Scrutton and Utter,
1968). Also, there is very little evidence that would suggest any significant activity of MC
in heart or skeletal muscle tissue (Chappell, 1968; Fiermonte et al., 1999; Klingenberg,
1970; LaNoue and Schoolwerth, 1979; Palmieri, 1994; Sluse et al., 1971). Furthermore,
since the anaplerotic contribution of PC is minimal in mammalian heart as well as skeletal
muscle tissue, in its absence, other anaplerotic pathways such as the malate-aspartate
shuttle need to be considered in the model, in order to to maintain the oxaloacetate
concentration at levels sufficient enough to sustain the physiological rates of citrate
synthesis in these tissues (Garland et al., 1969; LaNoue et al., 1970; LaNoue et al., 1972;
Srere, 1974; Williamson et al., 1972). A similar observation was made in the earlier
chapter, during the analysis of concentration control coefficients for the liver TCA cycle
model (see, pg. 108).
However, since it was crucial to first study the basic heart TCA cycle model before
including the malate-aspartate shuttle reactions; a hypothetical, simplified reversible
transport reaction, α-ketoglutarate transporter (α-KGexp) was included in the model
and it follows a reversible uni-uni kinetic model (Segel, 1993). α-KGexp is not a one-step
representation for the actual function of malate-aspartate shuttle in mammalian heart or
skeletal muscle tissue, but is intended only as a pointer or a placeholder to be replaced
later by a set of reactions representing the malate-aspartate shuttle in these tissues. Also,
during the development process, it was discovered that this model requires a small amount
of outflow to achieve a stable steady-state and since MC is no longer present in this model,
the required outflow reaction was chosen to be shown in the form of α-KGexp, which
may also be viewed as only a partial representation of malate-oxoglutarate transporter
(MOTx) – an integral transport reaction of the Malate-Aspartate shuttle. The enzyme
rate equation for α-KGexp is shown in eq. E.7 in Appendix E (see, pg. 240).
Initially, during the development of heart TCA cycle model, NADP+ -dependent
isocitrate dehydrogenase (IDHb) was included in this system along with NAD+ -dependent
isocitrate dehydrogenase (IDHa), similar to what we have already seen in the liver TCA
cycle model. However, during steady-state analysis of this early version of the model, it
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was discovered that both reactions act in the forward direction to produce α-ketoglutarate
from isocitrate and that IDHb is almost entirely responsible for whatever amount of
αKGm is produced through these reactions; while IDHa carries only an infinitesimally
small flux, which is nearly 1.5e+04 times lower than that of the flux through IDHb.
In liver TCA cycle model, due to its specific structural properties and the amount of
flux carried by pyruvate carboxylase (3-4 times the TCA cycle flux) and also the fact
that the only available outflow in that model was at the level of malate, both IDHa &
IDHb were functional and carried significant amount of flux, albeit in opposite directions.
However, in the case of heart TCA cycle model, the significant amount of influx via
PC is absent and the only outflow in this model is at the level of α-ketoglutarate, in
the form of α-KGexp. In our view, it is possible that in such a system, the resultant
TCA cycle flux requires and is sufficient to support only one reaction that converts
isocitrate to αKGm and based on the degrees of freedom associated with either of these
reactions, the model tends to allow IDHb to carry most of the flux; since it utilises
NADP+ as a co-substrate, which along with NADPH is an external metabolite and more
freely available than NADm+ or NADHm. Therefore, until the present heart TCA cycle
model is extended to include the malate-aspartate shuttle reactions, we decided that the
basic heart TCA cycle model in its current form should only contain NAD+ -dependent
isocitrate dehydrogenase (IDHa).
Therefore, in summary, other than these four changes to the liver TCA cycle
model, other reactions remain unchanged in the heart TCA cycle model, except their
corresponding model parameters and variables, which are updated according to the
enzyme kinetics data specific to the mammalian heart or skeletal muscle tissue. For ANT
& ATPsynth, original enzyme kinetics data from the liver TCA cycle model is kept as is,
due to the unavailability of satisfactory estimates in mammalian heart or skeletal muscle
tissue. The values of all updated model parameters (external metabolites & kinetic/
thermodynamic constants) are provided in the supplementary material, in Table III.2
(see, pg. XXIX). Also, complete details for the α-ketoglutarate transporter (α-KGexp)
reaction added to the heart TCA cycle model are shown in eq. E.7 in Appendix E (see,
pg. 240). For full details regarding net stoichiometric equations as well as enzyme rate
equations of the remaining 12 reactions, please refer to Appendix B (see, pg. 223).
The heart TCA cycle model includes the same 16 variables (internal metabolites) as
that of the liver TCA cycle model and they describe the concentrations of TCA cycle
intermediates, and of acetyl-CoA, CoAm, adenine nucleotides, NADm+, & NADHm. Each
of these variables in the model is assigned an initial value, based on literature data. Also,
this model includes 8 parameters that describe fixed quantities (external metabolites)
of model input (pyruvate), enzyme cofactors/ effectors (Q/ QH2 & Ca2+), inorganic
phosphates (Pim & Pic), and system outputs (CO2 & αKGc). For most of these 24
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metabolites, a range of values, largely from rat heart or skeletal muscle tissue were found
and a median value was used in the model. However, in the case of metabolites for which
satisfactory estimates could not be found in the literature, the original liver-specific
values were retained. Table 4.1 (see, pg. 149) shows the values of all the model variables
(internal metabolites & key fluxes) in heart or skeletal muscle tissue, taken from the
literature and compares them to the corresponding values predicted by the model at
initial steady-state.
The heart TCA cycle model consists of a system of 12 non-linear ordinary differential
equations, similar to the liver TCA cycle model, each of which describes the evolution
of one of the model variables (concentrations of internal metabolites) over time, from
their respective initial model values. However, due to the specific differences between
these two models, 5 out of 12 equations are slightly altered (viz., equations for – Isocitm,
αKGm, Malm, OAAm, and ATPm) and are described in Appendix E (see eqs. E.1 to E.5
on pg. 240). The 4 algebraic expressions that additionally define the concentrations of
conserved moieties have been removed from the heart TCA cycle model; due to their
redundancy with respect to the ScrumPy -specific, default internal parameters that are
assigned to each of the conserved totals by default, at model simulation (for further
details, please refer to pg. 22 from the liver TCA cycle model chapter).
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• Table 4.1. Values of TCA
cycle variables in heart tissue taken from the literature and predicted by the model a,b
Fluxes are in units of mmol/sec and concentrations in mM.
Literature Values
Variable
Range Median
Model Values
TCA cycle (CS) flux 0.03 – 0.08 0.06 4.33e-03
[
CoAm
]
0.01 – 0.08 0.046 2.05e-03[
AcCoAm
]
0.02 – 0.33 0.18 0.25[
Citm
]
0.03 – 4.0 2.01 0.49[
Isocitm
]
0.03 – 0.12 0.08 3.32e-02[
αKGm
]
0.01 – 0.8 0.4 6.00e-03[
Sucm
]
0.06 – 3.9 2.0 4.27e-02[
SCoAm
]
0.01 – 0.29 0.15 1.55e-04[
Fumm
]
6.9e-03 – 0.26 0.13 3.65e-02[
Malm
]
0.16 – 1.88 1.02 0.16[
OAAm
]
0.002 – 0.062 0.032 1.44e-05[
NAD+m
]
0.56 – 1.36 0.96 0.6[
NADHm
]
0.1 – 1.0 0.53 0.094
[
ADPm
]
Same as the liver
TCA cycle model
0.88[
ATPm
]
9.52
Free c
[
ADPc
]
4.47e-02
Free c
[
ATPc
]
4.77
a The predicted model values are obtained at steady-state, upon simulating the Heart TCA cycle model.
These are the same values shown in the analysis of initial steady-state of the model, in the results
section.
b An expanded version of this table, containing details of the source references for the literature data, is
provided in the supplementary material (see, Table III.1 on pg. XXVIII).
c Not bound to fixed sites; in the case of ATP, fixed-site binding is negligible.
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4.3 Results for the heart TCA cycle model
In this section, various kinetic as well as structural properties of the heart TCA cycle
model are studied using various methods of analysis, such as – ‘Elementary modes analy-
sis’, ‘Enzyme subset analysis’, ‘Steady-state analysis’, ‘Metabolic Control Analysis’, etc.
Similar to the liver TCA cycle model analysis, we will primarily focus on physiologically
significant key findings, in order to present a more thorough discussion of the presented
data.
Briefly, the following types of results will be presented:
1. Elementary modes analysis (see sec. 4.3.1 on pg. 150)
2. Enzyme subset analysis (see sec. 4.3.2 on pg. 152)
3. Initial steady-state data & Steady-state analysis (see sec. 4.3.3 on pg. 153)
4. Metabolic Control Analysis (MCA) results (see sec. 4.3.5 on pg. 170)
4.(a.) Flux control coefficient analysis results (see sec. 4.3.5.1 on pg. 170)
4.(b.) Concentration control coefficient analysis results (see sec. 4.3.5.2 on pg. 176)
4.(c.) Elasticity coefficient analysis results (see sec. 4.3.5.3 on pg. 184)
4.3.1 Elementary modes analysis of the heart TCA cycle model
The heart TCA cycle model contains a single elementary mode which consumes one
molecule of pyruvate to produce 3 CO2 molecules and 11 mitochondrial ATP that are
consequently utilised to produce 11 cytosolic ADP & Pi. In summary, the present
heart TCA cycle model performs optimally to produce a maximum possible amount
of mitochondrial ATP by an ideal/ textbook TCA cycle. Table 4.2 shows this single
elementary mode alongside its corresponding net stoichiometry.
Heart TCA cycle reactions ATP/ ADP- linked reactions
Modes PDH CS ACO SCS SDH FM MDH ANT
1 1 1 1 1 1 1 1 1 0 1 11 11
IDHa α-KGDH α-KGexp ATPsynth ATPhyd
ElMo 0
4.2.a
Reactants Products
ElMo 0 : 3 CO2 + QH2 + 11 Pic (1)11 Pim + Pyrm + Q
4.2.b
• Table 4.2. A table showing elementary modes for heart TCA cycle model.
• Table 4.2a shows the only elementary mode for the heart TCA cycle model; whereas, tbl. 4.2b shows its
corresponding net stoichiometry. • In tbs. 4.2a and 4.2b, fractions have been converted to decimals.
• All metabolites in tbl. 4.2b are, by necessity, external in the modelling sense.
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This elementary mode is similar to ElMo[3] & ElMo[2] of the updated liver TCA
cycle model and the “PC knock-out” model, respectively (see tbs. 2.3 and 3.1 on pgs. 33
and 124, respectively). Figure 4.3 shows a detailed account of the net mitochondrial
ATPm and NADHm production for this mode.
Mode 0
Net NADH = 4 Net ATPmit = 11
α-KGDH
1.0
PDH
1.0
CS
1.0
SCS
1.0
MDH1.0
1.0
FM
1.0
IDHa 1.0
1.0
1.0
1.0
1.0
10.0
ATPsynth
1.0
ANT11.0
ATPhyd
11.0
11.0
11.0
α-KGexp
0.0
Key:
Reaction that does not participate
in a given elementary mode
# of NADH
produced1.0
1.0
# of ATPmit
produced
• Figure 4.3. Infographics showing the stoichiometric account of the net mitochon-
drial ATPm and NADHm production for the heart TCA cycle model elementary mode.
• All the heart TCA cycle model reactions are represented in their minimal form. Only the absolutely
essential metabolites & co-factors are included in this diagram.
• In this figure, the arrowheads point towards the respective forward or reverse directions of the
participating reactions, specific to the elementary mode.
• Reactions shown in Grey, do not participate in the elementary mode. Whereas, reactions shown in
light Blue, function in their respective forward directions.
• Numbers within the arrows represent the respective reaction strengths (see tbl. 4.2a on pg. 150).
• ATPm is represented by a small Yellow circle and NADHm by a small Orange circle. Numbers within
these circles represent the number of molecules produced by the corresponding reaction. For any reaction,
the production of a metabolite is shown using a positive number and the consumption using a negative
number.
• Net NADHm production = NADHmPDH + NADHmIDHa + NADHmα-KGDH + NADHmMDH
• Net ATPm production = ATPmATPsynth + ATPmSCS
In the previous chapter, analysis of liver TCA cycle model elementary modes revealed
that in the absence of PC & MC, MDH would operate in its respective forward direction
and tbl. 4.2a and fig. 4.3 illustrate the same in the case of heart TCA cycle model (see
fig. 2.6 on pg. 38). The internal substrate cycle between IDHa & IDHb that exists in
the liver TCA cycle models is absent in this model, as it currently does not include the
NADP+ -dependent isocitrate dehydrogenase reaction. As mentioned earlier in Methods
(see, pg. 147), IDHb will be included in the heart TCA cycle model after it is extended
to incorporate the malate-aspartate shuttle (MAS) reactions.
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Table 4.3 illustrates the moiety conservation of ATP, NAD & CoA–related metabo-
lites in the heart TCA cycle model. The conservation relationships in the heart TCA
cycle model are exactly the same as they exist in the updated liver TCA cycle model
(see tbl. 2.5 on pg. 34).
Heart TCA cycle model
1
2
3
4
ATP
c
  :  ADP
c
ATP
m
  :  ADP
m
NADH
m
  :  NAD
m
AcCoA
m
  :  (SCoA
m 
, CoA
m
)
• Table 4.3. Moiety conservation in heart TCA cycle model
Therefore, this elementary modes analysis shows that we have successfully isolated
the 9 canonical TCA cycle reactions along with 3 ATP/ADP–linked reactions from the
updated liver TCA cycle model and the resulting structural framework appropriately
defines a mammalian heart or skeletal muscle-specific TCA cycle model.
4.3.2 Enzyme subset analysis of the heart TCA cycle model
The heart TCA cycle model contains a single enzyme subset that includes 12 out of 13
possible reactions in the model and tbl. 4.2a (see, pg. 150) shows the composition of this
enzyme subset, which is also the only elementary mode present in the heart TCA cycle
model. α-KGexp is a structurally dead reaction, since it carries an infinitesimally small
amount of flux. However, as mentioned earlier in Methods, it is nonetheless required for
the kinetic stability of the heart TCA cycle model.
Also, this enzyme subset analysis reveals that in the absence of PC & MC or any
other non-canonical TCA cycle reaction, the heart TCA cycle model enzyme subset is
devoid of any interruption between two participating reactions and includes all TCA
cycle reactions along with 3 ATP/ADP–linked reactions, unlike that of the liver TCA
cycle model (see fig. 2.8 on pg. 43). In future, after the introduction of malate-aspartate
shuttle reactions to the heart TCA cycle model, this enzyme subset is likely to break at
junctions where the two pathways interact with each other.
In the following sections, we look at kinetic/ dynamic properties of the heart TCA
cycle model and in some cases establish appropriate links with its structural properties
as well.
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4.3.3 Steady-state analysis of the heart TCA cycle model
The heart TCA cycle model was solved with the ‘initially defined’ values of all the
parameters & variables presented in Methods to obtain the ‘initial steady-state’ of the
model (see tbs. III.1 and III.2 on pg. XXIX & pg. XXVIII, respectively). Figures 4.4
and 4.5 respectively show the reaction fluxes & metabolite concentrations in the heart
TCA cycle model, at initial steady-state.
CS ATPhyd (ATPsynth × 10) + SCS
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• Figure 4.4. Fluxes for the heart TCA cycle model, at initial steady-state.
• In the heart TCA cycle model, since there is a single enzyme subset, we have represented the flux through
TCA cycle in the form of citrate synthase (CS) flux.
• In this graph, the light blue bar for ATPhyd represents total ATPm consumption and the dark blue bar
represents total ATPm production by the heart TCA cycle model, at initial steady-state.
• In order to calculate the total ATPm production flux in this model, the initial steady-state value for ATP
synthase (ATPsynth) flux have been scaled by a factor of 10; due to the difference in respective reaction
stoichiometries between ATPsynth (in mitochondria) and ATPhyd (in cytosol) and the initial steady-state
value of SCS flux is then added to it, in order to account for substrate-level phosphorylation.
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• Figure 4.5. A graph of TCA cycle
intermediate metabolite concentrations for the heart TCA cycle model, at initial steady-state.
• Y-axis : Metabolite concentration in logarithmic scale.
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Figure 4.4 (see, pg. 153) shows the magnitude of fluxes in the heart TCA cycle model,
at initial steady-state. Since, all 12 out of 13 reactions in this model comprise a single
enzyme subset, we have represented the flux through the TCA cycle in the form of citrate
synthase (CS) flux. This graph also shows that the total ATP production (ATPsynth)
& consumption (ATPhyd) fluxes in the heart TCA cycle model are well balanced, by
accounting for the stoichiometric difference between them, as well as considering the
substrate-level phosphorylation (SCS).
In the absence of anaplerotic contribution by pyruvate carboxylase, the initial steady-
state TCA cycle flux (flux through CS) in the heart TCA cycle model is approx. 1.4%
that of the updated liver TCA cycle model (see fig. 2.9 on pg. 46). Also, ATP synthase
flux in the heart TCA cycle model is approx. 7.0% that of the updated liver TCA cycle
model. However, at initial steady-state, the heart TCA cycle model ATP hydrolysis
flux is approx. 33.0% more than that of the updated liver TCA cycle model. As already
mentioned, lack of pyruvate carboxylase in the heart TCA cycle model is one of the
most important factors due to which this model exhibits such significantly altered initial
steady-state fluxes; however, the mammalian heart-specific enzyme kinetics data as well
as the mammalian heart-specific metabolite concentration values used in this model
could also be a factor, in part. Moreover, in the absence of PC, lack of malate-aspartate
shuttle reactions in the heart TCA cycle model could also be partly responsible for a
relatively lower TCA cycle flux than that of the liver TCA cycle model.
Figure 4.5 (see, pg. 153) shows the heart TCA cycle intermediate metabolites, at
initial steady-state. Among all heart TCA cycle intermediates, oxaloacetate initial
steady-state concentration is the lowest (1.4e-05 mM), followed by SCoA (1.6e-04 mM),
CoA (2.0e-03 mM) and α-ketoglutarate (6.0e-03 mM). However, without any basis of
comparison, it is rather difficult to elaborate on these results any further.
Therefore, in fig. 4.6 (see, pg. 155) we calculate the initial steady-state concentrations
of all TCAi’s as % initial model values and represent them as % change in the initial
model values by subtracting 100% (initial model value) from the calculated value (please
refer to the Y-axis scale in fig. 4.6). In other words, we calculate by how much any
given TCAi concentration has increased or decreased from its corresponding initial model
value, as the model achieves an initial steady-state, in percent. For better comparison,
we performed these calculations with the initial steady-state concentrations of all TCAi’s
from the liver TCA cycle model & the “PC knock-out” model, as well (see figs. 2.10
and 3.4 on pgs. 47 and 127, respectively). Thus, fig. 4.6 compares the liver, PCko & heart
TCA cycle model TCAi concentrations at initial steady-state, by representing them as %
change in their corresponding initial model values from a given model.
Figure 4.6 shows that in the heart TCA cycle model, the respective initial steady-
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• Figure 4.6. Comparison of the liver, PCko & heart TCA cycle model TCAi
concentrations in the form of ‘percent change in initial model values’, at initial steady-state.
• Y-axis : The initial steady-state TCAi concentrations represented as the ‘% change in their corresponding
initial model values’, per model.
• : Red line represents the ‘% change in initial model values’ in the liver TCA cycle model initial steady-state;
Grey line represents the ‘% change in initial model values’ in the PCko initial steady-state; and Black line
shows the ‘% change in initial model values’ in the heart TCA cycle model initial steady-state.
• : Zero-axis represents the initial model value of a given TCAi, in a given model.
• : Values along the positive Y-axis show ‘% increase in the initial model value’, whereas values along the
negative Y-axis show ‘% decrease in the initial model value’, per metabolite in a given model.
state concentrations of oxaloacetate, α-ketoglutarate, succinate, malate, coenzyme A and
succinyl-CoA decrease by approx. 90% – 99% that of their corresponding initial model
values. In the updated liver TCA cycle model, these TCAi’s decrease only by approx.
1% – 15% that of their corresponding initial model values; except succinyl-CoA, which
increases by approx. 40%. In the PCko model, these TCAi’s decrease moderately by
approx. 40% – 99% that of their corresponding initial model values; except succinyl-CoA,
which increases by approx. 75%. Also, between all 3 models, citrate and isocitrate
decrease by approx. 20% – 60% that of their corresponding initial model values.
In this graph, acetyl-CoA shows significant increase in all 3 models by approx. 5% –
350% that of its corresponding initial model values in these models. In the heart TCA
cycle as well as the PCko model, the initial steady-state concentration of mitochondrial
ATP increases by approx. 25% – 35% that of its corresponding initial model value;
whereas it decreases by approx. 3% in the liver TCA cycle model. The cytosolic ATP
concentration follows a similar pattern of changes between the 3 models. In the heart
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TCA cycle model, initial steady-state concentration of NADH decreases by approx. 25%
compared to its corresponding initial model value and NAD increases by approx. 5%;
whereas the other two models show an exactly opposite pattern of change.
Overall, fig. 4.6 shows that there exists a significant qualitative as well as quantitative
difference between the respective initial steady-state behaviours of the liver and the heart
TCA cycle models. It also shows that although a ‘zero PC activity’ in the PCko model
allows for a qualitatively similar behaviour as that of the heart TCA cycle model, in part;
it is nonetheless an approximation that utilises mammalian liver-specific enzyme kinetics
& metabolite concentration data. Therefore, through the comparison between these
three models, fig. 4.6 illustrates the importance of mammalian heart-specific enzyme
kinetics & metabolite concentration data applied to the heart TCA cycle model, over
any probable effects due to the absence of anaplerotic mechanisms in this model.
4.3.4 Dynamic responses of the heart TCA cycle model to the
variations in TCA cycle enzyme activities
In this section, successive steady-states of the heart TCA cycle model are analysed in
detail, in response to the variations in TCA cycle enzyme activities. Considering the
flux control coefficient distribution for the PCko model presented earlier (see fig. 3.13 on
pg. 139), ATPhyd appears to be the most controlling enzyme in a TCA cycle system
that lacks the pyruvate carboxylase activity. Also, as seen earlier, the respective flux
control coefficient distributions for the updated liver TCA cycle model, PCkd model, as
well as the reduced liver TCA cycle model, show that PDH is one of the key TCA cycle
enzymes that shares a majority of the TCA cycle flux control before rapidly exchanging
it with PC. Therefore, due to the absence of PC activity in the heart TCA cycle model,
ATPhyd as well as PDH are suspected to be key factors in controlling the flux through
the TCA cycle. Hence, from this analysis, we have presented steady-state data for a
wide range of variations in the respective activities of ATPhyd & PDH.
Since for both enzymes, we have covered a wide range of activity variations (a total
of six variations, ranging from weak to overload), we show the average steady-state
behaviour of the model at every activity variation in the form of a bar graph. Also,
since it is impossible to include such a large number of plots corresponding to each
activity variation per enzyme, the original steady-state analysis plots are not shown in
the supplementary material.
Figures 4.7 to 4.10 (see, pgs. 157 to 160, respectively) show the average steady-
state behaviour of the heart TCA cycle model, when ATP hydrolysis activity is varied
between 0.1x (weak) and 500x (overload), where ‘x’ is the initial model value for the
ATP hydrolysis activity (where, ‘x’ = 0.01 mM/sec; termed here as – basal activity).
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4.7.a. TCA cycle intermediate metabolites (TCAi) – Part 1
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4.7.b. TCA cycle intermediate metabolites (TCAi) – Part 2
• Figure 4.7. The effect of a wide range of ATP hydrolysis
activity variations on TCAi concentrations, against the change in ANT maximal activity.
• Six bars for every metabolite or reaction represent six ATPhyd activity variations, shown in light-to-dark
colour shades, indicating ‘weak’ to ‘overload’ ATPhyd activities.
• An average concentration or flux value was calculated for each metabolite or reaction, from all consecutive
steady-state values per dataset. They were then used as log10 values to generate the bar graph.
• The initial model value for ATPhyd activity in the heart TCA cycle model is 0.01 mM/sec and in this
graph, it is represented as the ‘basal activity’ or ‘1x’. ATPhyd activities included in this graph are as follows:
• Weak ATPhyd activity (0.1x) = 0.01 mM/sec (1x) ÷ 10 = 0.001 mM/sec
• Low ATPhyd activity (0.2x) = 0.01 mM/sec (1x) ÷ 5 = 0.002 mM/sec
• Basal ATPhyd activity (1x) = 0.01 mM/sec (1x)
• Mid/Moderate ATPhyd activity (10x) = 0.01 mM/sec (1x) × 10 = 0.1 mM/sec
• High ATPhyd activity (100x) = 0.01 mM/sec (1x) × 100 = 1.0 mM/sec
• Overload ATPhyd activity (500x) = 0.01 mM/sec (1x) × 500 = 5.0 mM/sec
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4.8.a. Mitochondrial adenine nucleotides
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4.8.b. Cytosolic adenine nucleotides
• Figure 4.8. The effect of a wide range of ATP hydrolysis activity variations on
mitochondrial & cytosolic adenine nucleotides, against the change in ANT maximal activity.
• For conditions, see fig. 4.7 on pg. 157.
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4.9.a. CoA–related metabolites
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4.9.b. NAD–related metabolites
• Figure 4.9. The effect of a wide range of ATP hydrolysis activity
variations on CoA– & NAD–related metabolites, against the change in ANT maximal activity.
• For conditions, see fig. 4.7 on pg. 157.
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• Figure 4.10. The effect of a wide range of ATP hydrolysis
activity variations on enzyme subset fluxes, against the change in ANT maximal activity.
• For conditions, see fig. 4.7 on pg. 157.
From the literature, we know that the cardiac or skeletal muscle are highly energy
demanding tissues and their cellular metabolism is accordingly optimised to respond
to any changes in the ATP demand. Therefore, in this analysis we test the heart TCA
cycle model (HRTTCA) against a wide range of energy demand by simulating the model
at various levels of ATP hydrolysis activity, from ‘weak’ (0.1x) to ‘overload’ (500x).
Thereby, we have attempted to study the steady-state behaviour of this model at 2
ATPhyd activity values that are lower than its ‘basal’ activity or initial model value
(‘weak’ & ‘low’), as well as at 3 activity values that are higher than its ‘basal’ activity
(‘mid’, ‘high’ & ‘overload’). Figures 4.7 to 4.10 (see, pgs. 157 to 160, respectively)
illustrate the average steady-state behaviour of the heart TCA cycle model against a
wide range of ATP hydrolysis activity. In all bar graphs presented here, bar representing
the initial model value or the ‘basal’ activity for a given parameter (e.g. ATPhyd) is
always placed in the middle, surrounded by bars representing other activity values.
Overall, these graphs show that after the mid-level increase in the ATPhyd activity
(10x), the heart TCA cycle model soon achieves a plateau phase, where any successive
increase in the ATPhyd activity (100x & 500x) has a minimal effect on the average
metabolite concentrations or reaction fluxes. However, in the case of ATPc (see fig. 4.8b
on pg. 158), these activity changes seem to have a significant effect on its average
steady-state concentration, which decreases further as the ATPhyd activity is increased
from 10x to 500x. In fact, at activities as high as that of 100 to 500 times the basal
activity of ATPhyd, fig. 4.10 (see, pg. 160) shows that the flux through TCA cycle as
well as ATPhyd does not change significantly, thus limiting the ANT flux as well, which
allows the ATPc concentration to fall significantly.
However, the heart TCA cycle model responds very well to ATPhyd activity changes
in the range of weak (0.1x) to mid-level (10x) increase, around its basal level of activity.
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Figure 4.10 (see, pg. 160) shows that the flux through TCA cycle as well as ATPhyd
increases significantly as the ATP hydrolysis activity is increased from 0.001 mM/sec
(weak) to 0.1 mM/sec (moderate). Literature evidence from enzymatic equilibrium
studies on perfused hearts in vitro and NADH fluorescence studies on intact hearts,
indicate that with increased workloads, net oxidation of mitochondrial NADH increases
along with increase in the TCA cycle turnover rate (Kobayashi and Neely, 1983; Neely
et al., 1972a; Nishiki et al., 1978; Williamson et al., 1976). Hence, the observed increase
in the TCA cycle flux in response to increased ATP hydrolysis activity in the heart
TCA cycle model, is in good agreement with the published experimental studies. Within
this range, all TCA cycle intermediate metabolites increase significantly as the ATPhyd
activity increases (see fig. 4.7 on pg. 157); except α-ketoglutarate, which falls sharply
across all ATPhyd activities (see, fig. 4.7a). Compared to all TCA cycle intermediates,
metabolites from the second half of TCA cycle such as, Sucm, Fumm, & Malm, all appear
to accumulate in the system with increase in the ATPhyd activity (see, fig. 4.7b). Lack of
transport reactions such as malate transporter, as well as the absence of malate-aspartate
shuttle reactions could be some of the reasons for such accumulation of TCAi’s.
Figure 4.9b (see, pg. 159) shows that within the range of 0.1x to 10x ATPhyd
activity, NAD–related metabolites exhibit significant changes in their average steady-
state concentrations, especially that of NADHm; which increases sharply as the ATPhyd
activity is increased. However, as mentioned earlier, both NADm+ as well as NADHm
concentrations appear to stabilise beyond this range. Figure 4.9a shows that the CoA
–related metabolites too respond similarly. Figure 4.8a (see, pg. 158) shows that the
concentration of mitochondrial ATP decreases in a relatively buffered fashion as the
ATPhyd activity is increased within this range, beyond which it stabilises. However, we
feel that this buffered behaviour could partly be due to the respective initial model values
of ATP–related metabolites, as these are the same values used in the liver TCA cycle
model. Therefore, this analysis shows that the heart TCA cycle model (HRTTCA) shows
a consistent steady-state behaviour across a wide range of ATP hydrolysis activity or
energy demand. Although, a 500 times increase in the ATPhyd activity can be considered
a physiologically extreme situation or even a disease condition, this heart TCA cycle
model performs robustly even at such physiological extremes.
If ATP hydrolysis represents the demand reaction in the heart TCA cycle model,
pyruvate dehydrogenase represents the supply or input reaction. Therefore, in the
following bar graphs we’ll test the heart TCA cycle model against a wide range of
increase in PDH maximal activity. Figures 4.11 to 4.14 (see, pgs. 162 to 165, respectively)
show the average steady-state behaviour of the heart TCA cycle model, when pyruvate
dehydrogenase activity is varied between 0.04x (weak) and 50x (overload), where ‘x’
is the initial model value for the pyruvate dehydrogenase activity (where, ‘x’ = 0.1885
mM/sec; termed here as – basal activity).
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4.11.a. TCA cycle intermediate metabolites (TCAi) – Part 1
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4.11.b. TCA cycle intermediate metabolites (TCAi) – Part 2
• Figure 4.11. The effect of a wide range of pyruvate dehydrogenase
activity variations on TCAi concentrations, against the change in ANT maximal activity.
• Six bars for every metabolite or reaction represent six PDH activity variations, shown in light-to-dark colour
shades, indicating ‘weak’ to ‘overload’ PDH activities.
• An average concentration or flux value was calculated for each metabolite or reaction, from all consecutive
steady-state values per dataset. They were then used as log10 values to generate the bar graph.
• The initial model value for PDH activity in the heart TCA cycle model is 0.1885 mM/sec and in this graph,
it is represented as the ‘basal activity’ or ‘1x’. PDH activities included in this graph are as follows:
• Weak PDH activity (0.04x) = 0.1885 mM/sec (1x) ÷ 25 = 0.00754 mM/sec
• Low PDH activity (0.1x) = 0.1885 mM/sec (1x) ÷ 10 = 0.01885 mM/sec
• Basal PDH activity (1x) = 0.1885 mM/sec (1x)
• Mid/Moderate PDH activity (5x) = 0.1885 mM/sec (1x) × 5 = 0.9425 mM/sec
• High PDH activity (10x) = 0.1885 mM/sec (1x) × 10 = 1.885 mM/sec
• Overload PDH activity (50x) = 0.1885 mM/sec (1x) × 50 = 9.425 mM/sec
— Ph.D. Thesis by Amar S. Ghaisas — Page 162
4. Heart TCA cycle model 4.3. Results for the heart TCA cycle . . .
ATPm ADPm
-0.5
-0.3
-0.1
0.1
0.3
0.5
0.7
0.9
1.1
PDH activity:  Weak (0.04x)
PDH activity:  Low (0.1x)
PDH activity:  Basal (1x)
PDH activity:  Mid (5x)
PDH activity:  High (10x)
PDH activity:  Overload (50x)
lo
g
1
0 
[A
v
er
a
g
e 
C
o
n
c
en
tr
a
ti
o
n
]
4.12.a. Mitochondrial adenine nucleotides
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4.12.b. Cytosolic adenine nucleotides
• Figure 4.12. The effect of a wide range of pyruvate dehydrogenase activity variations on
mitochondrial & cytosolic adenine nucleotides, against the change in ANT maximal activity.
• For conditions, see fig. 4.11 on pg. 162.
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4.13.a. CoA–related metabolites
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4.13.b. NAD–related metabolites
• Figure 4.13. The effect of a wide range of pyruvate dehydrogenase activity
variations on CoA– & NAD–related metabolites, against the change in ANT maximal activity.
• For conditions, see fig. 4.11 on pg. 162.
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• Figure 4.14. The effect of a wide range of pyruvate dehydrogenase
activity variations on enzyme subset fluxes, against the change in ANT maximal activity.
• For conditions, see fig. 4.11 on pg. 162.
From the literature, we know that the cellular pyruvate dehydrogenase activity
levels are regulated through a complex interaction of covalent modification via pyruvate
dehydrogenase kinase (PDHK) & pyruvate dehydrogenase phosphatase (PDHP), as well
as allosteric effectors, depending on varying metabolic situations, such as feeding and
fasting states. Therefore, in this analysis we test the heart TCA cycle model (HRTTCA)
against a wide range of acetyl-CoA supply by simulating the model at various levels of
pyruvate dehydrogenase activity, from ‘weak’ (0.04x) to ‘overload’ (50x). Thus, we have
studied the steady-state behaviour of this model at 2 PDH activity values that are lower
than its ‘basal’ activity or initial model value (‘weak’ & ‘low’), as well as at 3 activity
values that are higher than its ‘basal’ activity (‘mid’, ‘high’ & ‘overload’). Figures 4.11
to 4.14 (see pgs. 162 to 165, respectively) illustrate the average steady-state behaviour of
the heart TCA cycle model against a wide range of pyruvate dehydrogenase activity.
Overall, these graphs show that most TCA cycle intermediates in this model decrease
sharply in response to the increasing PDH activity or acetyl-CoA supply, except at the
‘weak’ level (0.04x); where, citrate, isocitrate, acetyl-CoA, NADHm, & ATPm, all show
significant decrease relative to their corresponding levels at the ‘low’ (0.1x) PDH activity.
It is possible that at 0.04x (0.00754 mM/sec), the pyruvate dehydrogenase activity
is insufficient to supply adequate amount of acetyl-CoA, due to which the resting
concentrations of TCA cycle intermediates fall. However, fig. 4.14 shows that the flux
through TCA cycle as well as ATPhyd remains fairly unchanged throughout the range
of increasing PDH activities, except at 50x activity of PDH (‘overload’); where both
these fluxes drop significantly. We may look at this situation as an ‘over-driven’ state,
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where other TCA cycle processes play catch-up with highly active PDH and fall short,
thereby causing a reduction in the total TCA cycle flux, exemplified by a severe drop
in the respective concentrations of most TCA cycle intermediates, such as – citrate,
isocitrate, coenzyme A, NADHm, ATPm etc. (see figs. 4.11a, 4.12a and 4.13 on pgs. 162,
163 and 164, respectively).
As shown in fig. 4.14 (see, pg. 165), the insignificant increase in the TCA cycle
flux achieved by increasing the PDH maximal activity is quite similar to the ‘single
gene modification experiments’ carried out by biotechnologists, in hope of increasing the
chosen metabolic pathway flux significantly by engineering an increase in a single target
enzyme (Fell, 1997). However, such attempts rarely succeed, because the ‘flux-enzyme
relationship’ discovered by Small and Kacser (1993), implies that changing the amount
of a single enzyme will have limited effects on the pathway flux, unless the flux control
coefficient is greater than 0.5 to start with (Fell, 1997).
This analysis shows that although most of the TCA cycle intermediates show
significant changes as the supply of acetyl-CoA or the PDH activity increases, the total
flux through TCA cycle remains fairly unchanged. However, as noted in the previous
chapter (see, pg. 80), a PDH maximal activity of 0.65 mM/sec (Fahien and Teller,
1992) represents the active PDH fraction under physiological conditions, which has been
reported to be between 50% and 100% in perfused rat heart (Dennis et al., 1979; Olson
et al., 1978; Reed et al., 1972). In the heart TCA cycle model, the initial model value
for PDH Vmax is even lower (0.1885 mM/sec; Kerbey et al., 1976; Kohn et al., 1979b).
Therefore, at 50x increase in the PDH maximal activity (9.425 mM/sec), the PDH
activity level falls well beyond physiological limits. Hence, the steady-state behaviour of
the heart TCA cycle model at such non-physiological values of PDH activity is unlikely
to have any physiological significance whatsoever.
Both the ATPhyd as well as PDH activity analyses shall be discussed further using the
metabolite ratio profiles presented in figs. 4.15 and 4.16 on pgs. 167 and 168, respectively.
Figures 4.15 and 4.16 describe the ‘energy status’ of heart TCA cycle model in terms of
key ratios like – [ATP/ADP]m, [ATP/ADP]c & [NADH/NAD+]m, against a wide range
of ATPhyd as well as PDH activities. Figures 4.15d and 4.16d provide a list of median
values for these ratios.
Note: In figs. 4.15a to 4.15c (see, pg. 167), the partial absence of data-points at
the ‘weak’ (0.1x; 0.001 mM/sec) level of ATP hydrolysis activity signifies that at such
a low level of ATPhyd activity, the heart TCA cycle model is unable to find a stable
steady-state; which is acceptable because this level of activity is at least 10 times lower
than the physiological resting level of ATP demand reported in Rabbit skeletal muscle
(Lambeth and Kushmerick, 2002).
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4.15.c. [NADH/NAD+]m
Median values
Weak Low Basal Mid High
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31.35 23.45 10.8 1.7 1.56 1.55
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4.15.d. Median values
• Figure 4.15. Variations
in the ‘Energy status’ of heart TCA cycle model: [ATP/ADP] & [NADH/NAD+]
ratios against ATPhyd activity variations, across the change in ANT maximal activity.
• Key for figs. 4.15a to 4.15c is as follows :
• [ATP/ADP]m : Weak (0.1x); Low (0.2x); Basal (1.0x);
Mid (10.0x); High (100.0x); Overload (500.0x)
• [ATP/ADP]c : Weak (0.1x); Low (0.2x); Basal (1.0x);
Mid (10.0x); High (100.0x); Overload (500.0x)
• [NADH/NAD+]m : Weak (0.1x); Low (0.2x); Basal (1.0x);
Mid (10.0x); High (100.0x); Overload (500.0x)
For figs. 4.15a to 4.15c :
• X-axis : log10[VANTmax ] – ANT maximal activity in logarithmic scale.
• Y-axis : Ratio of concentrations in logarithmic scale.
• The vertical black line represents the initial model value. At this point on the X-axis,
VANTmax = 1.52646 mM/sec in logarithmic scale.
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4.16.c. [NADH/NAD+]m
Median values
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475.2 644.4 390.2 146.8 78.5 2.17
Very 
High
NADH
m 
/ NAD
m
ATPm / ADPm
ATP
c 
/ ADP
c
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• Figure 4.16. Variations
in the ‘Energy status’ of heart TCA cycle model: [ATP/ADP] & [NADH/NAD+]
ratios against PDH activity variations, across the change in ANT maximal activity.
• Key for figs. 4.16a to 4.16c is as follows :
• [ATP/ADP]m : Weak; Low; Basal; Mid; High; Overload
• [ATP/ADP]c : Weak; Low; Basal; Mid; High; Overload
• [NADH/NAD+]m : Weak; Low; Basal; Mid; High; Overload
• X-axis : log10[VANTmax ] – ANT maximal activity in logarithmic scale. • Y-axis : Ratio of concentrations in
logarithmic scale. • The vertical black line represents the initial model value. At this point on the X-axis,
VANTmax = 1.52646 mM/sec in logarithmic scale.
Overall, figs. 4.15 and 4.16 (see pgs. 167 and 168, respectively) show that through
all variations of ATPhyd as well as PDH activities, metabolite ratio profiles of the heart
TCA cycle model follow a similar qualitative course of change. However, as shown in
fig. 4.15a, at ‘mid’ (10x), ‘high’ (100x) & ‘overload’ (500x) levels of ATPhyd activities,
the [ATP/ADP]m ratio drops significantly compared to the lower levels of ATPhyd
activity, as the ANT maximal activity is incremented further. Figure 4.15d clearly
distinguishes these levels of ATPhyd activity from others through their significantly
lower median values, viz.– 1.7, 1.56, & 1.55 for 10x, 100x, & 500x of ATPhyd maximal
activity, respectively. This distinction between the levels of ATPhyd activity can also be
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seen in fig. 4.8a (see, pg. 158), in terms of the average steady-state concentrations of
ATPm & ADPm respectively, albeit not as clearly. Also, at these same levels of ATPhyd
activities (i.e. mid, high, & overload), fig. 4.15c shows that the respective [NADH/NAD+]
m ratio profiles follow the same qualitative course of increase. Figure 4.15d shows a
common median value of 0.4 for the [NADH/NAD+]m ratio at all three activities of
ATP hydrolysis. Figure 4.9b (see, pg. 159) also shows this quantitatively in terms of the
average steady-state concentrations of NADm+ & NADHm, respectively.
As illustrated in fig. 4.16 (see, pg. 168), at ‘overload’ (50x; 9.425 mM/sec) level of
PDH activity, both the [ATP/ADP]m as well as [NADH/NAD+]m ratio profiles show
characteristically different course of change than that at other PDH activities; wherein,
the [ATP/ADP]m ratio drops further as the ANT maximal activity is incremented (see,
fig. 4.16a) and the [NADH/NAD+]m ratio attempts to recover from a severe initial drop
in its value (see, fig. 4.16c). In fact, as shown in fig. 4.16d, the corresponding median
value for the [ATP/ADP]m ratio (i.e. 0.17), signifies that at such a high level of PDH
activity, this ratio reverses and makes the system more ‘ADPm-rich’; which can also be
observed in fig. 4.12a (see, pg. 163) in terms of the average steady-state concentrations
of ATPm & ADPm, respectively. Also, at this high level of PDH activity, fig. 4.16d
shows a corresponding median value of 0.02 for the [NADH/NAD+]m ratio, which isn’t
that distinct from that of 0.045 at ‘high’ PDH activity and doesn’t really reflect the
characteristically different qualitative course of change taken by this ratio at the ‘overload’
level of PDH activity. However, this significant difference in the [NADH/NAD+]m ratio
between 50x activity and other levels of PDH activities, can be observed in fig. 4.13b
(see, pg. 164) in terms of the average steady-state concentrations of NADm+ & NADHm,
respectively. Regardless, as mentioned earlier on pg. 166, since this level of pyruvate
dehydrogenase activity (50x) should be considered physiologically anomalous, any further
discussion about the model behaviour at this level of PDH activity is futile.
As mentioned earlier, against the increased ATP-demand set by higher values of
ATPhyd activity, at ‘mid’ (10x), ‘high’ (100x) & ‘overload’ (500x) levels, the mitochon-
drial redox ([NADH/NAD+]m) as well as the energy ([ATP/ADP]m) states exhibit fairly
stabilised changes in their respective values, compared to those at lower levels of ATPhyd
activity (see fig. 4.15d on pg. 167). Incidentally, the experimental evidence from workload
intensity transition studies in intact mammalian hearts in vivo, also suggest of almost
constant [ADP], [PCr] (Phosphocreatine), [Pi] and NADH/NAD+ during workload
transitions (Balaban et al., 1986; Heineman and Balaban, 1993; Katz et al., 1987, 1989b;
Sharma et al., 2005). On the other hand, with increasing workloads, experimental studies
have reported larger changes in [ADP], [PCr], [Pi] and NADH/NAD+ in perfused heart
(From et al., 1990) and in isolated cardiac myocytes (White and Wittenberg, 1993) than
those in intact heart in vivo. Also, Heineman and Balaban (1990) in their excellent
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review paper include further evidence supporting the net oxidation of mitochondrial
NADH with increased workloads, by citing enzymatic equilibrium studies on perfused
hearts in vitro (Kobayashi and Neely, 1983; Neely et al., 1972a; Nishiki et al., 1978), as
well as NADH fluorescence studies on intact hearts (Williamson et al., 1976). Therefore,
the fairly stabilised redox & energy states in the heart TCA cycle model at ‘moderate’ to
‘very high’ ATP-demands, apparently reflect a similar physiological behaviour observed
in intact mammalian hearts in vivo, at increased workloads.
Moreover, in isolated rat heart mitochondria, using a wide variety of respiratory
substrates, NADH/NAD+ ratio was found to vary between 0.02 (with no substrate
added to the incubation medium) to 2.62 (with addition of 5 mM succinate to the
incubation medium) (Kerbey et al., 1976). The variation in [NADH/NAD+]m ratio
observed during both studies with increased maximal activities of ATPhyd as well as
PDH in the heart TCA cycle model (see figs. 4.15d and 4.16d on pgs. 167 and 168,
respectively), is well within this range of reported values. Overall, the median values
shown in figs. 4.15d and 4.16d for all variations in the respective maximal activities of
ATPhyd & PDH, illustrate the significant quantitative difference in the ‘energy status’
of the heart TCA cycle model, when subjected to large changes in key enzyme activities.
It also highlights the robustness of the metabolic system represented by this model;
which is a good indicator of its predictive capabilities, especially when combined with
the malate-aspartate shuttle reactions in the near future.
Now, in the following sections, we shall discuss the control properties of the heart
TCA cycle model in terms of the flux control coefficients, concentration control coefficients,
& elasticity coefficients.
4.3.5 Metabolic Control Analysis of the heart TCA cycle model
In this section, we’ll see the results of Metabolic Control Analysis (MCA) when applied
to the heart TCA cycle model, by observing the distribution of flux control coefficient
(CJ), concentration control coefficient (CS) and elasticity coefficient (εS).
4.3.5.1 Flux control coefficient analysis for the heart TCA cycle model
Since, the heart TCA cycle model contains a single enzyme subset comprising all TCA
cycle reactions, we’ll analyse the control of flux through CS as a representation of the
flux through TCA cycle. As the enzyme activities or metabolite concentrations vary,
their corresponding degree of control varies as well. Hence, we examined how the pattern
of control changed as these parameters were varied over a fixed range.
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Figures 4.17 to 4.19 (see pgs. 171 to 173, respectively), show the flux control
coefficients (CJ) calculated for the TCA cycle flux, for all enzymes in heart TCA cycle
model, across a fixed range of increasing maximal activities (ANT, ATPhyd, & PDH)
or metabolite concentrations (Pim, cAdNcsum, & αKGc). These CJ plots are presented
alongside a corresponding steady-state plot of CS flux across the same fixed range of a
given parameter (here, CS is the reaction ‘J’ on which CJ is calculated). In each plot,
result of the summation theorem is also included using a dotted line. In these plots, the
flux control coefficients are distributed between the range of −0.8 to 1.2 (unitless).
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• Figure 4.17. Control of
TCA cycle flux in the heart TCA cycle model: against the activities of ANT & ATPhyd.
• Key for figs. 4.17a and 4.17b is as follows :
PDH ; CS ; ACO ; IDHa ; α-KGDH ; SCS;
SDH ; FM ; MDH ; ATPsynth ; ANT ; ATPhyd;
α-KG exp ; Total Sum (dotted line)
• The vertical black line represents the initial model value. At this point, in figs. 4.17a and 4.17c,
V ANTmax = 1.52646 mM/sec and in figs. 4.17b and 4.17d, V
ATPhyd
max = 0.01 mM/sec, respectively. However, in
figs. 4.17a and 4.17c, the presented range of ANT maximal activity is only between 0.0 to 0.5 mM/sec and
therefore, V ANTmax initial model value is out of range in these plots.
• Orange dotted line shows the Summation theorem result across the entire range.
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• Figure 4.18. Control of TCA cycle flux in the
heart TCA cycle model: against changing PDH maximal activity & Pim concentration.
• Key for figs. 4.18a and 4.18b is as follows :
PDH ; CS ; ACO ; IDHa ; α-KGDH ; SCS;
SDH ; FM ; MDH ; ATPsynth ; ANT ; ATPhyd;
α-KG exp ; Total Sum (dotted line)
• The vertical black line represents the initial model value. At this point, in figs. 4.18a and 4.18c,
V PDHmax = 0.1885 mM/sec and in figs. 4.18b and 4.18d, [Pim] = 8.9 mM, respectively. However, in figs. 4.18b
and 4.18d, the presented range of Pim concentration is only between 0.0 to 1.0 mM and therefore, [Pim]
initial model value is out of range in these plots.
• Orange dotted line shows the Summation theorem result across the entire range.
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• Figure 4.19. Control of TCA
cycle flux in the heart TCA cycle model: against cAdNcsum total & αKGc concentration.
• Key for figs. 4.19a and 4.19b is as follows :
PDH ; CS ; ACO ; IDHa ; α-KGDH ; SCS;
SDH ; FM ; MDH ; ATPsynth ; ANT ; ATPhyd;
α-KG exp ; Total Sum (dotted line)
• The vertical black line represents the initial model value. At this point, in figs. 4.19a and 4.19c,
cAdNcsum total = 4.81 mM and in figs. 4.19b and 4.19d, [αKGc] = 0.006 mM, respectively. However, in
figs. 4.19b and 4.19d, the presented range of αKGc concentration is only between 0.0 to 0.001 mM and
therefore, [αKGc] initial model value is out of range in these plots.
• Orange dotted line shows the Summation theorem result across the entire range.
A plot of CJ against the enzyme maximal activity or concentration would normally
be expected to be hyperbolic, however for the heart TCA cycle model, the CJ distribution
pattern shown in figs. 4.17 to 4.19 (see pgs. 171 to 173, respectively) is distinctly sigmoidal.
An in-depth discussion from the previous chapter (see, pg. 94), suggests that it is due to
the saturation of one or more TCA cycle enzymes and if these enzyme(s) are desaturated
with respect to their corresponding substrate(s), a nearly-hyperbolic pattern of CJ
distribution can be restored.
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As predicted correctly through the control analysis of the PCko model (see, pg. 141),
in the absence of PC, the control of TCA cycle flux (flux through CS) in the heart
TCA cycle model is dominated largely by ATP hydrolysis. From figs. 4.17 to 4.19, it is
evident that ATPhyd has a relatively greater control of the TCA cycle flux; however, the
control is also distributed between PDH, α-KGDH, ATPsynth, & ANT. In most cases,
the control shared by ATPhyd increases or decreases to or from nearly a unity and the
amount of control shared by other four enzymes changes accordingly, across the given
parameter range. For instance in fig. 4.17a, CJ for ATPhyd increases gradually from
zero to nearly a unity as the ANT maximal activity is increased and accordingly, the
extent of control shared by the other four enzymes becomes minimal. On the contrary, in
fig. 4.17b, CJ for ATPhyd decreases gradually from unity to nearly zero as the ATPhyd
maximal activity is increased and accordingly, the extent of control shared by the other
four enzymes increases to account for the loss of control by ATPhyd. Unlike that of the
liver TCA cycle models, in this model the exchange of control between ATPhyd and
the other 4 enzymes is quite gradual and occurs over nearly 30% – 50% of the given
parameter range.
In these plots, pyruvate dehydrogenase shares a moderately negative flux control
coefficient value, which appears counter-intuitive. However, in the absence of PC, it is the
only input reaction in the heart TCA cycle model that supplies TCA cycle carbon in the
form of acetyl-CoA and constitutes the ‘supply block’, according to the ‘supply-demand
analysis’ put forward by Hofmeyr and Cornish-Bowden (2000) (see, pg. 75). Also,
structurally, all TCA cycle reactions of this model form a single enzyme subset that
includes PDH as well as 3 ATP/ADP–linked reactions; which makes PDH a branch
reaction in the linear sequence of other TCA cycle reactions. As a consequence of these
factors, a moderately negative flux control coefficient for PDH may seem appropriate.
Also, as discussed in Fell (1997), according to the supply-demand analysis of metabolic
control structures, the pathway flux can be controlled by the ‘demand block’ (in this case,
ATPhyd), only if CJHYD  CJPDH; where, J is the flux through CS. However, it requires
that the elasticity for the metabolite (M ) supplied (i.e. AcCoAm) with respect to the
‘supply block’ (i.e. PDH) must exceed its elasticity with respect to the ‘demand block’
(i.e. ATPhyd) or |εPDHAcCoA|  εHYDAcCoA; which is true in this case, since εPDHAcCoA = −0.3 and
εHYDAcCoA = 0.0 (as shown later, in fig. 4.25 on pg. 185). However, as the heart TCA cycle
model is extended to include the malate-aspartate shuttle reactions in near future, we
suspect that this negative coefficient value would disappear due to the additional branch
points being introduced downstream of PDH.
Similarly, based on the same concept, moderately high CJ values for ANT &
ATPsynth, as well as the significantly high control coefficient for ATPhyd can be
explained on the basis that these reactions comprise the ‘demand block’ of the heart
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TCA cycle model. Also, α-KGDH, despite being highly regulated, shares a small but
notable flux control coefficient with ANT & ATPsynth in the heart TCA cycle model.
At initial conditions of the heart TCA cycle model, figs. 4.17 to 4.19 show that
the flux through TCA cycle is controlled entirely by ATP hydrolysis; except in the
case of fig. 4.19a. In this particular case (see, fig. 4.19a), the control of TCA cycle
flux is distributed uniformly between ANT, ATPsynth, α-KGDH, MDH, CS, & PDH,
at initial conditions of the cAdNcsum total. In figs. 4.17a, 4.18b and 4.19b, though
the respective initial model values of ANT maximal activity, Pim concentration, and
αKGc concentration are out of the presented range, it is clear from their respective CJ
distribution patterns that at initial conditions, the control of TCA cycle flux will be
dominated by ATPhyd alone.
Also, fig. 4.18a (see, pg. 172) provides a further explanation for the insignificant
increase in TCA cycle flux, during the steady-state analysis at various levels of pyruvate
dehydrogenase activity (see fig. 4.14 on pg. 165). As shown in fig. 4.18a, with increase
in the PDH maximal activity, CJ for ATPhyd begins to drop from unity and CJ for
PDH becomes further negative. At the initial model value of PDH maximal activity or
at ‘basal’ activity of PDH (i.e. = 0.1885 mM/sec; 1.0x), the control of TCA cycle flux
rests entirely in ATPhyd. Figure 4.18a shows that CJ for ATPhyd dominates even when
the PDH maximal activity is increased by 5x (i.e. = 0.9425 mM/sec; ‘moderate’) or 10x
(i.e. = 1.885 mM/sec; ‘high’). It also shows that with increase in PDH maximal activity,
the significant loss of control shared by ATPhyd is picked up by α-KGDH, ANT &
ATPsynth. Moreover, when the PDH maximal activity is increased beyond 2.5 mM/sec,
the extent of control shared by ATPhyd is lost rapidly and gets counter-balanced by a
further negative CJ for PDH, along with a corresponding increase in the control shared
by α-KGDH, ANT & ATPsynth.
Therefore, fig. 4.18a shows that at very high activities of pyruvate dehydrogenase
(i.e. = 9.425 mM/sec; ‘overload’ ; 50x), the control shared by ATPhyd would be close
to zero, CJ for PDH would be highly negative and the control of TCA cycle flux
would be distributed uniformly between α-KGDH, ANT, ATPsynth, & PDH (negative).
Furthermore, fig. 4.18c (see, pg. 172) shows that a large increase in the PDH maximal
activity actually causes a marginal decrease in the TCA cycle flux (please note the
Y-axis); which means that further increase in PDH maximal activity (e.g. a 50x increase)
would actually reduce the TCA cycle flux even further.
In conclusion, this analysis suggests that in order to achieve a significant increase in
the TCA cycle flux at higher activities of pyruvate dehydrogenase, the activity of at least
one of the other controlling enzymes (i.e. α-KGDH, ANT & ATPsynth) must also be
increased simultaneously. During the discussion on steady-state analysis results shown
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in figs. 4.11 to 4.14 (see pgs. 162 to 165, respectively), we arrived at a similar conclusion
(see, pg. 166) and therefore the CJ distribution shown in fig. 4.18a lends further support
to our well-founded suspicion.
Also, fig. 4.19b (see, pg. 173) shows the distribution of flux control coefficients against
the increasing concentration of cytosolic α-ketoglutarate ([αKGc]) in the heart TCA cycle
model. It shows that with increase in [αKGc], the TCA cycle flux is largely controlled
by ATPhyd with minor extent control shared between PDH, ATPsynth, α-KGDH, &
ANT; which diminishes as the αKGc concentration is increased further. Although, the
initial model value of [αKGc] (0.006 mM) is beyond the range of concentration presented
in this plot, it is clear that at this value, CJ for ATPhyd would be close to unity; which
means that at and beyond the initial model value of [αKGc], the TCA cycle flux would
be controlled by ATPhyd alone. Figure 4.19d shows that the TCA cycle flux is increased
moderately by 3-fold, with increase in [αKGc]. It indicates that extending the heart
TCA cycle model by including the malate-aspartate shuttle reactions might help in
improving the flux through the TCA cycle, provided that the extended model results in
net exchange of mitochondrial α-ketoglutarate.
Also, figs. 4.17d and 4.19c (see, pgs. 171 and 173) show that the TCA cycle flux
is increased significantly, by nearly 3- to 4-times, with increase in the ATP hydrolysis
activity, as well as the conserved total of cytosolic adenine nucleotides (cAdNcsum) (please
note the Y-axis from both plots).
Therefore, overall, the emergent flux control properties of the heart TCA cycle
model adequately reflect the energy-demand driven nature of the myocardial metabolism,
qualitatively.
4.3.5.2 Concentration control coefficient analysis for the heart TCA cycle
model
In this section, we shall analyse the concentration control coefficients (CS) of TCA cycle
intermediate metabolites, calculated with respect to all enzymes in the model. The heart
TCA cycle model contains 16 internal metabolites, all of which can be analysed using
the concentration control coefficients. However, in this section, we have presented data
for only a selected group of metabolites, viz.– OAAm, Citm, AcCoAm, NADHm, ATPm,
ATPc, & Malm. These metabolites were selected based on the same reasons given in the
previous chapter (see, pg. 100). Figures 4.20 to 4.23 (see, pgs. 177 to 180, respectively)
show the distribution of concentration control coefficients for the selected TCA cycle
intermediate metabolites, against the change in ATP hydrolysis activity. Also, fig. 4.24
(see, pg. 181), provides a qualitative overview of the control distribution for all 16 internal
metabolites in the heart TCA cycle model, against the change in ATP hydrolysis activity.
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• Figure 4.20. Control of TCA cycle inter-
mediate metabolites: Distribution of concentration control coefficients calculated for the
respective concentrations of OAA & Citrate, against the changing maximal activity of ATPhyd.
• Key for figs. 4.20a and 4.20c is as follows :
PDH ; CS ; ACO ; IDHa ; α-KGDH ; SCS;
SDH ; FM ; MDH ; ATPsynth ; ANT ; ATPhyd;
α-KG exp ; Total Sum (dotted line)
• The vertical black line represents the initial model value. At this point, in figs. 4.20a to 4.20d,
V ATPhydmax = 0.01 mM/sec.
• Orange dotted line shows the Summation theorem result across the entire range. For concentration
control coefficients, since the sum is equal to zero, the dotted line is not easily visible.
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• Figure 4.21. Control of CoA- & NAD–related
metabolites: Distribution of concentration control coefficients calculated for the respective
concentrations of AcCoA & NADH, against the changing maximal activity of ATPhyd.
• Key for figs. 4.21a and 4.21c is as follows :
PDH ; CS ; ACO ; IDHa ; α-KGDH ; SCS;
SDH ; FM ; MDH ; ATPsynth ; ANT ; ATPhyd;
α-KG exp ; Total Sum (dotted line)
• The vertical black line represents the initial model value. At this point, in figs. 4.21a to 4.21d,
V ATPhydmax = 0.01 mM/sec.
• Orange dotted line shows the Summation theorem result across the entire range. For concentration
control coefficients, since the sum is equal to zero, the dotted line is not easily visible.
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• Figure 4.22. Control of ATP–
related metabolites: Distribution of concentration control coefficients calculated for the
respective concentrations of ATPm & ATPc, against the changing maximal activity of ATPhyd.
• Key for figs. 4.22a and 4.22c is as follows :
PDH ; CS ; ACO ; IDHa ; α-KGDH ; SCS;
SDH ; FM ; MDH ; ATPsynth ; ANT ; ATPhyd;
α-KG exp ; Total Sum (dotted line)
• The vertical black line represents the initial model value. At this point, in figs. 4.22a to 4.22d,
V ATPhydmax = 0.01 mM/sec.
• Orange dotted line shows the Summation theorem result across the entire range. For concentration
control coefficients, since the sum is equal to zero, the dotted line is not easily visible.
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• Figure 4.23. Control of
TCA cycle intermediate metabolites: Distribution of concentration control coefficients
calculated for the malate concentration, against the changing maximal activity of ATPhyd.
• Key for fig. 4.23a is as follows :
PDH ; CS ; ACO ; IDHa ; α-KGDH ; SCS;
SDH ; FM ; MDH ; ATPsynth ; ANT ; ATPhyd;
α-KG exp ; Total Sum (dotted line)
• The vertical black line represents the initial model value. At this point, in figs. 4.23a and 4.23b,
V ATPhydmax = 0.01 mM/sec.
• Orange dotted line shows the Summation theorem result across the entire range. For concentration
control coefficients, since the sum is equal to zero, the dotted line is not easily visible.
Figures 4.20 to 4.23 (see pgs. 177 to 180, respectively) show the concentration control
coefficients (CS) of OAAm, Citm, AcCoAm, NADHm, ATPm, ATPc, & Malm against the
change in ATP hydrolysis maximal activity. These concentration control coefficient plots
are presented alongside a steady-state plot of the corresponding metabolite concentration,
across the same parameter range (the metabolite concentration ‘S’ for which the coeffi-
cient, ‘CS’ is calculated). In these plots, concentration control coefficients are distributed
between the overall range of −1.5 to 2.0 (unitless). In each plot, a summation theorem
result is also shown using a dotted line; however, for concentration control coefficients,
since the sum is equal to zero, the dotted line coincides with the zero-axis and hence
may not be easily visible. Also in these plots, the emergent pattern of distribution for
concentration control coefficients is distinctively sigmoidal, like that of the flux control
coefficient distributions seen earlier in figs. 4.17 to 4.19 (see pgs. 171 to 173, respectively).
— Ph.D. Thesis by Amar S. Ghaisas — Page 180
4. Heart TCA cycle model 4.3. Results for the heart TCA cycle . . .
• Figure 4.24. Control of TCAi’s: An overview of CS distribution, against V ATPhydmax .
• This figure shows the overall distribution of concentration control coefficients for all TCA cycle intermediate
metabolites, with respect to all enzymes that share a moderate-to-high degree of control of the respective
concentrations; against the change in ATPhyd maximal activity.
• Enzymes shaded in grey have either no control of the respective metabolite concentrations, or an
infinitesimally small share of the overall control.
• This figure is based on the qualitative nature of the coefficient values (i.e. < 0, > 0, or ≈ 0) and does not
reflect the actual quantitative data.
From these plots, it is evident that the overall control of TCA cycle intermediates is
uniformly distributed between ATPhyd, ATPsynth, ANT, α-KGDH, & PDH, the same
overall set of enzymes that control the TCA cycle flux in this model. Figure 4.24 (see,
pg. 181), provides a qualitative overview of the control distribution for all 16 internal
metabolites in the heart TCA cycle model, against the change in ATP hydrolysis activity.
It shows the overall distribution of concentration control coefficients in the form of a
‘heat-map’, by considering all TCA cycle enzymes, for which the corresponding coefficient
values are: > 0 or < 0; and not  1 or ≈ 0. Therefore, for a given metabolite, all
enzymes that have positive coefficients (> 0) are shaded in green and those that have
negative coefficients (< 0) are shaded in red; whereas, enzymes with infinitesimally small
coefficients ( 1 or ≈ 0) are shaded in grey.
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From fig. 4.24 we may observe that, there are overall 5 distinct groups of TCA cycle
intermediates that exhibit a similar qualitative pattern of concentration control in terms
of the participating enzymes and they are as follows —
1. Group A contains citrate, isocitrate, & oxaloacetate and it shows positive coefficients
for α-KGDH, ATPhyd, ANT, ATPsynth, MDH, & CS (except, OAAm has a negative
CS for CS); whereas negative coefficients for PDH & IDHa.
2. Group B contains 4 TCA cycle intermediates from the second half of the TCA cycle
– succinate, fumarate, malate, & succinyl-CoA and it shows positive coefficients for
α-KGDH, ATPhyd, & ANT; whereas negative coefficients for ATPsynth, MDH, CS,
& PDH.
3. Group C contains CoAm & NADHm and it shows positive coefficients for α-KGDH,
ATPhyd, ANT, MDH, & CS; whereas negative coefficients for ATPsynth & PDH.
4. Group D contains ATP–related metabolites – ATPc, ATPm, ADPm, & ADPc. Since,
this is a group of conserved moieties, the constituent metabolites show a mirror-like
pattern of the overall qualitative distribution of concentration control. ATPc & ATPm
show positive coefficients for α-KGDH, MDH, & CS; whereas negative coefficients
for ATPhyd & PDH. Additionally, ATPc has a positive coefficient for ANT; whereas,
ATPm has a negative coefficient for ANT. On the other hand, ADPm shows an exact
mirror image of the corresponding concentration control pattern for ATPm. ADPc
also shows a mirror image of the corresponding control pattern for ATPc; however, in
this case, the individual coefficients for MDH & CS are infinitesimally small, unlike
in the case of ATPc, where they are distinctly positive.
5. Group E contains acetyl-CoA & NADm+ and it is nearly an exact complement of the
qualitative control pattern observed for the Group C metabolites, CoAm & NADHm.
For acetyl-CoA, the individual coefficients for MDH & CS are infinitesimally small,
unlike in the case of CoAm, where they are distinctly positive. Other than that, the
individual control patterns shown by AcCoAm & NADm+ are exact mirror images of
the individual control patterns for CoAm & NADHm, respectively. Therefore, they
both exhibit positive coefficients for ATPsynth & PDH; whereas negative coefficients
for α-KGDH, ATPhyd, & ANT. Additionally, NADm+ also shows negative coefficients
for MDH & CS.
Figure 4.24 also shows that the individual concentration control coefficients for ACO,
SDH, SCS, FM, & α-KGexp are either infinitesimally small or zero, for all 16 TCA
cycle intermediates of the heart TCA cycle model; which means that they have minimal
influence on the individual concentrations of all 16 TCA cycle intermediates. This figure
also shows that apart from the 3 Group A metabolites (Citm, Isocitm, & OAAm), IDHa
does not control the other 13 metabolite concentrations in the heart TCA cycle model.
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α-ketoglutarate (αKGm) shows infinitesimally small or zero coefficients for all 13 TCA
cycle enzymes. Another observation that emerges from this qualitative analysis is that,
α-KGDH, ATPhyd, & ANT have positive coefficients for all TCA cycle intermediates
through groups ‘A’ to ‘C’ ; whereas, PDH shows negative coefficients for all TCA cycle
intermediates through groups ‘A’ to ‘C’, plus ATPc & ATPm from Group D. Overall,
fig. 4.24 shows that in the heart TCA cycle model, 3 TCA cycle metabolite concentrations
are controlled by at least 8 enzymes (Citm, Isocitm, & OAAm), 10 concentrations are
controlled by at least 7 enzymes and 2 concentrations are controlled by at least 5 enzymes
(ADPc & AcCoAm).
Figure 4.20a (see, pg. 177) shows that against the change in ATPhyd maximal activity,
the control of oxaloacetate concentration ([OAAm]) is uniformly distributed between CS,
ATPhyd, ANT, ATPsynth, α-KGDH, MDH, PDH, IDHa; however, throughout the entire
range, citrate synthase maintains a nearly complete negative control of its concentration.
Moreover, at the initial model value of ATPhyd maximal activity (i.e. = 0.01 mM/sec),
[OAAm] is mainly controlled by ATPhyd & CS, with marginal contributions from other
enzymes; where, CS for ATPhyd is slightly more than +1 and CS for CS is exactly −1.
As a result, as shown in fig. 4.20b, the oxaloacetate concentration increases to 7-fold
with increase in ATPhyd activity.
Figure 4.20c (see, pg. 177) shows that against the change in ATPhyd maximal
activity, the control of citrate concentration ([Citm]) is uniformly distributed between α-
KGDH, ATPsynth, ATPhyd, PDH, IDHa, MDH, CS, & ANT; with moderately negative
coefficients for PDH & IDHa throughout the given range (please note the Y-axis). A
negative CS for PDH can be explained on the basis that in the heart TCA cycle model,
it represents the only branch point in otherwise linear sequence of TCA cycle enzymes
(for further explanation, please refer to pg. 174). Moreover, at the initial model value of
ATPhyd maximal activity, [Citm] is mainly controlled by α-KGDH, ATPsynth, ATPhyd,
PDH, & IDHa. Also, across the given range of ATPhyd activity, since the sum of positive
coefficients is more than that of the negative coefficients, citrate concentration increases
to 1.75-fold (as shown in fig. 4.20d).
Figure 4.21a (see, pg. 178) shows that against the change in ATPhyd maximal activity,
the acetyl-CoA concentration ([AcCoAm]) is mainly controlled by PDH, ATPhyd, α-
KGDH, & ANT. However, in this case, the positive (PDH) & negative coefficients
(ATPhyd, α-KGDH, & ANT) are so finely balanced that the acetyl-CoA concentration
does not change much throughout the range of ATPhyd activities (see, fig. 4.21b).
Moreover, this observation provides a further explanation for the insignificant changes
observed in the average steady-state concentration of acetyl-CoA, during the steady-state
analysis at varying ATPhyd activities (see fig. 4.9a on pg. 159).
— Ph.D. Thesis by Amar S. Ghaisas — Page 183
4. Heart TCA cycle model 4.3. Results for the heart TCA cycle . . .
Figure 4.22a (see, pg. 179) shows that against the change in ATPhyd maximal
activity, the concentration of mitochondrial ATP ([ATPm]) is controlled by ATPsynth,
α-KGDH, CS, MDH, ANT, ATPhyd, & PDH in a complicated pattern of exchange of
control between individual enzymes. At the initial model value of ATPhyd maximal
activity (i.e. = 0.01 mM/sec), [ATPm] is controlled by two pairs of enzymes, each with
positive (ATPsynth & α-KGDH) and negative coefficients (ATPhyd & PDH). On the
other hand, at 10x activity (i.e. = 0.1 mM/sec), [ATPm] is controlled by all 7 enzymes.
The resultant effect of such a complicated pattern of control is that the mitochondrial
ATP concentration is reduced moderately, as the ATPhyd activity increases from 0.01 to
0.1 mM/sec (see, fig. 4.22b).
Figure 4.23a (see, pg. 180) shows that against the change in ATPhyd maximal
activity, the control of malate concentration ([Malm]) is distributed uniformly between
ATPhyd, α-KGDH, ANT, CS, PDH, MDH, ATPsynth, & IDHa. In this case, ATPhyd,
α-KGDH, & ANT show large positive coefficients and CS, PDH, MDH, & ATPsynth show
moderately negative coefficients (please note the Y-axis). IDHa has a marginal negative
coefficient throughout the given range of ATPhyd activity. Since, malate transporter is
absent in the heart TCA cycle model, a collection of strong, positive control coefficients
overcomes the negative control exerted by enzymes that directly or indirectly consume
either malate or NADHm; which allows the malate concentration to increase to 250-fold
above its starting value (see, fig. 4.23b). Moreover, this observation provides a further
explanation for the significant accumulation of malate, observed during the steady-state
analysis at varying ATPhyd activities (see fig. 4.7a on pg. 157).
Therefore, overall, the emergent concentration control properties of the heart TCA
cycle model, highlight the fact that most metabolite concentrations in this model show
significant changes in their respective concentrations, only if either or all of the ‘demand
block’ enzymes are in control and thus reflect the energy-demand driven nature of this
model, qualitatively.
4.3.5.3 Elasticity coefficient analysis for the heart TCA cycle model
In this section, we shall analyse the elasticity coefficients (εS) of heart TCA cycle model,
calculated for all enzymes, with respect to all internal as well as external metabolites in
the model. Figure 4.25 (see, pg. 185) shows the distribution of elasticity coefficients for
the heart TCA cycle model, for all 15 enzymes in the model, calculated with respect to
28 metabolites that include internal as well as external metabolites. Figure 4.26 (see,
pg. 186) shows the connectivity theorem result that links the elasticity coefficients (εxaseS )
shown in fig. 4.25 and flux control coefficients (CJxase) computed at initial steady-state of
the heart TCA cycle model (see tbl. 4.4 on pg. 185).
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• Figure 4.25. Local properties of the heart TCA
cycle enzymes: The distribution of elasticity coefficients in the heart TCA cycle model.
• In this figure, positive εS values are shown in green and negative εS values are shown in red.
• Enzymes that are not affected by a given metabolite (‘S’), have elasticity values equal to zero and in this
figure, they are shaded in grey.
• All internal metabolites are shown in black and external metabolites are shown in blue.
• Table 4.4. CJ, computed at the initial
steady-state of heart TCA cycle model.
• These flux control coefficients are used in fig. 4.26
(see, pg. 186) for calculating the connectivity theorem.
• Here, ‘J’ represents the TCA cycle flux.
• All numbers in this table are rounded-up.
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• Figure 4.26. Connectivity relationships in the heart TCA cycle model:
Connectivity theorem result involving the elasticity coefficients (εxaseS ) shown in fig. 4.25
(pg. 185) and flux control coefficients (C Jxase) computed at initial steady-state (see tbl. 4.4
on pg. 185), such that for a given metabolite ‘S’, the total sum of all products of εxaseS &
C Jxase, calculated for each enzyme, should be equal to zero.
• ¶ : These metabolites are conserved within this system, which means their connectivity equations are
more complicated compared to the other metabolites in the system. For further explanation, please see
pg. 113. These rows represent combined connectivity equations of conserved metabolites in the liver TCA
cycle models; which also means that a number of individual equations are reduced compared to the total
number of metabolites in the model.
• Zeros with blueish background indicate numbers that are smaller than ±0.01 and range between ±1.0e-05
to ±1.0e-03.
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Figure 4.26 (see, pg. 186) shows the result of connectivity theorem equations for
elasticities given in fig. 4.25. This result was obtained by multiplying flux control
coefficients calculated at initial steady-state, by individual enzyme elasticities calculated
for all metabolites in the model and ultimately adding all such products to get a sum
total. This figure shows that the calculated flux control coefficients & individual enzyme
elasticities satisfy the connectivity theorem (Kacser and Burns, 1973), within acceptable
limits. According to the ratio form of connectivity theorem, flux control coefficients on
a particular pathway flux (‘J’), and elasticity coefficients on a given metabolite (‘S’),
calculated for each enzyme affected by ‘S’, are inversely proportional to each other (Fell,
1997); which means that enzymes with high flux control coefficient values have smaller
elasticities and vice versa. For further details regarding the calculation of connectivity
theorem results, please refer to pg. 113.
However in the heart TCA cycle model, since at initial conditions, the TCA cycle
flux is almost entirely controlled by ATPhyd, all other enzymes show minimal flux control
coefficient values (see tbl. 4.4 on pg. 185). Therefore, in fig. 4.25, it is rather difficult to
spot the aforementioned inverse relationship between the flux control coefficients and
elasticities. Nonetheless, SDH, SCS, & IDHa are some of the more easily observable
examples that show high elasticity values with respect to their individual substrates;
which indicates that they have minimal flux control coefficient values. Since, ATP
hydrolysis is defined as a simple, irreversible mass-action reaction, it shows an elasticity
coefficient of 1 for ATPc, despite having a nearly complete control of TCA cycle. α-KGexp
is defined as a reversible mass-action reaction and it shows an elasticity coefficient of 1
for α-ketoglutarate and a minimal negative coefficient for αKGc (shown as 0, in red);
because its flux control coefficient is minimal. It shows a minimal negative εS for αKGc
because, elasticities are calculated instantaneously (i.e. without simulating the model)
and such computation shows a relatively large positive flux value of α-KGexp (i.e. 0.334
mmol/sec); which means that at instantaneous calculation, α-KGexp mainly allows
the pool of TCAi to equilibrate with cytosolic α-ketoglutarate via its forward reaction.
Also, at instantaneous computation of fluxes, MDH & FM appear to carry fluxes in the
opposite direction of TCA cycle and therefore, their respective substrate and product
elasticities are reversed.
In fig. 4.25 aconitate hydratase (ACO) shows a large elasticity coefficient that is
far greater than 1. This enzyme represents a near-equilibrium reaction and for such
reactions, the elasticities with respect to substrate and product are mostly determined
by the degree of displacement of the reaction from equilibrium (or the disequilibrium
ratio (ρ)) rather than by their kinetic details, which can lead to much larger elasticity
values than that of the non-equilibrium reactions (Fell, 1997; Groen et al., 1982a; Kacser
and Burns, 1973; Westerhoff et al., 1984).
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Between the three dehydrogenase reactions, i.e., α-KGDH, PDH, & IDHa, the
product inhibition by NADHm appears to be strong, moderate and minimal respectively;
which means that the respective rates of these dehydrogenases respond to changes in the
NADHm concentration, in that order. A similar case can be made for the ATP-mediated
inhibition of IDHa, CS, & α-KGDH; where, their respective rates are 90%, 30%, &
10% responsive to changes in the ATPm concentration, assuming 100% as a maximum
possible response of an enzyme to changes in effector concentration. In the case of
pyruvate dehydrogenase, product inhibition by both NADHm as well as AcCoAm appears
to be fairly moderate in the heart TCA cycle model, based on their respective elasticity
coefficients; however according to Bremer, variations in the NADH/NAD+ ratio might
prove to be a more direct regulator of the PDH activity than the AcCoA/CoA ratio, in
general (Bremer, 1969). In the liver TCA cycle model, as shown in the earlier chapter
(see, pg. 113), based on its elasticity (−0.5), the rate of liver pyruvate dehydrogenase
was found to be substantially more responsive to changes in the concentration of NADH
than that of acetyl-CoA.
Therefore, a system-wide analysis of flux control coefficients, concentration control
coefficients, & elasticity coefficients illustrated how various metabolites, effectors and
enzymes interact with each other in the heart TCA cycle model at local as well as
system level. It also showed how the local and system level properties of this model
are related to each other and how one can predict certain systemic or localised effects
based on the relation between the two types of control properties for a given system.
The flux control coefficient and concentration control coefficient analyses also helped in
explaining some of the confounding observations seen during the steady-state analyses
carried out at increasing activities of ATPhyd or PDH. Thus, our discussion on these
analyses shows that Metabolic Control Analysis (MCA) is an immensely important and
useful quantitative tool, without which we would be left with vague concepts of enzyme
response to a metabolite that are often used for qualitative explanations of metabolic
regulation in several biochemistry textbooks.
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4.4 Discussion & Conclusions
The heart TCA cycle model was defined and built based on the valuable insights gained
from the analysis of liver TCA cycle model as well as the “PC knock-out” model, by
applying mammalian heart- or skeletal muscle-specific enzyme kinetics data to a selected
set of reactions from the liver TCA cycle model. This nascent version of the heart
TCA cycle model then went through a few iterations of troubleshooting, optimisation &
modifications to find stable steady-state solutions of the model, when simulated. Some of
the earlier versions of this model contained a few errors such as – NAD, NADH & OAA
concentrations, as well as the ATP hydrolysis activity still operated with liver-specific
values; and an oxaloacetate import reaction was added to stabilise the OAA concentration
and thereby the model itself . . . etc. Such errors were corrected and progressively updated
versions of the model were created and analysed further.
The oxaloacetate import reaction added in the earlier versions of the model was
physiologically unfounded as well as unreliable in terms of the model stability and
therefore had to be replaced with a better alternative solution. Analyses of liver, PCko
as well as the incipient versions of the heart TCA cycle models, constantly indicated
towards the inclusion of malate-aspartate shuttle reactions in the heart-specific TCA
cycle model and therefore, such an addition was planned as a future enhancement to this
model. However, until such enhancement can be made, a stopgap solution was devised in
the form of an α-ketoglutarate transporter reaction (α-KGexp), that partially represented
the abstract function of the malate-oxoglutarate transporter reaction (MOTx) from
malate-aspartate shuttle (see, Methods, for further details of α-KGexp). Moreover, based
on the preliminary analysis of this modified model, the NADP+ -dependent isocitrate
dehydrogenase reaction (IDHb) was also removed from the model (see, Methods, for
further details). Thus formed, a corrected, modified and optimised version of the heart
TCA cycle model was then thoroughly analysed and upon confirming its results, the
model was finalised and frozen as a stable version, until future enhancements.
The final analysis of the heart TCA cycle model presented earlier, offered some
unique and valuable perspective on the physiological characteristics of a heart-specific
TCA cycle system, in terms of its structural, dynamic as well as control properties. Some
of the key findings are as follows:
1. Our decision to remove the NADP+ -dependent isocitrate dehydrogenase reaction
(IDHb) from the heart TCA cycle model is described earlier in the Methods section.
However, from previous chapters we know that the internal substrate cycle between
IDHa & IDHb exists and is operational in heart mitochondria, as well (Sazanov and
Jackson, 1993; for further details as well as refs., please see earlier). We believe that
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the redundancy and errors it created in the heart TCA cycle model were specific to
its peculiar structure and given that this structural definition is subject to change
as a result of the proposed model enhancement with malate-aspartate shuttle, it is
likely to be reintroduced in the extended model in order to realign it, physiologically.
We suspect that its reintroduction in the extended heart TCA cycle model, would
restore the interrupted TCA cycle ‘spans’ observed in the liver TCA cycle model and
allow the IDHa & IDHb reactions to function as ‘independent reactions’. Moreover,
with the addition of malate-aspartate shuttle to the extended model, mitochondrial
malate dehydrogenase is also likely to act as an ‘independent reaction’.
Therefore, provided that the interrupted TCA cycle ‘spans’ as well as the independent
reactions are restored in the extended heart TCA cycle model, we believe that the
negative control coefficient values that were observed earlier for pyruvate dehydroge-
nase (see figs. 4.17 to 4.23 on pgs. 171 to 180, respectively) would also disappear, due
to additional branching of TCA cycle and that PDH would assume a more ‘positive’
role, in terms of allowing the TCA cycle flux to increase rather than decrease.
2. Although compared to the liver TCA cycle model, the emerged pattern of control
distributions in the heart TCA cycle model is quite straightforward, given that this
model is going to be extended further, it once again reiterates the need of constructing
simplified mathematical models that are capable of representing the fundamental
physiological characteristics of real metabolic systems. Keeping the proposed model
extensions in mind, we have to be very careful while designing such kinetic models
by avoiding any non-essential kinetic information; because with the integration of
multiple small models, the model complexity can reach critical levels very quickly!
Therefore, we must develop future heart-specific models with great care to avoid model
complexity, by including only those reactions or processes that are absolutely essential
for the overall biochemical function of the larger metabolic network in mammalian
myocardial mitochondria.
3. Structurally, the heart TCA cycle model is a theoretically ideal version of TCA cycle,
often described in biochemistry textbooks, that produces 11 molecules of ATPm & 3
molecules of CO2 per pyruvate. This model contains a single elementary mode, which
is also an enzyme subset. Compared to the structure of liver TCA cycle model, this
is a relatively simple model and yet, the kinetic properties that emerge from such a
simple structure are quite complex in terms of the dynamic interactions between its
components. Even its control properties require a careful second look, in order to
correctly asses their significance with respect to the overall function of the TCA cycle
described in this model.
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Therefore, this TCA cycle model is a perfect example that shows the real limitations
of a classical reductionist approach used in most biochemistry textbooks to describe
the physiological workings of an ‘ideal’ TCA cycle.
4. Structurally, the α-ketoglutarate transporter reaction (α-KGexp) is identified as a
‘dead reaction’. Also, the steady-state obtained by simulating the heart TCA cycle
model at initial conditions, shows that the flux through α-KGexp is infinitesimally
small and therefore it is almost inconsequential to the normal function of this model.
However, it is essential to stabilise this model and therefore retained. Nonetheless,
as described earlier, it represents a partially approximated form of the malate-
oxoglutarate transporter reaction (MOTx) and thereby creates an in-built point of
integration within the present heart TCA cycle model, for the proposed enhancement
with malate-aspartate shuttle reactions.
Moreover, fig. 4.19b (see, pg. 173) shows the distribution of control on TCA cycle flux
for a hypothetical situation, where cytosolic α-ketoglutarate concentration increases
incrementally. Although hypothetical for this model, such a situation is within
the realm of physiological probabilities and in the presence of a fully functional
malate-aspartate shuttle, under favourable conditions, it might even be a distinct
possibility. This particular situation is of special significance with respect to the
proposed extension of heart TCA cycle model because, fig. 4.19d shows that the
TCA cycle flux is increased moderately by 3-fold, with increase in [αKGc]. It thus
illustrates that if the extended model results in a net exchange of mitochondrial
α-ketoglutarate, then it is likely that we would see some improvement in the flux
through the TCA cycle.
5. The steady-state analysis at initial conditions of the heart TCA cycle model shows
that the TCA cycle flux (flux through CS) in this model is at least 100 times less
than that in the liver TCA cycle model. We believe that there are at least two factors
that are responsible for such a small amount of flux through the TCA cycle and they
are as follows —
5.(a.) The pyruvate carboxylase (PC) reaction is absent in the heart TCA cycle
model; whereas, as shown in the previous chapter, it makes a significant
anaplerotic contribution to the overall flux in liver TCA cycle models. Also,
in the present heart TCA cycle model, other anaplerotic reactions such as
those from the malate-aspartate shuttle are absent as well. Therefore, in this
model, apart from PDH, there is no other input reaction to incorporate any
additional carbon into the TCA cycle.
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5.(b.) The selected set of heart-specific enzyme kinetics data applied to the heart
TCA cycle model is also an important factor, which most certainly affects
the overall flux in this model. However, changing one or more enzyme
kinetics parameters in the model can alter the already established steady-
state behaviour to a variable degree. Changing the model parameters could
also affect the control of flux, due to change in the local properties or elasticities
of individual enzyme(s), according to the connectivity theorem from Metabolic
Control Analysis (Kacser and Burns, 1973); since, the ratio form of this
theorem shows that elasticities and flux control coefficients are inversely
proportional to each other (Fell, 1997). Therefore, it is prudent to commit
any parameter changes to the model, only after thoroughly assessing their
quantitative impact on a given system, based on their respective elasticities
as well as response coefficients (RJP; where, P is the model parameter & J is
the pathway flux; Fell, 1997; Westerhoff and Kell, 1987).
However, experimental data from published literature suggests that in mammalian
heart, the actual physiological range of TCA cycle flux isn’t far off from the initial
steady-state value of TCA cycle flux in this model. In perfused rat hearts, the
TCA cycle flux has been estimated to be in the range of 0.035 to 0.12 mmol/sec,
using 13C NMR spectra (Chance et al., 1983; Tran-Dinh et al., 1998; Weiss et al.,
1995) and enzymatic assay techniques (Safer and Williamson, 1973; Sundqvist et al.,
1989). 13C NMR studies in perfused rabbit hearts, show that the TCA cycle flux
ranges between 0.042 to 0.06 mmol/sec (Yu et al., 1995). A 13C NMR spectroscopic
evaluation of the TCA cycle flux in pig heart tissue shows that it varies between
0.034 to 0.053 mmol/sec, depending on experimental conditions (Panchal et al., 2000,
2001). Whereas, a classical study using enzymatic assay techniques in isolated rat
heart mitochondria, shows a much wider range of variation for the flux through TCA
cycle, between 0.017 to 0.231 mmol/sec (LaNoue and Williamson, 1971).
6. The steady-state analysis at various increasing levels of ATPhyd activities showed
that the redox and energy states of the heart TCA cycle model respond in a fairly
stabilised fashion at ‘moderate’ (10x) to ‘very high’ (500x) ATP-demands. However,
the model appears to respond well between the lower range of ATPhyd activities
from ‘weak’ (0.1x) to ‘moderate’ (10x). This is somewhat similar to a rectangular
hyperbolic curve observed in enzyme kinetics; where there are lag, exponential &
plateau phases of the curve.
This was a rather surprising result. Moreover, it even finds sufficient literature evidence,
which suggests that this particular model behaviour is similar to the observations
made in intact mammalian hearts in vivo, at increased workloads. However, we
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believe that such a response could partly be due to the respective initial model values
of ATP–related metabolites, as these are the same values used in the liver TCA cycle
model. Also, after extending the model with malate-aspartate shuttle reactions, there
is a possibility that this model behaviour could entirely disappear.
Nonetheless, for any mathematical model describing the cardiac or skeletal muscle
metabolism, it is extremely important that the model responds robustly across a wide
range of ATP-demands, due to the highly demand-based metabolic characteristics of
these tissues. Therefore, this entire analysis using a wide array of ATP hydrolysis
activities, is an important point of validation for the heart TCA cycle model, one
that better aligns this model with respect to the cardiac mitochondrial physiology.
7. At a glance, comparing the control properties between the mammalian liver- &
heart-specific models shows significant differences between the two model systems
that arise mainly due to structural (removal of PC, MC & IDHb) as well as kinetic
changes (application of heart-specific enzyme kinetics data). For instance, if we
compare the ‘heat-maps’ for the qualitative distribution of concentration control
coefficients between the two models, we can quickly visualise how the same metabolite
concentrations are controlled in a significantly different pattern of control distribution.
It not only highlights the fact that flux or concentration control coefficients of enzymes
is a system property of a given metabolic system, but also indicates the ability of
mathematical models to differentiate between tissue-specific metabolic characteristics
using different sets of enzyme kinetics data.
Therefore, using the knowledge and valuable insights gained from analysing the
already established liver TCA cycle model, we successfully built a ‘consensus’ kinetic
model of TCA cycle in mammalian heart or skeletal muscle mitochondria. For this model,
our design strategies were predicated on building a separate, standalone model of the
malate-aspartate shuttle, which would be combined later with this TCA cycle model.
Therefore, given this understanding, we constructed a heart-specific TCA cycle model
that is neither over-simplified nor too complex in terms of rate equations, reversibility
of reactions and regulatory interactions. A thorough analysis of this model resulted in
several significant findings, specific to the cardiac mitochondrial physiology. Now, it
would be interesting to find out how this model responds after it is combined with the
malate-aspartate shuttle reactions. However before we do that, in the following chapter,
we’ll first take a quick look at the standalone model of malate-aspartate shuttle.
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The Malate-aspartate shuttle
model
5.1 Overview
Throughout previous chapters on the liver TCA cycle model, PCko model and the heart
TCA cycle model, we have been talking about the malate-aspartate shuttle and how the
newly built heart TCA cycle model may need the additional anaplerotic input provided
by the shuttle reactions, especially in the absence of pyruvate carboxylase. We have also
talked about the limited availability of mitochondrial oxaloacetate (OAAm) and how it
affects the TCA cycle flux and how the malate-aspartate shuttle reactions could help
in maintaining the mitochondrial oxaloacetate concentration within physiological range.
Therefore, we set about constructing a heart-specific malate-aspartate shuttle model
(HRTMAS) based on the same modelling strategy we have followed so far. This a second
in the series of three heart-specific standalone models, where the heart TCA cycle model
was the first model built.
To begin with, we constructed a structural model comprising the TCA cycle reactions,
including the ATP/ADP–linked reactions, plus reactions from the malate-aspartate
shuttle. Elementary modes were computed for this structural model and then analysed in
detail. The elementary modes analysis suggested a single elementary mode that contained
a minimal possible set of reactions that result in a fully functional malate-aspartate
shuttle. Thus, this elementary mode was isolated as a separate model and converted to
a kinetic model by including appropriate rate equations based on the simplified, generic,
reversible bi-substrate equation (Chassagnole et al., 2001b; Rohwer et al., 2006). The
rate equation parameters and the model variables were initiated based on the published
literature data from heart mitochondria (preferably rat). This newly created malate-
aspartate shuttle model was then analysed in detail using structural as well as kinetic
analyses.
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However, in the context of this report, since the dynamic behaviour of the malate-
aspartate shuttle in the fully extended, heart integrated TCA cycle model (HRTTCA+) is
of more importance to us than its performance as a standalone model, we shall restrict our
discussion regarding the specific properties of this standalone malate-aspartate shuttle
model to an absolute minimum.
In Section 5.2, we shall discuss the definition & construction of the malate-aspartate
shuttle model (HRTMAS), in further detail. Section 5.3: Results for the Malate-Aspartate
shuttle model on pg. 197, describes a quick analytical overview of the emergent dynamic
properties of this model.
5.2 Methods: Model design and definition
As mentioned earlier, the Malate-aspartate shuttle model (HRTMAS) representing the
operation of heart or skeletal muscle-specific malate-aspartate shuttle was manually
constructed using ScrumPy, by modifying the isolated elementary mode from a structural
model built earlier. The model in ScrumPy format is available in Appendix G (see,
pg. 244) and is illustrated in fig. 5.1 (see, pg. 196). The final version of the updated
model contains 9 reactions and 21 metabolites.
5.2.1 Model definition
Since, this model is based on the same modelling strategy as that of the earlier models,
it follows the same design choices in terms of individual enzyme rate equations that are
represented using the generic reversible bi-substrate equation (Chassagnole et al., 2001b;
Rohwer et al., 2006), as explained in the earlier chapter.
As illustrated in Figure 5.1, the malate-aspartate shuttle model includes nine reac-
tions, comprising six malate-aspartate shuttle reactions, viz.– mitochondrial malate dehy-
drogenase (mMDH), cytosolic malate dehydrogenase (cMDH), mitochondrial glutamate-
oxoglutarate transaminase (mGOT), cytosolic glutamate-oxoglutarate transaminase
(cGOT), malate-oxoglutarate transporter (MOTx), & glutamate-aspartate transporter
(GATx); as well as three ATP/ADP–linked reactions, viz.– adenine-nucleotide translocase
(ANT), ATP synthase (ATPsynth), & ATP hydrolysis (ATPhyd). Except for ATPsynth
& ATPhyd, all other reactions in this model are defined as reversible. The three ATP/
ADP–linked reactions retain their original definitions from the earlier models. The
malate-aspartate shuttle reactions are mainly defined as reversible bi-substrate equations
with product inhibition and the already well defined mitochondrial malate dehydrogenase
reaction was used as an example equation.
The malate-aspartate shuttle model includes 16 variables (internal metabolites) that
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Malm
OAAm
mMDH
NADm
NADHm
α-KGm
Glutm
Aspm
mGOT
GATx
MOTx
α-KGc
Malc
Glutc
Aspc
OAAc
cMDH
NADc
NADHc
cGOT
ANT
ATPc
ADPc
ATPm
ADPm
Pic
ATPhyd
Mitochondria
Cytoplasm
ADPm + Pim
ATPm
ATPsynth
• Figure 5.1. Schematic illustrating the standlone malate-aspartate shuttle model.
• Internal metabolites: in Black; external metabolites: in Blue; reaction/ enzyme names: in Red .
• Reaction with double arrowheads is assumed to be reversible and reaction with single arrowhead is assumed
to be irreversible.
describe the concentrations of viz.– NADm+, NADHm, adenine nucleotides, as well as
mitochondrial α-ketoglutarate (αKGm), malate (Malm), oxaloacetate (OAAm), aspartate
(Aspm), & glutamate (Glutm); and their corresponding cytosolic metabolites (αKGc,
Malc, OAAc, Aspc, Glutc). Also, this model includes 8 parameters that describe fixed
quantities (external metabolites) of inorganic phosphates (Pim & Pic) and cytosolic NAD
& NADH (NADc+ & NADHc). For most of these 21 metabolites, a range of values, largely
from rat heart or skeletal muscle tissue were found and a median value was used in the
model as an initial model value. Both the cytosolic as well as mitochondrial NAD &
NADH concentrations are based on the published data from Kobayashi and Neely (1979).
In the malate-aspartate shuttle model, ATP hydrolysis is the only cytosolic reaction
that utilises ATPc and in the mitochondria, mMDH is the only dehydrogenase that
produces NADHm, which is consequently used by ATPsynth to produce ATPm. However,
compared to 3 or 4 dehydrogenase reactions of the TCA cycle model, the rate of ATP
production in this standlone malate-aspartate shuttle model is far too less and causes
model instability. Therefore, to stabilise the mitochondrial as well as the cytosolic
concentrations of adenine nucleotides in this model, the ANT reaction is slowed down
by 100x and the ATPhyd reaction is sped up by 10x. Although, such alterations are
unphysiological, in a standlone model such as this, which does not have any additional
carbon input in the form of pyruvate or amino acids, such steps are necessary to stabilise
the model and to find a stable steady-state solution upon model simulation.
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5.3 Results for the Malate-Aspartate shuttle model
In this section, we shall take a quick look at the significant properties of the standalone
malate-aspartate shuttle model (HRTMAS); since, we are more interested in finding out
how this model works in the fully extended form when combined with the heart TCA
cycle model, in the heart integrated TCA cycle model (HRTTCA+).
5.3.1 Elementary modes analysis of Malate-Aspartate shuttle model
The malate-aspartate shuttle model contains a single elementary mode which consumes
one molecule of NADHc to produce 2.5 mitochondrial ATP molecules via mitochondrial
malate dehydrogenase, that are consequently utilised to produce 2.5 cytosolic ADP & Pi.
Figure 5.2 shows this single elementary mode with its corresponding net stoichiometry,
alongside each reaction.
Malm
OAAm
mMDH
NADm
NADHm
α-KGm
Glutm
Aspm
mGOT
GATx
MOTx
α-KGc
Malc
Glutc
Aspc
OAAc
cMDH
NADc
NADHc
cGOT
ANT
ATPc
ADPc
ATPm
ADPm
Pic
ATPhyd
Mitochondria
Cytoplasm
ADPm + Pim
ATPm
ATPsynth
1.0
- 1.0
1.0
1.0
1.0
- 1.0
2.5
2.5
0.25
• Figure
5.2. Schematic illustrating the elementary modes of Malate-Aspartate shuttle model.
• Internal metabolites: in Black; external metabolites: in Blue; reaction/ enzyme names: in Red .
• The corresponding net stoichiometry is broken down and shown alongside each reaction in the elementary
mode.
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This elementary mode is exactly the same as the original elementary mode from
which this model was initiated, by isolating a single elementary mode from the structural
model containing TCA cycle & the malate-aspartate shuttle reactions. This mode shows
that in this standalone form, the malate-aspartate shuttle is not open-ended and that it
begins at the cytosolic malate dehydrogenase (cMDH) reaction by consuming NADHc
(which is a fixed quantity in this model). Also, in this model, since the cMDH is defined
in the same direction as that of the mitochondrial malate dehydrogenase (mMDH), it
functions in reverse direction in this mode, which actually is the physiological correct
direction for the cytosolic malate dehydrogenase.
In this elementary mode, since, cMDH reverses itself, the cytosolic glutamate-
oxoglutarate transaminase (cGOT) reaction reverses its direction as well and forms
cytosolic α-ketoglutarate & cytosolic aspartate; which tend to accumulate in this system.
The accumulation of αKGc & Aspc is caused by the positive directions of glutamate-
aspartate transporter (GATx) and malate-oxoglutarate transporter (MOTx) which trans-
port mitochondrial aspartate (Aspm) & mitochondrial α-ketoglutarate (αKGm) into the
cytosol, respectively. This is a reason why in the fully expanded model, we needed sink
reactions that would transport the excess amino acids to the blood stream (to fixed
quantities).
The malate-oxoglutarate transporter reaction imports cytosolic malate (Malc) into
the mitochondria; which is utilised by the mitochondrial malate dehydrogenase to produce
one molecule of NADHm and mitochondrial oxaloacetate (OAAm). ATP synthase
(ATPsynth) then utilises this single molecule of NADHm to produce 2.5 molecules of
mitochondrial ATP that are then consequently transported to the cytosol and hydrolysed
by ATPhyd.
— Ph.D. Thesis by Amar S. Ghaisas — Page 198
5. Malate-Aspartate shuttle model 5.3. Results for the Malate-Aspartate . . .
5.3.2 Flux control coefficient analysis for the Malate-Aspartate shuttle
model
In this section, we’ll see the results of Metabolic Control Analysis (MCA) when applied
to the malate-aspartate shuttle model, by observing the distribution of flux control
coefficient.
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• Figure 5.3. Control of malate-aspartate shuttle
flux in the malate-aspartate shuttle model: against the changing NADHc concentration.
• Key for figs. 5.3a and 5.3b is given in the plots.
• The vertical black line represents the initial model value. At this point, in figs. 5.3a and 5.3b,
[NADHc] = 0.00255 mM.
• In the malate-aspartate shuttle model, the cytosolic NAD & NADH are fixed quantities.
• Orange dotted line shows the Summation theorem result across the entire range.
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Figure 5.3 (see, pg. 199) shows the distribution of flux control coefficients for the
malate-aspartate shuttle flux (here, represented in the form of GATx flux; since there is
a single enzyme subset which contains all reactions of the model), against the increasing
concentration of NADHc (which is an external metabolite in this model). The CJ plot
is presented alongside a steady-state plot of the glutamate-aspartate transporter flux
across the same given range of NADHc concentration.
Figure 5.3 shows that the control of malate-aspartate shuttle flux is uniformly
distributed between ATPsynth, mitochondrial glutamate-oxoglutarate transaminase
(mGOT) and cytosolic glutamate-oxoglutarate transaminase (cGOT); whereas, other
enzymes share a minimal control of the flux. It also shows that the share of control gets
exchanged between ATPsynth & cGOT at high NADHc concentrations (almost 5 times
higher than its initial model value).
Moreover, fig. 5.3b shows that the flux through the malate-aspartate shuttle increases
with increase in the NADHc concentration. As shown earlier in the elementary modes
analysis, the malate-aspartate shuttle begins by consuming NADHc and therefore, this
result shows that if in the fully extended model, we can achieve a dynamic increase
of the NADHc concentration, the malate-aspartate shuttle flux also likely to increase.
Therefore, this result calls for the internalisation of cytosolic NAD & NADH by including
another pathway such as glycolysis to generate the cytosolic redox species dynamically
within the boundaries of the heart integrated TCA cycle model (HRTTCA+).
5.4 Discussion & Conclusions
In previous sections we saw a quick overview of the significant properties of a standalone
malate-aspartate shuttle model. The combination of elementary modes analysis results
as well as the analysis of flux control coefficients showed that the model responds
adequately to the variations in its input (i.e. NADHc). However, NADHc is an external
metabolite or a fixed quantity in this model and combining this model as is with the
heart TCA cycle model would mean that the transfer of reduction potential from cytosol
to the mitochondria would be external to the resulting system; which isn’t really helpful.
Therefore, we should find a way to internalise the cytosolic redox couple within the
system defined by the malate-aspartate shuttle reactions.
The need to transform the cytosolic redox couple into internal metabolites, called
for the incorporation of another pathway or a reaction that would dynamically cycle
between the cytosolic NAD & NADH. Therefore, we thought of incorporating a glycolytic
pathway into the extended model. In the following chapter, we describe this newly built
heart-specific glycolysis model.
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Chapter 6
The Heart glycolysis model
6.1 Overview
In the previous chapter on the malate-aspartate shuttle model (HRTMAS), we talked
about the need to generate cytosolic redox species (i.e. NADc+ & NADHc) dynamically
within the boundaries of the extended model of the TCA cycle, upon its integration with
the malate-aspartate shuttle model. Therefore, instead of representing the said reaction
in an assumed fashion, we decided to build a proper heart glycolysis model (HRTGlc) that
would contain all the reactions in their fully functional form. Also, a lot of the published
literature data was already available in publications such as Kashiwaya et al. (1994)
and Kobayashi and Neely (1979); which made the process of model building a bit easier.
Moreover, building a full glycolysis model had another advantage in that, the cytosolic
adenine nucleotides (i.e. ATPc & ADPc) were highly constrained in the TCA cycle
models seen earlier, due to a single reaction consuming and producing them and with
the addition of glycolytic reactions in the cytosol, we hoped that these constrains would
be comparatively less severe. Therefore, we set about constructing a heart glycolysis
model (HRTGlc) based on the same modelling strategy we have followed so far. This the
last in the series of three heart-specific standalone models, where the heart TCA cycle
model was the first model built.
Similar to the strategy followed during the construction of the malate-aspartate
shuttle model, we started with a structural model and then isolated the elementary
mode that represented a complete function of canonical glycolytic pathway, comprising
a minimal set of reactions. Thus, this elementary mode was isolated as a separate model
and converted to a kinetic model by including appropriate rate equations based on the
simplified, generic, reversible bi-substrate equation (Chassagnole et al., 2001b; Rohwer
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et al., 2006). The rate equation parameters and the model variables were initiated based
on the published literature data from heart mitochondria (preferably rat). This newly
created heart glycolysis model was then analysed in detail using structural as well as
kinetic analyses.
However, in the context of this report, since the dynamic behaviour of glycolysis in
the fully extended, heart integrated TCA cycle model (HRTTCA+) is of more importance
to us than its performance as a standalone model, we shall restrict our discussion
regarding the specific properties of this standalone heart glycolysis model to an absolute
minimum.
In Section 6.2, we shall discuss the definition & construction of the heart glycolysis
model (HRTGlc), in further detail. Section 6.3: Results for the Heart Glycolysis model
on pg. 206, describes a quick analytical overview of the emergent dynamic properties of
this model.
6.2 Methods: Model design and definition
As mentioned earlier, the Heart glycolysis model (HRTGlc) representing the operation
of heart or skeletal muscle-specific glycolysis was manually constructed using ScrumPy,
by modifying the isolated elementary mode from a structural model built earlier. The
model in ScrumPy format is available in Appendix H (see, pg. 247) and is illustrated in
fig. 6.1 (see, pg. 203). The final version of the updated model contains 17 reactions and
22 metabolites.
6.2.1 Model definition
Since, this model is based on the same modelling strategy as that of the earlier models,
it follows the same design choices in terms of individual enzyme rate equations that are
represented using the generic reversible bi-substrate equation (Chassagnole et al., 2001b;
Rohwer et al., 2006), as explained in the earlier chapter.
— Ph.D. Thesis by Amar S. Ghaisas — Page 202
6. Heart Glycolysis model 6.2. Methods
Glcblood
Glcc
GLUT4
G-6-P
HK
F-6-P
PGI
F-1,6-BP
PFK
GAP
DHAP ALD
TPI
1,3-BPG
NADc
NADHc
Pic
GAPDH
3-PG
PGK
2-PG
PGM
PEP
ENO
PK
Pyrc
Pyrm
Lacc
NADc
NADHc
LDH
MCT1
Lacblood
MCT1
NADc
NADHc
α-Glycerol-P
cGPD1
Pic
ATPhyd
G-6-P
G6Pexp
ATPc
ADPc
ATPc
ADPc
ATPc
ADPc
ATPc
ADPc
• Figure 6.1. Schematic illustrating the standalone heart glycolysis model.
• Internal metabolites: in Black; external metabolites: in Blue; reaction/ enzyme names: in Red .
• Reaction with double arrowheads is assumed to be reversible and reaction with single arrowhead is assumed
to be irreversible.
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As illustrated in Figure 6.1, the heart glycolysis model includes 17 reactions as
follows:
1. Ten canonical glycolysis reactions : hexokinase (HK), phosphoglucose isomerase
(PGI), phosphofructokinase (PFK), aldolase (ALD), triosephosphate isomerase (TPI),
glyceraldehyde phosphate dehydrogenase (GAPDH), phosphoglycerate kinase (PGK),
phosphoglycerate mutase (PGM), enolase (ENO), & pyruvate kinase (PK)
2. A reaction catalysed by lactate dehydrogenase (LDH)
3. A ATP hydrolysis (ATPhyd) reaction
4. Four transport reactions : glucose 6-phosphate export (G6Pexp), glucose transporter
type 4 (GLUT4), monocarboxylate transporter type 1 (mito. memb.) (MCT1Mm),
& monocarboxylate transporter type 1 (cell memb.) (MCT1Pm)
5. A reaction catalysed by cytosolic α-glycerol phosphate dehydrogenase type 1 (cGPD1)
Except for HK, cGPD1 & ATPhyd, all other reactions in this model are defined as
reversible. The ATP hydrolysis reaction retains its original definition from the earlier
models. The heart glycolysis model reactions are mainly defined as reversible bi-substrate
equations with product inhibition, where appropriate.
The heart glycolysis model includes 16 variables (internal metabolites) that describe
the concentrations of viz.–
1. glucose (Glc), lactate (Lac), & pyruvate (Pyrm)
2. glucose 6-phosphate (G6P), fructose 6-phosphate (F6P), fructose 1,6-bisphosphate
(F16BP), glyceraldehyde 3-phosphate (GAP), & dihydroxyacetone phosphate (DHAP)
3. 1,3-bisphosphoglycerate (13BPG), 3-phosphoglycerate (3PG), 2-phosphoglycerate
(2PG), & phosphoenolpyruvate (PEP)
4. NADc+, NADHc, ADPc, & ATPc
Also, this model includes 6 parameters that describe fixed quantities (external
metabolites), viz.–
1. blood pyruvate (PyrbL), blood glucose (GlcbL), & blood lactate (LacbL)
2. Pic, α-glycerol 3-phosphate (α-GLYp), & glucose 6-phosphate (external) (G6Px)
For most of these 22 metabolites, a range of values, largely from rat heart or skeletal
muscle tissue were found and a median value was used in the model as an initial model
value. Both the cytosolic as well as mitochondrial NAD & NADH concentrations are
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based on the published data from Kobayashi and Neely (1979).
In this model, the GLUT4 reaction is modelled as a simple reversible reaction with
product inhibition and the other complexities that exist in different types of glucose
transporters are overlooked to maintain the simplicity of this model. The hexokinase
is defined in the form of a irreversible reaction with product inhibition. The glucose
6-phosphate export reaction was added to the model at a later stage, during the model
stabilisation; however, it also signifies the point of exchange with glycogenolysis and
glycogen synthesizing reactions and in terms of glycogen utilisation by the heart muscle
during fasting stage it is quite relevant. It has assumed enzyme kinetics. The cytosolic
α-glycerol phosphate dehydrogenase type 1 (cGPD1) reaction was again added as another
model stabilisation reaction during optimisation and a physiologically relevant reaction
such as cGPD1 was chosen, because we wanted the material to leave the glycolytic
pathway based on the constraints enforced by the cytosolic redox couple, so that the
material leaves the pathway in a more physiologically aligned manner and ends up as α-
glycerol 3-phosphate (α-GLYp) (which is a fixed quantity). This reaction also signifies the
exit from glycolysis and formation of glycerol precursors. This reaction can be supported
on the basis of flux distribution going from DHAP to glycerol production (Achs and
Garfinkel, 1977; Kashiwaya et al., 1994). Also, based on its equilibrium constant (i.e. Keq
= 14000 unitless) in the direction of α-GLYp formation, it is physiologically unlikely that
it would go reverse, therefore it was modelled as an irreversible reaction. Also, the activity
of α-Glycerol 3-Phosphate oxidase is extremely low in heart muscle to be considered (i.e.
8 µmol/min/mg mitochondrial protein) and therefore it was not considered alongside
the dehydrogenase reaction in this model (Kashiwaya et al., 1994).
The cytosolic pyruvate transport to mitochondria and the lactate transport to blood
are represented by the monocarboxylate transporter type 1 (MCT1). Also, unlike the
malate-aspartate shuttle model, this model uses the basal value of ATP hydrolysis activity
that was established in the heart TCA cycle model (i.e. 0.01 mM/sec).
Thus established, we studied the structural as well as kinetic properties of this
model and in the following section, we shall take a quick look at some of the significant
properties of this mammalian heart-specific glycolytic system.
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6.3 Results for the Heart Glycolysis model
In this section, we shall take a quick look at the significant properties of the standalone
heart glycolysis model (HRTGlc); since, we are more interested in finding out how this
model works in the fully extended form when combined with the heart TCA cycle model,
in the heart integrated TCA cycle model (HRTTCA+).
6.3.1 Elementary modes analysis of Heart Glycolysis model
The heart glycolysis model contains three elementary modes and they are shown in
tbl. 6.1.
Modes GLUT4 HK PGI PFK ALD TPI cGPD1 GAPDH PGK PGM ENO PK LDH
ElMo 0 0 0 -0.5 0.5 0.5 0.5 -0.5 0 1 1 1 1 1 0 1 1 1.5
ElMo 1 1 1 0 1 1 1 0 1 1 1 1 1 1 1 0 0 0
ElMo 2 0 0 -1 1 1 1 0.5 1.5 0.5 0.5 0.5 0.5 0.5 1.5 -1 -1 0
ElMo 3 1.5 1.5 1 0.5 0.5 0.5 -0.5 0 1 1 1 1 1 0 1 1 0
ElMo 4 0.5 0.5 0 0.5 0.5 0.5 -0.5 0 1 1 1 1 1 0 1 1 1
ElMo 5 0 0 -1 1 1 1 0 1 1 1 1 1 1 1 0 0 1
G6P
exp
MCT1M
m
MCT1P
m ATPhyd
• Table 6.1. A table showing elementary modes for the heart glycolysis model.
• In this table, fractions have been converted decimals.
The three elementary modes shown in tbl. 6.1 are as follows:
1. ElMo[0]: This mode results in lactate formation with carbon coming from G6Px (or
glycogenolysis) and ends up with no glycerol precursors.
2. ElMo[1]: This elementary mode results in pyruvate formation with carbon coming
from blood glucose and also forms α-glycerol 3-phosphate.
3. ElMo[2] & ElMo[5]: These modes form pyruvate with the carbon that arrives from
G6Px (or glycogenolysis) as well as blood lactate and also forms α-GLYp.
4. ElMo[3] & ElMo[4]: These modes form lactate with the carbon coming from blood
glucose with no glycerol precursors. Also, ElMo[3] exports some material out to the
G6Px; whereas, ElMo[4] doesn’t.
Therefore, the elementary modes analysis shows that both the pyruvate as well as
lactate formations are possible with this model, where the carbon originates from two to
three different sources available in the model.
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6.3.2 Enzyme subset analysis of Heart Glycolysis model
The heart glycolysis model contains five enzyme subsets and they are shown in fig. 6.2.
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• Figure 6.2. Schematic illustrating the enzyme subsets in heart glycolysis model.
• Internal metabolites: in Black; external metabolites: in Blue; reaction/ enzyme names: in Red .
• Reaction with double arrowheads is assumed to be reversible and reaction with single arrowhead is assumed
to be irreversible.
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Figure 6.2 (see, pg. 207) shows that the heart glycolysis model contains 5 enzyme
subsets; wherein, the enzyme subsets for the “preparatory phase” (ESS#3) and the
“pay-off phase” (ESS#4) emerge as a result of this model’s structural definition. This is a
significant result of this structural analysis. Also, cGPD1 & MCT1Mm form a common
enzyme subset (ESS#2) and G6Pexp functions as an independent reaction. The model
also contains GLUT4 -based (ESS#5) and LDH -based (ESS#1) enzyme subsets.
6.3.3 Flux control coefficient analysis for the Heart Glycolysis model
In this section, we’ll see the results of Metabolic Control Analysis (MCA) when applied
to the heart TCA cycle model, by observing the distribution of flux control coefficient
(CJ).
Figure 6.3 (see, pg. 209) shows the distribution of flux control coefficients for the
glyceraldehyde phosphate dehydrogenase flux (ESS#4 flux), against the increasing
activity of hexokinase (which is an external metabolite in this model). The CJ plot is
presented alongside a steady-state plot of the glyceraldehyde phosphate dehydrogenase
flux across the same given range of hexokinase activity.
Figure 6.3 shows that the control of glyceraldehyde phosphate dehydrogenase flux is
uniformly distributed between GLUT4, ATP hydrolysis (ATPhyd) and hexokinase (HK);
whereas, other enzymes share a minimal control of the flux. It also shows that the share
of control gets exchanged between GLUT4 & HK much before the initial model value of
HK activity.
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• Figure 6.3. Control of glyceraldehyde phos-
phate dehydrogenase flux in the heart glycolysis model: against the hexokinase activity.
• Key for figs. 6.3a and 6.3b is given in the plots.
• The vertical black line represents the initial model value. At this point, in figs. 6.3a and 6.3b,
hexokinase activity = 0.88 mM/sec.
• Orange dotted line shows the Summation theorem result across the entire range.
6.4 Discussion & Conclusions
In previous sections we saw a quick overview of the significant properties of a standalone
heart glycolysis model. The combination of elementary modes analysis results, enzyme
subset results and the analysis of flux control coefficients showed that the model responds
adequately to the variations in the activities of key enzymes.
Therefore, it was concluded that this model is ready to be integrated with the heart
TCA cycle model as well as the malate-aspartate shuttle model. Thus, in the following
chapter, we describe the fully integrated model containing all three standalone models.
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Chapter 7
The Heart integrated TCA cycle
model
7.1 Overview
In this heart integrated TCA cycle model (HRTTCA+) the three previously seen heart-
specific models were combined to form an integrated system containing 37 reactions. In
the following section, we see its final composition.
7.2 Methods: Model design and definition
As mentioned earlier, the Heart integrated TCA cycle model (HRTTCA+) representing
the operation of heart or skeletal muscle-specific TCA cycle, malate-aspartate shuttle and
glycolysis was manually constructed using ScrumPy, by integrating these three standalone
models built earlier. The model in ScrumPy format is available in the standalone form
as presented earlier and is illustrated in fig. 7.1 (see, pg. 211). The final version of the
updated model contains 37 reactions and 54 metabolites.
7.2.1 Model definition
In addition to the reactions from these three standalone models, some sink reactions were
required for the removal of excess pyruvate, cytosolic glutamate and cytosolic aspartate;
therefore the required reactions were added in the form of reversible transport reactions.
The final result of the model definition is shown in fig. 7.1 (see, pg. 211). Also, for the
positive directions of the reactions as they are defined in the model, please refer to fig. 7.2
(see, pg. 212).
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GATx
Glutc
Aspc
Glutm
Aspm
mGOT
Glutm
OAAm
Aspm
α-KGm
mMDH
Malm
NADm
OAAm
NADHm
IDHa
Isocitm
NADm
α-KGm
NADHm
CO2+
IDHb
Isocitm
NADP
α-KGm
NADPH
CO2+
MOTx
Malc
α-KGc
Malm
α-KGm
cGOT
Glutc
OAAc
Aspc
α-KGc
cMDH
Malc
NADc
OAAc
NADHc
α-KGDH
α-KGm
NADm
SCoA
NADHm
CO2+
+ CoA
LDH
PYRc
NADHc
LACc
NADc
GAP DHAP
TPI
• Figure 7.2.
Schematic illustrating the positive reaction directions heart integrated TCA cycle model.
7.3 Results for the Heart integrated model
In this section, we shall take a quick look at the significant properties of the heart
integrated TCA cycle model (HRTTCA+).
7.3.1 Elementary modes analysis & Enzyme subset analysis of Heart
integrated model
The heart integrated TCA cycle model contains a total of 278 elementary modes and
9 enzyme subsets. The enzyme subsets of the heart integrated TCA cycle model are
shown in fig. 7.3 on pg. 213.
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7.3.2 Steady-state analysis for the Heart integrated model
In this section, we’ll see the results of steady-state analysis in the form of ‘percentage
response plots’ ; wherein, all the fluxes in the model at a given steady-state (e.g. initial
steady-state of the model or any other steady-state at differnt enzyme activity), are
recalculated in terms of percentages with respect to GLUT4 as 100% . These schematics
thus show us the flow of carbon through the integrated maze of reactions in this enhanced
model.
First, we show the ‘percentage response plot’ at the initial steady-state of the model
fig. 7.4, and then at a steady-state obtained by increasing the ATP hydrolysis activity
by 10x fig. 7.5.
Enzyme subset # 1
Enzyme subset # 2
Enzyme subset # 3
Enzyme subset # 4
Enzyme subset # 5
Enzyme subset # 6
Enzyme subset # 7
Enzyme subset # 8
Enzyme subset # 9
Independent flux
Internal metabolite
External metabolite
mMDH
mGOT
MOTx
GATx
cGOT
cMDH
PDH
CS
ACO
IDHa
IDHb
α-KGDH
SCS SDH
FM
Glutexp
Aspexp
MCT1Mm
PK
Pyrexp
LDH
MCT1Pm
ANT
ATPsynth
GLUT4
HK
PGI
PFK
ALD
TPI
GAPDH
PGK
PGM
ENO
cGPD1
ATPhyd
G6Pexp
100 %
86.53 %
13.47 %
71.35 %
-15.18 %
101.71 %
63.20 %
30.90 %
7.61 %
5.27 %
-2.34 %
2.34 %
-2.88 %
0.54 %
-0.54 %
4.73 %
0.17 %
7.44 %
4.44 %
66.57 %
49.69 %
• Figure 7.4. Schematic illustrating the
‘percentage response plot’ at the initial steady-state of the heart integrated TCA cycle model.
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Enzyme subset # 1
Enzyme subset # 2
Enzyme subset # 3
Enzyme subset # 4
Enzyme subset # 5
Enzyme subset # 6
Enzyme subset # 7
Enzyme subset # 8
Enzyme subset # 9
Independent flux
Internal metabolite
External metabolite
mMDH
mGOT
MOTx
GATx
cGOT
cMDH
PDH
CS
ACO
IDHa
IDHb
α-KGDH
SCS SDH
FM
Glutexp
Aspexp
MCT1Mm
PK
Pyrexp
LDH
MCT1Pm
ANT
ATPsynth
GLUT4
HK
PGI
PFK
ALD
TPI
GAPDH
PGK
PGM
ENO
cGPD1
ATPhyd
G6Pexp
100 %
89 %
11 %
42.4 %
-46.6 %
135.6 %
32.1 %
93.3 %
10.2 %
52.1 %
41.9 %
-41.9 %
41.8 %
0.1 %
-0.1 %
52 %
0.01 %
10.2 %
28.6 %
419.9 %
337.7 %
• Figure 7.5. Schematic illustrating the ‘percentage response
plot’ at steady-state, at 10x ATPhyd activity in the heart integrated TCA cycle model.
7.4 Discussion & Conclusions
At the beginning of this project, the basic idea involved developing a mammalian heart-
specific TCA cycle model that is both comprehensive in its ability to illustrate the
physiological behaviour of the pathway in tissues such as the mammalian heart or
skeletal-muscle as well as simple enough to include all the key biochemical interactions
in the pathway. As mentioned earlier, we started with the well established model of
TCA cycle in mammalian liver, developed within the CSMG. Analysis of this model
helped us understand the tissue-specific interactions in the TCA cycle, as well as the
overall physiological behaviour of the pathway and how to properly analyse it in detail
going forward. With the help of this understanding, we developed the mammalian
heart-specific TCA cycle model, which did not include the liver-specific reactions like
pyruvate carboxylase and malate carrier (malate-phosphate transporter). Also, due to
the structural limitations of this model, we decided to exclude the NADP+ -dependent
isocitrate dehydrogenase from this model, pending further investigation.
— Ph.D. Thesis by Amar S. Ghaisas — Page 215
7. Heart integrated model 7.4. Discussion
Analysis of the heart TCA cycle model revealed that in the absence of a large
anaplerotic input from the pyruvate carboxylase reaction, the model requires a similar
anaplerotic input from the reactions involving malate-aspartate shuttle, otherwise the
TCA cycle flux falls way below the physiologically expected range of values. Therefore, the
heart TCA cycle model analysis confirmed what we had suspected all along, that it would
need to be integrated with a model describing the malate-aspartate shuttle reactions
and therefore we went ahead with the development of malate-aspartate shuttle model.
This model was constructed using the same design principles as that of the previously
built TCA cycle models and was based on the simplified, generic, reversible bi-substrate
equation (Chassagnole et al., 2001b; Rohwer et al., 2006), modified where necessary
to account for more than two substrates and/or products. Equations of this form are
simple enough to include a limited number of parameters that are easily determined, and
do not require additional explicit assumptions to be made, yet adequately describe the
response of an enzyme to changes in both substrate and product concentrations within
the physiological range (Chassagnole et al., 2001b). By default, this equation assumes
competitive product inhibition with respect to the corresponding substrate (e.g. ADP
competitive with ATP), and non-competitive inhibition for unrelated substrate-product
pairs in multi-substrate reactions. Additional effector interactions are also considered
when necessary. In all cases, the simplest expression that adequately represents the
key kinetic properties of the enzyme is used. Throughout the models described in this
work, nearly all rate equations are based on such a simplified bi-substrate equation, as
it allowed us to maintain the model complexity to a bare minimum, while making the
models neither too complicated nor overly simplified.
The standalone malate-aspartate shuttle model analysis revealed its ability to respond
adequately in response to the change in its input, i.e. NADHc. When combined with
the already established heart TCA cycle model, the resultant system showed that the
inclusion of malate-aspartate shuttle does in fact improve the overall TCA cycle flux.
However, the malate-aspartate shuttle model in its standalone format included the
cytosolic NAD and NADH species as external metabolites or as fixed quantities, since
the malate-aspartate shuttle reactions in the cytosol do not recycle these species back
to their oxidised form, in the absence of other cytoplasmic reactions (e.g. glycolysis).
It meant that combining this model with the heart TCA cycle model, without any
further modifications, would have caused the factors influencing the transfer of reduction
potential between the cytosol and mitochondria to be external to the resulting system,
which would have been counterintuitive. This particular observation suggested that the
cytosolic redox couple should be internalised within the system defined by the malate-
aspartate shuttle reactions, by further modifications to this system. It called for the
incorporation of another pathway or a reaction that would dynamically cycle between
the cytosolic NAD and NADH. Therefore, we decided to develop a standalone model of
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the mammalian heart-specific glycolytic pathway and to incorporate into the extended
model. The decision to develop a full glycolytic model instead of including a single-step,
abstracted representation of glycolysis was based on the fact that the solution required
to address this problem had to be relevant to the cardiac physiology and the fact that
most of the required kinetic data in this tissue was already readily available.
Thus the heart integrated TCA cycle model (HRTTCA+) was formed by combining
three standalone models, viz.– the heart TCA cycle model (HRTTCA), the malate-
aspartate shuttle model (HRTMAS), and the heart glycolysis model (HRTGlc). Also,
three sink reactions were added to this extended model in the form of reversible transport
reactions in order to remove the excess pyruvate, cytosolic glutamate and cytosolic
aspartate from the system. As discussed earlier in the heart TCA cycle model chapter
(see, pg. 147), the NADP+ -dependent isocitrate dehydrogenase (IDHb) reaction was
reintroduced into this extended model. Also, certain kinetic parameters were tweaked
during the final optimisation process in order to achieve a stable steady-state solution
for this integrated model of the heart TCA cycle.
This fully extended heart TCA cycle model was analysed in great detail and its
observed pattern of behaviour was studied against the standalone TCA cycle model as
a point of reference. The structural analysis of the heart integrated TCA cycle model
showed that there are 278 elementary modes and 9 enzyme subsets in the model. The
shortest elementary mode describes the futile cycle between IDHa and IDHb and consists
of 5 reactions. The other two relatively shorter modes contain 7 & 11 reactions out of
the possible 37 reactions in this model. The longest elementary modes of this integrated
model contain a total of 30 reactions; which means that a group of 7 reactions do not
participate in these modes. There are 10 such modes in this model, 5 of those are based
on IDHa and the other 5 are their respective IDHb complements, similar to what we
observed earlier in the case of TCA cycle models. All 10 modes utilise glucose as the
sole carbon input and the pyruvate formed as a result of glycolysis feeds into either a
fully functioning TCA cycle with malate-aspartate shuttle or the MDH-deficient TCA
cycle with malate-aspartate shuttle. In all of these ten modes, at least 50% of the
total incoming glucose gets converted to lactate and the rest of it to pyruvate, which
then enters mitochondria to form citrate via the TCA cycle. However, a handful of
these longest elementary modes produce only a fractional amount of ATP that can be
hydrolysed in the cytosol via ATPhyd. Analysis of all 278 elementary modes reveals
that in order to maximise the ATP production in this integrated system, the optimal
number of reactions participating in a given elementary mode must be no less that 28
and no more 29, barring a single exception. However, the solitary exceptional mode
lacks entire glycolysis and produces pyruvate via external lactate, thus allowing the TCA
cycle to function. The elementary mode containing 29 reactions converts glucose to
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pyruvate without any lactate, G6Px (assumed here as an exit from glycolysis to glycogen
synthesis), or α-glycerol 3-phosphate (α-GLYp); resulting in a total of 14.5 molecules of
ATP. Whereas, the elementary mode consisting 28 reactions produces pyruvate from
G6Px (assumed here as an entry into glycolysis via glycogenolysis) without any lactate
or α-GLYp production; thereby resulting in a total of 15 molecules of ATP. Interestingly,
in both these cases, mitochondrial MDH (mMDH) is positive and carries exactly twice
the amount of flux through the TCA cycle or malate-aspartate shuttle.
The 9 enzyme subsets of this integrated model includes 4 subsets in glycolysis, 2 in
the TCA cycle, 2 in malate-aspartate shuttle, and the remaining subset describes the
exchange of excess cytosolic amino acids with external media (i.e. blood). The 4 glycolytic
subsets comprise of glucose entry and phosphorylation via hexokinase, “preparatory”
and “pay-off” phases, and a lactate production subset. The two TCA cycle subsets
include a subset of pyruvate entry into the mitochondria and its conversion to isocitrate
and a subset comprising the decarboxylative reduction of α-ketoglutarate to malate.
Whereas, the two malate-aspartate shuttle enzyme subsets include one containing GATx
and mGOT, while the other containing MOTx, cGOT, and cMDH. The TCA cycle as
well as the glycolytic enzyme subsets of this integrated system are identical to those
observed in the standalone liver TCA cycle model and the mammalian heart-specific
glycolysis model, respectively.
Steady-state analysis of the heart integrated TCA cycle model shows the dynamic
responses of this system to changes in various enzyme activities. For instance, in the
case of increasing ATPhyd activity or the ATP-demand, the model shows higher TCA
cycle activity corresponding to increased amino acid import and higher mGOT/GATx
activity, with comparatively increased amount of lactate production. While several such
interesting steady-state as well as control coefficient distribution scenarios were tested
for this extended model, the detailed analysis and discussion of which remains open
to interpretaion depending on the exact nature of inquiry, since such large metabolic
systems often tend to be highly complex in terms of their analysis.
Therefore in conclusion, the heart integrated TCA cycle model (HRTTCA+) was
successfully created and analysed. The model shows adequate responses aginst changes
in enzyme activities or metabolite concentrations. The heart integrated TCA cycle model
offers several key physiologically relevant end-points against which it can be validated,
some of these end-points include, viz.– blood glucose, blood lactate, blood pyruvate etc.
and yet, the model shows that its function can be enhanced with the help of additional
biochemical pathways, such as the creatine - creatine phosphate shuttle and an enhanced
version of the electron transport chain.
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Appendix A: Differential and Algebraic
Equations for liver TCA cycle models
d[ AcCoAm ]
dt = νPDH − νCS (A.1)
d[ Citm ]
dt = νCS − νACO (A.2)
d[ Isocitm ]
dt = νACO − νIDHa − νIDHb (A.3)
d[αKGm ]
dt = νIDHa + νIDHb − ναKGDH (A.4)
d[ SCoAm ]
dt = ναKGDH − νSCS (A.5)
d[ Sucm ]
dt = νSCS − νSDH (A.6)
d[ Fumm ]
dt = νSDH − νFM (A.7)
d[ Malm ]
dt = νFM − νMDH − νMC (A.8)
d[ OAAm ]
dt = νPC + νMDH − νCS (A.9)
d
[
NAD+m
]
dt = 4 ·νATPsynth − νPDH − νIDHa − ναKGDH − νMDH (A.10)
d[ ATPm ]
dt = 10 ·νATPsynth + νSCS − νPC − νANT (A.11)
d[ ATPc ]
dt = νANT − νATPhyd (A.12)
[ CoAm ] =
[
CoATotm
]
− [ AcCoAm ] − [ SCoAm ] (A.13)
[ NADHm ] = [ NTot ] −
[
NAD+m
]
(A.14)
[ ADPm ] =
[
ATotm
]
− [ ATPm ] (A.15)
[ ADPc ] =
[
ATotc
]
− [ ATPc ] (A.16)
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liver TCA cycle reactions
B.1 Pyruvate Carboxylase
Pyruvate carboxylase (PC) catalyses the following net reaction:
Pyruvate + ATPm + HCO3− −−⇀↽− Oxaloacetate + ADPm + Pim (B.1)
Although acetyl-CoA is not an absolute requirement for catalytic activity of mammalian
PC (McClure et al., 1971), it is an effective allosteric activator of the enzyme. Acetyl-CoA
reduces the apparent Km values of both pyruvate and bicarbonate, but also increases the
average maximal activity by around a factor of five (Ashman et al., 1972; Scrutton, 1974;
Scrutton and White, 1972). At low acetyl-CoA (< 0.25 µM), the Km values of pyruvate
and bicarbonate decrease markedly and PC maximal activity shows little change; whereas,
at concentrations that approach or exceed the apparent Ka of acetyl-CoA (> 0.25 µM)
this pattern is reversed, with changes in maximal activity being more pronounced than
those in the substrate Km values (Scrutton and White, 1972). However, it seems unlikely
that acetyl-CoA is responsible for any significant regulation of PC activity within the
physiological context, since the mitochondrial concentration of acetyl-CoA is at least a
factor of ten higher than the apparent Ka (Kimmich and Rasmussen, 1969). Mg2+ in
excess of ATP also activates PC, by increasing the maximal activity only (Keech and
Barritt, 1967; McClure and Lardy, 1971). In contrast to acetyl-CoA, the mitochondrial
free Mg2+ concentration is in the region of the Ka, and hence this is suggested to
represent an important regulatory interaction (Blair, 1969).
At physiological pyruvate concentration, both ADP and Pi are competitive inhibitors
with respect to ATP (McClure et al., 1971). Ca2+ is also a potent inhibitor, possibly
at least partly through competition with free Mg2+ (Kimmich and Rasmussen, 1969).
However, these interactions have been suggested to have little physiological relevance
(McClure and Lardy, 1971). The mitochondrial concentration of ATP is proposed to
— Ph.D. Thesis by Amar S. Ghaisas — Page 221
Appendix B. B.1. Pyruvate Carboxylase
be sufficient to maintain PC activity, irrespective of small changes in ADP and Pi
concentrations. Furthermore, the Ka for Ca2+ is around 100 times greater than the
mitochondrial Ca2+ concentration, while the free Mg2+ concentration would seem to be
sufficiently high to counteract competitive inhibition by Ca2+. At physiological pH, the
affinity for acetyl-CoA is dependent upon pyruvate concentration; this dependence is
particularly notable at low pyruvate (concentrations less than 0.5 mM) (Scrutton, 1974).
Both ATP and bicarbonate increase the affinity of each other; similarly ADP and Pi
each enhance the binding of the other (McClure et al., 1971).
In liver TCA cycle models, given the complexity of the regulatory interactions of PC,
the inter-dependence of substrate and effector affinities has not been modelled explicitly;
instead, the effects are approximated through use of Km values. However in these models,
the apparent maximal activity of PC is defined as a function of Mg2+ and acetyl-CoA
concentrations; which is determined dynamically through a separate algebraic expression
and substituted into the rate equation during simulation of the model.
PC kinetics are modelled using an extended version of the generic rate equation that
allows for three substrates/ products. Terms for product inhibition by oxaloacetate, ADP
and Pi are included in the expression by default, but additional competitive inhibition
by Ca2+ is not considered, given that this seems unlikely to be physiologically relevant.
νPC =
1
KATPm
(
1+[ADPm]KADPm
)(
1+[Pim]KPim
)+ [ATPm]

×
VPC, app
([
Pyrm
]
· [HCO3-] · [ATPm]−
[OAAm] · [ADPm] · [Pim]
Keq
)

(
KPyrm ·KHCO3−
)
(
1 +
[
Pyrm
]
KPyrm
)1 +
[
HCO3−
]
KHCO3−
+ ( [OAAm]KOAAm
)

(B.2)
Where, VPC, app = VPC,min +
(
VPC,max −VPC,min
)
· α · β (B.3)
and, α = [AcCoAm]
n(
KAcCoAm + [AcCoAm]
)n (B.4)
β =
[
Mg2+
]
KMg2+ +
[
Mg2+
] (B.5)
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B.2 Pyruvate Dehydrogenase
The pyruvate dehydrogenase (PDH) complex catalyses the following net reaction:
Pyruvate + NAD+m + CoAm + H2O−−→Acetyl-CoA + NADHm + CO2 (B.6)
Given the magnitude of the equilibrium constant for the forward reaction (Keq =
1.2e+06 at pH 8.0; Alberty 2003b), this step is treated as irreversible.
PDH activity is regulated through covalent modification, i.e. through phosphoryla-
tion and dephosphorylation by pyruvate dehydrogenase kinase (PDHK) and pyruvate
dehydrogenase phosphatase (PDHP) (Holness and Sugden, 2003). However, as a sim-
plification, the apparent maximal activity of PDH is taken to be constant and these
interactions are not currently represented in the model.
An irreversible form of the generic rate equation, modified to account for three
substrates/ products, is used to represent PDH kinetics. Product inhibition by acetyl-
CoA and NADHm, competitive with respect to CoAm and NADm+, respectively (Tsai
et al., 1973) is considered. CO2 is assumed not to affect the rate of the reaction.
νPDH =
1(
KPyrm +
[
Pyrm
])
×
VPDH
([
Pyrm
]
·
[
NAD+m
]
· [CoAm]
)
KNAD+m
(
1 + [NADHm]KNADHm
)
+
[
NAD+m
]KCoAm
(
1+ [AcCoAm]KAcCoAm
)
+[CoAm]
 (B.7)
B.3 Citrate Synthase
Citrate synthase (CS) catalyses the following net reaction:
Oxaloacetate + Acetyl-CoA + H2O −−⇀↽− Citrate + CoAm (B.8)
Although this step is generally regarded as irreversible, due to a large equilibrium
constant for the forward reaction (Keq = 1.13e+09 at pH 8.0; Alberty 2003b); when con-
sidered as a coupled system with the reaction catalysed by MDH, the overall equilibrium
constant indicates a reversible process (Srere, 1972).
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Succinyl-CoA and ATP are apparently the most significant effectors of purified
rat liver CS, acting as a competitive inhibitors with respect to acetyl-CoA (Shepherd
and Garland, 1969; Smith and Williamson, 1971). At low Mg2+ concentration (<
1 mM), it seems that unchelated ATP is the inhibitor. However, at higher Mg2+
concentrations, such as that within the mitochondrion, the Mg-ATP complex may also
be inhibitory (Shepherd and Garland, 1969). Currently, in liver TCA cycle models, the
Mg2+ concentration is fixed at 0.37 mM (Corkey et al., 1986).
The generic rate equation, modified to include terms representing competitive
inhibition by both succinyl-CoA and Mg-ATP in addition to product inhibition by
citrate, is used to model CS kinetics.
νCS =
1KOAAm
1 +
[
Citm
]
KCitm
+ [OAAm]

×
VCS
[OAAm] · [AcCoAm]−
[
Citm
]
·
[
CoAm
]
Keq

KAcCoAm
1 +
[
SCoAm
]
KSCoAm
+
[
ATPm
]
KATPm
+
[
CoAm
]
KCoAm
+ [AcCoAm]

(B.9)
B.4 Aconitase
Aconitate hydratase (ACO) catalyses the following net reaction:
Citrate −−⇀↽− Isocitrate + H2O (B.10)
A reversible uni-uni rate law (Segel, 1993), with product inhibition by isocitrate, is
used to represent this step.
νACO =
VACO
[Citm ]−
[
Isocitm
]
Keq

KCitm
1 +
[
Isocitm
]
KIsocitm
+ [Citm ]
(B.11)
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B.5 NAD+-Dependent Isocitrate Dehydrogenase
NAD+ -dependent isocitrate dehydrogenase (IDHa) catalyses the following net reaction:
Isocitrate + NAD+m + H2O −−→ α-ketoglutarate + NADHm + CO2 (B.12)
Although the reaction is in principle reversible, due to inadequate binding of both
α-ketoglutarate and CO2, this has not been observed in practice (Plaut, 1970), and
therefore for the purposes of modelling we have considered the step to be effectively
irreversible.
For the activity of IDHa, a low concentration of either Mg2+ (Gabriel and Plaut,
1982), Mn2+ or Co2+ is required, and in fact, Mg-isocitrate is more likely to be the
physiological substrate (Plaut et al., 1974). Since Mg2+ is in excess within the mitochon-
drion, activation by this ion is not explicitly represented in the model. For the heart
enzyme, the binding of isocitrate is cooperative however, under typical mitochondrial
conditions, the Hill coefficient is near unity (Gabriel and Plaut, 1982; Plaut et al., 1974);
whereas, Michaelis-Menton kinetics have been observed for the liver enzyme (Plaut and
Aogaichi, 1968).
Both heart and liver NAD+ -dependent isocitrate dehydrogenase are activated by
ADP, but inhibited by ATP; the former effector reduces the apparent Km for isocitrate,
while the latter is competitive with respect to NADm+ (Chen and Plaut, 1963; Plaut
and Aogaichi, 1968). Some other TCA cycle models have assumed that unchelated
ADP and ATP are the true effectors (Bazil et al., 2010; Kohn et al., 1979a; Wu et al.,
2007). However, on the basis of the available experimental data, it is not possible to
exclude inhibition by chelated ATP (Chen and Plaut, 1963; Plaut and Aogaichi, 1968),
although the Mg-ADP complex is apparently inactive (Plaut et al., 1974). In practice,
the distinction between unchelated and Mg-complexed ADP is relatively unimportant,
since the mitochondrial concentrations are similar (Akerboom et al., 1978; Magnus and
Keizer, 1997). Finally, Ca2+ also binds to mammalian IDHa, having a modest activating
effect within a physiological concentration range (Rutter and Denton, 1988).
NAD+ -dependent isocitrate dehydrogenase kinetics are modelled using a modified,
irreversible form of the generic rate equation. Product inhibition by NADHm is considered,
but α-ketoglutarate and CO2 are assumed to have no influence on reaction rate (Chen
and Plaut, 1963; Plaut and Aogaichi, 1968). The expression also takes into account the
activation of the enzyme by unchelated ADP and Ca2+, as well as competitive inhibition
by the Mg-ATP complex.
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Appendix B. B.6. NADP+ -Dependent Isocitrate Dehy . . .
νIDHa =
1

(
KIsocitm
)n/1 +
[
ADP3−m
]
KADP3−m

1 +
[
Ca2+
]
KCa2+

+ [Isocitm]n

×
VIDHa
(
[Isocitm]n ·
[
NAD+m
])
KNAD+m
(
1 + [ATPm]KATPm
+ [NADHm]KNADHm
)
+
[
NAD+m
] (B.13)
Where,
[
ADP3−m
]
= fADP3−m ·
[
ADPm
]
(B.14)
The conversion factor fADP3−m gives the fraction of total mitochondrial ADP that is
unchelated, and hence ionized (Magnus and Keizer, 1997), and is defined in the supple-
mentary material (see tbl. I.2 on pg. III).
B.6 NADP+-Dependent Isocitrate Dehydrogenase
NADP+ -dependent isocitrate dehydrogenase (IDHb) catalyses the following net reaction:
Isocitrate + NADP+ + H2O −−⇀↽− α-ketoglutarate + NADPH + CO2 (B.15)
Although the NADP+ -dependent enzyme from liver mitochondria represents only 25%
of the cellular complement (Lowenstein, 1967), and is responsible for only 10–12% of
total tissue isocitrate dehydrogenase (IDH) activity, the maximal catalytic capability
is apparently up to 14 times greater than that of the NAD+ -dependent form (Smith
and Plaut, 1979). Considering the apparent irreversibility of the NAD+ -dependent
isocitrate dehydrogenase, Sazanov and Jackson (1994) have proposed the operation of a
substrate cycle in which α-ketoglutarate (αKGm) generated by IDHa is converted back
to isocitrate by IDHb, which thus contributes to regulation of the TCA cycle. Evidence
for the existence of such a cycle has been provided by mass isotopomer distribution
studies in both heart and liver (Comte et al., 1997, 2002; Des Rosiers et al., 1994).
Unlike its NAD+ -associated counterpart, IDHb is not allosteric, but is subject
to product inhibition by both α-ketoglutarate and NADPH, and by either CO2 or
bicarbonate; NADPH is competitive with NADP+, but the reported kinetics of inhibition
by α-ketoglutarate and CO2 are more complex (Uhr et al., 1974). For the purposes of
liver TCA cycle models, α-ketoglutarate is assumed to be competitive with respect to
isocitrate and CO2 is taken to be a non-competitive inhibitor.
The extended, generic rate equation is used to represent NADP+ -dependent isocitrate
dehydrogenase kinetics. The expression includes an additional term representing non-
competitive inhibition by CO2.
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Appendix B. B.7. α-Ketoglutarate Dehydrogenase
νIDHb =
1(
1 + [CO2]KCO2
)
×
VIDHb
(
[Isocitm] ·
[
NADP+
]
− [αKGm] · [NADPH]Keq
)
KIsocitm
(
1+[αKGm]KαKGm
)
+ [Isocitm]
KNADP+
(
1+[NADPH]KNADPH
)
+ [NADP+]
 (B.16)
B.7 α-Ketoglutarate Dehydrogenase
α-ketoglutarate dehydrogenase (α-KGDH) catalyses the following net reaction:
α-ketoglutarate + NAD+m + CoAm + H2O−−→ Succinyl-CoA + NADHm + CO2 (B.17)
Given the magnitude of the equilibrium constant for the forward reaction (Keq =
1.72e+07 at pH 8.0; Alberty 2003b), this step is treated as irreversible.
α-KGDH is activated by both ADP and Ca2+, which independently reduce the
apparent Km for α-ketoglutarate without affecting the maximal rate (McCormack and
Denton, 1979). Conversely, ATP inhibits the enzyme, increasing the apparent Km for
α-ketoglutarate (McCormack and Denton, 1979). The effects of ADP and ATP were
determined in the presence of Mg2+ (McCormack and Denton, 1979). Product inhibition
by succinyl-CoA is competitive with respect to CoAm. Inhibition by NADHm was
originally described as non-competitive (Smith et al., 1974), but has been treated as
competitive in other TCA cycle models (Bazil et al., 2010; Wu et al., 2007). In fact,
latest analysis of the original data (Smith et al., 1974), indicates that competition by
NADHm is mixed with respect to both α-ketoglutarate and NADm+, although competition
between NADm+ and NADHm is the more important component of the inhibition.
α-KGDH kinetics are modelled using an irreversible, modified form of the generic rate
equation that takes into account activation by ADP and Ca2+, competitive inhibition by
ATP and succinyl-CoA, and mixed inhibition by NADHm with respect to NADm+.
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Appendix B. B.8. Succinyl-CoA Synthetase
ναKGDH =
1
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(
1+ [NADHm]KNADHm, c
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(
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(
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)
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(B.18)
B.8 Succinyl-CoA Synthetase
Succinyl-CoA synthetase (SCS) catalyses the following net reaction:
Succinyl-CoA + GDP + Pim −−⇀↽− Succinate + CoAm + GTP (B.19)
SCS kinetics are represented by an extended version of the generic rate equation.
Competitive binding between GTP and Pi has been reported (Cha and Parks, 1964), and
this is represented in addition to product inhibition by succinate and CoAm. Since the
apparent equilibrium constant for the interconversion of adenine and guanine nucleotides
is likely to be close to unity (Alberty, 2003b), ADP and ATP are substituted for GDP
and GTP in the expression.
νSCS =
1
KSCoAm
(
1 + [Sucm]KSucm
)(
1 + [CoAm]KCoAm
)+ [SCoAm]

×
VSCS
(
[SCoAm] · [ADPm] · [Pim]−
[Sucm] · [CoAm] · [ATPm]
Keq
)
(KADPm ·KPim
)
(
1+[ADPm]KADPm
)(
1+[Pim]KPim
)
+
(
[ATPm]
KATPm
)

(B.20)
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Appendix B. B.10. Succinate Dehydrogenase
B.9 Succinate Dehydrogenase
Succinate dehydrogenase (SDH) catalyses the following net reaction:
Succinate + Q −−⇀↽− Fumarate + QH2 (B.21)
The generic rate equation is used to model SDH kinetics. In addition to being subject
to product inhibition by fumarate and QH2, the reaction is inhibited by oxaloacetate,
which is competitive with respect to succinate (Hatefi and Stiggall, 1976).
νSDH =
1KQ
1 +
[
QH2
]
KQH2
 + [Q ]

×
VSDH
[Sucm ] · [Q ] −
[
Fumm
]
·
[
QH2
]
Keq

KSucm
1 +
[
OAAm
]
KOAAm
+
[
Fumm
]
KFumm
 + [Sucm ]

(B.22)
B.10 Fumarase
Fumarate hydratase (FM) catalyses the following net reaction:
Fumarate −−⇀↽− Malate (B.23)
The rate equation used is a reversible uni-uni rate law (Segel, 1993), with product
inhibition by malate.
νFM =
VFM
[Fumm ] −
[
Malm
]
Keq

KFumm
1 +
[
Malm
]
KMalm
 + [Fumm ]
(B.24)
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Appendix B. B.12. Malate Dehydrogenase
B.11 Malate Dehydrogenase
Mitochondrial malate dehydrogenase (MDH) catalyses the following net reaction:
Malate + NAD+m −−⇀↽− Oxaloacetate + NADHm (B.25)
The standard generic rate equation is used for this step, with product inhibition by
oxaloacetate and NADHm.
νMDH =
1KMalm
(
1 + [OAAm ]KOAAm
)
+ [Malm ]

×
VMDH
(
[Malm ] ·
[
NAD+m
]
− [OAAm ] · [NADHm ]Keq
)
KNAD+m
(
1 + [NADHm ]KNADHm
)
+
[
NAD+m
] (B.26)
B.12 Adenine-Nucleotide Translocase
The adenine-nucleotide translocase (ANT) is an ATP/ ADP co-transporter that exchanges
endogenous and exogenous ionized adenine nucleotides across the inner mitochondrial
membrane:
ATP4−m + ADP3−c ←→ ATP4−c + ADP3−m (B.27)
The standard generic rate equation is used for this step.
νANT =
1KADP3−c
1 +
[
ATP4−c
]
KATP4−c
 + [ADP3−c ]

×
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[ATP4−m ] · [ADP3−c ] −
[
ADP3−m
]
·
[
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]
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
KATP4−m
1 +
[
ADP3−m
]
KADP3−m
 + [ATP4−m ]

(B.28)
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Appendix B. B.14. Malate-Phosphate Exchange
Where,
[
ATP4−m
]
= fATP4−m ·
[
ATPm
]
(B.29)
[
ADP3−m
]
= fADP3−m ·
[
ADPm
]
(B.30)
[
ATP4−c
]
= fATP4−c ·
[
ATPc
]
(B.31)
[
ADP3−c
]
= fADP3−c ·
[
ADPc
]
(B.32)
The conversion factors fATP4−m , fADP3−m , fATP4−c and fADP3−c give the fractions of the
respective total adenine nucleotides that are ionized (Magnus and Keizer, 1997), and are
defined in the supplementary material (see tbl. I.2 on pg. III).
B.13 Malate-Phosphate Exchange
The malate carrier (malate-phosphate transporter) (MC) exchanges endogenous and ex-
ogenous malate and inorganic phosphate (Pi) across the inner mitochondrial membrane:
Malm + Pic ←→ Malc + Pim (B.33)
The standard generic rate equation is used for this step.
νMC =
VMC
(
[Malm ] · [Pic ] −
[Pim ] · [Malc ]
Keq
)
KMalm
(
1 + [Pim ]KPim
)
+ [ Malm ]
KPic
(
1 + [Malc ]KMalc
)
+ [ Pic ]
 (B.34)
B.14 ATP Synthesis
ATP synthesis is represented as a simple, single-step process that converts NADHm
generated via the TCA cycle to ATP:
10 ADPm + 10 Pim + 4 NADHm −−→ 10 ATPm + 4 NAD+m (B.35)
The stoichiometry of the process reflects the total number of protons used in the
generation of one molecule of ATP; i.e. by both ATP synthase and Pi import into the
matrix. The process is assumed to be saturable and irreversible, and hence is modelled
with an extended, irreversible form of the generic rate equation.
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Appendix B. B.15. ATP Hydrolysis
νATPsynth =
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(B.36)
B.15 ATP Hydrolysis
Cytosolic ATP demand is modelled as a simple first-order flux:
ATPc −−→ ADPc + Pic (B.37)
νATPhyd = fATPhyd ·
[
ATP4−c
]
(B.38)
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Appendix C: The updated liver TCA
cycle model in ScrumPy format
• Listing C.1. ScrumPy code for the updated liver TCA cycle model. 
1 #### All metabolites are in mM ####
3 #### External metabolites (Model Parameters) ####
5 x_CO2 = 1.63 x_Pyr = 0.2 x_Q = 0.24 x_QH2 = 0.27 x_NADPH = 1.85
6 x_Ca2p = 0.006 x_NADP = 0.31 x_HCO3 = 21.2 x_Malc = 0.47
7 x_Mg2p = 0.37 x_Pim = 8.9 x_Pic = 4.2
9 #### Conserved totals (Model Parameters) ####
11 N_Tot = 2.1 Adn_Totm = 10.4 Adn_Totc = 4.81 CoA_Tot = 2.7
13 #### Internal metabolites (Model Variables) ####
15 AcCoA = 0.33 Cit = 4.42 OAA = 0.00041 IsoCit = 0.28 aKG = 1.57
16 Suc = 1.59 Fum = 0.35 Malm = 1.43 ATPm = 7.53 NADH = N_Tot - NAD
17 NAD = 1.28 ATPc = 4.761 SCoA = 0.48 ADPm = Adn_Totm - ATPm
18 CoA = CoA_Tot - (AcCoA + SCoA) ADPc = Adn_Totc - ATPc
20 #### TCA Cycle Reactions ####
22 #### Pyruvate Dehydrogenase (PDH) ####
23 PDH:
25 x_Pyr + NAD + CoA -> x_CO2 + NADH + AcCoA
27 (V_PDH * x_Pyr * NAD * CoA)/((K_PDH_Pyr + x_Pyr) * (K_PDH_NAD * (1 +
28 NADH/K_PDH_NADH) + NAD) * (K_PDH_CoA * (1 + AcCoA/K_PDH_AcCoA) + CoA))
30 V_PDH=0.648 K_PDH_Pyr=0.01 K_PDH_NAD=0.064 K_PDH_CoA = 0.012
31 K_PDH_NADH=0.044 K_PDH_AcCoA=0.029
33 #### Citrate synthase (CS) ####
34 CS:
36 OAA + AcCoA <> Cit + CoA
38 (V_CS * ((OAA * AcCoA) - ((Cit * CoA)/Keq_CS)))/ ((K_CS_OAA * (1 + Cit
39 /K_CS_Cit) + OAA) * ((K_CS_AcCoA *(1 + (SCoA/K_CS_SCoA)
40 + (ATPm/K_CS_ATPm) + (CoA/K_CS_CoA)))+ AcCoA))
42 V_CS=13.75 Keq_CS=1.13e+09 K_CS_OAA=0.002 K_CS_Cit=1.6
43 K_CS_AcCoA=0.016 K_CS_SCoA=0.14 K_CS_ATPm=0.55 K_CS_CoA=0.067
45 #### Aconitase (ACO) ####
46 ACO:
48 Cit <> IsoCit
50 (V_ACO*(Cit-(IsoCit/Keq_ACO)))/((K_ACO_Cit*(1+IsoCit/K_ACO_IsoCit))+Cit)
52 V_ACO=1.674 Keq_ACO=0.0685 K_ACO_Cit=0.62 K_ACO_IsoCit=0.2
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54 #### NAD+-dependent Isocitrate Dehydrogenase (IDHa) ####
55 IDHa:
57 IsoCit + NAD -> aKG + NADH + x_CO2
59 (V_IDHa*(IsoCit**n_IDHa)*NAD)/((((K_IDHa_IsoCit**n_IDHa)/((1+(ADPm
60 *f_IDHa_ADPm)/K_IDHa_ADPm)*(1 + x_Ca2p/K_IDHa_Ca2p)))+(IsoCit**n_IDHa))
61 *((K_IDHa_NAD*(1+(ATPm/K_IDHa_ATPm)+(NADH /K_IDHa_NADH)))+NAD))
63 V_IDHa=1.58 n_IDHa=1 K_IDHa_IsoCit=0.56 f_IDHa_ADPm=0.818
64 K_IDHa_ADPm=0.05 K_IDHa_Ca2p=0.00112 K_IDHa_NAD=0.07
65 K_IDHa_ATPm=0.118 K_IDHa_NADH=0.029
67 #### NADP+-dependent Isocitrate Dehydrogenase (IDHb) ####
68 IDHb:
70 IsoCit + x_NADP <> aKG + x_NADPH + x_CO2
72 (V_IDHb * ((IsoCit * x_NADP) - (aKG * x_NADPH/Keq_IDHb)))
73 /(((K_IDHb_IsoCit * (1 + aKG/K_IDHb_aKG)) + IsoCit) * ((K_IDHb_NADP
74 * (1 + x_NADPH/K_IDHb_NADPH)) + x_NADP) * (1 + x_CO2/K_IDHb_CO2))
76 V_IDHb=5.4188 Keq_IDHb=43.8 K_IDHb_CO2=3.8 K_IDHb_aKG=0.44
77 K_IDHb_NADP=0.0056 K_IDHb_NADPH=0.0056 K_IDHb_IsoCit=0.0084
79 #### alpha-Ketoglutarate Dehydrogenase (aKGDH) ####
80 aKGDH:
82 aKG + NAD + CoA -> x_CO2 + NADH + SCoA
84 ((V_aKGDH * aKG * NAD * CoA)/(1 + NADH/K_NADH_u))/((((K_aKGDH_aKG
85 * (1 + ATPm/K_aKGDH_ATPm))/((1 + ADPm/K_aKGDH_ADPm) * (1 + x_Ca2p
86 /K_aKGDH_Ca2p))) + aKG) * (((K_aKGDH_NAD * (1 + NADH/K_NADH_c))/(1 +
87 NADH/K_NADH_u)) + NAD) * ((K_aKGDH_CoA * (1 + SCoA/K_aKGDH_SCoA)) + CoA))
89 V_aKGDH=27 K_NADH_u=0.0258 K_aKGDH_aKG=0.126 K_aKGDH_ADPm=0.1
90 K_aKGDH_Ca2p=0.0012 K_aKGDH_ATPm=0.1 K_aKGDH_NAD=0.01932
91 K_NADH_c=0.00354 K_aKGDH_CoA=0.025 K_aKGDH_SCoA=0.0069
93 #### Succinyl-CoA synthetase (SCS) ####
94 SCS:
96 SCoA + ADPm + x_Pim <> Suc + CoA + ATPm
98 (V_SCS*((SCoA*ADPm*x_Pim)-((Suc*CoA*ATPm)/Keq_SCS)))/(((K_SCS_SCoA*(1+
99 Suc/K_SCS_Suc)*(1+CoA/K_SCS_CoA))+SCoA)*(K_SCS_ADPm*K_SCS_Pim)*(((1+
100 ADPm/K_SCS_ADPm)*(1+x_Pim/K_SCS_Pim))+(ATPm/K_SCS_ATPm)))
102 V_SCS=4.2 Keq_SCS=1.3 K_SCS_SCoA=0.011 K_SCS_Suc=70
103 K_SCS_CoA=0.02 K_SCS_ADPm=0.002 K_SCS_Pim=0.15 K_SCS_ATPm=0.005
105 #### Succinate Dehydrogenase (SDH) ####
106 SDH:
108 Suc + x_Q <> Fum + x_QH2
110 (V_SDH*((Suc*x_Q)-((Fum*x_QH2)/Keq_SDH)))/((K_SDH_Suc*(1+(OAA/K_SDH_OAA)
111 +(Fum/K_SDH_Fum))+Suc)*((K_SDH_Q*(1+x_QH2/K_SDH_QH2))+x_Q))
113 V_SDH=0.48 Keq_SDH=1.01 K_SDH_Suc=0.13 K_SDH_OAA=0.0015
114 K_SDH_Fum=1.3 K_SDH_Q=0.0003 K_SDH_QH2=0.0015
116 ####
— Ph.D. Thesis by Amar S. Ghaisas — Page 234
118 #### Fumarase (FM) ####
119 FM:
121 Fum <> Malm
123 (V_FM * (Fum - Malm/Keq_FM))/((K_FM_Fum * (1 + Malm/K_FM_Malm)) + Fum)
125 V_FM=7.696 Keq_FM=4.34 K_FM_Fum=0.015 K_FM_Malm=0.18
127 #### Malate Dehydrogenase (MDH) ####
128 MDH:
130 Malm + NAD <> OAA + NADH
132 (V_MDH * ((Malm * NAD) - ((OAA * NADH)/Keq_MDH)))/(((K_MDH_Malm * (1 +
133 OAA/K_MDH_OAA)) + Malm) * ((K_MDH_NAD * (1 + NADH/K_MDH_NADH)) + NAD))
135 V_MDH=26.752 Keq_MDH=0.000125 K_MDH_Malm=1.1 K_MDH_NAD=0.114
136 K_MDH_OAA=0.0055 K_MDH_NADH=0.005
138 #### ATP synthesis (ATPsynth) ####
139 ATPsynth:
141 4 NADH + 10 ADPm + 10 x_Pim -> 4 NAD + 10 ATPm
143 (V_ATPsynth * NADH * ADPm * x_Pim)/(((K_ATPsynth_NADH * (1 + NAD
144 /K_ATPsynth_NAD)) + NADH) * (K_ATPsynth_ADPm * K_ATPsynth_Pim) * (((1 +
145 ADPm/K_ATPsynth_ADPm)*(1+x_Pim/K_ATPsynth_Pim))+(ATPm/K_ATPsynth_ATPm)))
147 V_ATPsynth=0.886637 K_ATPsynth_NADH=0.88 K_ATPsynth_NAD=1.2
148 K_ATPsynth_ADPm=3.1 K_ATPsynth_Pim=8.9 K_ATPsynth_ATPm=7.3
150 #### Adenine Nucleotide Translocase (ANT) ####
151 ANT:
153 ATPm + ADPc <> ADPm + ATPc
155 (V_ANT*((f_ANT_ATPm*ATPm*f_ANT_ADPc*ADPc)-((f_ANT_ATPm*ADPm*f_ANT_ATPc
156 *ATPc)/Keq_ANT)))/(((K_ANT_ATPm*(1+((f_ANT_ADPm*ADPm)/K_ANT_ADPm)))
157 +(f_ANT_ATPm*ATPm))*((K_ANT_ADPc*(1+((f_ANT_ATPc * ATPc)/K_ANT_ATPc)))
158 +(f_ANT_ADPc * ADPc)))
160 V_ANT=1.52646 f_ANT_ATPm=0.0526 f_ANT_ADPc=0.45 Keq_ANT=118
161 f_ANT_ADPm=0.818 f_ANT_ATPc=0.05 K_ANT_ATPm=0.03 K_ANT_ADPm=0.02
162 K_ANT_ADPc=0.02 K_ANT_ATPc=0.03
164 #### ATP Hydrolysis (ATPhyd) ####
165 ATPhyd:
167 ATPc -> ADPc + x_Pic
169 V_ATPhyd * ATPc
171 V_ATPhyd = 0.00769203
173 #### Malate-Phosphate transporter (Malate Carrier) (MC) ####
174 MC:
176 Malm + x_Pic <> x_Pim + x_Malc
178 (V_MC * ((Malm * x_Pic) - ((x_Pim * x_Malc)/Keq_MC)))/(((K_MC_Malm * (1 +
179 x_Pim/K_MC_Pim)) + Malm) * ((K_MC_Pic * (1 + x_Malc/K_MC_Malc)) + x_Pic))
181 V_MC=23.2574 Keq_MC=1.52 K_MC_Malm=0.9 K_MC_Pim=0.72
182 K_MC_Pic=0.76 K_MC_Malc=0.2
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184 #### Pyruvate Carboxylase (PC) ####
185 PC:
187 x_Pyr + x_HCO3 + ATPm <> OAA + ADPm + x_Pim
189 V_coeff*((Vmin_PC+(Vmax_PC-Vmin_PC)*(AcCoA**n_PC/(Km_AcCoA_PC + AcCoA)
190 **n_PC)*(x_Mg2p/(x_Mg2p+Km_Mg2p_PC))) #---- (see, [1] given below)
191 *((x_Pyr*x_HCO3*ATPm)-((OAA*ADPm*x_Pim)/Keq_PC))/((K_PC_Pyr*K_PC_HCO3)
192 *(((1+x_Pyr/K_PC_Pyr)*(1+x_HCO3/K_PC_HCO3))+(OAA/K_PC_OAA))
193 *((K_PC_ATPm*(1+ADPm/K_PC_ADPm)*(1+x_Pim/K_PC_Pim))+ATPm)))
195 n_PC=2 Keq_PC=10.98 K_PC_Pyr=0.14 K_PC_HCO3=3 K_PC_OAA=0.1
196 K_PC_ATPm=0.134 K_PC_ADPm=0.35 K_PC_Pim=6 Vmin_PC=1.02
197 Vmax_PC=Vmin_PC*5 Km_AcCoA_PC=0.06 Km_Mg2p_PC=0.5 V_coeff=1.0
199 # ‘V_coeff’ is only a rate multiplication factor, as it multiplies the entire
200 # rate equation by 1. For analyses, to change the maximal rate of PC, the
201 # user must vary the value of ‘V_coeff’ within a permissible range.
203 ########
205 # A function that dynamically calculates the value of ‘Vapp_PC’ at model
206 # simulation
208 # Vmin_PC+(Vmax_PC-Vmin_PC)*(AcCoA**n_PC/(Km_AcCoA_PC+AcCoA)**n_PC)
209 # *(x_Mg2p/(x_Mg2p+Km_Mg2p_PC)) = Vapp_PC #--------- [1]
211 # Vmin_PC = 1.02
213 # Vmax_PC = Vmin_PC * 5
215 # Vm_AcCoA = (AcCoA**n_PC) / ((Km_AcCoA_PC + AcCoA)**n_PC)
217 # Vm_Mg2p = (x_Mg2p) /(x_Mg2p + Km_Mg2p_PC)
219 # Km_AcCoA_PC = 0.06
220 # Km_Mg2p_PC = 0.5
222 # Vapp_PC = 1.02 +(4.08 * (AcCoA**2 / (Km_AcCoA_PC + AcCoA)**2)
223 # * (x_Mg2p /(x_Mg2p + Km_Mg2p_PC)))
225 ######## 
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Appendix D: A Python function to
compute the overall variability in the
apparent maximal activity of PC (V PCapp)
As discussed earlier on pg. 28, in order to produce a single dataset/ plot comprising all
possible variations of the V PCapp value, we designed a specifically-modified Python function.
It can compute the value of V PCapp within a given range of enzyme activity/ metabolite
concentration, between two fixed points (a ‘low’ & a ‘high’ point) that are ‘X’ multiples
of the original activity/ concentration; and it performs separate simulations for every
key enzyme or metabolite.
Therefore in this function, for every key enzyme or metabolite, its maximal activity/
metabolite concentration was changed from 1/5th (0.2X) the initial model value (X)
to 5–times the initial model value (5X). For example, in the liver TCA cycle model,
the initial model value of PDH maximal activity is 0.65 mM/sec (X). So, using this
method, PDH maximal activity was changed ranging from 0.13 (0.2X) to 3.25 mM/sec
(5X). Thus, in a separate simulation for every key enzyme or metabolite, the value of
V PCapp was computed against increasing enzyme activity/ metabolite concentration that
ranged between 0.2X and 5X. When the data from each simulation was combined in a
common dataset, a ‘dummy range’ from 1 to 50 arbitrary units was created specifically
for plotting purposes; thereby creating a dataset that contained a single column of the
dummy range and a column each for the computed V PCapp values against key TCA cycle
enzyme activities/ metabolite concentrations.
Therefore, if we assume a dataset with 50 rows (i0 to i49) & 4 columns (j0 to j3) :
• j0 : a column for ‘dummy range’ (X-axis)
• j1 : a column for V PCapp values against PDH maximal activity (Y-axis)
• j2 : a column for V PCapp values against ATPsynth maximal activity (Y-axis)
• j3 : a column for V PCapp values against some other key enzyme activity (Y-axis)
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Then in this dataset,
• i0 j0 : a point on X-axis at enzyme activity = 0.2X (= 1 in arbitrary units)
(where, V PDHmax = 0.13 mM/sec or V
ATPsynth
max = 0.18 mM/sec)
• i49 j0 : a point on X-axis at enzyme activity = 5X (= 50 in arbitrary units)
(where, V PDHmax = 3.25 mM/sec or V
ATPsynth
max = 4.5 mM/sec)
Also,
• i0 j1 : a point on Y-axis representing the value of V PCapp computed at,
V PDHmax = 0.2X = 0.2 × 0.65 = 0.13 mM/sec
• i49 j1 : a point on Y-axis representing the value of V PCapp computed at,
V PDHmax = 5X = 5 × 0.65 = 3.25 mM/sec
Similarly, i0 j2 & i49 j2 can be explained w.r.t. V
ATPsynth
max and i0 j3 & i49 j3 can be
explained w.r.t. some other key enzyme activity/ metabolite concentration.
Thus, in a single plot, we were able to combine all computed variations in the
apparent maximal activity of PC against change in key TCA cycle enzyme activities/
metabolite concentrations.
Listing D.1 shows the original code for this function implemented in Python.
• Listing D.1. A Python code for computing the V PCapp variability. 
1 from Data import DataSets# Map parameter names to the initial model values
3 InitVals = {"V_PDH":(0.65),"V_aKGDH":(27),"x_Pyr":(0.2),"x_Mg2p":(0.37)}
5 def StepScan(m, axis=InitVals, PName="V_PDH", Model=
6 "_PCwt_LVRv6", Xval=5, nP=100, Tincr=100, SimT=500, Tolr=1.0E-07):
8 nSt = nP-1 # Number of divisions to be made of the given range
9 m.SSTol = Tolr # Set the steady-state tolerance level
11 InitState = m.GetState() # Fetch initial state in ‘InitState’
13 m.Simulate(Tincr,SimT) # Time-simulation.
14 m.FindSS() # Steady-state search
15 m.IsOK() # Check the steady-state validity
16 ssState = m.GetState() # Fetch initial steady-state in ‘ssState’
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18 m.SetFromState(InitState) # Load the values stored in ‘InitState’
20 Pini = axis.get(PName) # Fetch "init" value for selected parameter
21 Plow = Pini/Xval # Calc. "low" value for selected parameter
22 Phi = Pini*Xval # Calc. "high" value for selected parameter
23 incr = (Phi - Plow)/nSt # Calculate the increment size
25 print "Scanning x-axis: ", PName, "with : Xlow at - ", Plow,
26 " and Xhi at - ", Phi, "\n"
28 ds = m.NewDataSet(UpdateIfNotOK="Zero") # Define a new, empty dataset
29 tmp = DataSets.DataSet() # Define another empty dataset.
30 dout = [] # A list to store "VappPC" values
32 m.SetFromState(ssState) # Load the values stored in ‘ssState’
33 Pstart = Plow - incr
34 m[PName] = Pstart # Re-initiate the parameter’s value
36 print "Starting the scan from Steady state. \n"
37 print "Initialized the model value of ", PName, " at ", Pstart, "\n"
39 FILE = PName + "_VappPCvalScn_LowHiXval_" + str(Xval) + "_Frm_" +
40 str(Plow) + "_To_" + str(Phi) + Model + ".txt"
42 for n in range(nP): # Start the "for-loop"
43 m[PName] += incr # Increment the value of PName
44 m.FindSS() # Steady-state search
45 if not m.IsOK(): # If "valid" SS = false, pre-simulate
46 m.Simulate(Tincr, SimT) # Pre-simulation to help find SS
47 m.FindSS() # Steady-state search
48 if m.IsOK(): # If "valid" SS = true:
50 Vapp_PC = m["Vmin_PC"] +(m["Vmax_PC"] - m["Vmin_PC"])
51 * (m["AcCoA"]**m["n_PC"] / (m["Km_AcCoA_PC"] + m["AcCoA"])
52 **m["n_PC"]) * (m["x_Mg2p"] /(m["x_Mg2p"] + m["Km_Mg2p_PC"]))
54 # "VappPC" function as defined in the model
56 dout.append(Vapp_PC) # Add the calc. "VappPC" value to list
57 ds.Update() # Update the empty dataset {ds}
58 else: # else, do nothing & exit loop
60 ds.MakeFirstCol(PName) # Manipulate {ds} as needed
61 ds.DelCol(1)
63 tmp.NewCol(ds.GetCol(0), PName) # Add info. to other dataset from {ds}
64 tmp.NewCol(dout, "Vapp_PC") # Add the list of "VappPC" values
66 tmp.WriteFile(FILE) # Save the dataset
68 m.SetFromState(InitState) # Reload the values from ‘InitState’
70 print "Initial state restored with [SetFromState]. \n"
71 print "Data saved in : ", FILE, "\n" 
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Appendix E: Differential and Rate
equations: heart TCA cycle model
E.1 Differential equations for the heart TCA cycle model
As mentioned in the heart TCA cycle model chapter, only those Differential equations
that are different between the heart & liver-specific TCA cycle models are shown here.
d[ Isocitm ]
dt = νACO − νIDHa (E.1)
d[αKGm ]
dt = νIDHa − ναKGDH − ναKGexp (E.2)
d[ Malm ]
dt = νFM − νMDH (E.3)
d[ OAAm ]
dt = νMDH − νCS (E.4)
d[ ATPm ]
dt = 10 ·νATPsynth + νSCS − νANT (E.5)
E.2 Rate equations for the heart TCA cycle model
As mentioned in the heart TCA cycle model chapter, details for only the newly added
α-ketoglutarate transporter reaction (α-KGexp) are shown here.
E.2.1 α-ketoglutarate transporter
α-ketoglutarate transporter (α-KGexp) catalyses the following net reaction:
αKGm −−⇀↽− αKGc (E.6)
A reversible uni-uni rate law (Segel, 1993) is used to represent this step.
ναKGexp = VαKGexp
[αKGm ]−
[
αKGc
]
Keq
 (E.7)
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Appendix F: The heart TCA cycle
model in ScrumPy format
• Listing F.1. ScrumPy code for the heart TCA cycle model. 
1 #### All metabolites are in mM ####
3 #### External metabolites (Model Parameters) ####
5 x_CO2 = 1.63 x_Pyr = 0.2 x_Q = 0.24 x_QH2 = 0.27 x_Ca2p = 0.006
6 x_aKGc = 0.006 x_Pim = 8.9 x_Pic = 4.2
8 #### Internal metabolites (Model Variables) ####
10 AcCoA = 0.12947 Cit = 1.01379 OAAm = 0.034 IsoCit = 0.067586
11 Suc = 1.3 Fum = 0.026 Malm = 1.88 ATPm = 7.53 NADHm = 0.129
12 aKGm = 0.34 NADm = 0.56 ATPc = 4.761 SCoA = 0.066
13 CoA = 0.0535 ADPc = 0.049 ADPm = 2.87
15 #### TCA Cycle Reactions ####
17 #### Pyruvate Dehydrogenase (PDH) ####
18 PDH:
20 x_Pyr + NADm + CoA -> x_CO2 + NADHm + AcCoA
22 (V_PDH * x_Pyr * NADm * CoA)/((K_PDH_Pyr + x_Pyr) * (K_PDH_NADm * (1 +
23 NADHm/K_PDH_NADHm) + NADm) * (K_PDH_CoA * (1 + AcCoA/K_PDH_AcCoA) + CoA))
25 V_PDH=0.1885 K_PDH_Pyr=0.028 K_PDH_NADm=0.0607 K_PDH_CoA =
0.006
26 K_PDH_NADHm=0.044 K_PDH_AcCoA=0.029
28 #### Citrate synthase (CS) ####
29 CS:
31 OAAm + AcCoA <> Cit + CoA
33 (V_CS * ((OAAm * AcCoA) - ((Cit * CoA)/Keq_CS)))/ ((K_CS_OAAm * (1 + Cit
34 /K_CS_Cit) + OAAm) * ((K_CS_AcCoA *(1 + (SCoA/K_CS_SCoA)
35 + (ATPm/K_CS_ATPm) + (CoA/K_CS_CoA)))+ AcCoA))
37 V_CS=2.5433 Keq_CS=1.01e+06 K_CS_OAAm=0.005 K_CS_Cit=1.6
38 K_CS_AcCoA=0.005 K_CS_SCoA=0.13 K_CS_ATPm=0.7 K_CS_CoA=0.067
40 #### Aconitase (ACO) ####
41 ACO:
43 Cit <> IsoCit
45 (V_ACO*(Cit-(IsoCit/Keq_ACO)))/((K_ACO_Cit*(1+IsoCit/K_ACO_IsoCit))+Cit)
47 V_ACO=2.27 Keq_ACO=0.0685 K_ACO_Cit=0.62 K_ACO_IsoCit=0.2
49 ####
50 ####
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52 #### NAD+-dependent Isocitrate Dehydrogenase (IDHa) ####
53 IDHa:
55 IsoCit + NADm -> aKGm + NADHm + x_CO2
57 (V_IDHa*(IsoCit**n_IDHa)*NADm)/((((K_IDHa_IsoCit**n_IDHa)/((1+(ADPm
58 *f_IDHa_ADPm)/K_IDHa_ADPm)*(1 + x_Ca2p/K_IDHa_Ca2p)))+(IsoCit**n_IDHa))
59 *((K_IDHa_NADm*(1+(ATPm/K_IDHa_ATPm)+(NADHm /K_IDHa_NADHm)))+NADm))
61 V_IDHa=1.371 n_IDHa=2.7 K_IDHa_IsoCit=0.557 f_IDHa_ADPm=0.818
62 K_IDHa_ADPm=0.05 K_IDHa_Ca2p=0.00112 K_IDHa_NADm=0.074
63 K_IDHa_ATPm=0.091 K_IDHa_NADHm=0.029
65 #### alpha-Ketoglutarate Dehydrogenase (aKGDH) ####
66 aKGDH:
68 aKGm + NADm + CoA -> x_CO2 + NADHm + SCoA
70 ((V_aKGDH * aKGm * NADm * CoA)/(1 + NADHm/K_NADHm_u))/((((K_aKGDH_aKGm
71 * (1 + ATPm/K_aKGDH_ATPm))/((1 + ADPm/K_aKGDH_ADPm) * (1 + x_Ca2p
72 /K_aKGDH_Ca2p))) + aKGm) * (((K_aKGDH_NADm * (1 + NADHm/K_NADHm_c))/(1 +
73 NADHm/K_NADHm_u)) + NADm) * ((K_aKGDH_CoA * (1 + SCoA/K_aKGDH_SCoA)) +
CoA))
75 V_aKGDH=7.4426 K_NADHm_u=0.0258 K_aKGDH_aKGm=0.08
K_aKGDH_ADPm=0.1
76 K_aKGDH_Ca2p=0.0012 K_aKGDH_ATPm=0.1 K_aKGDH_NADm=0.01932
77 K_NADHm_c=0.00354 K_aKGDH_CoA=0.025 K_aKGDH_SCoA=0.0069
79 #### Succinyl-CoA synthetase (SCS) ####
80 SCS:
82 SCoA + ADPm + x_Pim <> Suc + CoA + ATPm
84 (V_SCS*((SCoA*ADPm*x_Pim)-((Suc*CoA*ATPm)/Keq_SCS)))/(((K_SCS_SCoA*(1+
85 Suc/K_SCS_Suc)*(1+CoA/K_SCS_CoA))+SCoA)*(K_SCS_ADPm*K_SCS_Pim)*(((1+
86 ADPm/K_SCS_ADPm)*(1+x_Pim/K_SCS_Pim))+(ATPm/K_SCS_ATPm)))
88 V_SCS=3.1082 Keq_SCS=0.78 K_SCS_SCoA=0.011 K_SCS_Suc=70
89 K_SCS_CoA=0.02 K_SCS_ADPm=0.002 K_SCS_Pim=0.15 K_SCS_ATPm=0.005
91 #### Succinate Dehydrogenase (SDH) ####
92 SDH:
94 Suc + x_Q <> Fum + x_QH2
96 (V_SDH*((Suc*x_Q)-((Fum*x_QH2)/Keq_SDH)))/((K_SDH_Suc*(1+(OAAm/K_SDH_OAAm
)
97 +(Fum/K_SDH_Fum))+Suc)*((K_SDH_Q*(1+x_QH2/K_SDH_QH2))+x_Q))
99 V_SDH=0.4792 Keq_SDH=1.01 K_SDH_Suc=0.13 K_SDH_OAAm=0.0015
100 K_SDH_Fum=1.3 K_SDH_Q=0.0003 K_SDH_QH2=0.0015
102 #### Fumarase (FM) ####
103 FM:
105 Fum <> Malm
107 (V_FM * (Fum - Malm/Keq_FM))/((K_FM_Fum * (1 + Malm/K_FM_Malm)) + Fum)
109 V_FM=7.9252 Keq_FM=4.34 K_FM_Fum=0.00174 K_FM_Malm=0.00379
111 ####
112 ####
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114 #### Malate Dehydrogenase (mMDH) ####
115 mMDH:
117 Malm + NADm <> OAAm + NADHm
119 (V_mMDH * ((Malm * NADm) - ((OAAm * NADHm)/Keq_mMDH)))/(((K_mMDH_Malm *
(1 +
120 OAAm/K_mMDH_OAAm)) + Malm) * ((K_mMDH_NADm * (1 + NADHm/K_mMDH_NADHm)) +
NADm))
122 V_mMDH=1.0266668 Keq_mMDH=0.000023 K_mMDH_Malm=1.1
K_mMDH_NADm=0.3
123 K_mMDH_OAAm=0.0055 K_mMDH_NADHm=0.005
125 #### ATP synthesis (ATPsynth) ####
126 ATPsynth:
128 4 NADHm + 10 ADPm + 10 x_Pim -> 4 NADm + 10 ATPm
130 (V_ATPsynth * NADHm * ADPm * x_Pim)/(((K_ATPsynth_NADHm * (1 + NADm
131 /K_ATPsynth_NADm)) + NADHm) * (K_ATPsynth_ADPm * K_ATPsynth_Pim) * (((1 +
132 ADPm/K_ATPsynth_ADPm)*(1+x_Pim/K_ATPsynth_Pim))+(ATPm/K_ATPsynth_ATPm)))
134 V_ATPsynth=0.886637 K_ATPsynth_NADHm=0.88 K_ATPsynth_NADm=1.2
135 K_ATPsynth_ADPm=3.1 K_ATPsynth_Pim=8.9 K_ATPsynth_ATPm=7.3
137 #### Adenine Nucleotide Translocase (ANT) ####
138 ANT:
140 ATPm + ADPc <> ADPm + ATPc
142 (V_ANT*((f_ANT_ATPm*ATPm*f_ANT_ADPc*ADPc)-((f_ANT_ATPm*ADPm*f_ANT_ATPc
143 *ATPc)/Keq_ANT)))/(((K_ANT_ATPm*(1+((f_ANT_ADPm*ADPm)/K_ANT_ADPm)))
144 +(f_ANT_ATPm*ATPm))*((K_ANT_ADPc*(1+((f_ANT_ATPc * ATPc)/K_ANT_ATPc)))
145 +(f_ANT_ADPc * ADPc)))
147 V_ANT=1.52646 f_ANT_ATPm=0.0526 f_ANT_ADPc=0.45 Keq_ANT=118
148 f_ANT_ADPm=0.818 f_ANT_ATPc=0.05 K_ANT_ATPm=0.03 K_ANT_ADPm=0.02
149 K_ANT_ADPc=0.02 K_ANT_ATPc=0.03
151 #### ATP Hydrolysis (ATPhyd) ####
152 ATPhyd:
154 ATPc -> ADPc + x_Pic
156 V_ATPhyd * ATPc
158 V_ATPhyd = 0.01 #ATP demand at rest (Low)
160 ## V_ATPhyd = 0.10167 #ATP demand (Moderate)
161 ## V_ATPhyd = 0.97333 #ATP demand during exercise (High)
162 ## V_ATPhyd = 5.0 #ATP demand (Hypothetical Test!) (Overload)
164 ## These values are for Rabbit skeletal muscle from PMID: 12220081.
166 #### alpha-Ketoglutarate transporter (aKG_exp) ####
167 aKGmFlush:
169 aKGm <> x_aKGc
171 V_aKGmFlush * (aKGm - (x_aKGc/Keq_aKGmFlush))
173 V_aKGmFlush = 1.0 Keq_aKGmFlush = 1.0 
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Appendix G: The Malate-Aspartate
shuttle model in ScrumPy format
• Listing G.1. ScrumPy code for the Malate-Aspartate shuttle model. 
1 #### All metabolites are in mM ####
3 #### External metabolites (Model Parameters) ####
5 x_Pim = 8.9 x_Pic = 4.2 x_NADHc = 0.00255 x_NADtot = 1.03755
6 x_NADc = x_NADtot - x_NADHc
8 #### Internal metabolites (Model Variables) ####
10 NADm = 0.56 NADHm = 0.129 ATPm = 7.53 ADPm = 2.87
11 Aspc = 3.42 Glutc = 6.78 Malc = 0.024 aKGc = 0.004 OAAc = 0.002
12 Malm = 1.88 aKGm = 0.34 Aspm = 1.564 Glutm = 2.5
13 OAAm = 0.034 ATPc = 4.761 ADPc = 0.049
15 #### TCA Cycle Reactions ####
17 #### mitochondrial malate dehydrogenase (mMDH) ####
18 mMDH:
20 Malm + NADm <> OAAm + NADHm
22 (V_mMDH * ((Malm * NADm) - ((OAAm * NADHm)/Keq_mMDH)))/(((K_mMDH_Malm *
23 (1 + OAAm/K_mMDH_OAAm)) + Malm) * ((K_mMDH_NADm * (1 + NADHm
24 /K_mMDH_NADHm)) + NADm))
26 V_mMDH = 25.66667 Keq_mMDH = 0.000023 K_mMDH_Malm = 1.1
27 K_mMDH_OAAm = 0.0055 K_mMDH_NADm = 0.3 K_mMDH_NADHm = 0.005
29 #### ATP synthesis (ATPsynth) ####
30 ATPsynth:
32 4 NADHm + 10 ADPm + 10 x_Pim -> 4 NADm + 10 ATPm
34 (V_ATPsynth * NADHm * ADPm * x_Pim)/(((K_ATPsynth_NADHm * (1 + NADm
35 /K_ATPsynth_NADm)) + NADHm) * (K_ATPsynth_ADPm * K_ATPsynth_Pim) * (((1 +
36 ADPm/K_ATPsynth_ADPm)*(1+x_Pim/K_ATPsynth_Pim))+(ATPm/K_ATPsynth_ATPm)))
38 V_ATPsynth=0.886637 K_ATPsynth_NADHm=0.88 K_ATPsynth_NADm=1.2
39 K_ATPsynth_ADPm=3.1 K_ATPsynth_Pim=8.9 K_ATPsynth_ATPm=7.3
41 #### Adenine Nucleotide Translocase (ANT) ####
42 ANT:
44 ATPm + ADPc <> ADPm + ATPc
46 (V_ANT*((f_ANT_ATPm*ATPm*f_ANT_ADPc*ADPc)-((f_ANT_ATPm*ADPm*f_ANT_ATPc
47 *ATPc)/Keq_ANT)))/(((K_ANT_ATPm*(1+((f_ANT_ADPm*ADPm)/K_ANT_ADPm)))
48 +(f_ANT_ATPm*ATPm))*((K_ANT_ADPc*(1+((f_ANT_ATPc * ATPc)/K_ANT_ATPc)))
49 +(f_ANT_ADPc * ADPc)))
51 V_ANT=1.52646/100 f_ANT_ATPm=0.0526 f_ANT_ADPc=0.45 Keq_ANT=118
52 f_ANT_ADPm=0.818 f_ANT_ATPc=0.05 K_ANT_ATPm=0.03 K_ANT_ADPm=0.02
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53 K_ANT_ADPc=0.02 K_ANT_ATPc=0.03
55 #### ATP Hydrolysis (ATPhyd) ####
56 ATPhyd:
58 ATPc -> ADPc + x_Pic
60 V_ATPhyd * ATPc
62 V_ATPhyd = 0.10167 #ATP demand (Moderate)
64 ## V_ATPhyd = 0.01 #ATP demand at rest (Low)
65 ## V_ATPhyd = 0.97333 #ATP demand during exercise (High)
66 ## V_ATPhyd = 5.0 #ATP demand (Hypothetical Test!) (Overload)
68 ## These values are for Rabbit skeletal muscle from PMID: 12220081.
70 #### Malate-Aspartate Shuttle (MAS) ####
72 #### glutamate-aspartate transporter (GATx) ####
73 GATx:
75 Glutc + Aspm <> Glutm + Aspc
77 (V_GATx * ((Aspm * Glutc) - ((Aspc * Glutm)/Keq_GATx)))/
78 (((Km_GATx_Aspm * (1 + (Glutm / Km_GATx_Glutm))) + Aspm)
79 *((Km_GATx_Glutc * (1 + (Aspc /Km_GATx_Aspc))) + Glutc))
81 V_GATx = 5.0E-01 Keq_GATx = 118 Km_GATx_Aspm = 0.055
82 Km_GATx_Glutm = 0.5 Km_GATx_Glutc = 3.0 Km_GATx_Aspc = 3.5
84 #### malate-oxoglutarate transporter (MOTx) ####
85 MOTx:
87 Malc + aKGm <> Malm + aKGc
89 (V_MOTx * ((aKGm * Malc) - (aKGc * Malm)))/(((Km_MOTx_aKGm *
90 (1 + (Malm / Km_MOTx_Malm))) + aKGm)*((Km_MOTx_Malc *
91 (1 + (aKGc /Km_MOTx_aKGc))) + Malc))
93 V_MOTx = 14.266 Km_MOTx_Malm = 1.30 Km_MOTx_aKGm = 1.29
94 Km_MOTx_Malc = 0.21 Km_MOTx_aKGc = 0.0135
96 #### mitochondrial glutamate-oxoglutarate transaminase (mGOT)
####
97 mGOT:
99 OAAm + Glutm <> aKGm + Aspm
101 (V_mGOT * ((OAAm * Glutm) - ((aKGm * Aspm)/Keq_mGOT)))/
102 (((Km_mGOT_OAAm * (1 + (aKGm / Km_mGOT_aKGm))) + OAAm)
103 *((Km_mGOT_Glutm * (1 + (Aspm /Km_mGOT_Aspm))) + Glutm))
105 V_mGOT = 0.11667/10 Keq_mGOT = 7.1428
106 Km_mGOT_OAAm = 0.088 Km_mGOT_aKGm = 0.43
107 Km_mGOT_Glutm = 8.9 Km_mGOT_Aspm = 3.9
109 #### cytosolic glutamate-oxoglutarate transaminase (cGOT) ####
110 cGOT:
112 OAAc + Glutc <> aKGc + Aspc
114 (V_cGOT * ((OAAc * Glutc) - ((aKGc * Aspc)/Keq_cGOT)))/
115 (((Km_cGOT_OAAc * (1 + (aKGc / Km_cGOT_aKGc))) + OAAc)
116 *((Km_cGOT_Glutc * (1 + (Aspc /Km_cGOT_Aspc))) + Glutc))
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118 V_cGOT = 0.069*10 Keq_cGOT = 0.3 Km_cGOT_OAAc = 0.095
119 Km_cGOT_aKGc = 0.38 Km_cGOT_Glutc = 9.6 Km_cGOT_Aspc = 4.4
121 #### cytosolic malate dehydrogenase (cMDH) ####
122 cMDH:
124 Malc + x_NADc <> OAAc + x_NADHc
126 (V_cMDH * ((Malc * x_NADc) - ((OAAc * x_NADHc)/Keq_cMDH)))/
127 (((K_cMDH_Malc * (1 + (OAAc/K_cMDH_OAAc))) + Malc)
128 * ((K_cMDH_NADc * (1 + (x_NADHc/K_cMDH_NADHc))) + x_NADc))
130 V_cMDH = 0.57 Keq_cMDH = 0.000023 K_cMDH_Malc = 1.3
131 K_cMDH_OAAc = 0.09 K_cMDH_NADc = 0.16 K_cMDH_NADHc = 0.019 
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Appendix H: The Heart Glycolysis
model in ScrumPy format
• Listing H.1. ScrumPy code for the Heart Glycolysis model. 
1 #### All metabolites are in mM ####
3 #### External metabolites (Model Parameters) ####
5 x_GLCb = 4.2 x_LACb = 0.7 x_PYRm = 0.2 x_Pic = 4.2
6 x_G6P = 0.00270 x_aGlycerol3P = 0.125
8 #### Internal metabolites (Model Variables) ####
10 Glc = 2.251 G6P = 0.270 F6P = 0.066 F16BP = 0.056
11 GAP = 2.592 DHAP = 0.058 B13PG = 1.39 P3G = 0.114
12 P2G = 0.014 PEP = 0.021 PYRc = 0.088 Lac = 1.093
13 FreeATPc = 4.761 FreeADPc = 0.049 NADc = 1.035
14 NADHc = 0.00255
16 #### Glycolysis Model (Heart/ Skeletal Muscle) ####
18 #### Blood Export Reactions ####
19 MCT1Pm:
21 Lac <> x_LACb
23 (V_MCT1Pm * (Lac - (x_LACb / Keq_MCT1Pm))) / ((K_MCT1Pm_Lac *
24 (1 + (x_LACb / K_MCT1Pm_xLACb))) + Lac)
26 V_MCT1Pm = 1.1 Keq_MCT1Pm = 1.0 K_MCT1Pm_Lac = 2.27
27 K_MCT1Pm_xLACb = 2.27
29 #### Glycolysis Reactions ####
31 GLUT4:
33 x_GLCb <> Glc
35 (V_GLUT4 * (x_GLCb - (Glc / Keq_GLUT4))) / ((K_GLUT4_xGLCb *
36 (1 + (Glc / K_GLUT4_Glc))) + x_GLCb)
38 V_GLUT4 = 0.10667 Keq_GLUT4 = 1.0 K_GLUT4_xGLCb = 2.0
39 K_GLUT4_Glc = 2.0
41 HK:
43 Glc + FreeATPc -> G6P + FreeADPc
45 (V_HK * Glc * FreeATPc)/((K_HK_FreeATPc + FreeATPc)* (K_HK_Glc *
46 (1 + (G6P / K_HK_G6P)) + Glc))
48 V_HK = 0.88 K_HK_Glc = 0.072 K_HK_FreeATPc = 0.236
49 K_HK_G6P = 0.253
51 PGI:
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53 G6P <> F6P
55 (V_PGI * (G6P - (F6P / Keq_PGI))) / ((K_PGI_G6P * (1 + (F6P /
56 K_PGI_F6P))) + G6P)
58 V_PGI = 16.10667 Keq_PGI = 0.3 K_PGI_G6P = 0.425
59 K_PGI_F6P = 0.031
61 G6PExp:
63 G6P <> x_G6P
65 V_G6PExp * (G6P - (x_G6P / Keq_G6PExp))
67 V_G6PExp = 0.3 Keq_G6PExp = 1.0
69 PFK:
71 F6P + FreeATPc <> F16BP + FreeADPc
73 (V_PFK * (F6P * FreeATPc) - ((F16BP * FreeADPc) / Keq_PFK)) /
74 (((K_PFK_F6P * (1 + (F16BP / K_PFK_F16BP))) + F6P)
75 * ((K_PFK_FreeATPc * (1 + (FreeADPc / K_PFK_FreeADPc))) + FreeATPc))
77 V_PFK = 2.12533 Keq_PFK = 1320.0 K_PFK_F16BP = 4.02
78 K_PFK_F6P = 0.224 K_PFK_FreeATPc = 0.127 K_PFK_FreeADPc = 2.71
80 ALD:
82 F16BP <> GAP + DHAP
84 (V_ALD * (F16BP - ((GAP * DHAP) / Keq_ALD))) / ((K_ALD_F16BP *
85 (1 + ((GAP / K_ALD_GAP) + (DHAP / K_ALD_DHAP)))) + F16BP)
87 V_ALD = 1.58667 Keq_ALD = 0.0987 K_ALD_F16BP = 0.038
88 K_ALD_GAP = 1.1 K_ALD_DHAP = 2.1
90 TPI:
92 GAP <> DHAP
94 (V_TPI * (GAP - (DHAP / Keq_TPI))) / ((K_TPI_GAP * (1 +
95 (DHAP / K_TPI_DHAP))) + GAP)
97 V_TPI = 61.0 Keq_TPI = 22.0 K_TPI_GAP = 0.32
98 K_TPI_DHAP = 0.61
100 ####
102 cGPD1:
104 DHAP + NADHc -> x_aGlycerol3P + NADc
106 (V_cGPD1 * (DHAP / K_cGPD1_DHAP) * (NADHc / K_cGPD1_NADHc)) /
107 ((1 + (DHAP / K_cGPD1_DHAP)) * (1 + (NADHc / K_cGPD1_NADHc)))
109 V_cGPD1 = 0.11 K_cGPD1_DHAP = 0.192535 K_cGPD1_NADHc = 0.001
111 GAPDH:
113 GAP + NADc + x_Pic <> B13PG + NADHc
115 (V_GAPDH * ((GAP * NADc) - ((B13PG * NADHc) / Keq_GAPDH))) /
116 (((K_GAPDH_GAP * (1 + (B13PG / K_GAPDH_B13PG))) + GAP)
117 * ((K_GAPDH_NADc * (1 + (NADHc / K_GAPDH_NADHc))) + NADc) *
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118 (1 + (x_Pic / K_GAPDH_xPic)))
120 V_GAPDH = 8.56 Keq_GAPDH = 0.604 K_GAPDH_GAP = 0.042
121 K_GAPDH_B13PG = 0.0008 K_GAPDH_NADc = 0.058 K_GAPDH_xPic = 1.42
122 K_GAPDH_NADHc = 0.0033
124 PGK:
126 B13PG + FreeADPc <> P3G + FreeATPc
128 (V_PGK * ((B13PG * FreeADPc) - ((P3G * FreeATPc) / Keq_PGK))) /
129 (((K_PGK_B13PG * (1 + (P3G / K_PGK_P3G))) + B13PG)
130 * ((K_PGK_FreeADPc * (1 + (FreeATPc / K_PGK_FreeATPc))) + FreeADPc))
132 V_PGK = 401.60 Keq_PGK = 3767.0 K_PGK_B13PG = 0.021
133 K_PGK_P3G = 1.2 K_PGK_FreeADPc = 0.008 K_PGK_FreeATPc = 0.565
135 PGM:
137 P3G <> P2G
139 (V_PGM * (P3G - (P2G / Keq_PGM))) / ((K_PGM_P3G * (1 +
140 (P2G / K_PGM_P2G))) + P3G)
142 V_PGM = 17.9733 Keq_PGM = 0.11 K_PGM_P3G = 0.145
143 K_PGM_P2G = 0.014
145 ENO:
147 P2G <> PEP
149 (V_ENO * (P2G - (PEP / Keq_ENO))) / ((K_ENO_P2G *
150 (1 + (PEP / K_ENO_PEP))) + P2G)
152 V_ENO = 2.96 Keq_ENO = 4.0 K_ENO_P2G = 0.045
153 K_ENO_PEP = 0.37
155 PK:
157 PEP + FreeADPc <> PYRc + FreeATPc
159 (V_PK * ((PEP * FreeADPc) - ((PYRc * FreeATPc) / Keq_PK))) /
160 (((K_PK_PEP * (1 + (PYRc / K_PK_PYRc))) + PEP)
161 * ((K_PK_FreeADPc * (1 + (FreeATPc / K_PK_FreeATPc))) + FreeADPc))
163 V_PK = 15.09333 Keq_PK = 12000.0 K_PK_PEP = 0.11
164 K_PK_FreeADPc = 0.268 K_PK_PYRc = 7.05
165 K_PK_FreeATPc = 0.82
167 LDH:
169 PYRc + NADHc <> Lac + NADc
171 (V_LDH * ((PYRc * NADHc) - ((Lac * NADc) / Keq_LDH))) /
172 (((K_LDH_PYRc * (1 + (Lac / K_LDH_Lac))) + PYRc)
173 * ((K_LDH_NADHc * (1 + (NADc / K_LDH_NADc))) + NADHc))
175 V_LDH = 9.9 Keq_LDH = 78500.0 K_LDH_PYRc = 0.125
176 K_LDH_NADHc = 0.001 K_LDH_Lac = 0.17 K_LDH_NADc = 0.253
178 MCT1Mm:
180 PYRc <> x_PYRm
182 (V_MCT1Mm * (PYRc - (x_PYRm / Keq_MCT1Mm))) /
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183 ((K_MCT1Mm_PYRc * (1 + (x_PYRm / K_MCT1Mm_xPYRm))) + PYRc)
185 V_MCT1Mm = 0.079 Keq_MCT1Mm = 1.0 K_MCT1Mm_PYRc = 0.15
186 K_MCT1Mm_xPYRm = 0.4
188 ATPhyd:
190 FreeATPc -> FreeADPc + x_Pic
192 V_ATPhyd * FreeATPc
194 V_ATPhyd = 0.01 #ATP demand at rest (Low)
196 ## V_ATPhyd = 0.10167 #ATP demand (Moderate)
197 ## V_ATPhyd = 0.97333 #ATP demand during exercise (High)
199 ## These values are for Rabbit skeletal muscle from PMID: 12220081. 
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Supplement I: Liver TCA cycle models
I.1 Suppl. data : Model definition for liver TCA model
• Supplemental Table I.1. Values of TCA cycle
variables in liver tissue taken from the literature and predicted by the model j,k,l,m,n
Fluxes are in units of mmol/sec and concentrations in mM.
Literature Values
Variable
Range Median
Model
Values
Reference
TCA cycle
(CS) flux
0.04 – 0.48 0.24 0.27 (9; 11; 13; 24; 30; 32; 41; 55; 104; 121)
PC flux 0.05 – 4.5 b 0.70 b 0.82 (9; 13; 30; 32; 83; 104)
MDH flux −0.63 –
−4.0e-04 c
−0.07 −0.55 (9; 30; 104)
MC flux 0.03 – 1.0 d 0.34 0.82 (9; 30; 104)[
CoAm
]a 0.31 – 1.93 1.92 1.67 (152; 154)[
AcCoAm
]
0.14 – 0.49 0.25 0.35 (38; 118; 152; 154)[
Citm
]
1.7 – 5.5 3.73 3.57 (2; 58; 116; 118; 165)[
Isocitm
]
0.14 – 0.62 0.15 0.19 (58; 116; 152)[
αKGm
]
0.38 – 2.8 1.3 1.34 (58; 116; 118; 121)[
Sucm
]
1.5 – h 1.64 (118)[
SCoAm
]
0.30 – 1.4 – h 0.68 (123)[
Fumm
]
– – h 0.34 –[
Malm
]
0.23 – 2.5 1.26 1.41 (36; 58; 68; 118; 151; 152)[
OAAm
] 4.0e-05 –
2.71e-02
2.26e-03 4.05e-04 (36; 118; 121; 126; 151; 152)[
NAD+m
]
0.41 – 1.93 1.25 1.22 i (48; 103; 117; 152)[
NADHm
]
0.20 – 1.25 0.51 0.88 i (48; 103; 117; 122; 152)[
ADPm
]
3.11 – 9.0 e 6.12 e 3.06 (2; 82; 111; 118; 133; 165)[
ATPm
]
3.19 – 13.65 f 7.64 f 7.34 (2; 58; 82; 111; 118; 133; 165)
Free g
[
ADPc
]
0.04 – 0.20 0.17 0.14 (21; 26; 94; 139)
Free g
[
ATPc
]
2.62 – 7.4 4.76 4.67 (2; 22; 31; 111; 118; 133; 136)
a In the original liver TCA cycle model, CoAm was a fixed parameter. In the updated liver TCA cycle model, it
has been correctly re-defined as a model variable.
b PC flux apparently ranges between 1.3 and 9.4 times TCA cycle flux in liver, and is on average around three
times TCA cycle flux (Baranyai and Blum, 1989; Beylot et al., 1995; Des Rosiers et al., 1995; Di Donato
et al., 1993; Magnusson et al., 1991; Rabkin and Blum, 1985).
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c MDH flux apparently ranges between −1.3 and −0.01 times TCA cycle flux in liver, and is on average around
−0.3 times TCA cycle flux (Baranyai and Blum, 1989; Des Rosiers et al., 1995; Rabkin and Blum, 1985).
d MC flux apparently ranges between 0.67 and 2.1 times TCA cycle flux in liver, and is on average around 1.4
times TCA cycle flux (Baranyai and Blum, 1989; Des Rosiers et al., 1995; Rabkin and Blum, 1985).
e Calculated from reported total mitochondrial ADP concentrations, assuming that
[
MgADP
]
is approximately
55% of total free [ADPm] (Akerboom et al., 1978; Magnus and Keizer, 1997).
f Calculated from reported total mitochondrial ATP concentrations, assuming that
[
MgATP
]
is approximately
95% of total free [ATPm] (Akerboom et al., 1978; Magnus and Keizer, 1997).
g Not bound to fixed sites; in the case of ATP, fixed-site binding can be viewed as negligible (Magnus and
Keizer, 1997).
h Fewer than three reported values, hence a median value was not determined.
i Total liver tissue mitochondrial [NAD+m ] + [NADHm ] apparently varies between 0.75 and 3.0 mM, and is on
average 2.1 mM (Hawtrey, 1962; Purvis, 1960; Siess et al., 1982a; Williamson, 1969).
j The predicted model values are obtained at steady-state, upon simulating the updated liver TCA cycle model.
These are the same values shown in the analysis of initial initial steady-state of the model, in the results
section.
k Table I.1 is reproduced from the main text of the article and expanded to include the sources of the literature
data.
l Metabolite and effector concentrations reported in units of moles per gram of wet or dry tissue weight were
converted to units of mM assuming a liver tissue dry/wet weight ratio of 0.26 (Söling, 1982) and a cell
volume/weight ratio of 2.1 ml g−1 dry weight (Siess et al., 1982b).
m Concentrations reported in units of moles per gram of mitochondrial protein were similarly converted assuming
a mitochondrial protein density of 272500 mg l−1 (Vinnakota and Bassingthwaighte, 2004).
n In determining mitochondrial fluxes and concentrations, the mitochondrial/cell volume ratio for liver tissue
was taken to be 0.1 (Söling, 1982).
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Parameter values are largely derived from the literature, and unless otherwise specified
are for mammalian (predominantly rat) liver mitochondria. Wherever possible, values
determined under conditions approximating the in vivo mitochondrial environment are
used; a mitochondrial matrix pH of 8 is assumed (Abad et al., 2004; Lambert and Brand,
2004; Llopis et al., 1998; Matsuyama et al., 2000; Wiederkehr et al., 2009). Concentrations
were converted to units of mM, and from cellular/ cytosolic to mitochondrial, using the
conversion factors listed above.
• Supplemental Table I.2. Parameter Values for the Liver TCA cycle model
Equation Parameter Value Units Reference
A.16 [ATotc ] 4.81 b,d mM
(2; 21; 118; 133; 139)
(22; 26; 31; 94; 136)
B.13 & B.18 [Ca2+]a 6.0e-03 mM (22)
B.16
[
CO2
]
1.63 mM (139)
A.13 [CoATotm ] 2.7 mM –
B.2 [HCO 3 –] 21.2 mM (139)
B.34
[
Malc
]
0.47 b mM (36; 118; 152)
B.5 [Mg2+]a 0.37 mM (22)
A.15 [ATotm ] 10.4 b,c mM (2; 111; 118; 133; 165)
B.16
[
NADP
]
0.31 b mM (48; 117; 118; 152)[
NADPH
]
1.85 b mM (48; 117; 118; 122; 152)
A.14
[
NTot
]
2.1 b,g mM (48; 103; 117; 118; 122; 152)
B.2, B.20,
B.34 & B.36
[
Pim
]
8.9 mM (118)
B.34
[
Pic
]
4.2 b mM (2; 31; 118; 129)
B.2 & B.7
[
Pyrm
]
0.2 e mM (68; 118)
B.22
[
Q
]
0.24 f mM (11; 12)[
QH2
]
0.27 mM (11; 12)
B.2
Keq 10.98 h unitless (158)
KPyrm 0.14 mM (87)
KHCO 3 – 3.0 mM (113)
KATPm 0.134 i mM (6)
(Continued on next page . . .)
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B.2
KOAAm 0.1 mM (87)
KADPm 0.35 mM (89)
KPim 6.0 mM (89)
B.3
VPCmin 1.02 j mM/sec (6; 35; 112; 113)
VPCmax 5.1 k,l mM/sec (35)
B.4
KAcCoAm 0.06 mM (87)
n 2.0 – (88)
B.5 KMg2+ 0.5 mM (87)
B.7
VPDH 0.648 k,m mM/sec (35)
KPyrm 0.01 mM (114)
KNAD+m 0.064 mM (106)
KCoAm 0.012 n mM (130)
KNADHm 0.044 o mM (5)
KAcCoAm 0.029 p mM (5)
B.9
VCS 13.75 k mM/sec (35)
Keq 1.13e+09 q unitless (4)
KOAAm 2.0e-03 mM (115)
KAcCoAm 0.016 mM (115)
KCitm 1.6 n mM (123)
KCoAm 0.067 n mM (123)
KSCoAm 0.14 mM (123)
KATPm 0.55 mM (115)
B.11
VACO 1.674 k,r mM/sec (34; 42; 142)
Keq 0.0685 q unitless (4)
KCitm 0.62 s mM (143)
KIsocitm 0.2 s mM (143)
B.13
VIDHa 1.58 k mM/sec (35)
n 1.0 – (101)
KNAD+m 0.07
n mM (102)
(Continued on next page . . .)
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B.13
KNADHm 0.029 b mM (23; 100; 101)
KATPm 0.118 n mM (102)
KIsocitm 0.56 p mM (107)
KADP3–m 0.05
n mM (102)
KCa2+ 1.12e-03 p mM (91)
B.14 & B.29 fADP3–m 0.818
t unitless (82)
B.16
VIDHb 5.419 k mM/sec (35)
Keq 43.8 u unitless (68; 77)
KIsocitm 8.4e-03 s mM (51)
KNADP 5.6e-03 s mM (51)
KαKGm 0.44 n mM (78)
KNADPH 5.6e-03 n mM (78)
KCO2 3.8 n mM (78)
B.18
VαKGDH 27.0 mM/sec (35)
KCoAm 0.025 s mM (46)
KNADH , c 3.54e-03 s,v mM (124)
KSCoAm 6.9e-03 s mM (124)
KATPm 0.1 s mM (90)
KNADH , u 0.0258 s,v mM (124)
KαKGm 0.126 s,v mM (124)
KADPm 0.1 s mM (90)
KCa2+ 1.2e-03 p mM (107)
KNAD+m 0.0193
s,v mM (124)
B.20
VSCS 4.2 k,w mM/sec (8; 19; 35)
Keq 1.3 q unitless (4)
KSCoAm 0.011 s mM (18)
KADPm 2.0e-03 s mM (18)
KPim 0.15 s mM (18)
KSucm 70.0 s mM (18)
KCoAm 0.02 s mM (18)
(Continued on next page . . .)
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B.20 KATPm 5.0e-03 s mM (18)
B.22
VSDH 0.48 k,s mM/sec (3; 140)
Keq 1.01 q unitless (4)
KSucm 0.13 n mM (40)
KQ 3.0e-04 n mM (40)
KFumm 1.3 s mM (29)
KQH2 1.5e-03 n mM (40)
KOAAm 1.5e-03 n mM (29; 162)
B.24
VFM 7.696 k mM/sec (35)
Keq 4.34 b unitless (4; 14; 15; 67)
KFumm 0.015 mM (62)
KMalm 0.18 mM (62)
B.26
VMDH 26.752 k mM/sec (35)
Keq 1.25e-04 n unitless (49)
KMalm 1.1 mM (25)
KNAD+m 0.114 mM (25)
KOAAm 5.5e-03 n mM (49)
KNADHm 5.0e-03 s mM (57)
B.28
VANT 1.527 x mM/sec –
Keq 118.0 y unitless (50; 60; 92)
KATP4–m 0.03
b mM (33; 59; 66; 92; 157)
KADP3–c 0.02
b mM (33; 59; 66; 92; 141; 157)
KADP3–m 0.02
b mM (33; 59; 66; 92; 157)
KATP4–c 0.03
b mM (33; 59; 66; 92; 141; 157)
B.29
fATP4–m 5.26e-02
z unitless (82)
fATP4–c 0.05 unitless (82)
fADP3–c 0.45 unitless (82)
B.34
VMC 23.257 x mM/sec –
Keq 1.52 unitless (53)
(Continued on next page . . .)
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B.34
KMalm 0.9 mM (53)
KPic 0.76 mM (53)
KPim 0.72 mM (53)
KMalc 0.2 mM (53)
B.36
VATPsynth 0.887
x mM/sec –
KNADHm 0.88 aa mM –
KADPm 3.1 aa mM –
KPim 8.9 aa mM –
KNAD+m 1.2
aa mM –
KATPm 7.3 aa mM –
B.38 fATPhyd 7.69e-03
x sec-1 –
a Refers to free concentration.
b Average of reported values.
c Sum of the reported Mg-ADP and Mg-ATP concentrations, assuming that the magnesium-complexed
species represent 55% and 95% of free ADP and ATP, respectively (Magnus and Keizer, 1997).
e Within range of reported values.
f Calculated from total ubiquinone concentration, assuming [QH2] = 0.27 mM (Benard, 2006; Benard
et al., 2006).
g Sum of reported NAD and NADH concentrations.
h The value represents the Keq taking [HCO −3 ] as the substrate, calculated from the Keq for total [CO2]
reported in the source (Wood et al., 1966).
i Determined in sheep kidney; determined in chicken liver.
j The basal activity of PC is approx. 20% of the activity of the maximally activated enzyme (Ashman
et al., 1972; Fahien and Teller, 1992; Scrutton, 1974; Scrutton and White, 1972).
k Calculated from the reported mitochondrial concentration and specific activity, taking into account
the number of active sites within the holoenzyme.
l Assumed to represent the activity of the maximally activated enzyme.
m Assumed to represent the physiological level of activation.
n Determined in bovine heart.
o Determined in rat kidney.
p Determined in rat heart.
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q Calculated from the thermodynamic properties of the species involved in the reaction (Alberty, 2003).
r Enzyme concentration estimated from the specific activities of the crude extract and the purified
enzyme from rat liver (Eprintsev et al., 2002; Guarriero-Bobyleva et al., 1973), according to the
methodology of Albe et al., 1990; specific activity determined in pig heart (Villafranca and Mildvan,
1971b).
s Determined in pig heart.
t fADP3−m = 0.45/0.55, assuming [ADP
3−] = 0.45× [ADP] (total free ADP), and
[ADP] = [ADP 3−] + [MgADP] (Magnus and Keizer, 1997).
u At a fixed total mitochondrial [CO2] concentration of 22.8 mM (Veech et al., 1979).
v Original data (Smith et al., 1974) re-fitted to a mixed inhibition model.
w Specific activity determined in pig heart (Cha and Parks, 1964b).
x Fitted value.
y Calculated from the Nernst equation (Metelkin et al., 2006), assuming that the membrane potential
provides 85% of the driving force for nucleotide translocation (Klingenberg and Rottenberg, 1977),
and taking Ψ to be 150 mV (Holian and Wilson, 1980; Klingenberg and Rottenberg, 1977).
z fATP4−m = 0.05/0.95, assuming [ATP
4−] = 0.05× [ATP] (total free ATP), and
[ATP] = [ATP 4−] + [MgATP] (Magnus and Keizer, 1997).
aa Set equal to the steady-state concentration of the metabolite.
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I.2 Suppl. data : Steady-state analysis of liver model
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• Supplemental Figure I.1. Change
in the metabolic status of CoA between the two liver TCA cycle models: Effect on
TCAi concentrations against the change in maximal activities of MC & PC, respectively.
• Key for figs. I.1a to I.1d is as follows :
OAAm ; Citm ; Isocitm ; αKGm ; Sucm ; Fumm ; Malm
• Supplementary data for fig. 2.16a on pg. 54.
• The vertical black line represents the initial model value. At this point, in figs. I.1a and I.1b,
V MCmax = 23.2574 mM/sec and in figs. I.1c and I.1d, V PCmax = 2.26234 mM/sec (apparent velocity).
• Y-axes for figs. I.1a and I.1b have been set within a limited range of concentration values (in mM), to
avoid the possible plot-line compression due to extreme values.
• Note the substantially different Y-axis scales between figs. I.1a and I.1c compared with figs. I.1b and I.1d,
respectively.
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Supplement I. Suppl. data : Steady-state analysis of liver model
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• Supplemental Figure I.2. Change in the metabolic status
of CoA between the two liver TCA cycle models: Effect on mitochondrial & cytosolic
ATP/ADP concentrations against the change in maximal activities of MC & PC, respectively.
• Key for figs. I.2a to I.2d is as follows :
ATPm ; ADPm ; ATPc ; ADPc
mitochondrial ATP+ADP (total) ; cytosolic ATP+ADP (total)
• Supplementary data for fig. 2.16b on pg. 54 and for figs. 2.22a and 2.22b on pg. 68.
• The vertical black line represents the initial model value. At this point, in figs. I.2a and I.2b,
V MCmax = 23.2574 mM/sec and in figs. I.2c and I.2d, V PCmax = 2.26234 mM/sec (apparent velocity), respectively.
• Note the substantially different Y-axis scales between figs. I.2c and I.2d.
— Ph.D. Thesis by Amar S. Ghaisas — Page X
Supplement I. Suppl. data : Steady-state analysis of liver model
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• Supplemental Figure I.3. Change in the metabolic status
of CoA between the two liver TCA cycle models: Effect on mitochondrial NAD+/
NADH concentrations against the change in maximal activities of MC & PC, respectively.
• Key for figs. I.3a to I.3d is as follows :
NADm+ ; NADHm ; mitochondrial NAD+/ NADH (total)
• Supplementary data for fig. 2.16c on pg. 55 and for fig. 2.22c on pg. 68.
• The vertical black line represents the initial model value. At this point, in figs. I.3a and I.3b,
V MCmax = 23.2574 mM/sec and in figs. I.3c and I.3d, V PCmax = 2.26234 mM/sec (apparent velocity), respectively.
• Note the substantially different Y-axis scales between figs. I.3c and I.3d.
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Supplement I. Suppl. data : Steady-state analysis of liver model
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• Supplemental Figure I.4. Change in
the metabolic status of CoA between the two liver TCA cycle models: Effect on key
Liver TCA cycle fluxes against the change in maximal activities of MC & PC, respectively.
• Key for figs. I.4a to I.4d is as follows :
IDHa ; CS ; IDHb ; PC ; MDH
• Supplementary data for fig. 2.17 on pg. 56.
• The vertical black line represents the initial model value. At this point, in figs. I.4a and I.4b,
V MCmax = 23.2574 mM/sec and in figs. I.4c and I.4d, V PCmax = 2.26234 mM/sec (apparent velocity), respectively.
• Note the substantially different Y-axis scales between figs. I.4a and I.4c compared with figs. I.4b and I.4d,
respectively.
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Supplement I. Suppl. data : Steady-state analysis of liver model
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• Supplemental Figure I.5. Change
in the metabolic status of CoA between the two liver TCA cycle models: Effect on
TCAi concentrations against the change in concentrations of Pim & Pyrm, respectively.
• Key for figs. I.5a to I.5d is as follows :
OAAm ; Citm ; Isocitm ; αKGm ; Sucm ; Fumm ; Malm
• Supplementary data for fig. 2.19a on pg. 62.
• The vertical black line represents the initial model value. At this point, in figs. I.5a and I.5b,
[Pim] = 8.9 mM and in figs. I.5c and I.5d, [Pyrm] = 0.2 mM, respectively.
• Note the substantially different Y-axis scales between figs. I.5a and I.5c compared with figs. I.5b and I.5d,
respectively.
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Supplement I. Suppl. data : Steady-state analysis of liver model
 0
 5
 10
 15
 20
 2  4  6  8  10  12  14  16  18  20
C
o
n
ce
n
tr
at
io
n
 (
m
M
)
External mitochondrial [Pi] (mM)
Original Liver TCA cycle model - LVRTCA
OGI
I.6.a
 0
 2
 4
 6
 8
 10
 12
 2  4  6  8  10  12  14  16  18  20
C
o
n
ce
n
tr
at
io
n
 (
m
M
)
External mitochondrial [Pi] (mM)
Updated Liver TCA cycle model - LVRTCA
UPD
I.6.b
 0
 2
 4
 6
 8
 10
 12
 0.1  0.2  0.3  0.4  0.5  0.6  0.7  0.8  0.9  1
C
o
n
ce
n
tr
at
io
n
 (
m
M
)
External Pyruvate concentration (mM)
Original Liver TCA cycle model - LVRTCA
OGI
I.6.c
 0
 2
 4
 6
 8
 10
 12
 0.1  0.2  0.3  0.4  0.5  0.6  0.7  0.8  0.9  1
C
o
n
ce
n
tr
at
io
n
 (
m
M
)
External Pyruvate concentration (mM)
Updated Liver TCA cycle model - LVRTCA
UPD
I.6.d
• Supplemental Figure I.6. Change in the metabolic status
of CoA between the two liver TCA cycle models: Effect on mitochondrial & cytosolic
ATP/ ADP concentrations against the change in concentrations of Pim & Pyrm, respectively.
• Key for figs. I.6a to I.6d is as follows :
ATPm ; ADPm ; ATPc ; ADPc
mitochondrial ATP+ADP (total) ; cytosolic ATP+ADP (total)
• Supplementary data for fig. 2.19b on pg. 62 and for figs. 2.23a, 2.23b, 2.24a and 2.24b on pgs. 69
and 70.
• The vertical black line represents the initial model value. At this point, in figs. I.6a and I.6b,
[Pim] = 8.9 mM and in figs. I.6c and I.6d, [Pyrm] = 0.2 mM, respectively.
• Note the substantially different Y-axis scales between figs. I.6a and I.6b.
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Supplement I. Suppl. data : Steady-state analysis of liver model
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• Supplemental Figure I.7. Change in the metabolic status
of CoA between the two liver TCA cycle models: Effect on mitochondrial NAD+/
NADH concentrations against the change in concentrations of Pim & Pyrm, respectively.
• Key for figs. I.7a to I.7d is as follows :
NADm+ ; NADHm ; mitochondrial NAD+/ NADH (total)
• Supplementary data for fig. 2.19c on pg. 63 and for figs. 2.23c and 2.24c on pgs. 69 and 70.
• The vertical black line represents the initial model value. At this point, in figs. I.7a and I.7b,
[Pim] = 8.9 mM and in figs. I.7c and I.7d, [Pyrm] = 0.2 mM, respectively.
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Supplement I. Suppl. data : Steady-state analysis of liver model
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• Supplemental Figure I.8. Change in
the metabolic status of CoA between the two liver TCA cycle models: Effect on key
Liver TCA cycle fluxes against the change in concentrations of Pim & Pyrm, respectively.
• Key for figs. I.8a to I.8d is as follows :
IDHa ; CS ; IDHb ; PC ; MDH
• Supplementary data for fig. 2.20 on pg. 64.
• The vertical black line represents the initial model value. At this point, in figs. I.8a and I.8b,
[Pim] = 8.9 mM and in figs. I.8c and I.8d, [Pyrm] = 0.2 mM, respectively.
• Note the substantially different Y-axis scales between figs. I.8a and I.8c compared with figs. I.8b and I.8d,
respectively.
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Supplement I. Suppl. data : Steady-state analysis of liver model
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• Supplemental Figure I.9. Change
in the metabolic status of CoA between the two liver TCA cycle models: Effect on
ATP/ADP-linked fluxes against the change in concentrations of Pim & Pyrm, respectively.
• Key for figs. I.9a to I.9d is as follows :
ATPsynth ; SCS ; ATPhyd ; PC
• Supplementary data for fig. 2.21 on pg. 65.
• The vertical black line represents the initial model value. At this point, in figs. I.9a and I.9b,
[Pim] = 8.9 mM and in figs. I.9c and I.9d, [Pyrm] = 0.2 mM, respectively.
• Note the substantially different Y-axis scales between figs. I.9a and I.9c compared with figs. I.9b and I.9d,
respectively.
• In this figure, the ATP synthase (ATPsynth) flux have been scaled by a factor of 10; due to the
difference in respective reaction stoichiometries between ATPsynth (in mitochondria) and ATPhyd (in
cytosol).
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Supplement I. Suppl. data : CJ’s for the liver TCA cycle model
I.3 Suppl. data : CJ’s for the liver TCA cycle model
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• Supplemental Figure
I.10. Control of the TCA cycle flux: Distribution of flux control coefficients calculated
for the flux through CS, against the change in concentrations of Pim & Pyrm, respectively.
• Key for figs. I.10a and I.10b is as follows :
PDH ; CS ; ACO ; IDHa ; α-KGDH ; SCS;
SDH ; FM ; MDH ; ATPsynth ; ANT ; ATPhyd;
PC ; MC ; IDHb ; Total Sum (dotted line)
• The vertical black line represents the initial model value. At this point, in figs. I.10a and I.10c,
[Pim] = 8.9 mM and in figs. I.10b and I.10d, [Pyrm] = 0.2 mM, respectively.
• Figure I.10b: The Orange dotted line that represents the Summation theorem result, shows some dropouts.
This is due to an erroneous Summation theorem result (less than or greater than unity) at that point; which
in turn is a result of an unstable steady-state. Hence, such data points are excluded from these plots.
• Corresponding flux control coefficient plots for the original liver TCA cycle model are both qualita-
tively as well as quantitatively similar to the data shown above and therefore not included here.
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Supplement I. Suppl. data : CJ’s for the liver TCA cycle model
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• Supplemental Figure
I.11. Control of the TCA cycle flux: Distribution of flux control coefficients calculated
for the flux through CS, against the change in maximal activities of PC & MC, respectively.
• Key for figs. I.11a and I.11b is as follows :
PDH ; CS ; ACO ; IDHa ; α-KGDH ; SCS;
SDH ; FM ; MDH ; ATPsynth ; ANT ; ATPhyd;
PC ; MC ; IDHb ; Total Sum (dotted line)
• The vertical black line represents the initial model value. At this point, in figs. I.11a and I.11c,
V PCmax = 2.26234 mM/sec (apparent velocity) and in figs. I.11b and I.11d, V MCmax = 23.2574 mM/sec, respectively.
• Orange dotted line shows the Summation theorem result across the entire range.
• Corresponding flux control coefficient plots for the original liver TCA cycle model are both qualita-
tively as well as quantitatively similar to the data shown above and therefore not included here.
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Supplement I. Suppl. data : CS’s for the liver TCA cycle model
I.4 Suppl. data : CS’s for the liver TCA cycle model
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• Supplemental Figure I.12. Control of TCA cycle intermediate metabolites:
Distribution of concentration control coefficients calculated for the respective concentra-
tions of – αKG & Malate; against the changing maximal activity of pyruvate carboxylase.
• Key for figs. I.12a and I.12c is as follows :
PDH ; CS ; ACO ; IDHa ; α-KGDH ; SCS;
SDH ; FM ; MDH ; ATPsynth ; ANT ; ATPhyd;
PC ; MC ; IDHb ; Total Sum (dotted line)
• The vertical black line represents the initial model value. At this point, in figs. I.12a to I.12d,
V PCmax = 2.26234 mM/sec (apparent velocity).
• Orange dotted line shows the Summation theorem result across the entire range. For concentration
control coefficients, since the sum is equal to zero, the dotted line is not easily visible.
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Supplement I. Suppl. data : CS’s for the liver TCA cycle model
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I.13.c. CNAD, Updated model
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I.13.d. [NAD+], Updated model
• Supplemental Figure I.13. Control of CoA- & NAD–related metabolites:
Distribution of concentration control coefficients calculated for the respective concentra-
tions of – CoA & NAD+; against the changing maximal activity of pyruvate carboxylase.
• Key for figs. I.13a and I.13c is as follows :
PDH ; CS ; ACO ; IDHa ; α-KGDH ; SCS;
SDH ; FM ; MDH ; ATPsynth ; ANT ; ATPhyd;
PC ; MC ; IDHb ; Total Sum (dotted line)
• The vertical black line represents the initial model value. At this point, in figs. I.13a to I.13d,
V PCmax = 2.26234 mM/sec (apparent velocity).
• Orange dotted line shows the Summation theorem result across the entire range. For concentration
control coefficients, since the sum is equal to zero, the dotted line is not easily visible.
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• Supplemental Figure I.14. Control of ADP-related metabolites:
Distribution of concentration control coefficients calculated for the respective concentra-
tions of – ADPm & ADPc; against the changing maximal activity of pyruvate carboxylase.
• Key for figs. I.14a and I.14c is as follows :
PDH ; CS ; ACO ; IDHa ; α-KGDH ; SCS;
SDH ; FM ; MDH ; ATPsynth ; ANT ; ATPhyd;
PC ; MC ; IDHb ; Total Sum (dotted line)
• The vertical black line represents the initial model value. At this point, in figs. I.14a to I.14d,
V PCmax = 2.26234 mM/sec (apparent velocity).
• Orange dotted line shows the Summation theorem result across the entire range. For concentration
control coefficients, since the sum is equal to zero, the dotted line is not easily visible.
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Supplement II: “PC knock-out” model
II.1 Suppl. data : Steady-state analysis of PCko model
-2
 0
 2
 4
 6
 8
 10
 12
 14
 0.5  1  1.5  2
C
o
n
ce
n
tr
at
io
n
 (
m
M
)
PDH maximal activity (mM/sec)
Updated Liver TCA cycle model - LVRTCA
UPD
II.1.a
-0.5
 0
 0.5
 1
 1.5
 2
 2.5
 3
 3.5
 0.2  0.4  0.6  0.8  1  1.2  1.4  1.6  1.8  2
C
o
n
ce
n
tr
at
io
n
 (
m
M
)
PDH maximal activity (mM/sec)
PC knockout model of Liver TCA cycle - PCko
II.1.b
-10
-5
 0
 5
 10
 15
 20
 25
 30
 35
 2  4  6  8  10  12  14  16  18  20
C
o
n
ce
n
tr
at
io
n
 (
m
M
)
External mitochondrial [Pi] (mM)
Updated Liver TCA cycle model - LVRTCA
UPD
II.1.c
-1
 0
 1
 2
 3
 4
 5
 6
 7
 8
 2  4  6  8  10  12  14  16  18  20
C
o
n
ce
n
tr
at
io
n
 (
m
M
)
External mitochondrial [Pi] (mM)
PC knockout model of Liver TCA cycle - PCko
II.1.d
• Supplemental Figure II.1. Concentrations of TCAi’s : effect
of PC ‘knock-out’ (PCko) in comparison with the PC ‘wild-type’ (PCwt i.e. LVRTCAUPD).
• Key for figs. II.1a to II.1d is as follows :
OAAm; Citm; Isocitm; αKGm; Sucm; Fumm; Malm
• Supplementary data for the fig. 3.6a on pg. 130.
• The vertical black line represents the initial model value. At this point, in figs. II.1a and II.1b,
V PDHmax = 0.648 mM/sec and in figs. II.1c and II.1d, [Pim] = 8.9 mM, respectively.
• Note the substantially different Y-axis scales between figs. II.1a and II.1c compared with figs. II.1b and II.1d,
respectively.
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Supplement II. Suppl. data : Steady-state analysis of PCko model
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• Supplemental Figure II.2. Concentrations of ATP–related metabolites: effect
of PC ‘knock-out’ (PCko) in comparison with the PC ‘wild-type’ (PCwt i.e. LVRTCAUPD).
• Key for figs. II.2a to II.2d is as follows :
ATPm ; ADPm ; ATPc ; ADPc
mitochondrial ATP+ADP (total) ; cytosolic ATP+ADP (total)
• Supplementary data for fig. 3.6b on pg. 130 and for figs. 3.11a, 3.11b, 3.12a and 3.12b on pgs. 137
and 138.
• The vertical black line represents the initial model value. At this point, in figs. II.2a and II.2b,
V PDHmax = 0.648 mM/sec and in figs. II.2c and II.2d, [Pim] = 8.9 mM, respectively.
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Supplement II. Suppl. data : Steady-state analysis of PCko model
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II.3.d
• Supplemental Figure II.3. Concentrations of NAD–related metabolites: effect
of PC ‘knock-out’ (PCko) in comparison with the PC ‘wild-type’ (PCwt i.e. LVRTCAUPD).
• Key for figs. II.3a to II.3d is as follows :
NADm+ ; NADHm ; mitochondrial NAD+/ NADH (total)
• Supplementary data for fig. 3.6c on pg. 131 and for figs. 3.11c and 3.12c on pgs. 137 and 138.
• The vertical black line represents the initial model value. At this point, in figs. II.3a and II.3b,
V PDHmax = 0.648 mM/sec and in figs. II.3c and II.3d, [Pim] = 8.9 mM, respectively.
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Supplement II. Suppl. data : Steady-state analysis of PCko model
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• Supplemental Figure II.4. Concentrations of CoA–related metabolites: effect
of PC ‘knock-out’ (PCko) in comparison with the PC ‘wild-type’ (PCwt i.e. LVRTCAUPD).
• Key for figs. II.4a to II.4d is as follows :
AcCoAm ; CoAm ; SCoAm ; Total CoA content
• Supplementary data for fig. 3.6c on pg. 131.
• The vertical black line represents the initial model value. At this point, in figs. II.4a and II.4b,
V PDHmax = 0.648 mM/sec and in figs. II.4c and II.4d, [Pim] = 8.9 mM, respectively.
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Supplement II. Suppl. data : Steady-state analysis of PCko model
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• Supplemental Figure II.5. Liver TCA
cycle fluxes against changes in Pim concentration & PDH maximal activity: effect
of PC ‘knock-out’ (PCko) in comparison with the PC ‘wild-type’ (PCwt i.e. LVRTCAUPD).
• Key for figs. II.5a to II.5d is as follows :
IDHa; CS; IDHb; PC; MDH
• Supplementary data for the figs. 3.7 and 3.8 on pgs. 132 and 133.
• The vertical black line represents the initial model value. At this point, in figs. II.5a and II.5b,
V PDHmax = 0.648 mM/sec and in figs. II.5c and II.5d, [Pim] = 8.9 mM, respectively.
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Supplement III: Heart TCA cycle model
III.1 Suppl. data : Model definition for heart TCA model
• Supplemental Table III.1. Values of TCA
cycle variables in heart tissue taken from the literature and predicted by the model a,b,c
Fluxes are in units of mmol/sec and concentrations in mM.
Literature Values
Variable
Range Median
Model
Values
Reference
TCA cycle
(CS) flux 0.03 – 0.08 0.06 4.33e-03 (20; 72; 96; 97; 108; 132; 137; 145; 160)[
CoAm
]
0.01 – 0.08 0.046 2.05e-03 (3; 27; 37; 45; 127; 131; 150; 163)[
AcCoAm
]
0.02 – 0.33 0.18 0.25 (72; 99; 156; 160)
[
Citm
]
0.03 – 4.0 2.01 0.49
(3; 54; 73; 131; 150; 153; 164)
(80; 84; 96; 105; 128; 132; 159)
(97; 108; 109; 134; 156; 160; 163)[
Isocitm
]
0.03 – 0.12 0.08 3.32e-02 (54; 105; 153)
[
αKGm
]
0.01 – 0.8 0.4 6.00e-03
(47; 74; 80; 105; 108; 132; 160; 163)
(3; 17; 54; 73; 109; 131; 156; 159)[
Sucm
]
0.06 – 3.9 2.0 4.27e-02 (17; 73; 80; 96; 97; 128; 131; 159; 163)[
SCoAm
]
0.01 – 0.29 0.15 1.55e-04 (44; 161; 163)[
Fumm
]
6.9e-03 – 0.26 0.13 3.65e-02 (17; 54; 80; 96; 97; 131)
[
Malm
]
0.16 – 1.88 1.02 0.16
(73; 80; 96; 105; 128; 131; 153; 159)
(47; 97; 108; 109; 132; 134; 163)[
OAAm
]
0.002 – 0.062 0.032 1.44e-05 (39; 80; 105; 108; 134; 153; 156; 160; 163)[
NAD+m
]
0.56 – 1.36 0.96 0.6 (61; 153; 163)[
NADHm
]
0.1 – 1.0 0.53 0.094 (61; 72; 93; 98; 153; 156; 163)[
ADPm
]
Same as the liver
TCA cycle model
0.88
Same as the liver
TCA cycle model
[
ATPm
]
9.52
Free d
[
ADPc
]
4.47e-02
Free d
[
ATPc
]
4.77
a The predicted model values are obtained at steady-state, upon simulating the Heart TCA cycle model. These
are the same values shown in the analysis of initial steady-state of the model, in the results section.
b Metabolite and effector concentrations reported in units of moles per gram of wet or dry tissue weight were
converted to units of mM assuming a heart tissue dry/wet weight ratio of 0.2 (Lopaschuk et al., 1992) and a
cell volume/weight ratio of 2.0 ml g−1 dry weight (Idell-Wenger et al., 1978; Yu et al., 1995).
c Concentrations reported in units of moles per gram of mitochondrial protein were similarly converted assuming
a mitochondrial protein density of 272500 mg l−1 (Vinnakota and Bassingthwaighte, 2004).
d Not bound to fixed sites; in the case of ATP, fixed-site binding is negligible (Magnus and Keizer, 1997).
— Ph.D. Thesis by Amar S. Ghaisas — Page XXVIII
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Parameter values are largely derived from the literature, and unless otherwise
specified are for mammalian (predominantly rat) heart mitochondria. Wherever possible,
values determined under conditions approximating the in vivo mitochondrial environment
are used; a mitochondrial matrix pH of 8 is assumed (1; 70; 76; 86; 146). Concentrations
were converted to units of mM, and from cellular/ cytosolic to mitochondrial, using the
conversion factors listed above.
• Supplemental Table III.2. Parameter Values for the Heart TCA cycle model
Equation l Parameter Value Units Reference
E.7
[
αKGc
]
6.0e-03 mM –
A.16 [ATotc ]
Same as the liver TCA cycle model
B.13 & B.18 [Ca2+]
B.6, B.12 &
B.17
[
CO2
]
A.15 [ATotm ]
B.20 & B.36
[
Pim
]
B.37
[
Pic
]
B.7
[
Pyrm
]
B.22
[
Q
]
[
QH2
]
B.7
VPDH 0.1885 a,b mM/sec (56; 65)
KPyrm 0.028 mM (120; 147; 148)
KNAD+m 0.0607 mM (10; 65; 106; 138; 149; 159)
KCoAm 0.006 mM (65; 148)
KNADHm Same as the liver TCA cycle model
KAcCoAm
B.9
VCS 2.5433 a,c mM/sec (95; 125)
Keq 1.01e+06 d unitless (43)
KOAAm 5.0e-03 mM (95; 125)
KAcCoAm 5.0e-03 mM (69; 95; 125)
KSCoAm 0.13 mM (10; 65; 123; 159)
(Continued on next page . . .)
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B.9
KATPm 0.70 mM (75; 95; 115)
KCitm Same as the liver TCA cycle model
KCoAm
B.11
VACO 2.27 a,e mM/sec (7; 125)
Keq
Same as the liver TCA cycle modelKCitm
KIsocitm
B.13
VIDHa 1.371 a,f mM/sec (3; 7; 126)
n 2.7 – (28; 107)
KNAD+m 0.074 mM (63; 64; 65; 102; 159)
KATPm 0.091 mM (63; 64; 65; 159)
KIsocitm
Same as the liver TCA cycle model
KNADHm
KADP3–m
KCa2+
B.14 & B.29 fADP3–m
E.7
VαKGexp 1.0 mM/sec –
Keq 1.0 unitless –
B.18
VαKGDH 7.4426 mM/sec (3; 85; 110)
KαKGm 0.08 g mM (64; 155; 159)
KCoAm
Same as the liver TCA cycle model
KNADH , c
KSCoAm
KATPm
KNADH , u
KADPm
KCa2+
KNAD+m
(Continued on next page . . .)
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B.20
VSCS 3.1082 a,h mM/sec (3; 19; 93)
Keq 0.78 unitless (81)
KSCoAm
Same as the liver TCA cycle model
KADPm
KPim
KSucm
KCoAm
KATPm
B.22
VSDH
Same as the liver TCA cycle model
Keq
KSucm
KQ
KFumm
KQH2
KOAAm
B.24
VFM 7.93 a mM/sec (7; 126)
KFumm 1.74e-03 mM (16; 159)
KMalm 3.80e-03 mM (16; 159)
Keq Same as the liver TCA cycle model
B.26
VMDH 1.03 a,i,j mM/sec (57)
Keq 2.3e-05 unitless (125)
KNAD+m 0.3 mM (57; 135; 159)
KMalm
Same as the liver TCA cycle modelKOAAm
KNADHm
B.28
VANT
Same as the liver TCA cycle model
Keq
KATP4–m
KADP3–c
(Continued on next page . . .)
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B.28
KADP3–m
Same as the liver TCA cycle model
KATP4–c
B.29
fATP4–m
fATP4–c
fADP3–c
B.36
VATPsynth
Same as the liver TCA cycle model
KNADHm
KADPm
KPim
KNAD+m
KATPm
B.38 fATPhyd 0.01
k sec-1 (71)
a Calculated from the reported mitochondrial concentration and specific activity, taking into account
the number of active sites within the holoenzyme.
b Assumed to represent the physiological level of activation.
c Calculated using the rat heart enzyme, purified using a tris–HCl buffer maintained at pH 8.1 and at
28°C (Moriyama and Srere, 1971).
d Calculated from the thermodynamic properties of the species involved in the reaction. Calculated
using the pig heart enzyme, purified at pH 7.0 and at 38°C (Guynn et al., 1973).
e Enzyme concentration estimated from the specific activities of the crude extract and the purified
enzyme from rat liver (Eprintsev et al., 2002; Guarriero-Bobyleva et al., 1973), according to the
methodology of Albe et al., 1990; specific activity determined in bovine heart (Bachmann et al., 1966;
Srere, 1972a).
f The enzyme specific activity was determined in the bovine heart mitochondria.
g Calculated using the rat heart enzyme, purified using a tris–Cl buffer maintained at pH 7.2 and at
28°C (Williamson et al., 1973; Wu et al., 2007).
h Calculated using the specific activity of pig heart enzyme, purified using a potassium phosphate
(KH2PO4) buffer maintained at pH 7.4 and at 30°C (Cha and Parks, 1964b; Mogilevskaya et al.,
2006).
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i Calculated using the specific activity of pig heart enzyme, purified using a tris–acetate buffer maintained
at pH 8.0 and at 25°C (Kimball et al., 1979).
j The originally calculated Vmax value of 25.66667 mM/sec was divided by a factor of 25 during the
model optimisation process.
k Estimated rate of ATP demand at rest (basal activity), in the rabbit skeletal muscle (Lambeth and
Kushmerick, 2002). The estimates at moderate and high level of ATP demand are also provided in
the same citation.
l As mentioned in the heart TCA cycle model chapter, apart from the α-ketoglutarate transporter
reaction (α-KG exp), all the other enzymatic reactions are essentially common between the heart &
the liver-specific TCA cycle models, in terms of their individual rate equations. Therefore in this table,
only the αKGc concentration parameter, as well as the rate parameters for α-KG exp reaction point to
the appropriate equation defined in the heart-specific model. All the remaining parameters listed in
this table, point to the reaction equations included within the liver TCA cycle model chapter appendix
(Please refer to Appendix B on pgs. pg. 221 to pg. 232).
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